

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:16:16 ; Search time 0.001 Seconds
(without alignments)
589.248 Million cell updates/sec

Title: US-10-006-191-79
Perfect score: 27
Sequence: 1 agagtggacaaaagtacatgttg 27

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 886 seqs, 10912 residues

Total number of hits satisfying chosen parameters: 1772

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 886 summaries

Database : rng19.seq *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20	74.1	20	1	ADB5654
C 2	20	74.1	20	1	ADB5671
C 3	20	74.1	20	1	ADB5655
C 4	20	74.1	20	1	ADB5670
C 5	16	59.3	20	1	ADB5653
C 6	14.4	53.3	20	1	ABK40462
C 7	14.4	53.3	20	1	ADJ37525
C 8	14.4	53.3	20	1	ADG56449
C 9	14	51.9	20	1	ADB5669
C 10	12.2	45.2	17	1	AAV36534
C 11	12.2	45.2	17	1	ABV99418
C 12	12.2	45.2	17	1	ADL49182
C 13	12.2	45.2	17	1	ADL49182
C 14	12.2	45.2	17	1	ADL50023
C 15	11.4	42.2	13	1	ABC78606
C 16	11.4	42.2	13	1	ABC78607
C 17	11.4	42.2	13	1	ABC78609
C 18	11.4	42.2	13	1	ABC30594
C 19	11.4	42.2	13	1	ABC78608
C 20	11.4	42.2	13	1	ABC24651
C 21	11.4	42.2	13	1	ABC24650
C 22	11.4	42.2	13	1	ABC30595
C 23	11.4	42.2	15	1	AAV30977
C 24	11.4	42.2	15	1	ABK19330
C 25	11	40.7	15	1	ABK70527
C 26	10.8	40.0	15	1	AAV15778
C 27	10.8	40.0	15	1	AAV73958
C 28	10.4	38.5	12	1	ABH91622
C 29	10.4	38.5	12	1	ABH103636
C 30	10.4	38.5	12	1	ABH74839
C 31	10.4	38.5	12	1	ABH71745
C 32	10.4	38.5	12	1	ABH49941
C 33	10.4	38.5	12	1	ABH52271

C 34	10.4	38.5	12	1	ABH71735	Oligonucleotide pr
C 35	10.4	38.5	12	1	ABH49627	Oligonucleotide pr
C 36	10.4	38.5	12	1	ABH33967	Oligonucleotide pr
C 37	10.4	38.5	12	1	ABH42142	Oligonucleotide pr
C 38	10.4	38.5	12	1	ABH107774	Oligonucleotide pr
C 39	10.4	38.5	13	1	ABC72025	Oligonucleotide pr
C 40	10.4	38.5	13	1	ABC56759	Oligonucleotide pr
C 41	10.4	38.5	13	1	ABH48560	Oligonucleotide pr
C 42	10.4	38.5	13	1	ABH34854	Oligonucleotide pr
C 43	10.4	38.5	13	1	ABF34989	Oligonucleotide pr
C 44	10.4	38.5	13	1	ABH48561	Oligonucleotide pr
C 45	10.4	38.5	13	1	ABF34988	Oligonucleotide pr
C 46	10.4	38.5	13	1	ABC56760	Oligonucleotide pr
C 47	10.4	38.5	13	1	ABC72021	Oligonucleotide pr
C 48	10.4	38.5	13	1	ABC58336	Oligonucleotide pr
C 49	10.4	38.5	13	1	ABC79759	Oligonucleotide pr
C 50	10.4	38.5	13	1	ABH08279	Oligonucleotide pr
C 51	10.4	38.5	13	1	ABH34855	Oligonucleotide pr
C 52	10.4	38.5	13	1	ABH48563	Oligonucleotide pr
C 53	10.4	38.5	13	1	ABH08276	Oligonucleotide pr
C 54	10.4	38.5	13	1	ABC56758	Oligonucleotide pr
C 55	10.4	38.5	13	1	ABH48552	Oligonucleotide pr
C 56	10.4	38.5	13	1	ABC58337	Oligonucleotide pr
C 57	10.4	38.5	13	1	ABC79758	Oligonucleotide pr
C 58	10.4	38.5	13	1	ABC56761	Oligonucleotide pr
C 59	10.4	38.5	13	1	ABH08277	Oligonucleotide pr
C 60	10.4	38.5	13	1	ABC72020	Oligonucleotide pr
C 61	10.4	38.5	13	1	ABC72024	Oligonucleotide pr
C 62	10.4	38.5	13	1	ABH08278	Oligonucleotide pr
C 63	10	37.0	10	1	ABK23686	Transcript tag DNA
C 64	10	37.0	10	1	ABH08935	Oligonucleotide pr
C 65	10	37.0	10	1	ABC90746	Oligonucleotide pr
C 66	10	37.0	10	1	ABH08934	Oligonucleotide pr
C 67	10	37.0	10	1	ABC90747	Oligonucleotide pr
C 68	9.8	36.3	13	1	ABC70173	Oligonucleotide pr
C 69	9.8	36.3	13	1	ABC24649	Oligonucleotide pr
C 70	9.8	36.3	13	1	ABC83940	Oligonucleotide pr
C 71	9.8	36.3	13	1	ABC89770	Oligonucleotide pr
C 72	9.8	36.3	13	1	ABC69703	Oligonucleotide pr
C 73	9.8	36.3	13	1	ABF73956	Oligonucleotide pr
C 74	9.8	36.3	13	1	ABH35801	Oligonucleotide pr
C 75	9.8	36.3	13	1	ABC23838	Oligonucleotide pr
C 76	9.8	36.3	13	1	ABC24988	Oligonucleotide pr
C 77	9.8	36.3	13	1	ABC30596	Oligonucleotide pr
C 78	9.8	36.3	13	1	ABC83931	Oligonucleotide pr
C 79	9.8	36.3	13	1	ABC84116	Oligonucleotide pr
C 80	9.8	36.3	13	1	ABC89375	Oligonucleotide pr
C 81	9.8	36.3	13	1	ABF41324	Oligonucleotide pr
C 82	9.8	36.3	13	1	ABH22579	Oligonucleotide pr
C 83	9.8	36.3	13	1	ABH44353	Oligonucleotide pr
C 84	9.8	36.3	13	1	ABC23839	Oligonucleotide pr
C 85	9.8	36.3	13	1	ABC78604	Oligonucleotide pr
C 86	9.8	36.3	13	1	ABC56765	Oligonucleotide pr
C 87	9.8	36.3	13	1	ABC12793	Oligonucleotide pr
C 88	9.8	36.3	13	1	ABC89771	Oligonucleotide pr
C 89	9.8	36.3	13	1	ABF68250	Oligonucleotide pr
C 90	9.8	36.3	13	1	ABF70020	Oligonucleotide pr
C 91	9.8	36.3	13	1	ABF53803	Oligonucleotide pr
C 92	9.8	36.3	13	1	ABH52974	Oligonucleotide pr
C 93	9.8	36.3	13	1	ABC70172	Oligonucleotide pr
C 94	9.8	36.3	13	1	ABC50758	Oligonucleotide pr
C 95	9.8	36.3	13	1	ABC36264	Oligonucleotide pr
C 96	9.8	36.3	13	1	ABC89773	Oligonucleotide pr
C 97	9.8	36.3	13	1	ABH35800	Oligonucleotide pr
C 98	9.8	36.3	13	1	ABH50898	Oligonucleotide pr
C 99	9.8	36.3	13	1	ABC83933	Oligonucleotide pr
C 100	9.8	36.3	13	1	ABC83943	Oligonucleotide pr
C 101	9.8	36.3	13	1	ABF41325	Oligonucleotide pr
C 102	9.8	36.3	13	1	ABC24989	Oligonucleotide pr
C 103	9.8	36.3	13	1	ABC58322	Oligonucleotide pr
C 104	9.8	36.3	13	1	ABF70021	Oligonucleotide pr
C 105	9.8	36.3	13	1	ABF73957	Oligonucleotide pr
C 106	9.8	36.3	13	1	ABH10604	Oligonucleotide pr

107	9.8	36.3	13	1	ABH25793	Oligonucleotide SE	C 180	9.4	34.8	12	1	ABI315542	Oligonucleotide pr
108	9.8	36.3	13	1	ABCS0760	Oligonucleotide SE	181	9.4	34.8	12	1	ABI15399	Oligonucleotide pr
C 109	9.8	36.3	13	1	ABCS0761	Oligonucleotide SE	182	9.4	34.8	12	1	ABI77265	Oligonucleotide pr
C 110	9.8	36.3	13	1	ABCS1941	Oligonucleotide SE	183	9.4	34.8	12	1	ABI30122	Oligonucleotide pr
C 111	9.8	36.3	13	1	ABCS1151	Oligonucleotide SE	184	9.4	34.8	12	1	ABI78505	Oligonucleotide pr
C 112	9.8	36.3	13	1	ABF93510	Oligonucleotide SE	185	9.4	34.8	12	1	ABI44044	Oligonucleotide pr
C 113	9.8	36.3	13	1	ABF93511	Oligonucleotide SE	186	9.4	34.8	12	1	ABI78763	Oligonucleotide pr
C 114	9.8	36.3	13	1	ABCS9851	Oligonucleotide SE	187	9.4	34.8	12	1	ABH94302	Oligonucleotide pr
C 115	9.8	36.3	13	1	ABCS9330	Oligonucleotide SE	188	9.4	34.8	12	1	ABH53219	Oligonucleotide pr
C 116	9.8	36.3	13	1	ABCS8342	Oligonucleotide SE	189	9.4	34.8	12	1	ABH90151	Oligonucleotide pr
C 117	9.8	36.3	13	1	ABCS6989	Oligonucleotide SE	190	9.4	34.8	12	1	ABH22109	Oligonucleotide pr
C 118	9.8	36.3	13	1	ABH10605	Oligonucleotide SE	191	9.4	34.8	12	1	ABH83316	Oligonucleotide pr
C 119	9.8	36.3	13	1	ABH52975	Oligonucleotide SE	192	9.4	34.8	12	1	ABH84060	Oligonucleotide pr
C 120	9.8	36.3	13	1	ABCS0759	Oligonucleotide SE	193	9.4	34.8	12	1	ABI40875	Oligonucleotide pr
C 121	9.8	36.3	13	1	ABCS6265	Oligonucleotide SE	194	9.4	34.8	12	1	ABI42569	Oligonucleotide pr
C 122	9.8	36.3	13	1	ABF68251	Oligonucleotide SE	195	9.4	34.8	12	1	ABI37195	Oligonucleotide pr
C 123	9.8	36.3	13	1	ABF69708	Oligonucleotide SE	196	9.4	34.8	12	1	ABH54798	Oligonucleotide pr
C 124	9.8	36.3	13	1	ABF76503	Oligonucleotide SE	197	9.4	34.8	12	1	ABH93701	Oligonucleotide pr
C 125	9.8	36.3	13	1	ABH63860	Oligonucleotide SE	198	9.4	34.8	12	1	ABH14680	Oligonucleotide pr
C 126	9.8	36.3	13	1	ABCS6988	Oligonucleotide SE	199	9.4	34.8	12	1	ABI40783	Oligonucleotide pr
C 127	9.8	36.3	13	1	ABCS1292	Oligonucleotide SE	200	9.4	34.8	12	1	ABI78290	Oligonucleotide pr
C 128	9.8	36.3	13	1	ABF14296	Oligonucleotide SE	201	9.4	34.8	12	1	ABH78637	Oligonucleotide pr
C 129	9.8	36.3	13	1	ABF69772	Oligonucleotide SE	202	9.4	34.8	12	1	ABH93832	Oligonucleotide pr
C 130	9.8	36.3	13	1	ABF76502	Oligonucleotide SE	203	9.4	34.8	12	1	ABH83231	Oligonucleotide pr
C 131	9.8	36.3	13	1	ABH35792	Oligonucleotide SE	204	9.4	34.8	12	1	ABH09796	Oligonucleotide pr
C 132	9.8	36.3	13	1	ABH63861	Oligonucleotide SE	205	9.4	34.8	12	1	ABH12365	Oligonucleotide pr
C 133	9.8	36.3	13	1	ABCS6764	Oligonucleotide SE	206	9.4	34.8	12	1	ABH89498	Oligonucleotide pr
C 134	9.8	36.3	13	1	ABF93511	Oligonucleotide SE	207	9.4	34.8	12	1	ABH84402	Oligonucleotide pr
C 135	9.8	36.3	13	1	ABF53802	Oligonucleotide SE	208	9.4	34.8	12	1	ABI38855	Oligonucleotide pr
C 136	9.8	36.3	13	1	ABH50899	Oligonucleotide SE	209	9.4	34.8	12	1	ABH45404	Oligonucleotide pr
C 137	9.8	36.3	13	1	ABCS0759	Oligonucleotide SE	210	9.4	34.8	12	1	ABH56339	Oligonucleotide pr
C 138	9.8	36.3	13	1	ABCS0597	Oligonucleotide SE	211	9.4	34.8	12	1	ABH68410	Oligonucleotide pr
C 139	9.8	36.3	13	1	ABCS4117	Oligonucleotide SE	212	9.4	34.8	12	1	ABH68300	Oligonucleotide pr
C 140	9.8	36.3	13	1	ABCS12791	Oligonucleotide SE	213	9.4	34.8	12	1	ABI21237	Oligonucleotide pr
C 141	9.8	36.3	13	1	ABCS9374	Oligonucleotide SE	214	9.4	34.8	12	1	ABI30123	Oligonucleotide pr
C 142	9.8	36.3	13	1	ABF67701	Oligonucleotide SE	215	9.4	34.8	12	1	ABH86927	Oligonucleotide pr
C 143	9.8	36.3	13	1	ABF14297	Oligonucleotide SE	216	9.4	34.8	12	1	ABH87135	Oligonucleotide pr
C 144	9.8	36.3	13	1	ABH20578	Oligonucleotide SE	217	9.4	34.8	12	1	ABI40400	Oligonucleotide pr
C 145	9.8	36.3	13	1	ABH10605	Oligonucleotide SE	218	9.4	34.8	12	1	ABH58632	Oligonucleotide pr
C 146	9.8	36.3	13	1	ABH44354	Oligonucleotide SE	219	9.4	34.8	12	1	ABH72035	Oligonucleotide pr
C 147	9.8	36.3	13	1	ABH48258	Oligonucleotide SE	220	9.4	34.8	12	1	ABH29882	Oligonucleotide pr
C 148	9.8	36.3	13	1	ABCS73508	Oligonucleotide SE	221	9.4	34.8	12	1	ABI14679	Oligonucleotide pr
C 149	9.8	36.3	13	1	ABCS98510	Oligonucleotide SE	222	9.4	34.8	12	1	ABI71311	Oligonucleotide pr
C 150	9.8	36.3	13	1	ABCS2648	Oligonucleotide SE	223	9.4	34.8	12	1	ABH64496	Oligonucleotide pr
C 151	9.8	36.3	13	1	ABCS7805	Oligonucleotide SE	224	9.4	34.8	12	1	ADP69380	Human Goodpasture
C 152	9.8	36.3	13	1	ABH10602	Oligonucleotide SE	225	9.4	34.8	12	1	ADK15494	Human Goodpasture
C 153	9.8	36.3	13	1	ABH44355	Oligonucleotide SE	226	9.4	34.8	13	1	AAV11048	Human ribozyme tar
C 154	9.8	36.3	13	1	ABCS8323	Oligonucleotide SE	227	9.4	34.8	13	1	AAV22299	Human ribozyme tar
C 155	9.8	36.3	13	1	ABCS9932	Oligonucleotide SE	228	9.4	34.8	13	1	ABC92353	Oligonucleotide SE
C 156	9.8	36.3	13	1	ABCS11550	Oligonucleotide SE	229	9.4	34.8	13	1	ABC74081	Oligonucleotide SE
C 157	9.8	36.3	13	1	ABCS1790	Oligonucleotide SE	230	9.4	34.8	13	1	ABC27364	Oligonucleotide SE
C 158	9.8	36.3	13	1	ABF67700	Oligonucleotide SE	231	9.4	34.8	13	1	ABC34246	Oligonucleotide SE
C 159	9.8	36.3	13	1	ABH44352	Oligonucleotide SE	232	9.4	34.8	13	1	ABH13694	Oligonucleotide SE
C 160	9.8	36.3	13	1	ADL09225	SP6 promoter DNA f	233	9.4	34.8	13	1	ABH14498	Oligonucleotide SE
C 161	9.8	36.3	13	1	ADL09227	SP6 promoter DNA f	234	9.4	34.8	13	1	ABH19288	Oligonucleotide SE
C 162	9.4	34.8	11	1	ABH55111	Genomic DNA methyl	235	9.4	34.8	13	1	ABF52884	Oligonucleotide SE
C 163	9.4	34.8	11	1	ABH55112	Genomic DNA methyl	236	9.4	34.8	13	1	ABF52895	Oligonucleotide SE
C 164	9.4	34.8	11	1	ABH67983	Human skin EST 576	237	9.4	34.8	13	1	ABH42366	Oligonucleotide SE
C 165	9.4	34.8	11	1	ABH67984	Human skin EST 765	238	9.4	34.8	13	1	ABH19843	Oligonucleotide SE
C 166	9.4	34.8	11	1	ABH70995	Human skin EST 878	239	9.4	34.8	13	1	ABH50709	Oligonucleotide SE
C 167	9.4	34.8	11	1	ABH62443	Human skin EST 229	240	9.4	34.8	13	1	ABH87018	Oligonucleotide SE
C 168	9.4	34.8	11	1	ABH63574	Human skin EST 136	241	9.4	34.8	13	1	ABH19351	Oligonucleotide SE
C 169	9.4	34.8	12	1	ABH74664	Oligonucleotide pr	242	9.4	34.8	13	1	ABH72689	Oligonucleotide SE
C 170	9.4	34.8	12	1	ABH13743	Oligonucleotide pr	243	9.4	34.8	13	1	ABH03654	Oligonucleotide SE
C 171	9.4	34.8	12	1	ABH87797	Oligonucleotide pr	244	9.4	34.8	13	1	ABH34746	Oligonucleotide SE
C 172	9.4	34.8	12	1	ABH10896	Oligonucleotide pr	245	9.4	34.8	13	1	ABH35161	Oligonucleotide SE
C 173	9.4	34.8	12	1	ABH181066	Oligonucleotide pr	246	9.4	34.8	13	1	ABH89734	Oligonucleotide SE
C 174	9.4	34.8	12	1	ABH67812	Oligonucleotide pr	247	9.4	34.8	13	1	ABH16645	Oligonucleotide SE
C 175	9.4	34.8	12	1	ABH71906	Oligonucleotide pr	248	9.4	34.8	13	1	ABH52425	Oligonucleotide SE
C 176	9.4	34.8	12	1	ABH127613	Oligonucleotide pr	249	9.4	34.8	13	1	ABH59440	Oligonucleotide SE
C 177	9.4	34.8	12	1	ABH78288	Oligonucleotide pr	250	9.4	34.8	13	1	ABH61415	Oligonucleotide SE
C 178	9.4	34.8	12	1	ABH19684	Oligonucleotide pr	251	9.4	34.8	13	1	ABH19842	Oligonucleotide SE
C 179	9.4	34.8	12	1	ABH29884	Oligonucleotide pr	252	9.4	34.8	13	1	ABH57080	Oligonucleotide SE

C 253 9.4 34.8 13 1 ABC60017 Oligonucleotide SE C 326 9.4 34.8 13 1 ABC82015 Oligonucleotide SE
C 254 9.4 34.8 13 1 ABP12588 Oligonucleotide SE C 327 9.4 34.8 13 1 ABF08256 Oligonucleotide SE
C 255 9.4 34.8 13 1 ABP13161 Oligonucleotide SE C 328 9.4 34.8 13 1 ABC60088 Oligonucleotide SE
C 256 9.4 34.8 13 1 ABC90277 Oligonucleotide SE C 329 9.4 34.8 13 1 ABF24340 Oligonucleotide SE
C 257 9.4 34.8 13 1 ABF22036 Oligonucleotide SE C 330 9.4 34.8 13 1 ABH04241 Oligonucleotide SE
C 258 9.4 34.8 13 1 ABF22040 Oligonucleotide SE C 331 9.4 34.8 13 1 ABF05020 Oligonucleotide SE
C 259 9.4 34.8 13 1 ABF32562 Oligonucleotide SE C 332 9.4 34.8 13 1 ABC82014 Oligonucleotide SE
C 260 9.4 34.8 13 1 ABH23614 Oligonucleotide SE C 333 9.4 34.8 13 1 ABC34247 Oligonucleotide SE
C 261 9.4 34.8 13 1 ABF98926 Oligonucleotide SE C 334 9.4 34.8 13 1 ABC87019 Oligonucleotide SE
C 262 9.4 34.8 13 1 ABF53024 Oligonucleotide SE C 335 9.4 34.8 13 1 ABF12094 Oligonucleotide SE
C 263 9.4 34.8 13 1 ABH04240 Oligonucleotide SE C 336 9.4 34.8 13 1 ABF33254 Oligonucleotide SE
C 264 9.4 34.8 13 1 ABF88892 Oligonucleotide SE C 337 9.4 34.8 13 1 ABF75257 Oligonucleotide SE
C 265 9.4 34.8 13 1 ABC47954 Oligonucleotide SE C 338 9.4 34.8 13 1 ABH08734 Oligonucleotide SE
C 266 9.4 34.8 13 1 ABC26270 Oligonucleotide SE C 339 9.4 34.8 13 1 ABH34747 Oligonucleotide SE
C 267 9.4 34.8 13 1 ABF22037 Oligonucleotide SE C 340 9.4 34.8 13 1 ABC57081 Oligonucleotide SE
C 268 9.4 34.8 13 1 ABF35563 Oligonucleotide SE C 341 9.4 34.8 13 1 ABF12589 Oligonucleotide SE
C 269 9.4 34.8 13 1 ABF70173 Oligonucleotide SE C 342 9.4 34.8 13 1 ABP13695 Oligonucleotide SE
C 270 9.4 34.8 13 1 ABH08735 Oligonucleotide SE C 343 9.4 34.8 13 1 ABG16210 Oligonucleotide SE
C 271 9.4 34.8 13 1 ABH35883 Oligonucleotide SE C 344 9.4 34.8 13 1 ABH17680 Oligonucleotide SE
C 272 9.4 34.8 13 1 ABF60968 Oligonucleotide SE C 345 9.4 34.8 13 1 ABH19289 Oligonucleotide SE
C 273 9.4 34.8 13 1 ABF90882 Oligonucleotide SE C 346 9.4 34.8 13 1 ABF96441 Oligonucleotide SE
C 274 9.4 34.8 13 1 ABF90883 Oligonucleotide SE C 347 9.4 34.8 13 1 ABH03655 Oligonucleotide SE
C 275 9.4 34.8 13 1 ABC17571 Oligonucleotide SE C 348 9.4 34.8 13 1 ABH31181 Oligonucleotide SE
C 276 9.4 34.8 13 1 ABC18565 Oligonucleotide SE C 349 9.4 34.8 13 1 ABH52424 Oligonucleotide SE
C 277 9.4 34.8 13 1 ABC47955 Oligonucleotide SE C 350 9.4 34.8 13 1 ABC92352 Oligonucleotide SE
C 278 9.4 34.8 13 1 ABC49583 Oligonucleotide SE C 351 9.4 34.8 13 1 ABC17570 Oligonucleotide SE
C 279 9.4 34.8 13 1 ABC17148 Oligonucleotide SE C 352 9.4 34.8 13 1 ABF55032 Oligonucleotide SE
C 280 9.4 34.8 13 1 ABF32563 Oligonucleotide SE C 353 9.4 34.8 13 1 ABF55257 Oligonucleotide SE
C 281 9.4 34.8 13 1 ABF77176 Oligonucleotide SE C 354 9.4 34.8 13 1 ABF08267 Oligonucleotide SE
C 282 9.4 34.8 13 1 ABH30878 Oligonucleotide SE C 355 9.4 34.8 13 1 ABF32561 Oligonucleotide SE
C 283 9.4 34.8 13 1 ABH30879 Oligonucleotide SE C 356 9.4 34.8 13 1 ABF72397 Oligonucleotide SE
C 284 9.4 34.8 13 1 ABF82059 Oligonucleotide SE C 357 9.4 34.8 13 1 ABF98925 Oligonucleotide SE
C 285 9.4 34.8 13 1 ABH42367 Oligonucleotide SE C 358 9.4 34.8 13 1 ABF75256 Oligonucleotide SE
C 286 9.4 34.8 13 1 ABC29311 Oligonucleotide SE C 359 9.4 34.8 13 1 ABF60279 Oligonucleotide SE
C 287 9.4 34.8 13 1 ABC55033 Oligonucleotide SE C 360 9.4 34.8 13 1 ABF89730 Oligonucleotide SE
C 288 9.4 34.8 13 1 ABC57078 Oligonucleotide SE C 361 9.4 34.8 13 1 ABH16643 Oligonucleotide SE
C 289 9.4 34.8 13 1 ABH17681 Oligonucleotide SE C 362 9.4 34.8 13 1 ABC19844 Oligonucleotide SE
C 290 9.4 34.8 13 1 ABF70172 Oligonucleotide SE C 363 9.4 34.8 13 1 ABC19845 Oligonucleotide SE
C 291 9.4 34.8 13 1 ABF53025 Oligonucleotide SE C 364 9.4 34.8 13 1 ABC311732 Oligonucleotide SE
C 292 9.4 34.8 13 1 ABF5461 Oligonucleotide SE C 365 9.4 34.8 13 1 ABF06916 Oligonucleotide SE
C 293 9.4 34.8 13 1 ABF5415 Oligonucleotide SE C 366 9.4 34.8 13 1 ABC82013 Oligonucleotide SE
C 294 9.4 34.8 13 1 ABH16644 Oligonucleotide SE C 367 9.4 34.8 13 1 ABF13360 Oligonucleotide SE
C 295 9.4 34.8 13 1 ABH46083 Oligonucleotide SE C 368 9.4 34.8 13 1 ABC90276 Oligonucleotide SE
C 296 9.4 34.8 13 1 ABC60089 Oligonucleotide SE C 369 9.4 34.8 13 1 ABF35562 Oligonucleotide SE
C 297 9.4 34.8 13 1 ABC7149 Oligonucleotide SE C 370 9.4 34.8 13 1 ABF99477 Oligonucleotide SE
C 298 9.4 34.8 13 1 ABF23828 Oligonucleotide SE C 371 9.4 34.8 13 1 ABF82250 Oligonucleotide SE
C 299 9.4 34.8 13 1 ABF24341 Oligonucleotide SE C 372 9.4 34.8 13 1 ABF60278 Oligonucleotide SE
C 300 9.4 34.8 13 1 ABF32560 Oligonucleotide SE C 373 9.4 34.8 13 1 ABF89735 Oligonucleotide SE
C 301 9.4 34.8 13 1 ABF32561 Oligonucleotide SE C 374 9.4 34.8 13 1 ABF90884 Oligonucleotide SE
C 302 9.4 34.8 13 1 ABF32562 Oligonucleotide SE C 375 9.4 34.8 13 1 ABH51383 Oligonucleotide SE
C 303 9.4 34.8 13 1 ABF33058 Oligonucleotide SE C 376 9.4 34.8 13 1 ABC23309 Oligonucleotide SE
C 304 9.4 34.8 13 1 ABF33059 Oligonucleotide SE C 377 9.4 34.8 13 1 ABC74080 Oligonucleotide SE
C 305 9.4 34.8 13 1 ABH19350 Oligonucleotide SE C 378 9.4 34.8 13 1 ABF72396 Oligonucleotide SE
C 306 9.4 34.8 13 1 ABF95142 Oligonucleotide SE C 379 9.4 34.8 13 1 ABF98924 Oligonucleotide SE
C 307 9.4 34.8 13 1 ABF72688 Oligonucleotide SE C 380 9.4 34.8 13 1 ABH03814 Oligonucleotide SE
C 308 9.4 34.8 13 1 ABF98927 Oligonucleotide SE C 381 9.4 34.8 13 1 ABF82058 Oligonucleotide SE
C 309 9.4 34.8 13 1 ABH03815 Oligonucleotide SE C 382 9.4 34.8 13 1 ABF89731 Oligonucleotide SE
C 310 9.4 34.8 13 1 ABH35882 Oligonucleotide SE C 383 9.4 34.8 13 1 ABC27165 Oligonucleotide SE
C 311 9.4 34.8 13 1 ABF69269 Oligonucleotide SE C 384 9.4 34.8 13 1 ABF08271 Oligonucleotide SE
C 312 9.4 34.8 13 1 ABC49582 Oligonucleotide SE C 385 9.4 34.8 13 1 ABF14499 Oligonucleotide SE
C 313 9.4 34.8 13 1 ABC31733 Oligonucleotide SE C 386 9.4 34.8 13 1 ABC16311 Oligonucleotide SE
C 314 9.4 34.8 13 1 ABF22041 Oligonucleotide SE C 387 9.4 34.8 13 1 ABF95143 Oligonucleotide SE
C 315 9.4 34.8 13 1 ABF96440 Oligonucleotide SE C 388 9.4 34.8 13 1 ABH23615 Oligonucleotide SE
C 316 9.4 34.8 13 1 ABF77177 Oligonucleotide SE C 389 9.4 34.8 13 1 ABF99476 Oligonucleotide SE
C 317 9.4 34.8 13 1 ABF55460 Oligonucleotide SE C 390 9.4 34.8 13 1 ABH35160 Oligonucleotide SE
C 318 9.4 34.8 13 1 ABF62251 Oligonucleotide SE C 391 9.4 34.8 13 1 ABF90885 Oligonucleotide SE
C 319 9.4 34.8 13 1 ABF65414 Oligonucleotide SE C 392 9.4 34.8 13 1 ABH16642 Oligonucleotide SE
C 320 9.4 34.8 13 1 ABC18564 Oligonucleotide SE C 393 9.4 34.8 13 1 ABH46082 Oligonucleotide SE
C 321 9.4 34.8 13 1 ABC23308 Oligonucleotide SE C 394 9.4 34.8 13 1 ABH59441 Oligonucleotide SE
C 322 9.4 34.8 13 1 ABC05974 Oligonucleotide SE C 395 9.4 34.8 13 1 ABH61414 Oligonucleotide SE
C 323 9.4 34.8 13 1 ABC05975 Oligonucleotide SE C 396 9.4 34.8 13 1 ABC26271 Oligonucleotide SE
C 324 9.4 34.8 13 1 ABF06917 Oligonucleotide SE C 397 9.4 34.8 13 1 ABC29310 Oligonucleotide SE
C 325 9.4 34.8 13 1 ABC82012 Oligonucleotide SE C 398 9.4 34.8 13 1 ABF05021 Oligonucleotide SE

399	9.4	34.8	13	1	ABC55256	Oligonucleotide SE	C 472	8.8	32.6	12	1	ABI43598	Oligonucleotide pr
400	9.4	34.8	13	1	ABF0870	Oligonucleotide SE	C 473	8.8	32.6	12	1	ABI48638	Oligonucleotide pr
401	9.4	34.8	13	1	ABC60016	Oligonucleotide SE	474	8.8	32.6	12	1	ABH70189	Oligonucleotide pr
402	9.4	34.8	13	1	ABF12095	Oligonucleotide SE	475	8.8	32.6	12	1	ABI33966	Oligonucleotide pr
C 403	9.4	34.8	13	1	ABF33255	Oligonucleotide SE	476	8.8	32.6	12	1	ABI36798	Oligonucleotide pr
C 404	9.4	34.8	13	1	ABF36212	Oligonucleotide SE	C 477	8.8	32.6	12	1	ABI48139	Oligonucleotide pr
C 405	9.4	34.8	13	1	ABH31180	Oligonucleotide SE	478	8.8	32.6	12	1	ABF71978	Oligonucleotide pr
C 406	9.4	34.8	13	1	ABF86893	Oligonucleotide SE	C 479	8.8	32.6	12	1	ABI73808	Oligonucleotide pr
C 407	9.4	34.8	13	1	ABH51982	Oligonucleotide SE	480	8.8	32.6	12	1	ABI60517	Oligonucleotide pr
C 408	9.4	34.8	13	1	ACA62425	Hepatitis B virus	481	8.8	32.6	12	1	ABH1509	Oligonucleotide pr
C 409	9.4	34.8	13	1	AAZ78143	Human dendritic ce	482	8.8	32.6	12	1	ABH97913	Oligonucleotide pr
C 410	9.4	34.8	13	1	AAZ83777	Metastatic breast	483	8.8	32.6	12	1	ABI23994	Oligonucleotide pr
C 411	9.4	34.8	13	1	AAF36621	Yeast NORF gene SA	C 484	8.8	32.6	12	1	ABH74578	Oligonucleotide pr
C 412	9.4	34.8	13	1	AAF36059	Yeast NORF gene SA	C 485	8.8	32.6	12	1	ABH74973	Oligonucleotide pr
C 413	9.4	34.8	13	1	AAF34702	Yeast NORF gene SA	C 486	8.8	32.6	12	1	ABH76558	Oligonucleotide pr
C 414	9.4	34.8	13	1	ABF35200	Yeast NORF gene SA	C 487	8.8	32.6	12	1	ABH80858	Oligonucleotide pr
C 415	9.4	34.8	13	1	ABF70543	Human G. protein-co	488	8.8	32.6	12	1	ABH88907	Oligonucleotide pr
C 416	9.4	34.8	13	1	ABV69773	Human skin EST 755	489	8.8	32.6	12	1	ABH47584	Oligonucleotide pr
C 417	9.4	34.8	13	1	ABV66253	Human skin EST 403	C 490	8.8	32.6	12	1	ABH53872	Oligonucleotide pr
C 418	9.4	34.8	13	1	ABV62352	Human skin EST 138	491	8.8	32.6	12	1	ABH68385	Oligonucleotide pr
C 419	9.4	34.8	13	1	ABX191964	Human Pan-Endothel	C 492	8.8	32.6	12	1	ABH56219	Oligonucleotide pr
C 420	9.4	34.8	13	1	ABX71989	DNA tag used to id	C 493	8.8	32.6	12	1	ABH61542	Oligonucleotide pr
C 421	9.4	34.8	13	1	ADQ34600	Human facial skin-	C 494	8.8	32.6	12	1	ABH20408	Oligonucleotide pr
C 422	9.4	34.8	13	1	ADQ32402	Oligonucleotide pr	C 495	8.8	32.6	12	1	ABH85618	Oligonucleotide pr
C 423	9.4	34.8	13	1	ABF67341	Oligonucleotide pr	C 496	8.8	32.6	12	1	ABH10848	Oligonucleotide pr
C 424	9.4	34.8	13	1	ABH51628	Oligonucleotide pr	C 497	8.8	32.6	12	1	ABH86504	Oligonucleotide pr
C 425	9.4	34.8	13	1	ABH19573	Oligonucleotide pr	C 498	8.8	32.6	12	1	ABH37828	Oligonucleotide pr
C 426	9.4	34.8	13	1	ABH68656	Oligonucleotide pr	C 499	8.8	32.6	12	1	ABH91107	Oligonucleotide pr
C 427	9.4	34.8	13	1	ABH709342	Oligonucleotide pr	C 500	8.8	32.6	12	1	ABH46624	Oligonucleotide pr
C 428	9.4	34.8	13	1	ABH94836	Oligonucleotide pr	501	8.8	32.6	12	1	ABH56299	Oligonucleotide pr
C 429	9.4	34.8	13	1	ABH104057	Oligonucleotide pr	502	8.8	32.6	12	1	ABH59543	Oligonucleotide pr
C 430	9.4	34.8	13	1	ABH79192	Oligonucleotide pr	503	8.8	32.6	12	1	ABH80453	Oligonucleotide pr
C 431	9.4	34.8	13	1	ABH83707	Oligonucleotide pr	504	8.8	32.6	12	1	ABH68117	Oligonucleotide pr
C 432	9.4	34.8	13	1	ABH11382	Oligonucleotide pr	C 505	8.8	32.6	12	1	ABH73323	Oligonucleotide pr
C 433	9.4	34.8	13	1	ABH43475	Oligonucleotide pr	C 506	8.8	32.6	12	1	ABH83888	Oligonucleotide pr
C 434	9.4	34.8	13	1	ABH16564	Oligonucleotide pr	C 507	8.8	32.6	12	1	ABH90635	Oligonucleotide pr
C 435	9.4	34.8	13	1	ABH63012	Oligonucleotide pr	C 508	8.8	32.6	12	1	ABH91770	Oligonucleotide pr
C 436	9.4	34.8	13	1	ABH79659	Oligonucleotide pr	509	8.8	32.6	12	1	ABH60352	Oligonucleotide pr
C 437	9.4	34.8	13	1	ABH69606	Oligonucleotide pr	510	8.8	32.6	12	1	ABH74908	Oligonucleotide pr
C 438	9.4	34.8	13	1	ABH73239	Oligonucleotide pr	511	8.8	32.6	12	1	ABH76096	Oligonucleotide pr
C 439	9.4	34.8	13	1	ABH101684	Oligonucleotide pr	C 512	8.8	32.6	12	1	ABH65524	Oligonucleotide pr
C 440	9.4	34.8	13	1	ABH06155	Oligonucleotide pr	513	8.8	32.6	12	1	ABH65731	Oligonucleotide pr
C 441	9.4	34.8	13	1	ABH12796	Oligonucleotide pr	514	8.8	32.6	12	1	ABH77539	Oligonucleotide pr
C 442	9.4	34.8	13	1	ABH44225	Oligonucleotide pr	C 515	8.8	32.6	12	1	ABH83514	Oligonucleotide pr
C 443	9.4	34.8	13	1	ABH49223	Oligonucleotide pr	C 516	8.8	32.6	12	1	ABH39222	Oligonucleotide pr
C 444	9.4	34.8	13	1	ABH174456	Oligonucleotide pr	C 517	8.8	32.6	12	1	ABH48414	Oligonucleotide pr
C 445	9.4	34.8	13	1	ABH77494	Oligonucleotide pr	C 518	8.8	32.6	12	1	ABH73304	Oligonucleotide pr
C 446	9.4	34.8	13	1	ABH97775	Oligonucleotide pr	519	8.8	32.6	12	1	ABH74430	Oligonucleotide pr
C 447	9.4	34.8	13	1	ABH99926	Oligonucleotide pr	C 520	8.8	32.6	12	1	ABH77088	Oligonucleotide pr
C 448	9.4	34.8	13	1	ABH99926	Oligonucleotide pr	521	8.8	32.6	12	1	ABH703021	Oligonucleotide pr
C 449	9.4	34.8	13	1	ABH11682	Oligonucleotide pr	C 522	8.8	32.6	12	1	ABH81421	Oligonucleotide pr
C 450	9.4	34.8	13	1	ABH40821	Oligonucleotide pr	C 523	8.8	32.6	12	1	ABH82314	Oligonucleotide pr
C 451	9.4	34.8	13	1	ABH90835	Oligonucleotide pr	C 524	8.8	32.6	12	1	ABH109379	Oligonucleotide pr
C 452	9.4	34.8	13	1	ABH52092	Oligonucleotide pr	C 525	8.8	32.6	12	1	ABH13600	Oligonucleotide pr
C 453	9.4	34.8	13	1	ABH57321	Oligonucleotide pr	526	8.8	32.6	12	1	ABH91463	Oligonucleotide pr
C 454	9.4	34.8	13	1	ABH162405	Oligonucleotide pr	C 527	8.8	32.6	12	1	ABH91653	Oligonucleotide pr
C 455	9.4	34.8	13	1	ABH71095	Oligonucleotide pr	C 528	8.8	32.6	12	1	ABH55743	Oligonucleotide pr
C 456	9.4	34.8	13	1	ABH100641	Oligonucleotide pr	C 529	8.8	32.6	12	1	ABH69810	Oligonucleotide pr
C 457	9.4	34.8	13	1	ABH81103	Oligonucleotide pr	530	8.8	32.6	12	1	ABH70259	Oligonucleotide pr
C 458	9.4	34.8	13	1	ABH10822	Oligonucleotide pr	531	8.8	32.6	12	1	ABH74416	Oligonucleotide pr
C 459	9.4	34.8	13	1	ABH31515	Oligonucleotide pr	C 532	8.8	32.6	12	1	ABH75308	Oligonucleotide pr
C 460	9.4	34.8	13	1	ABH10551	Oligonucleotide pr	C 533	8.8	32.6	12	1	ABH76464	Oligonucleotide pr
C 461	9.4	34.8	13	1	ABH89652	Oligonucleotide pr	534	8.8	32.6	12	1	ABH70658	Oligonucleotide pr
C 462	9.4	34.8	13	1	ABH50659	Oligonucleotide pr	535	8.8	32.6	12	1	ABH99406	Oligonucleotide pr
C 463	9.4	34.8	13	1	ABH154006	Oligonucleotide pr	C 536	8.8	32.6	12	1	ABH74790	Oligonucleotide pr
C 464	9.4	34.8	13	1	ABH70902	Oligonucleotide pr	537	8.8	32.6	12	1	ABH25180	Oligonucleotide pr
C 465	9.4	34.8	13	1	ABH62037	Oligonucleotide pr	C 538	8.8	32.6	12	1	ABH03377	Oligonucleotide pr
C 466	9.4	34.8	13	1	ABH93579	Oligonucleotide pr	C 539	8.8	32.6	12	1	ABH78775	Oligonucleotide pr
C 467	9.4	34.8	13	1	ABH94835	Oligonucleotide pr	540	8.8	32.6	12	1	ABH29999	Oligonucleotide pr
C 468	9.4	34.8	13	1	ABH10273	Oligonucleotide pr	C 541	8.8	32.6	12	1	ABH13012	Oligonucleotide pr
C 469	9.4	34.8	13	1	ABH130087	Oligonucleotide pr	C 542	8.8	32.6	12	1	ABH166523	Oligonucleotide pr
C 470	9.4	34.8	13	1	ABH88743	Oligonucleotide pr	C 543	8.8	32.6	12	1	ABH181819	Oligonucleotide pr
C 471	9.4	34.8	13	1	ABH90387	Oligonucleotide pr	544	8.8	32.6	12	1	ABH77349	Oligonucleotide pr

545	8.8	32.6	12	1	ABI07835	Oligonucleotide pr	c 618	8.4	31.1	11	1	AAH55107	Genomic DNA methyl
546	8.8	32.6	12	1	ABI33492	Oligonucleotide pr	c 619	8.4	31.1	11	1	AAH55108	Genomic DNA methyl
547	8.8	32.6	12	1	ABH08943	Oligonucleotide pr	c 620	8.4	31.1	11	1	ABQ86506	Human skin stress/
548	8.8	32.6	12	1	ABH08758	Oligonucleotide pr	c 621	8.4	31.1	11	1	ABQ87043	Human skin stress/
549	8.8	32.6	12	1	ABI37226	Oligonucleotide pr	c 622	8.4	31.1	11	1	ABQ87534	Human skin stress/
550	8.8	32.6	12	1	ABH90339	Oligonucleotide pr	c 623	8.4	31.1	11	1	ABQ87282	Human skin stress/
551	8.8	32.6	12	1	ABI50778	Oligonucleotide pr	c 624	8.4	31.1	11	1	ABQ87534	Human skin stress/
552	8.8	32.6	12	1	ABI53415	Oligonucleotide pr	c 625	8.4	31.1	11	1	ABV40034	Human skin EST 182
553	8.8	32.6	12	1	ABH93581	Oligonucleotide pr	c 626	8.4	31.1	11	1	ABV69946	Human skin EST 773
554	8.8	32.6	12	1	ABH70836	Oligonucleotide pr	c 627	8.4	31.1	11	1	ABV67422	Human skin EST 520
555	8.8	32.6	12	1	ABI00546	Oligonucleotide pr	c 628	8.4	31.1	11	1	ABV69109	Human skin EST 689
556	8.8	32.6	12	1	ABH79073	Oligonucleotide pr	c 629	8.4	31.1	11	1	ABV66433	Human skin EST 421
557	8.8	32.6	12	1	ABI23888	Oligonucleotide pr	c 630	8.4	31.1	11	1	ABV71455	Human skin EST 924
558	8.8	32.6	12	1	ABI33246	Oligonucleotide pr	c 631	8.4	31.1	11	1	ABV62525	Human skin EST 311
559	8.8	32.6	12	1	ABI37243	Oligonucleotide pr	c 632	8.4	31.1	11	1	ABV64573	Human skin EST 235
560	8.8	32.6	12	1	ABI49693	Oligonucleotide pr	c 633	8.4	31.1	11	1	ABV66821	Human skin EST 460
561	8.8	32.6	12	1	ABI74720	Oligonucleotide pr	c 634	8.4	31.1	11	1	ABV50066	Human skin EST 295
562	8.8	32.6	12	1	ABI62368	Oligonucleotide pr	c 635	8.4	31.1	11	1	ABV71994	Human skin EST 978
563	8.8	32.6	12	1	ABI76317	Oligonucleotide pr	c 636	8.4	31.1	11	1	ABV68903	Human skin EST 688
564	8.8	32.6	12	1	ABI65421	Oligonucleotide pr	c 637	8.4	31.1	11	1	ABV55861	Human skin EST 364
565	8.8	32.6	12	1	ABH73752	Oligonucleotide pr	c 638	8.4	31.1	11	1	ABV66721	Human skin EST 450
566	8.8	32.6	12	1	ABI35991	Oligonucleotide pr	c 639	8.4	31.1	11	1	ABV67158	Human skin EST 494
567	8.8	32.6	12	1	ABI60121	Oligonucleotide pr	c 640	8.4	31.1	11	1	ABV66189	Human skin EST 397
568	8.8	32.6	12	1	ABI02621	Oligonucleotide pr	c 641	8.4	31.1	11	1	ACL92008	Short human Tumour
569	8.8	32.6	12	1	ABH81997	Oligonucleotide pr	c 642	8.4	31.1	11	1	AC61503	Modified promoter
570	8.8	32.6	12	1	ABI08371	Oligonucleotide pr	c 643	8.4	31.1	11	1	ABX71933	DNA tag used to id
571	8.8	32.6	12	1	ABI08674	Oligonucleotide pr	c 644	8.4	31.1	11	1	ADQ29874	Human VRL exon 1a
572	8.8	32.6	12	1	ABH87275	Oligonucleotide pr	c 645	8.4	31.1	11	1	ADQ29856	Murine VRL exon 1a
573	8.8	32.6	12	1	ABI47891	Oligonucleotide pr	c 646	8.4	31.1	11	1	ADQ35599	Human hair-bearing
574	8.8	32.6	12	1	ABI62180	Oligonucleotide pr	c 647	8.4	31.1	11	1	ADQ35819	Human hair-bearing
575	8.8	32.6	12	1	ABI63029	Oligonucleotide pr	c 648	8.4	31.1	11	1	ADQ36261	Human hair-bearing
576	8.8	32.6	12	1	ABX15954	Oligonucleotide pr	c 649	8.4	31.1	11	1	ADQ36457	Human hair-bearing
577	8.8	32.6	12	1	ABX16005	Antisense oligonuc	c 650	8.4	31.1	11	1	ADQ35802	Human hair-bearing
578	8.4	31.1	10	1	AAQ38703	2'-O-methyl oligon	c 651	8.4	31.1	11	1	ADQ34842	Human facial skin-
579	8.4	31.1	10	1	AAH96111	Calibration oligon	c 652	8.4	31.1	11	1	ADQ32947	Human facial skin-
580	8.4	31.1	10	1	AAZ86266	Metastatic breast	c 653	8.4	31.1	11	1	ADQ33099	Human facial skin-
581	8.4	31.1	10	1	AAZ86089	Metastatic breast	c 654	8.4	31.1	11	1	ADQ33003	Human facial skin-
582	8.4	31.1	10	1	AAZ81055	Metastatic breast	c 655	8.4	31.1	11	1	ADQ32752	Human facial skin-
583	8.4	31.1	10	1	AAZ88682	Ras RNA binding 2'	c 656	8.4	31.1	12	1	AAC93147	Newcastle disease
584	8.4	31.1	10	1	AAH63248	Human colon epithe	c 657	8.4	31.1	12	1	ABH94949	Oligonucleotide pr
585	8.4	31.1	10	1	AAH63310	Human colon epithe	c 658	8.4	31.1	12	1	ABH94949	Oligonucleotide pr
586	8.4	31.1	10	1	AAH63362	Human melanocyte s	c 659	8.4	31.1	12	1	ABH70818	Oligonucleotide pr
587	8.4	31.1	10	1	AAH63364	Human melanocyte s	c 660	8.4	31.1	12	1	ABH70818	Oligonucleotide pr
588	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 661	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
589	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 662	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
590	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 663	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
591	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 664	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
592	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 665	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
593	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 666	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
594	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 667	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
595	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 668	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
596	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 669	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
597	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 670	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
598	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 671	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
599	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 672	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
600	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 673	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
601	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 674	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
602	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 675	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
603	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 676	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
604	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 677	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
605	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 678	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
606	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 679	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
607	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 680	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
608	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 681	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
609	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 682	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
610	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 683	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
611	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 684	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
612	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 685	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
613	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 686	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
614	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 687	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
615	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 688	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
616	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 689	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
617	8.4	31.1	10	1	AAH74044	Human SLC6A4 allel	c 690	8.4	31.1	12	1	ABH74210	Oligonucleotide pr

C 691	8.4	31.1	12	1	ABI03629	Oligonucleotide pr
C 692	8.4	31.1	12	1	ABH79574	Oligonucleotide pr
C 693	8.4	31.1	12	1	ABI07513	Oligonucleotide pr
C 694	8.4	31.1	12	1	ABI07790	Oligonucleotide pr
C 695	8.4	31.1	12	1	ABI48543	Oligonucleotide pr
C 696	8.4	31.1	12	1	ABI53698	Oligonucleotide pr
C 697	8.4	31.1	12	1	ABI70210	Oligonucleotide pr
C 698	8.4	31.1	12	1	ABI60008	Oligonucleotide pr
C 699	8.4	31.1	12	1	ABI74866	Oligonucleotide pr
C 700	8.4	31.1	12	1	ABH7627	Oligonucleotide pr
C 701	8.4	31.1	12	1	ABH70324	Oligonucleotide pr
C 702	8.4	31.1	12	1	ABH82215	Oligonucleotide pr
C 703	8.4	31.1	12	1	ABH86310	Oligonucleotide pr
C 704	8.4	31.1	12	1	ABI12868	Oligonucleotide pr
C 705	8.4	31.1	12	1	ABI41915	Oligonucleotide pr
C 706	8.4	31.1	12	1	ABI49149	Oligonucleotide pr
C 707	8.4	31.1	12	1	ABI69154	Oligonucleotide pr
C 708	8.4	31.1	12	1	ABI74582	Oligonucleotide pr
C 709	8.4	31.1	12	1	ABH69592	Oligonucleotide pr
C 710	8.4	31.1	12	1	ABH74068	Oligonucleotide pr
C 711	8.4	31.1	12	1	ABH74532	Oligonucleotide pr
C 712	8.4	31.1	12	1	ABH99576	Oligonucleotide pr
C 713	8.4	31.1	12	1	ABH75004	Oligonucleotide pr
C 714	8.4	31.1	12	1	ABI25982	Oligonucleotide pr
C 715	8.4	31.1	12	1	ABI26700	Oligonucleotide pr
C 716	8.4	31.1	12	1	ABI44041	Oligonucleotide pr
C 717	8.4	31.1	12	1	ABI54160	Oligonucleotide pr
C 718	8.4	31.1	12	1	ABI55384	Oligonucleotide pr
C 719	8.4	31.1	12	1	ABI70168	Oligonucleotide pr
C 720	8.4	31.1	12	1	ABI59356	Oligonucleotide pr
C 721	8.4	31.1	12	1	ABI73371	Oligonucleotide pr
C 722	8.4	31.1	12	1	ABI22008	Oligonucleotide pr
C 723	8.4	31.1	12	1	ABH7647	Oligonucleotide pr
C 724	8.4	31.1	12	1	ABH96376	Oligonucleotide pr
C 725	8.4	31.1	12	1	ABI44319	Oligonucleotide pr
C 726	8.4	31.1	12	1	ABI45183	Oligonucleotide pr
C 727	8.4	31.1	12	1	ABI55245	Oligonucleotide pr
C 728	8.4	31.1	12	1	ABI63409	Oligonucleotide pr
C 729	8.4	31.1	12	1	ABI80489	Oligonucleotide pr
C 730	8.4	31.1	12	1	ABI25674	Oligonucleotide pr
C 731	8.4	31.1	12	1	ABH27809	Oligonucleotide pr
C 732	8.4	31.1	12	1	ABH78190	Oligonucleotide pr
C 733	8.4	31.1	12	1	ABH30496	Oligonucleotide pr
C 734	8.4	31.1	12	1	ABI07772	Oligonucleotide pr
C 735	8.4	31.1	12	1	ABI16233	Oligonucleotide pr
C 736	8.4	31.1	12	1	ABI50633	Oligonucleotide pr
C 737	8.4	31.1	12	1	ABI69035	Oligonucleotide pr
C 738	8.4	31.1	12	1	ABI80435	Oligonucleotide pr
C 739	8.4	31.1	12	1	ABH94461	Oligonucleotide pr
C 740	8.4	31.1	12	1	ABI19759	Oligonucleotide pr
C 741	8.4	31.1	12	1	ABI02122	Oligonucleotide pr
C 742	8.4	31.1	12	1	ABI03729	Oligonucleotide pr
C 743	8.4	31.1	12	1	ABI31308	Oligonucleotide pr
C 744	8.4	31.1	12	1	ABI44477	Oligonucleotide pr
C 745	8.4	31.1	12	1	ABI44147	Oligonucleotide pr
C 746	8.4	31.1	12	1	ABI45966	Oligonucleotide pr
C 747	8.4	31.1	12	1	ABI70868	Oligonucleotide pr
C 748	8.4	31.1	12	1	ABI57581	Oligonucleotide pr
C 749	8.4	31.1	12	1	ABI74058	Oligonucleotide pr
C 750	8.4	31.1	12	1	ABI76381	Oligonucleotide pr
C 751	8.4	31.1	12	1	ABI63441	Oligonucleotide pr
C 752	8.4	31.1	12	1	ABI80040	Oligonucleotide pr
C 753	8.4	31.1	12	1	ABI80160	Oligonucleotide pr
C 754	8.4	31.1	12	1	ABH68088	Oligonucleotide pr
C 755	8.4	31.1	12	1	ABH73743	Oligonucleotide pr
C 756	8.4	31.1	12	1	ABI00070	Oligonucleotide pr
C 757	8.4	31.1	12	1	ABH83889	Oligonucleotide pr
C 758	8.4	31.1	12	1	ABI39196	Oligonucleotide pr
C 759	8.4	31.1	12	1	ABI40471	Oligonucleotide pr
C 760	8.4	31.1	12	1	ABH92093	Oligonucleotide pr
C 761	8.4	31.1	12	1	ABI48451	Oligonucleotide pr
C 762	8.4	31.1	12	1	ABI68097	Oligonucleotide pr
C 763	8.4	31.1	12	1	ABI68747	Oligonucleotide pr
C 764	8.4	31.1	12	1	ABI56919	Oligonucleotide pr
C 765	8.4	31.1	12	1	ABI62778	Oligonucleotide pr
C 766	8.4	31.1	12	1	ABI77268	Oligonucleotide pr
C 767	8.4	31.1	12	1	ABI65580	Oligonucleotide pr
C 768	8.4	31.1	12	1	ABI66101	Oligonucleotide pr
C 769	8.4	31.1	12	1	ABI80039	Oligonucleotide pr
C 770	8.4	31.1	12	1	ABH71218	Oligonucleotide pr
C 771	8.4	31.1	12	1	ABI26809	Oligonucleotide pr
C 772	8.4	31.1	12	1	ABI02095	Oligonucleotide pr
C 773	8.4	31.1	12	1	ABI02251	Oligonucleotide pr
C 774	8.4	31.1	12	1	ABI03272	Oligonucleotide pr
C 775	8.4	31.1	12	1	ABH78244	Oligonucleotide pr
C 776	8.4	31.1	12	1	ABI30491	Oligonucleotide pr
C 777	8.4	31.1	12	1	ABH80892	Oligonucleotide pr
C 778	8.4	31.1	12	1	ABI08067	Oligonucleotide pr
C 779	8.4	31.1	12	1	ABH84767	Oligonucleotide pr
C 780	8.4	31.1	12	1	ABI37811	Oligonucleotide pr
C 781	8.4	31.1	12	1	ABI14259	Oligonucleotide pr
C 782	8.4	31.1	12	1	ABI49736	Oligonucleotide pr
C 783	8.4	31.1	12	1	ABI74883	Oligonucleotide pr
C 784	8.4	31.1	12	1	ABI18050	Oligonucleotide pr
C 785	8.4	31.1	12	1	ABH93224	Oligonucleotide pr
C 786	8.4	31.1	12	1	ABH68672	Oligonucleotide pr
C 787	8.4	31.1	12	1	ABH74218	Oligonucleotide pr
C 788	8.4	31.1	12	1	ABH99975	Oligonucleotide pr
C 789	8.4	31.1	12	1	ABH75361	Oligonucleotide pr
C 790	8.4	31.1	12	1	ABI27718	Oligonucleotide pr
C 791	8.4	31.1	12	1	ABI07423	Oligonucleotide pr
C 792	8.4	31.1	12	1	ABI07539	Oligonucleotide pr
C 793	8.4	31.1	12	1	ABH86141	Oligonucleotide pr
C 794	8.4	31.1	12	1	ABI17314	Oligonucleotide pr
C 795	8.4	31.1	12	1	ABI43376	Oligonucleotide pr
C 796	8.4	31.1	12	1	ABI48057	Oligonucleotide pr
C 797	8.4	31.1	12	1	ABI54181	Oligonucleotide pr
C 798	8.4	31.1	12	1	ABI54184	Oligonucleotide pr
C 799	8.4	31.1	12	1	ABI68709	Oligonucleotide pr
C 800	8.4	31.1	12	1	ABI68786	Oligonucleotide pr
C 801	8.4	31.1	12	1	ABI56803	Oligonucleotide pr
C 802	8.4	31.1	12	1	ABI73769	Oligonucleotide pr
C 803	8.4	31.1	12	1	ABI78192	Oligonucleotide pr
C 804	8.4	31.1	12	1	ABH67593	Oligonucleotide pr
C 805	8.4	31.1	12	1	ABH67895	Oligonucleotide pr
C 806	8.4	31.1	12	1	ABH77338	Oligonucleotide pr
C 807	8.4	31.1	12	1	ABI34133	Oligonucleotide pr
C 808	8.4	31.1	12	1	ABI36475	Oligonucleotide pr
C 809	8.4	31.1	12	1	ABI43240	Oligonucleotide pr
C 810	8.4	31.1	12	1	ABI44537	Oligonucleotide pr
C 811	8.4	31.1	12	1	ABI45007	Oligonucleotide pr
C 812	8.4	31.1	12	1	ABI50001	Oligonucleotide pr
C 813	8.4	31.1	12	1	ABI56185	Oligonucleotide pr
C 814	8.4	31.1	12	1	ABI76427	Oligonucleotide pr
C 815	8.4	31.1	12	1	ABI78268	Oligonucleotide pr
C 816	8.4	31.1	12	1	ABI79156	Oligonucleotide pr
C 817	8.4	31.1	12	1	ABI79510	Oligonucleotide pr
C 818	8.4	31.1	12	1	ABI65753	Oligonucleotide pr
C 819	8.4	31.1	12	1	ABH73741	Oligonucleotide pr
C 820	8.4	31.1	12	1	ABH78716	Oligonucleotide pr
C 821	8.4	31.1	12	1	ABH78834	Oligonucleotide pr
C 822	8.4	31.1	12	1	ABH82209	Oligonucleotide pr
C 823	8.4	31.1	12	1	ABH82461	Oligonucleotide pr
C 824	8.4	31.1	12	1	ABH84318	Oligonucleotide pr
C 825	8.4	31.1	12	1	ABH84351	Oligonucleotide pr
C 826	8.4	31.1	12	1	ABI70904	Oligonucleotide pr
C 827	8.4	31.1	12	1	ABI62344	Oligonucleotide pr
C 828	8.4	31.1	12	1	ABI65740	Oligonucleotide pr
C 829	8.4	31.1	12	1	ABH67811	Oligonucleotide pr
C 830	8.4	31.1	12	1	ABH67811	Oligonucleotide pr
C 831	8.4	31.1	12	1	ABH67811	Oligonucleotide pr
C 832	8.4	31.1	12	1	ABH67811	Oligonucleotide pr
C 833	8.4	31.1	12	1	ABH67811	Oligonucleotide pr
C 834	8.4	31.1	12	1	ABH74722	Oligonucleotide pr
C 835	8.4	31.1	12	1	ABH99973	Oligonucleotide pr
C 836	8.4	31.1	12	1	ABI26971	Oligonucleotide pr

```
C 837 8.4 31.1 12 1 ABH77510 Oligonucleotide pr
C 838 8.4 31.1 12 1 ABH03900 Oligonucleotide pr
C 839 8.4 31.1 12 1 ABH83255 Oligonucleotide pr
C 840 8.4 31.1 12 1 ABH33514 Oligonucleotide pr
C 841 8.4 31.1 12 1 ABH42680 Oligonucleotide pr
C 842 8.4 31.1 12 1 ABH44148 Oligonucleotide pr
C 843 8.4 31.1 12 1 ABH55912 Oligonucleotide pr
C 844 8.4 31.1 12 1 ABH56477 Oligonucleotide pr
C 845 8.4 31.1 12 1 ABH71747 Oligonucleotide pr
C 846 8.4 31.1 12 1 ABH72421 Oligonucleotide pr
C 847 8.4 31.1 12 1 ABH761602 Oligonucleotide pr
C 848 8.4 31.1 12 1 ABH75967 Oligonucleotide pr
C 849 8.4 31.1 12 1 ABH62899 Oligonucleotide pr
C 850 8.4 31.1 12 1 ABH65459 Oligonucleotide pr
C 851 8.4 31.1 12 1 ABH68673 Oligonucleotide pr
C 852 8.4 31.1 12 1 ABH77024 Oligonucleotide pr
C 853 8.4 31.1 12 1 ABH04988 Oligonucleotide pr
C 854 8.4 31.1 12 1 ABH05944 Oligonucleotide pr
C 855 8.4 31.1 12 1 ABH07069 Oligonucleotide pr
C 856 8.4 31.1 12 1 ABH82172 Oligonucleotide pr
C 857 8.4 31.1 12 1 ABH84146 Oligonucleotide pr
C 858 8.4 31.1 12 1 ABH87939 Oligonucleotide pr
C 859 8.4 31.1 12 1 ABH89692 Oligonucleotide pr
C 860 8.4 31.1 12 1 ABH44215 Oligonucleotide pr
C 861 8.4 31.1 12 1 ABH67950 Oligonucleotide pr
C 862 8.4 31.1 12 1 ABH70580 Oligonucleotide pr
C 863 8.4 31.1 12 1 ABH75910 Oligonucleotide pr
C 864 8.4 31.1 12 1 ABH67100 Oligonucleotide pr
C 865 8.4 31.1 12 1 ABH92370 Oligonucleotide pr
C 866 8.4 31.1 12 1 ABH68307 Oligonucleotide pr
C 867 8.4 31.1 12 1 ABH18919 Oligonucleotide pr
C 868 8.4 31.1 12 1 ABH97542 Oligonucleotide pr
C 869 8.4 31.1 12 1 ABH74170 Oligonucleotide pr
C 870 8.4 31.1 12 1 ABH74595 Oligonucleotide pr
C 871 8.4 31.1 12 1 ABH33553 Oligonucleotide pr
C 872 8.4 31.1 12 1 ABH09881 Oligonucleotide pr
C 873 8.4 31.1 12 1 ABH84528 Oligonucleotide pr
C 874 8.4 31.1 12 1 ABH36547 Oligonucleotide pr
C 875 8.4 31.1 12 1 ABH14509 Oligonucleotide pr
C 876 8.4 31.1 12 1 ABH40947 Oligonucleotide pr
C 877 8.4 31.1 12 1 ABH18668 Oligonucleotide pr
C 878 8.4 31.1 12 1 ABH51360 Oligonucleotide pr
C 879 8.4 31.1 12 1 ABH51468 Oligonucleotide pr
C 880 8.4 31.1 12 1 ABH76055 Oligonucleotide pr
C 881 8.4 31.1 12 1 ABH64981 Oligonucleotide pr
C 882 8.4 31.1 12 1 ABH66823 Oligonucleotide pr
C 883 8.4 31.1 12 1 ABH80759 Oligonucleotide pr
C 884 8.4 31.1 12 1 ABH234313 HIV-1 reverse tran
C 885 8.4 31.1 12 1 ADF78584 Chromosomal abnorm
C 886 8.4 31.1 12 1 ADF78619 Chromosomal abnorm
```

ALIGNMENTS

```
RESULT 1
ADB25654/c
ID ADB25654 standard; DNA; 20 BP.
XX
AC ADB25654;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human connective tissue growth factor antisense oligo DNA (seqid 47).
XX
KW antisense; human; ss; connective tissue growth factor; CTGF;
KW chromosome 6q23.1; ctgofact; fibroblast inducible secreted protein;
KW fisp-12; NOV2;
KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;
KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;
KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;
KW scleroderma; atherosclerosis; cystostatic; dermatological;
KW antiarteriosclerotic.
```

```
XX Homo sapiens.
OS
XX
FH Key Location/Qualifiers
FT modified_base 1..20 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone, where 1-5 and
FT 16-20 are 2' methoxyethyl nucleotides. All cytidines are
FT 5-methylcytidines"
XX
XX WO2003053340-A2.
XX
XX 03-JUL-2003.
XX
XX 09-DEC-2002; 2002WO-US038618.
XX
XX 10-DEC-2001; 2001US-00006191.
XX (ISIS-) ISIS PHARM INC.
XX
XX Gaarde WA, Watt AT;
XX
XX WPI; 2003-559091/52.
XX
XX New antisense oligonucleotides for modulating connective tissue growth
XX factor expression, particularly useful for treating cancers (e.g. breast
XX or prostate cancer), pulmonary or renal fibrosis, scleroderma or
XX atherosclerosis.
XX
XX Claim 3; Page 85; 139pp; English.
```

```
XX This invention relates to novel methods for modulating the expression of
XX connective tissue growth factor (CTGF) by antisense oligonucleotides.
XX CTGF has been mapped to human chromosome region 6q23.1, and is also known
XX as ctgofact, fibroblast inducible secreted protein, fisp-12, NOV2,
XX insulin-like growth factor binding protein-related protein 2, IGFBP-rp2,
XX IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and
XX promote chemotaxis of fibroblasts, however, it is also upregulated in
XX acute lymphoblastic leukaemia and in tumour or endothelial cells
XX associated with the vasculature. Accordingly, antisense oligonucleotides
XX that inhibit the expression of CTGF in cells or tissues can be used in
XX gene therapy to treat various conditions including hyperproliferative
XX disorders (particularly cancer, e.g. breast, prostate or renal cancer),
XX pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
XX such, the present invention describes these antisense oligos as having
XX cytosstatic, dermatological and antiarteriosclerotic activities. This
XX oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
XX with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
XX human CTGF of the invention.
```

SQ Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 74.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1,2;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGACCAAAAGTTACA 2232
Db 20 GAGTGTGACCAAAAGTTACA 1

RESULT 2
ADB25671/c
ID ADB25671 standard; DNA; 20 BP.
XX
AC ADB25671;
XX

DT 20-NOV-2003 (first entry)
XX
DE Human connective tissue growth factor antisense oligo DNA (seqid 64).
XX
KW antisense; human; ss; connective tissue growth factor; CTGF;

KW chromosome 6q23.1; ctgfact; fibroblast inducible secreted protein;
 KW fisp-12; NOV2;
 KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;
 KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;
 KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;
 KW scleroderma; atherosclerosis; cytostatic; dermatological;
 KW antiarteriosclerotic.
 XX
 OS Homo sapiens.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone, where 1-5 and
 FT 16-20 are 2' methoxyethyl nucleotides. All cytidines are
 FT 5-methylcytidines"
 XX
 XX
 PN WO2003053340-A2.
 XX
 XX
 PD 03-JUL-2003.
 XX
 XX
 PF 09-DEC-2002; 2002WO-US038618.
 XX
 XX
 PR 10-DEC-2001; 2001US-00006191.
 XX
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX
 PI Gaarde WA, Watt AT;
 XX
 DR WPI; 2003-559091/52.
 XX
 XX
 PT New antisense oligonucleotides for modulating connective tissue growth
 PT factor expression, particularly useful for treating cancers (e.g. breast
 PT or prostate cancer), pulmonary or renal fibrosis, scleroderma or
 PT atherosclerosis.
 XX
 PS Claim 3; Page 85; 139pp; English.
 XX
 CC This invention relates to novel methods for modulating the expression of
 CC connective tissue growth factor (CTGF) by antisense oligonucleotides.
 CC CTGF has been mapped to human chromosome region 6q23.1, and is also known
 CC as ctgfact, fibroblast inducible secreted protein, fisp-12, NOV2,
 CC insulin-like growth factor binding protein-related protein 2, IGFBP-rp2,
 CC IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and
 CC promote chemotaxis of fibroblasts, however, it is also upregulated in
 CC acute lymphoblastic leukaemia and in tumour or endothelial cells
 CC associated with the vasculature. Accordingly, antisense oligonucleotides
 CC that inhibit the expression of CTGF in cells or tissues can be used in
 CC gene therapy to treat various conditions including hyperproliferative
 CC disorders (particularly cancer, e.g. breast, prostate or renal cancer),
 CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
 CC such, the present invention describes these antisense oligos as having
 CC cytostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CTGF of the invention.
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 74.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTTACATGTTG 2238
 DB 20 GACCAAAAGTTACATGTTG 1
 RESULT 3
 ADB25655/c
 ID ADB25655 standard; DNA; 20 BP.
 XX

AC ADB25655;
 XX
 DT 20-NOV-2003 (first entry)
 DE Human connective tissue growth factor antisense oligo DNA (SeqID 48).
 XX
 KW antisense; human; ss; connective tissue growth factor; CTGF;
 KW chromosome 6q23.1; ctgfact; fibroblast inducible secreted protein;
 KW fisp-12; NOV2;
 KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;
 KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;
 KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;
 KW scleroderma; atherosclerosis; cytostatic; dermatological;
 KW antiarteriosclerotic.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone, where 1-5 and
 FT 16-20 are 2' methoxyethyl nucleotides. All cytidines are
 FT 5-methylcytidines"
 XX
 XX
 PN WO2003053340-A2.
 XX
 XX
 PD 03-JUL-2003.
 XX
 XX
 PF 09-DEC-2002; 2002WO-US038618.
 XX
 XX
 PR 10-DEC-2001; 2001US-00006191.
 XX
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX
 PI Gaarde WA, Watt AT;
 XX
 DR WPI; 2003-559091/52.
 XX
 XX
 PT New antisense oligonucleotides for modulating connective tissue growth
 PT factor expression, particularly useful for treating cancers (e.g. breast
 PT or prostate cancer), pulmonary or renal fibrosis, scleroderma or
 PT atherosclerosis.
 XX
 PS Claim 3; Page 85; 139pp; English.
 XX
 CC This invention relates to novel methods for modulating the expression of
 CC connective tissue growth factor (CTGF) by antisense oligonucleotides.
 CC CTGF has been mapped to human chromosome region 6q23.1, and is also known
 CC as ctgfact, fibroblast inducible secreted protein, fisp-12, NOV2,
 CC insulin-like growth factor binding protein-related protein 2, IGFBP-rp2,
 CC IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and
 CC promote chemotaxis of fibroblasts, however, it is also upregulated in
 CC acute lymphoblastic leukaemia and in tumour or endothelial cells
 CC associated with the vasculature. Accordingly, antisense oligonucleotides
 CC that inhibit the expression of CTGF in cells or tissues can be used in
 CC gene therapy to treat various conditions including hyperproliferative
 CC disorders (particularly cancer, e.g. breast, prostate or renal cancer),
 CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
 CC such, the present invention describes these antisense oligos as having
 CC cytostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CTGF of the invention.
 XX
 SQ Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 74.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAGTTACATGTTT 2237
 |||||

DB 20 TGACCAAAAGTTACATGTTT 1

RESULT 4
ADB25670/c

ID ADB25670 standard; DNA; 20 BP.

XX AC ADB25670;

XX DT 20-NOV-2003 (first entry)

XX DE Human connective tissue growth factor antisense oligo DNA (SeqID 63).

XX KW antisense; human; ss; connective tissue growth factor; CTGF;

XX KW chromosome 6q23.1; ctgofact; fibroblast inducible secreted protein;

XX KW fisp-12; NOV2;

XX KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;

XX KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;

XX KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;

XX KW scleroderma; atherosclerosis; cytostatic; dermatological;

XX KW antiarteriosclerotic.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= phosphorothioate backbone, where 1-5 and 16-20 are 2' methoxyethyl nucleotides. All cytidines are 5-methylcytidines"

XX PN WO2003053340-A2.

XX PD 03-JUL-2003.

XX PF 09-DEC-2002; 2002WO-US038618.

XX PR 10-DEC-2001; 2001US-00006191.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Gaarde WA, Watt AT;

XX DR WPI; 2003-559091/52.

XX PT New antisense oligonucleotides for modulating connective tissue growth factor expression, particularly useful for treating cancers (e.g. breast or prostate cancer), pulmonary or renal fibrosis, scleroderma or atherosclerosis.

XX PS Claim 3; Page 85; 139pp; English.

XX CC This invention relates to novel methods for modulating the expression of connective tissue growth factor (CTGF) by antisense oligonucleotides. CTGF has been mapped to human chromosome region 6q23.1, and is also known as ctgofact, fibroblast inducible secreted protein, fisp-12, NOV2, insulin-like growth factor binding protein-related protein 2, IGFBP-rp2, IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and promote chemotaxis of fibroblasts, however, it is also upregulated in acute lymphoblastic leukaemia and in tumour or endothelial cells associated with the vasculature. Accordingly, antisense oligonucleotides that inhibit the expression of CTGF in cells or tissues can be used in gene therapy to treat various conditions including hyperproliferative disorders (particularly cancer, e.g. breast, prostate or renal cancer), pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As such, the present invention describes these antisense oligos as having such a cytostatic, dermatological and antiarteriosclerotic activities. This oligonucleotide sequence is a chimeric phosphorothioate antisense oligo with 2' MOE wings and a deoxy gap, which is used to inhibit expression of human CTGF of the invention.

XX SQ Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 74.1%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.2;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAGTTAC 2231

DB 20 AGAGTGTGACCAAAAGTTAC 1

RESULT 5
ADB25653/c

ID ADB25653 standard; DNA; 20 BP.

XX AC ADB25653;

XX DT 20-NOV-2003 (first entry)

XX DE Human connective tissue growth factor antisense oligo DNA (SeqID 46).

XX KW antisense; human; ss; connective tissue growth factor; CTGF;

XX KW chromosome 6q23.1; ctgofact; fibroblast inducible secreted protein;

XX KW fisp-12; NOV2;

XX KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;

XX KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;

XX KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;

XX KW scleroderma; atherosclerosis; cytostatic; dermatological;

XX KW antiarteriosclerotic.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= phosphorothioate backbone, where 1-5 and 16-20 are 2' methoxyethyl nucleotides. All cytidines are 5-methylcytidines"

XX PN WO2003053340-A2.

XX PD 03-JUL-2003.

XX PF 09-DEC-2002; 2002WO-US038618.

XX PR 10-DEC-2001; 2001US-00006191.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Gaarde WA, Watt AT;

XX DR WPI; 2003-559091/52.

XX PT New antisense oligonucleotides for modulating connective tissue growth factor expression, particularly useful for treating cancers (e.g. breast or prostate cancer), pulmonary or renal fibrosis, scleroderma or atherosclerosis.

XX PS Claim 3; Page 85; 139pp; English.

XX CC This invention relates to novel methods for modulating the expression of connective tissue growth factor (CTGF) by antisense oligonucleotides. CTGF has been mapped to human chromosome region 6q23.1, and is also known as ctgofact, fibroblast inducible secreted protein, fisp-12, NOV2, insulin-like growth factor binding protein-related protein 2, IGFBP-rp2, IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and promote chemotaxis of fibroblasts, however, it is also upregulated in acute lymphoblastic leukaemia and in tumour or endothelial cells associated with the vasculature. Accordingly, antisense oligonucleotides that inhibit the expression of CTGF in cells or tissues can be used in gene therapy to treat various conditions including hyperproliferative disorders (particularly cancer, e.g. breast, prostate or renal cancer), pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As such, the present invention describes these antisense oligos as having such a cytostatic, dermatological and antiarteriosclerotic activities. This oligonucleotide sequence is a chimeric phosphorothioate antisense oligo with 2' MOE wings and a deoxy gap, which is used to inhibit expression of human CTGF of the invention.

CC such, the present invention describes these antisense oligos as having
 CC cytostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CRGF of the invention.

XX
 SQ Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 59.3%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAG 2227
 Db 16 AGAGTGTGACCAAAAG 1

RESULT 6
 ABK40462/c
 ID ABK40462 standard; DNA; 20 BP.
 XX
 AC ABK40462;

XX 15-JUL-2002 (first entry)

XX Forward PCR primer for gene amplification analysis of human PRO4980.

XX Human; PRO; benign tumour; malignant tumour; lymphoid malignancy;
 KW leukaemia; neuronal disorder; stromal disorder; blastocoele disorder;
 KW inflammatory disorder; immune disorder; angiogenic disorder; cytostatic;
 KW neuroprotective; PCR; primer; ss.

XX Homo sapiens.

XX WO200153486-A1.

XX 26-JUL-2001.

XX 11-FEB-2000; 2000WO-US003565.

XX 08-MAR-1999; 99WO-US005028.

XX 11-MAR-1999; 99US-0123972P.

XX 11-MAY-1999; 99US-0133459P.

XX 02-JUN-1999; 99WO-US012252.

XX 22-JUN-1999; 99US-0140650P.

XX 22-JUN-1999; 99US-0140853P.

XX 20-JUL-1999; 99US-0144758P.

XX 26-JUL-1999; 99US-0145698P.

XX 28-JUL-1999; 99US-0146222P.

XX 17-AUG-1999; 99US-0149395P.

XX 31-AUG-1999; 99US-0151689P.

XX 01-SEP-1999; 99WO-US020111.

XX 13-SEP-1999; 99WO-US021090.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 05-JAN-2000; 2000WO-US000219.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
 PI Marsters SA, Pan J, Pitti RM, Roy NA, Smith V, Stone DM;
 PI Watanabe CK, Wood WI;
 XX WPI; 2002-205567/26.

XX Thirty five nucleic acids encoding PRO polypeptides, useful for treating
 PT benign or malignant tumors, leukemias and lymphoid malignancies,
 PT inflammatory, angiogenic and immunologic disorders.
 XX
 XX Example 26; Page 147; 302pp; English.
 XX
 XX The present invention relates to the isolation of novel human PRO

CC polypeptides (AAU86128-AAU86162) and the polynucleotide sequences
 CC encoding them. The PRO polypeptides, agonists, antagonists or anti-PRO
 CC antibodies are useful for treating benign or malignant tumours (e.g.
 CC renal, kidney, bladder, breast, etc), leukaemias and lymphoid
 CC malignancies, other disorders such as neuronal, glial, astrocytal,
 CC hypothalamic, glandular, macrophagal, stromal and blastocoele disorders,
 CC inflammatory, immune and angiogenic disorders. The polynucleotide
 CC sequences are also useful in gene therapy. The present sequence
 CC represents a PCR primer used in the methods of the present invention

XX
 SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 53.3%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 28;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAG 2227
 Db 20 AGAGTGTGACCAAAAG 5

RESULT 7
 ADJ37525/c
 ID ADJ37525 standard; DNA; 20 BP.
 XX
 AC ADJ37525;

XX 22-APR-2004 (first entry)

XX Tumour therapy associated PRO4980 primer seq id 244.

XX cytostatic; gene therapy; PRO; PRO197; PRO207; PRO226; PRO232; PRO243;
 KW PRO256; PRO269; PRO274; PRO304; PRO339; PRO358; PRO379; PRO1185;
 KW PRO1245; PRO1759; PRO3775; PRO7133; PRO7168; PRO5725; PRO202; PRO206;
 KW PRO264; PRO313; PRO342; PRO542; PRO773; PRO861; PRO1216; PRO1686;
 KW PRO1800; PRO3562; PRO3850; PRO539; PRO4316; PRO4980; cancer; tumour;
 KW neoplastic cell growth; neoplastic cell proliferation; carcinoma;
 KW lymphoma; blastoma; sarcoma; leukaemia; primer; ss.

XX Homo sapiens.

XX US2003211096-A1.

XX 13-NOV-2003.

XX 02-AUG-2002; 2002US-00211858.

XX 31-AUG-1999; 99US-0151689P.

XX 11-FEB-2000; 2000WO-US003565.

XX 09-AUG-2001; 2001US-00927796.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
 PI Marsters SA, Pan J, Pitti RM, Roy NA, Smith V, Stone DM;
 PI Watanabe CK, Wood WI;
 XX WPI; 2003-901564/82.

XX New isolated PRO polypeptides, useful as targets for the diagnosis,
 PT prevention and treatment of cancers, e.g. lymphoma, blastoma, sarcoma or
 PT leukemia, and as predictors of the prognosis of tumor treatment.

XX Example 26; SEQ ID NO 244; 307pp; English.

XX The invention describes an isolated PRO polypeptide. The PRO polypeptide
 CC has at least 80% amino acid sequence identity to: (1) any one of 35 fully
 CC defined sequences of 104-954 amino acids (designated P1-P35) given in the
 CC specification, with or without its associated signal peptide; (2) an
 CC extracellular domain of any one of the polypeptides of P1-P35, with or
 CC without its associated signal peptide; or (3) an amino acid sequence
 CC encoded by the full-length coding sequence of the DNA deposited under
 CC ATCC accession number 209284, 209358, 209376, 209250, 209508, 209379,

CC acute lymphoblastic leukaemia and in tumour or endothelial cells
 CC associated with the vasculature. Accordingly, antisense oligonucleotides
 CC that inhibit the expression of CTGF in cells or tissues can be used in
 CC gene therapy to treat various conditions including hyperproliferative
 CC disorders (particularly cancer, e.g. breast, prostate or renal cancer),
 CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
 CC such, the present invention describes these antisense oligos as having
 CC cytostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate, antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CTGF of the invention.

XX
 SQ Sequence 20 BP; 6 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 51.9%; Score 14; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAA 2225

DB 14 AGAGTGTGACCAAA 1

RESULT 10
 AAV96534/c
 ID AAV96534 standard; RNA; 17 BP.

XX AC AAV96534;
 XX AC AAV96534;

DT 01-MAR-1999 (first entry)

DE Potato citrate synthase target sequence position 812.

XX Solanidine; glucosyltransferase; potato; citrate synthase; target;
 KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
 KW flower formation; cleavage; solanaceous plant; ss.

XX Solanum tuberosum.

XX WO9832843-A2.

XX 30-JUL-1998.

XX 14-JAN-1998; 98WO-US000738.

XX 28-JAN-1997; 97US-0036545P.

XX 28-JAN-1997; 97US-0036599P.

XX 24-NOV-1997; 97US-00979416.

XX (RIBO-) RIBOZYME PHARM INC.

XX Zwick MG, Mscwigen JA;

XX WPI; 1998-427939/36.

XX New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
 PT biosynthesis or regulating flowering.

XX Claim 53; Page 54; 79pp; English.

XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC -cleaving activity (e.g. ribozymes) which are capable of modulating the
 CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or
 CC (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
 CC AAV96354 represent potato solanidine glucosyltransferase hammerhead and
 CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
 CC AAV96734 represent potato solanidine glucosyltransferase target
 CC sequences. AAV96733 to AAV97170, and AAV97171 to AAV97195 represent
 CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.
 CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
 CC synthase target sequences. Ribozymes of the present invention can be used
 CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,
 CC particularly potato but also tomato, pepper, aubergine and ditura or to

CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
 CC arugula, kale, collards, chard, beet, turnip, sweet potato and turf
 CC grass. Also the ribozymes can be used for RNA manipulation in the same
 CC way that restriction endonucleases are for DNA, as well as to examine
 CC genetic drift and mutations in plants and to detect specific RNA. The
 CC ribozymes can be targeted to specific genes or to consensus sequences
 CC within a family of related genes, and being catalytic need to be present
 CC at only very low concentrations

XX Sequence 17 BP; 5 A; 4 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 45.2%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 72;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAAGTTTACA 2232

DB 17 TGTGACCAAAAGTTTACA 1

RESULT 11

ABV89418

ID ABV89418 standard; DNA; 17 BP.

XX AC ABV89418;

XX AC ABV89418;

DT 23-DEC-2002 (first entry)

DE Human POSHL1 scanning oligonucleotide SEQ ID NO 131.

XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW Gene therapy; transgenic; ss.

XX Homo sapiens.

XX EP1239051-A2.

XX 11-SEP-2002.

XX 28-JAN-2002; 2002EP-00001165.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 23-MAY-2001; 2001WO-US000670.

XX 10-OCT-2001; 2001US-0328205P.

XX (AEOM-) AEOMICA INC.

XX Shannon M;

XX WPI; 2002-684061/74.

XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL

XX -1, useful for treating disorders associated with decreased expression or

XX activity of human POSHL1.

XX Example 2; SEQ ID NO 131; 60pp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful

CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human PSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Berwent by the European Patent Office

XX SQ Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2219 TGACCAAAAGTTACATG 2234
DB 1 TCAGCAGAGTTACATG 17

RESULT 12
ADI48826
ID ADI48826 standard; DNA; 17 BP.
AC ADI48826;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID1329.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
PN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313354/30.

XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumours and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; SEQ ID NO 1329; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by degeneration and/or treatment of viral diseases that
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedseq_sequences
XX
SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTTACATG 2235
DB 1 GATCAAAAATTACTGT 17

RESULT 13
ADL49182/c
ID ADL49182 standard; RNA; 17 BP.
XX
AC ADL49182;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #296.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.

XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2715; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 2 C; 2 G; 0 T; 7 U; 0 Other;
Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2217 GTGACCAAAAGTTACAT 2233
DB 17 GTGAACAAATATTACAT 1
RESULT 14
ADL50023/c
ID ADL50023 standard; RNA; 17 BP.
XX
AC ADL50023;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1137.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PK3; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PK3;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHEARM INC.
XX
XX Blatt L, Chowira B, Haerberli P, Meswigen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3556; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PK3. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2216 TGTGACCAAAAGTTACA 2232
DB 17 TGTGACCGCAAGTCACA 1
RESULT 15
ABC78606
ID ABC78606 standard; DNA; 13 BP.
XX
AC ABC78606;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 78623 for detecting SNP TSC00200009.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 78623; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 42.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTTG 2238
DB 1 AGTTATATGTTTG 13

peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.

WO200177384-A2.

18-OCT-2001.

06-APR-2001; 2001WO-IB000713.

07-APR-2000; 2000DE-01019173.

(EPIG-) EPIGENOMICS AG.

Olek A, Piepenbrock C, Berlin K;

WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 78626; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 42.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTTG 2238
| | | | | | | | | | | | | | |
Db 13 AGTTACATGTTTG 1

RESULT 18
ABC30594
ID ABC30594 standard; DNA; 13 BP.
XX AC ABC30594;
XX 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 30611 for detecting SNP TSC0009381.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX SN

peptide nucleic acid; cytosine methylation; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.

WO200177384-A2.

18-OCT-2001.

06-APR-2001; 2001WO-IB000713.

07-APR-2000; 2000DE-01019173.

(EPIG-) EPIGENOMICS AG.

Olek A, Piepenbrock C, Berlin K;

WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 78624; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 42.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTTG 2238
| | | | | | | | | | | | | | |
Db 13 AGTTACATGTTTG 1

RESULT 17
ABC78609/c
ID ABC78609 standard; DNA; 13 BP.
XX AC ABC78609;
XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 78626 for detecting SNP TSC0020009.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 30611; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 76;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACATGTT 2236
 DB 1 AAAGTTATATGTT 13
 RESULT 19
 ID ABC78608 standard; DNA; 13 BP.
 XX ABC78608;
 AC
 XX 21-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 78625 for detecting SNP TSC0020009.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 78625; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 76;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 DB 1 AGTTACTGTTG 13
 RESULT 20
 ID ABC24651 standard; DNA; 13 BP.
 XX ABC24651;
 AC
 XX 20-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 24568 for detecting SNP TSC0005912.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 24668; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 4 C; 1 G; 3 T; 0 U; 0 Other;

AC	ABC30595;
XX	
DT	20-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 30612 for detecting SNP TSC0009381.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO2001177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 30612; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
	Query Match 42.2%; Score 11.4; DB 1; Length 13;
	Best Local Similarity 92.3%; Pred.No.76;
	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2224 AAAGTTACATGTT 2236
Db	13 AAAGTTATAGTT 1
RESULT 23	
AAAX30977/c	
ID	AAAX30977 standard; DNA; 15 BP.
XX	
AC	AAAX30977;
XX	
DT	21-MAY-1999 (first entry)
XX	
DE	Tag sequence of a transcript increased in colorectal cancer.
XX	
KW	Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW	diagnosis; prognosis; treatment; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO9853319-A2.

XX PD 26-NOV-1998.
 XX PF 20-MAY-1998; 98WO-US010277.
 XX PR 21-MAY-1997; 97US-0047352P.
 XX PA (UYJO) UNIV JOHNS HOPKINS.
 XX PI Vogelstein B, Kinzler KW;
 XX DR WPI; 1999-070161/06.
 XX PT Use of isolated gene transcripts - useful for developing products for the
 PT diagnosis, prognosis and treatment of cancers, particularly colon and
 PT pancreatic cancer.
 XX PS Claim 2; Page 23; 120pp; English.
 XX CC AAX30947-31815 represent tag sequences of transcripts that are
 CC differentially expressed in colorectal cancer, in pancreatic cancer, or
 CC in both. The tag sequences can be used to identify genes by matching the
 CC tag to a gen data base member, or by using the tag sequences as probes to
 CC isolate unidentified genes from cDNA libraries. The tag sequences can
 CC also be used in a method for diagnosing colon or pancreatic cancer in a
 CC sample suspected of being neoplastic. The method comprises comparing the
 CC level of at least one transcript in a first sample of a tissue to a
 CC second sample, where the first sample is a colonic tissue suspected of
 CC being neoplastic and the second sample is a normal human colonic tissue.
 CC The transcript is identified by a tag selected from AAX30947-31815. The
 CC methods of the invention can be used in the diagnosis, prognosis and
 CC treatment of cancer
 XX SQ Sequence 15 BP; 3 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 93;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACATG 2234
 Db 13 CAAAATTACATG 1
 RESULT 24
 ABK31930/c
 ID ABK31930 standard; DNA; 15 BP.
 XX AC ABK31930;
 XX DT 23-APR-2002 (first entry)
 XX DE Human colon cancer SAGE tag #31.
 XX KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
 KW serial analysis of gene expression; diagnostic; prognostic; probe;
 KW cancer marker; ss.
 XX OS Homo sapiens.
 XX US6333152-B1.
 XX PD 25-DEC-2001.
 XX PF 20-MAY-1998; 98US-00081645.
 XX PR 20-MAY-1998; 98US-00081646.
 XX PA (UYJO) UNIV JOHNS HOPKINS.
 XX PI Vogelstein B, Kinzler KW, Zhang L, Zhou W;
 XX WPI; 2002-153821/20.

XX PT New human nucleic acid containing specific SAGE tags, useful as
 PT diagnostic markers for cancer, also derived probes.
 XX PS Disclosure; Col 15; 161pp; English.
 XX CC The invention relates to an isolated, purified human nucleic acid (I)
 CC that has the same sequence as a mRNA found in humans and is a SAGE
 CC (serial analysis of gene expression) tag comprising a single stranded
 CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
 CC diagnostic and prognostic markers of cancer, especially of the colon and
 CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
 CC SAGE tags of the invention
 XX SQ Sequence 15 BP; 3 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 93;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACATG 2234
 Db 13 CAAAATTACATG 1
 RESULT 25
 ABK70527
 ID ABK70527 standard; DNA; 15 BP.
 XX AC ABK70527;
 XX DT 15-JUL-2002 (first entry)
 XX DE Human G protein-coupled receptor 7 allele-specific probe #11.
 XX KW Human; G protein-coupled receptor 7; GPR7; haplotyping; SNP;
 KW psychological disorder; neurological disorder; probe; ss;
 XX OS Homo sapiens.
 XX WO200222644-A1.
 XX PD 21-MAR-2002.
 XX PF 17-SEP-2001; 2001WO-US029207.
 XX PR 15-SEP-2000; 2000US-0232900P.
 XX PA (GENA-) GENAISSANCE PHARM INC.
 XX PI Koshy B, Sanchis A, Tirrell C;
 XX WPI; 2002-383121/41.
 XX PT Novel genetic variants of G protein-coupled receptor 7 gene useful for
 PT therapeutic purposes and for expressing GPR7 protein useful in
 PT identifying drugs to treat psychological and neurological disorders.
 XX PS Claim 16; Page 13; 69pp; English.
 XX CC The invention relates to an isolated polynucleotide (I) comprising a
 CC nucleotide sequence which is a polymorphic variant of a reference
 CC sequence for G-protein coupled receptor 7 (GPR7) gene or its fragment, or
 CC a polymorphic variant of a reference sequence for a GPR7 cDNA or its
 CC fragment. The encoded polypeptide (II) is useful for screening for drugs
 CC targeting the polypeptide. (I) is useful for identifying an association
 CC between a trait such as a clinical response to a drug targeting GPR7 and
 CC a haplotype or haplotype pair of GPR7 gene. Such methods have
 CC applicability in developing diagnostic tests and therapeutic treatments
 CC psychological and neurological disorders. (I) is useful for studying the
 CC expression and function of GPR7 and expressing GPR7 protein for use in
 CC screening for candidate drugs to treat diseases related to GPR7 activity.

CC The polymorphism and haplotype data are useful for validating whether
 CC GPR7 is a suitable target for drugs to treat psychological and
 CC neurological disorders, screening for such drugs and reducing bias in
 CC clinical trials of such drugs. (I) is useful for therapeutic purposes.
 CC Establishing the GPR7 haplotype or haplotype pair of an individual is
 CC useful for improving the efficiency and reliability of several steps in
 CC the discovery and development of drugs for treating diseases associated
 CC with GPR7 activity psychological and neurological disorders. The
 CC haplotyping method is useful to validate GPR7 as a candidate target for
 CC treating a specific condition or disease predicted to be associated with
 CC GPR7 activity. The method is also useful in screening for compounds
 CC targeting GPR7 to treat a specific condition or disease predicted to be
 CC associated with GPR7 activity, e.g. detecting which of the GPR7
 CC haplotypes or haplotype pairs present in individual members of a
 CC population with the specific disease of interest enables one to screen
 CC for compounds that display the highest desired agonist or antagonist
 CC activity for each of the most frequent GPR7 isoforms present in the
 CC disease population. A polymorphic variant of GPR7 is useful in studying
 CC the effect of the variation on the biological activity of GPR7, on the
 CC binding affinity of candidate drugs targeting GPR7 for the treatment of
 CC psychological and neurological disorders and in assays to measure the
 CC binding affinities of one or more candidate drugs targeting the GPR7
 CC protein. (I) is useful for studying expression of the GPR7 isoforms in
 CC vivo, for in vivo screening and testing of drugs against GPR7 protein and
 CC for testing the efficacy of therapeutic agents and compounds for
 CC psychological and neurological disorders in a biological system. Antibody
 CC to (II) is useful for diagnostic and prognostic formats and therapeutic
 CC methods, for immunoprecipitating (II) from solution, for detecting GPR7
 CC protein isoforms in biological samples, frozen tissue sections, cells
 CC which have been fixed or unfixed and prepared on slides, for use in
 CC immunocytochemical, immunohistochemical and immunofluorescence
 CC techniques. ABK70517-ABK70558 represent human GPR7 allele-specific probes
 CC and primers used in haplotyping of human GPR7 as described in the
 CC invention.

XX
 SQ Sequence 15 BP; 5 A; 2 C; 2 G; 5 T; 0 U; 1 Other;

Query Match 40.7%; Score 11; DB 1; Length 15;
 Best Local Similarity 84.6%; Pred. No. 1.2e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAGTTACATG 2234

Db 3 CTAAGTTACATG 15

RESULT 26

AAD15778/c

ID AAD15778 standard; DNA; 15 BP.

XX AAD15778;

DT 15-NOV-2001 (first entry)

DE Human interleukin 15 (IL-15) gene polymorphism detecting ASO primer #26.

XX Human; interleukin 15; IL-15; gene therapy; chromosome 4q31; infection;
 KW drug screening; anthropological lineage; paternity testing; HIV; primer;
 KW Human Immunodeficiency Virus; forensic application; T-cell leukaemia;
 KW ASO; allele-specific oligonucleotide; ss.

XX Homo sapiens.

XX WO200158914-A2.

XX 16-AUG-2001.

XX 08-FEB-2001; 2001WO-US004130.

XX 08-FEB-2000; 2000US-0181059P.

XX (GENA-) GENAISSANCE PHARM INC.

XX

PI

Anastasio AE, Chew A, Denton RR, Nandabalan K, Stephens JC;

XX WPI; 2001-522460/57.

XX Novel polymorphisms comprising one of 11, P81-P811, single nucleotide
 PT polymorphisms in human interleukin-15 gene, and useful for treating
 PT disorders affected by expression of function of interleukin-15 isogene.

XX Claim 16; Page 17; 78pp; English.

XX The present sequence is allele-specific oligonucleotide (ASO) primer
 CC useful for detecting human interleukin-15 (IL-15) gene polymorphism
 CC located on chromosome 4q31. The polymorphic variants of IL-15 genes are
 CC useful for studying the expression and function of IL-15 and expressing
 CC IL-15 protein for use in useful for screening for candidate drugs to
 CC treat diseases related to IL-15 activity. Genotyping or haplotyping an
 CC individual at the novel IL-15 polymorphic sites are useful for studying
 CC population diversity, anthropological lineage, the significance of
 CC diversity and lineage of the phenotypic level, paternity testing,
 CC forensic applications and for identifying associations between IL-15
 CC genetic variation and a trait such as level of drug response or
 CC susceptibility to disease. Identifying an association between a genotype
 CC or haplotype and a trait, is useful for developing diagnostic tests and
 CC therapeutic treatments for infections, human immunodeficiency virus and
 CC T-cell leukaemia. The identification of an association between a clinical
 CC response and a genotype or haplotype (or haplotype pair) for the IL-15
 CC gene may be the basis for designing a diagnostic method to determine
 CC those individuals who will or will not respond to the treatment, or
 CC alternatively, will respond at a lower level and thus may require more
 CC treatment, i.e. a greater dose of a drug. The genotyping or haplotyping
 CC methods are also useful for developing drugs targeting IL-15. The
 CC genotyping and haplotyping methods are also useful in designing clinical
 CC trials. IL-15 DNA is useful for therapeutic purposes for treating
 CC disorders affected by expression of function of novel IL-15 isogene and
 CC also in gene therapy. Expression of an IL-15 isogene may be turned off by
 CC transforming a targetted organ, tissue or cell population of an
 CC expression vector that expresses high levels of untranslatable mRNA for
 CC the isogene

XX Sequence 15 BP; 4 A; 3 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 40.0%; Score 10.8; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.3e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAGTTACATG 2234

Db 14 CATAAGTTACATG 1

RESULT 27

AAF73958

ID AAF73958 standard; DNA; 15 BP.

XX AAF73958;

DT 30-APR-2001 (first entry)

XX Human SLC6A4 allele-specific oligonucleotide primer #78.

XX Solute carrier family 6 neurotransmitter transporter; section 4; SLC6A4;
 KW genotyping; allele specific oligonucleotide; ss.

XX Homo sapiens.

XX WO200109161-A1.

XX 08-FEB-2001.

XX 31-JUL-2000; 2000WO-US020638.

XX 29-JUL-1999; 99US-0146290P.

XX

PA (GENA-) GENAISSANCE PHARM INC.

XX Denton RR, Duda A, Mandabalan K, Sanchis A, Stephens JC;

XX WPI; 2001-123317/13.

XX New isolated polynucleotide comprising a polymorphic variant for the
PT solute carrier family 6 neurotransmitter transporter, serotonin member 4
PT gene for identifying drugs for treating disorders related to expression
PT of the protein.

XX Claim 12; Page 21; 152pp; English.

XX The present invention relates to a polymorphic variant of a reference
CC sequence for the solute carrier family 6 neurotransmitter transporter,
CC serotonin member 4 (SLC6A4) gene or a fragment of it or a sequence
CC complementary to the first sequence. The invention is used in producing a
CC recombinant organism that can be used to express SLC6A4 for protein
CC structure analysis and binding studies. A composition comprising a
CC genotyping oligonucleotide is used to detect a polymorphism in the SLC6A4
CC gene

XX Sequence 15 BP; 7 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 40.0%; Score 10.8; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.3e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTACAT 2233

Db 1 ATCAAAAGTTAGAT 14

RESULT 28

ABH81622/c

ID ABH81622 standard; DNA; 12 BP.

XX ABH81622;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 281615 for detecting SNP TSC0009939.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-13000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 281615; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 3 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 12;

Best Local Similarity 91.7%; Pred. No. 1.2e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237

Db 12 AGTTACGTTT 1

RESULT 29

ABI03636/c

ID ABI03636 standard; DNA; 12 BP.

XX ABI03636;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 303609 for detecting SNP TSC0020550.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-13000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 303609; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 39.5%; Score 10.4; DB 1; Length 12;

Best Local Similarity 91.7%; Pred. No. 1.2e+02;

XX PF 06-APR-2001; 2001WO-IB000713.
 XX XX 07-APR-2000; 2000DE-01019173.
 XX XX (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX XX WPI; 2001-657177/75.
 XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX XX Claim 1; SEQ ID NO 349914; 29pp + Sequence Listing; German.
 XX XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 SQ Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTT 2236
 Db 1 AAGTTATATGTT 12
 RESULT 33
 ABI52271
 ID ABI52271 standard; DNA; 12 BP.
 XX AC ABI52271;
 XX XX 22-FEB-2002 (first entry)
 XX XX Oligonucleotide primer SEQ ID NO 352244 for detecting SNP TSC0047757.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX 06-APR-2001; 2001WO-IB000713.
 XX XX 07-APR-2000; 2000DE-01019173.
 XX XX (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX XX WPI; 2001-657177/75.
 XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
 XX Claim 1; SEQ ID NO 352244; 29pp + Sequence Listing; German.
 XX XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX XX Sequence 12 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
 SQ Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTACATGTT 2235
 Db 1 AAGTTATATGTT 12
 RESULT 34
 ABH71735/C
 ID ABH71735 standard; DNA; 12 BP.
 XX AC ABH71735;
 XX XX 22-FEB-2002 (first entry)
 XX XX Oligonucleotide primer SEQ ID NO 271712 for detecting SNP TSC0002597.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX 06-APR-2001; 2001WO-IB000713.
 XX XX 07-APR-2000; 2000DE-01019173.
 XX XX (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX XX WPI; 2001-657177/75.
 XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX XX Claim 1; SEQ ID NO 271712; 29pp + Sequence Listing; German.
 XX XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX XX Sequence 12 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
 SQ Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTACATGTT 2235
 Db 1 AAGTTATATGTT 12
 RESULT 34
 ABH71735/C
 ID ABH71735 standard; DNA; 12 BP.
 XX AC ABH71735;
 XX XX 22-FEB-2002 (first entry)
 XX XX Oligonucleotide primer SEQ ID NO 271712 for detecting SNP TSC0002597.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX 06-APR-2001; 2001WO-IB000713.
 XX XX 07-APR-2000; 2000DE-01019173.
 XX XX (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX XX WPI; 2001-657177/75.
 XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX XX Claim 1; SEQ ID NO 271712; 29pp + Sequence Listing; German.
 XX XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAGTTACAT 2233
 Db 12 CAAAGTTACAT 1

RESULT 35

ABI49627/C
 ID ABI49627 standard; DNA; 12 BP.
 XX AC
 AC ABI49627;
 XX DT 22-FEB-2002 (first entry)
 XX DE
 XX Oligonucleotide primer SEQ ID NO 349600 for detecting SNP TSC0046229.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX DT 06-APR-2001; 2001WO-IB000713.
 XX PF 07-APR-2000; 2000DE-01019173.
 XX PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 349600; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAGTTACAT 2233
 Db 12 CAAAGTTACAT 1

XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAGTTACAT 2233
 Db 12 CAAAGTTACAT 1

RESULT 36

ABI33967
 ID ABI33967 standard; DNA; 12 BP.
 XX AC
 AC ABI33967;
 XX DT 22-FEB-2002 (first entry)
 XX DE
 XX Oligonucleotide primer SEQ ID NO 333940 for detecting SNP TSC0037852.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX DT 06-APR-2001; 2001WO-IB000713.
 XX PF 07-APR-2000; 2000DE-01019173.
 XX PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 333940; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTTG 2238
 Db 1 GTTACATGTTTG 12

RESULT 37

ABI42142
 ID ABI42142 standard; DNA; 12 BP.

XX AC
 AC ABI42142;
 XX DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 342115 for detecting SNP TSC0007737.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 342115; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 SQ
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 SQ
 XX Query Match 38.5%; Score 10.4; DB 1; Length 12;
 XX Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACATG 2234
 DB 1 AAAAGTTAAATG 12
 RESULT 38
 ABI0774/C
 ID ABI0774 standard; DNA; 12 BP.
 AC
 XX ABI0774;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 307747 for detecting SNP TSC0022661.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 307747; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 XX Query Match 38.5%; Score 10.4; DB 1; Length 12;
 XX Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTT 2237
 DB 12 AGTTATATGTTT 1
 RESULT 39
 ABC72025/C
 ID ABC72025 standard; DNA; 13 BP.
 AC
 XX ABC72025;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 72042 for detecting SNP TSC0018618.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 72042; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic

```
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 5 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238
DB 12 GTTACGTGTTTG 1
|||||
RESULT 40
ABC56759/c
ID ABC56759 standard; DNA; 13 BP.
XX
AC ABC56759;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 56776 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 56776; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 1 Other;

acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238
DB 12 GTTACGTGTTTG 1
|||||
RESULT 40
ABC56759/c
ID ABC56759 standard; DNA; 13 BP.
XX
AC ABC56759;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 56776 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 56776; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 5 C; 1 G; 1 T; 0 U; 0 Other;
```

```
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
DB 13 AGTTATATGTTT 2
|||||
RESULT 41
ABH48560/c
ID ABH48560 standard; DNA; 13 BP.
XX
AC ABH48560;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248537 for detecting SNP TSC0060746.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 248537; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTTACA 2232
DB 13 CCAAAATTTACA 2
|||||
RESULT 42
ABH34854
ID ABH34854 standard; DNA; 13 BP.
```

```

XX ABH34854;
AC
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 234831 for detecting SNP TSC0057326.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 234831; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABH9989, ABH00010-ABH9989 and ABT00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABH9989, ABH00010-ABH9989 and ABT00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2226 AGTTACATGTTT 2237
XX
XX Db 1 AGTTAAATGTTT 12
XX
XX RESULT 43
XX ABF34989
XX ID ABF34989 standard; DNA; 13 BP.
XX
XX AC ABF34989;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 134986 for detecting SNP TSC0033649.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX

```

```

PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 134986; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABH9989, ABH00010-ABH9989 and ABT00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTACAT 2233
XX
XX Db 1 CAAAATTACAT 12
XX
XX RESULT 44
XX ABH48561
XX ID ABH48561 standard; DNA; 13 BP.
XX
XX AC ABH48561;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248538 for detecting SNP TSC0060746.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```



```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 248538; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAGTTACAT 2232
Db 1 CCAAAATTACAT 12
XX
RESULT 45
ABF34988/c
ID ABF34988 standard; DNA; 13 BP.
AC ABF34988;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 134985 for detecting SNP TSC0033649.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 134985; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
XX

```

```

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2222 CAAAAGTTACAT 2233
Db 13 CAAAATTACAT 2
XX
RESULT 46
ABC56760
ID ABC56760 standard; DNA; 13 BP.
XX
AC ABC56760;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 56777 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 56777; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 1 Other;
XX
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX

```



```
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX PS Claim 1; SEQ ID NO 79776; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, cardiovascular, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2220 ACCAAAAGTTTAC 2231
XX Db 2 ACCAAAAGTTTAC 13
XX
XX RESULT 50
XX ABH08279
XX ID ABH08279 standard; DNA; 13 BP.
XX AC ABH08279;
XX XX
XX 22-FEB-2002 (first entry)
XX DT
XX DE Oligonucleotide SEQ ID NO 208256 for detecting SNP TSC0050908.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX XX
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX XX
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
```

```
PS Claim 1; SEQ ID NO 208256; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, cardiovascular, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 13 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTACAT 2233
XX Db 2 CAAAAGTTTACAT 13
XX
XX RESULT 51
XX ABH34855/c
XX ID ABH34855 standard; DNA; 13 BP.
XX AC ABH34855;
XX XX
XX 22-FEB-2002 (first entry)
XX DT
XX DE Oligonucleotide SEQ ID NO 234832 for detecting SNP TSC0057326.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX XX
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX XX
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX PS Claim 1; SEQ ID NO 234832; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, cardiovascular, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
```

```

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
DB 13 AGTTAAATGTTT 2

RESULT 52
ABH48563
ID ABH48563 standard; DNA; 13 BP.
XX
AC ABH48563;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248540 for detecting SNP TSC0060746.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248540 for detecting SNP TSC0060746.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 248540; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTTACA 2232
DB 1 CCAAAACTTACA 12

RESULT 54
ABC56758
ID ABC56758 standard; DNA; 13 BP.
XX
AC ABC56758;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 56775 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 248540; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTTACA 2232
DB 1 CCAAAACTTACA 12

```

```

RESULT 53
ABH08276/c
ID ABH08276 standard; DNA; 13 BP.
XX
AC ABH08276;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 208253 for detecting SNP TSC0050908.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 208253; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACAT 2233
DB 12 CAAAATTTCAT 1

RESULT 54
ABC56758
ID ABC56758 standard; DNA; 13 BP.
XX
AC ABC56758;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 56775 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 208253; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACAT 2233
DB 12 CAAAATTTCAT 1

```


CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTT 2237

Db 12 AGTTACGTTT 1

RESULT 57

ABC79758/c
 ID ABC79758 standard; DNA; 13 BP.

AC ABC79758;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 79775 for detecting SNP TSC0020261.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 79775; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2220 ACCAAAGTTTAC 2231
 Db 12 ACCAAAGTTTAC 1

RESULT 58

ABC56761/c
 ID ABC56761 standard; DNA; 13 BP.

AC ABC56761;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 56778 for detecting SNP TSC0015380.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 56778; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 6 A; 3 C; 1 G; 2 T; 0 U; 1 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTT 2237

Db 13 AGTTACGTTT 2

RESULT 59

ABH08277
 ID ABH08277 standard; DNA; 13 BP.

XX ABH08277;

XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 208254 for detecting SNP TSC0050908.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 208254; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAGCTTACAT 2233
Db 2 CAAAGTTTACAT 13
RESULT 60
ABC72020
ID ABC72020 standard; DNA; 13 BP.
XX AC ABC72020;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 72037 for detecting SNP TSC0018618.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PD 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 72037; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTTG 2238
Db 2 GTTATGTTTG 13
RESULT 61
ABC72024
ID ABC72024 standard; DNA; 13 BP.
XX AC ABC72024;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 72041 for detecting SNP TSC0018618.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 72041; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 1 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238

DB 2 GTTACGTTGTTG 13

RESULT 62

ABH08278/c
ID ABH08278 standard; DNA; 13 BP.

AC ABH08278;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 208255 for detecting SNP TSC0050908.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 208255; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACAT 2233

DB 12 CAAAACCTACAT 1

RESULT 63

ABK23686/c
ID ABK23686 standard; DNA; 10 BP.

AC ABK23686;

XX 09-APR-2002 (first entry)

XX Transcript tag DNA sequence #275 induced or suppressed by N-myc.

XX Myc-dependent downstream gene; neoplastic; cancer; growth; invasion;
XX spread; myc target; myc tag; SAGE; serial analysis of gene expression;
XX myc oncogene; N-myc; human neuroblastoma; cytostatic; ds.

OS Homo sapiens.

XX WO200185941-A2.

XX 15-NOV-2001.

XX 11-MAY-2001; 2001WO-NL000361.

XX 11-MAY-2000; 2000EP-00201698.

XX 29-JUN-2000; 2000EP-00202284.

XX (UYAM-) UNIV AMSTERDAM ACAD ZIEKENHUIS BIJ VAN.

XX Versteeg R, Caron HN;

XX WPI; 2002-066603/09.

XX A new nucleic acid library of myc-dependent downstream genes capable of
XX supporting a neoplastic characteristic of cancer is useful to find new
XX therapies and diagnoses for cancer.

XX Disclosure; Page 56; 69pp; English.

XX The present invention relates to a nucleic acid library comprising myc-
XX dependent downstream genes or their functional fragments essentially
XX capable of supporting a neoplastic character of cancer such as growth,
XX invasion or spread. These myc target or tag sequences are identified by
XX SAGE (serial analysis of gene expression). The library is useful to find
XX new diagnoses and treatments for cancer. The invention is also useful to
XX enhance production of recombinant proteins in a production system with
XX high expression of endogenous or transfected myc oncogenes. ABK23412-
XX ABK23828 represent transcript tag DNA sequences that are activated or
XX repressed by N-myc in human neuroblastoma

XX SQ Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 37.0%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAAGTTA 2230

DB 10 CCAAAAAGTTA 1

RESULT 64

ABH08935/c
ID ABH08935 standard; DNA; 13 BP.
XX AC ABH08935;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 208912 for detecting SNP TSC0007531.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 208912; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 6 A; 3 C; 1 G; 2 T; 0 U; 1 Other;

Query Match 37.0%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237

DB 12 AGTTACGCTGTT 1

RESULT 65

ABC90726/c
ID ABC90726 standard; DNA; 13 BP.
XX AC ABC90726;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 90743 for detecting SNP TSC0022741.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

PS Claim 1; SEQ ID NO 90743; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;

Query Match 37.0%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTTA 2230

DB 13 RACCAAAAATTA 2

RESULT 66

ABH08934
ID ABH08934 standard; DNA; 13 BP.
XX AC ABH08934;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 208911 for detecting SNP TSC0007531.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 208911; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 1 Other;
 Query Match 37.0%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 1.6e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTT 2237
 DB 2 AGTTACGTGTY 13
 RESULT 67
 ABC90727
 ID ABC90727 standard; DNA; 13 BP.
 XX
 AC ABC90727;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 90744 for detecting SNP TSC0022741.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR Oligonucleotide SEQ ID NO 90744 for detecting SNP TSC0022741.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 90744; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
 Query Match 37.0%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 1.6e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTTA 2230
 DB 1 RACCAAAAGTTA 12
 RESULT 68
 ABC70173/c
 ID ABC70173 standard; DNA; 13 BP.
 XX
 AC ABC70173;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 70190 for detecting SNP TSC0018249.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 70190; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;

```

Query Match      36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATGT 2235
DB 13 AAAAGTTATATT 1

RESULT 69
ABC24649
ID ABC24649 standard; DNA; 13 BP.
AC ABC24649;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 24666 for detecting SNP TSC0005912.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 24666; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match      36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTACAT 2233
DB 1 CCAACATTCAT 13

RESULT 70
ABC83940
ID ABC83940 standard; DNA; 13 BP.

```

```

XX ABC83940;
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 83957 for detecting SNP TSC0021124.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 83957; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match      36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTTG 2238
DB 1 AGTTACGCGTTTG 13

RESULT 71
ABC89770
ID ABC89770 standard; DNA; 13 BP.
XX
XX ABC89770;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 89787 for detecting SNP TSC0022507.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX

```


CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2224 AAGTTACATGTT 2236
 DB 1 AATTTATATGTT 13

RESULT 74
 ABH35801
 ID ABH35801 standard; DNA; 13 BP.
 XX
 AC ABH35801;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 235778 for detecting SNP TSC0009202.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 235778; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 3 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTTACA 2232
 DB 1 AACAAAGTTTACA 13

RESULT 75
 ABC23838/C
 ID ABC23838 standard; DNA; 13 BP.
 XX
 AC ABC23838;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 23855 for detecting SNP TSC0005417.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 23855; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTTACA 2232
 DB 13 ACTAAAGTTTACA 1

RESULT 76
 ABC24988
 ID ABC24988 standard; DNA; 13 BP.
 XX
 AC ABC24988;
 XX
 DT 20-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 25005 for detecting SNP TSC0006056.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 25005; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
 XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 2224 AAAGTTACATGTT 2236
 Db 1 AAAGATATATGTT 13
 RESULT 77
 ABC30596
 ID ABC30596 standard; DNA; 13 BP.
 AC ABC30596;
 AC ABC30596;
 XX 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 30613 for detecting SNP TSC0009381.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 30613; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 2224 AAAGTTACATGTT 2236
 Db 1 AAAGTTGATGTT 13
 RESULT 78
 ABC83931/c
 ID ABC83931 standard; DNA; 13 BP.
 AC ABC83931;
 AC ABC83931;
 XX 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 83948 for detecting SNP TSC0021124.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX 06-APR-2001; 2001WO-IB000713.

PS Claim 1; SEQ ID NO 83948; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 6 A; 3 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
||||| |||||

Db 13 AGTTACGTTG 1

RESULT 79

ABC84116
ID ABC84116 standard; DNA; 13 BP.

XX AC ABC84116;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 84133 for detecting SNP TSC0021160.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single-nucleotide polymorphisms and cytosine PT methylation status.

XX Claim 1; SEQ ID NO 84133; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGTT 2236
||||| |||||

Db 1 AAAGTTATATTT 13

RESULT 80

ABC9375
ID ABC9375 standard; DNA; 13 BP.

XX AC ABC9375;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 89392 for detecting SNP TSC0022411.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single-nucleotide polymorphisms and cytosine PT methylation status.

XX Claim 1; SEQ ID NO 89392; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTACA 2232
||||| |||||

Db 1 ACCTAAAATTACA 13

PI Olek A, Piepenbrock C, Berlin K;
DR WPI; 2001-657177/75.
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 244330; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 2;
QY 2220 ACCAAAGTTTACA 2232
Db 1 ACCAAAGTTTACA 13
RESULT 84
ABC23839
ID ABC23839 standard; DNA; 13 BP.
XX
XX ABC23839;
AC
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 23856 for detecting SNP TSC0005417.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 23856; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 2;
QY 2220 ACCAAAGTTTACA 2232
Db 1 ACTAAAGTTTACA 13
RESULT 85
ABC78604
ID ABC78604 standard; DNA; 13 BP.
XX
XX ABC78604;
AC
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 78621 for detecting SNP TSC0020009.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 78621; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
QY

Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
Db 1 AGTTATGTTG 13

RESULT 86
ABC56765/c
ID ABC56765 standard; DNA; 13 BP.
AC ABC56765;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 56782 for detecting SNP TSC0015381.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 56782; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 4 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
Db 13 AAGTTACGGGTTT 1

RESULT 87
ABC12793
ID ABC12793 standard; DNA; 13 BP.
XX
XX ABC12793;

XX
DT 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 12800 for detecting SNP TSC0002995.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 12800; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTACAT 2233
Db 1 CCAAAATTTAAAT 13

RESULT 88
ABC89771/c
ID ABC89771 standard; DNA; 13 BP.
XX
XX ABC89771;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 89788 for detecting SNP TSC0022507.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

DB 13 AAATTACATTTT 1

RESULT 91

ABF53803
 ID ABF53803 standard; DNA; 13 BP.

AC ABF53803;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 153800 for detecting SNP TSC0038881.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 153800; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 3 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTTACA 2232

|||||

Db 1 ACAAAAGCTTACA 13

RESULT 92

ABH52974/C
 ID ABH52974 standard; DNA; 13 BP.

AC ABH52974;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 252951 for detecting SNP TSC0061698.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 252951; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

DB 13 AAATTACATTTT 1

RESULT 93

ABC70172
 ID ABC70172 standard; DNA; 13 BP.

AC ABC70172;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 70189 for detecting SNP TSC0018249.

```
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 70189; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTACATGTT 2235
XX
XX Db 1 AAAAGTATATGTT 13
XX
XX RESULT 94
XX ABC50758
XX ID ABC50758 standard; DNA; 13 BP.
XX
XX AC ABC50758;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 50775 for detecting SNP TSC0014233.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PS 07-APR-2000; 2000DE-01019173.
XX
```

```
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 50775; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2225 AAGTTACATGTTT 2237
XX
XX Db 1 AAGTTATATGTT 13
XX
XX RESULT 95
XX ABC36264
XX ID ABC36264 standard; DNA; 13 BP.
XX
XX AC ABC36264;
XX
XX DT 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 36281 for detecting SNP TSC0011393.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 36281; 29pp + Sequence Listing; German.
XX
```

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
 Db 1 AATTACGCTTTT 13

RESULT 96
 ABC89773/c
 ID ABC89773 standard; DNA; 13 BP.
 AC ABC89773;
 XX 21-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 89790 for detecting SNP TSC0022507.
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PD 18-OCT-2001.
 PF 05-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 89790; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
 Db 13 AAGTTATATTTT 1

RESULT 97
 ABH35800/c
 ID ABH35800 standard; DNA; 13 BP.
 AC ABH35800;
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 235777 for detecting SNP TSC0009202.
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 235777; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 2 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTTACA 2232
 Db 13 AACAAAGTTTACA 1

RESULT 98
 ABH50898

```

ID ABH50898 standard; DNA; 13 BP.
XX
AC ABH50899;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 250875 for detecting SNP TSC0061240.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
FR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 250875; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2224 AAAGTTACATGTT 2236
DB 1 AAAGTTAGATATT 13
XX
XX RESULT 99
XX ABC83933/C
XX ID ABC83933 standard; DNA; 13 BP.
XX
AC ABC83933;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 83950 for detecting SNP TSC0021124.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.

```

```

XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 83950; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTG 2238
DB 13 AGTTATATGTCG 1
XX
XX RESULT 100
XX ABC83943/C
XX ID ABC83943 standard; DNA; 13 BP.
XX
AC ABC83943;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 83960 for detecting SNP TSC0021124.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
FR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 8360; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 4 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 DB 13 AGTTACATGTTG 1
 RESULT 101
 ABF41325/C
 ID ABF41325 standard; DNA; 13 BP.
 XX
 AC ABF41325;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 141322 for detecting SNP TSC0035419.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Claim 1; SEQ ID NO 141322; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACATGT 2235
 DB 13 AAAAGTTATTTGT 1
 RESULT 102
 ABC24989/C
 ID ABC24989 standard; DNA; 13 BP.
 XX
 AC ABC24989;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 25006 for detecting SNP TSC0006056.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 CC Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 25006; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGTT 2236
 DB 13 AAAGATATATGTT 1

RESULT 103
 ABC58322
 ID ABC58322 standard; DNA; 13 BP.
 XX
 AC ABC58322;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 58339 for detecting SNP TSC0015654.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 58339; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
 XX
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX

QY 2215 GTGTGACCAAAAG 2227
 DB 1 GTGTGACCAAGG 13

RESULT 104
 ABF70021
 ID ABF70021 standard; DNA; 13 BP.
 XX
 AC ABF70021;
 XX
 DT 22-FEB-2002 (first entry)
 XX

XX
 DE Oligonucleotide SEQ ID NO 170018 for detecting SNP TSC0042449.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 170018; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
 XX
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX

QY 2225 AAGTTACATGTT 2237
 DB 1 AAGTTACATATT 13

RESULT 105
 ABF73957/c
 ID ABF73957 standard; DNA; 13 BP.
 XX
 AC ABF73957;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 173954 for detecting SNP TSC0043299.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB0000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 173954; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
SQ
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAGTTACATGTT 2236
DB 13 AATTATATGTT 1
XX
XX RESULT 106
XX ABH10604
XX ID ABH10604 standard; DNA; 13 BP.
XX AC ABH10604;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 210581 for detecting SNP TSC0051414.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 210581; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
SQ
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2225 AAGTTACATGTT 2237
DB 1 AATTACATGTT 13
XX
XX RESULT 107
XX ABH35793
XX ID ABH35793 standard; DNA; 13 BP.
XX AC ABH35793;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 235770 for detecting SNP TSC0009202.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 235770; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.8%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2225 AAGTTACATGTT 2237
DB 1 AATTACATGTT 13
XX
XX RESULT 107
XX ABH35793
XX ID ABH35793 standard; DNA; 13 BP.
XX AC ABH35793;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 235770 for detecting SNP TSC0009202.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTTACA 2232
Db 1 AAAAAAATTACA 13
|||||
|||||

RESULT 108
ABC50760
ID ABC50760 standard; DNA; 13 BP.
XX AC ABC50760;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 50777 for detecting SNP TSC0014233.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 50777; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
Db 13 AAGTTAGATGTGT 1
|||||
|||||

RESULT 110
ABC83941/C
ID ABC83941 standard; DNA; 13 BP.
XX AC ABC83941;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 83958 for detecting SNP TSC0021124.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 83958; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABT0010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
Db 13 AGTTACGCTTG 1

RESULT 111
ABC11551/c
ID ABC11551 standard; DNA; 13 BP.
XX
XX ABC11551;
AC
XX
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 11550 for detecting SNP TSC0002804.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PP
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA

XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 11550; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABT0010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATGT 2235
Db 13 AAATGTTAATGT 1

RESULT 112
ABF93510/c
ID ABF93510 standard; DNA; 13 BP.
XX
XX ABF93510;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 193507 for detecting SNP TSC0047603.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PP
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 193507; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTTACA 2232
Db 13 ACCAAACTTAA 1
|||||

RESULT 113
ABC98511
ID ABC98511 standard; DNA; 13 BP.
XX AC ABC98511;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 98528 for detecting SNP TSC0024492.
XX SN: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX OS WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 98528; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTTACA 2232
Db 13 ACCAAACTTAA 1
|||||

RESULT 113
ABC98511
ID ABC98511 standard; DNA; 13 BP.
XX AC ABC98511;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 98528 for detecting SNP TSC0024492.
XX SN: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX OS WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 98528; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTTACA 2232
Db 1 ACCAAACTTACA 13
|||||

RESULT 114
ABC83930
ID ABC83930 standard; DNA; 13 BP.
XX AC ABC83930;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 83947 for detecting SNP TSC0021124.
XX SN: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX OS WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 83947; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2226 AGTTACATGTTG 2238
Db 1 AGTTACATGTTG 13
|||||

RESULT 115
ABC83942
ID ABC83942 standard; DNA; 13 BP.
XX

AC ABC83942;
 XX
 XX DT 21-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 83959 for detecting SNP TSC0021124.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPiG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 83959; 29pp + Sequence Listing; German.
 XX
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ASI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 2 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2226 AGTTACATGTTG 2238
 XX
 XX DB 1 AGTTACATGTTG 13
 XX
 XX RESULT 116
 XX ABC36989/c
 XX ID ABC36989 standard; DNA; 13 BP.
 XX
 XX AC ABC36989;
 XX
 XX XX 20-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 37006 for detecting SNP TSC0011565.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX

XX 18-OCT-2001.
 XX
 XX PD 06-APR-2001; 2001WO-IB000713.
 XX
 XX PF 07-APR-2000; 2000DE-01019173.
 XX
 XX PR (EPiG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 37006; 29pp + Sequence Listing; German.
 XX
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2224 AAAGTTACATGTT 2236
 XX
 XX DB 13 AAAGTTACATGTT 1
 XX
 XX RESULT 117
 XX ABH10605/c
 XX ID ABH10605 standard; DNA; 13 BP.
 XX
 XX AC ABH10605;
 XX
 XX XX 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 210582 for detecting SNP TSC0051414.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPiG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 210582; 29pp + Sequence Listing; German.

PS This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

Db 13 AATTACATGTTT 1

RESULT 118

ABH52975

ID ABH52975 standard; DNA; 13 BP.

XX ABH52975;

AC ABH52975;

XX 22-FEB-2002 (first entry)

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 252952 for detecting SNP TSC0061698.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 252952; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

Db 1 AATTACATGTTT 13

RESULT 119

ABC50759/C

ID ABC50759 standard; DNA; 13 BP.

XX ABC50759;

AC ABC50759;

XX 21-FEB-2002 (first entry)

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 50776 for detecting SNP TSC0014233.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 50776; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

```

Db      13 AAGTTATATGTT 1
      ||||| |||||
RESULT 120
ABC36265/c
ID      ABC36265 standard; DNA; 13 BP.
XX
XX
AC      ABC36265;
XX
XX      20-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 36282 for detecting SNP TSC0011393.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      Oligonucleotide SEQ ID NO 36282 for detecting SNP TSC0011393.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 36282; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 7 A; 2 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match      36.3%; Score 9.8; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX      Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX      QY      2225 AAGTTACATGTTT 2237
XX      ||||| |||||
Db      13 AATTTACGTTT 1
      ||||| |||||
RESULT 121
ABF68251/c
ID      ABF68251 standard; DNA; 13 BP.
XX
XX
AC      ABF68251;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 168248 for detecting SNP TSC0042083.
XX

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 168248; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX      Query Match      36.3%; Score 9.8; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX      Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX      QY      2223 AAAAGTTACATGT 2235
XX      ||||| |||||
Db      13 AAAATTAAATGT 1
      ||||| |||||
RESULT 122
ABF69708
ID      ABF69708 standard; DNA; 13 BP.
XX
XX
AC      ABF69708;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 169705 for detecting SNP TSC0007737.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX

```


PR 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 169705; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2224 AAGTTACATGTT 2236
DB 1 AATGTATATGTT 13
RESULT 123
ABF76603/C
ID ABF76603 standard; DNA; 13 BP.
XX
XX ABF76603;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 176600 for detecting SNP TSC0043818.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 176600; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTG 2238
DB 13 AGTTAAATTTTG 1
RESULT 124
ABH63860
ID ABH63860 standard; DNA; 13 BP.
XX
XX ABH63860;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 263837 for detecting SNP TSC0063954.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 263837; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

```

XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTG 2238
Db 1 AGTTTATGTTG 13

RESULT 125
ABC36988
ID ABC36988 standard; DNA; 13 BP.
XX AC ABC36988;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 37005 for detecting SNP TSC0011565.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 37005; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2224 AAAGTTACATGTT 2236
Db 1 AAAGTTAGATTTT 13

RESULT 126
ABC36988
ID ABC36988 standard; DNA; 13 BP.
XX AC ABC36988;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 37005 for detecting SNP TSC0011565.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 37005; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2224 AAAGTTACATGTT 2236
Db 1 AAAGTTAGATTTT 13

RESULT 126
ABC36988
ID ABC36988 standard; DNA; 13 BP.
XX AC ABC36988;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 114293 for detecting SNP TSC0028617.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

```

XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTTACAT 2233
Db 13 CCAAAAGTTTAAAT 1

RESULT 127
ABF14296
ID ABF14296 standard; DNA; 13 BP.
XX AC ABF14296;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 114293 for detecting SNP TSC0028617.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

```
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 114293; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2226 AGTTACATGTTTG 2238
DB 1 AGTTAAATATTTG 13
RESULT 128
ABC89772
XX ABC89772 standard; DNA; 13 BP.
XX AC ABC89772;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 89789 for detecting SNP TSC0022507.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI
```

```
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 89789; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2225 AAGTTACATGTTT 2237
DB 1 AAGTTATATTTT 13
RESULT 129
ABF76602
XX ABF76602 standard; DNA; 13 BP.
XX AC ABF76602;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 176599 for detecting SNP TSC0043818.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 176599; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
```

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 Db 1 AGTTAAATTTTG 13
 RESULT 130
 ABH35792/c
 ID ABH35792 standard; DNA; 13 BP.
 XX
 AC ABH35792;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 235769 for detecting SNP TSC0009202.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 235769; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 Db 1 AGTTAAATTTTG 13
 RESULT 132
 ABC56764
 ID ABC56764 standard; DNA; 13 BP.
 XX
 AC ABC56764;
 XX

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAGATTACA 2232
 Db 13 AACAAAATTACA 1
 RESULT 131
 ABH63861/c
 ID ABH63861 standard; DNA; 13 BP.
 XX
 AC ABH63861;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 263838 for detecting SNP TSC0063954.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 263838; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 Db 13 AGTTTATGTTG 1
 RESULT 132
 ABC56764
 ID ABC56764 standard; DNA; 13 BP.
 XX
 AC ABC56764;
 XX

```

DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 56781 for detecting SNP TSC0015381.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 56781; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 1 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2225 AAGTTACAGGTTT 2237
DB 1 AAGTTACGGGTTT 13
    |||||
    |||||

RESULT 133
ABF93511
ID ID ABF93511 standard; DNA; 13 BP.
XX
XX AC ABF93511;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 193508 for detecting SNP TSC0047603.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.

```

```

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 193508; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2220 ACCAAAGATTACA 2232
DB 1 ACCAAAGCTTAAA 13
    |||||
    |||||

RESULT 134
ABF53802/C
ID ID ABF53802 standard; DNA; 13 BP.
XX
XX AC ABF53802;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 153799 for detecting SNP TSC0038881.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```

```

PT methylation status.
PS Claim 1; SEQ ID NO 153799; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB 13 ACAAAAGTTTACA 1
|||||
RESULT 135
ABH50899/c
ID ABH50899 standard; DNA; 13 BP.
XX
XX ABH50899;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 250876 for detecting SNP TSC0061240.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 250876; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB 13 ACAAAAGTTTACA 1
|||||
RESULT 136
ABC48259/c
ID ABC48259 standard; DNA; 13 BP.
XX
XX ABC48259;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 48276 for detecting SNP TSC0013776.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 48276; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATGTT 2236
DB 13 AGAGTTATATGTT 1
|||||

```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 30614; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATGTT 2236
Db 13 AAAGTTGATGTT 1
RESULT 139
ABC84117/C
ID ABC84117 standard; DNA; 13 BP.
XX
XX ABC84117;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 84134 for detecting SNP TSC0021150.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

RESULT 137
ABC73509
ID ABC73509 standard; DNA; 13 BP.
XX
XX ABC73509;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 73526 for detecting SNP TSC0018934.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 73526; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAAGTTACA 2232
Db 1 ACCAAAAAATACA 13
RESULT 138
ABC30597/C
ID ABC30597 standard; DNA; 13 BP.
XX
XX ABC30597;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 30614 for detecting SNP TSC0009381.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX


```
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTACA 2232
Db 13 ACCTAAATTTG 1

RESULT 142
ABF67701/c
ID ABF67701 standard; DNA; 13 BP.
XX
AC ABF67701;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 167698 for detecting SNP TSC0041968.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 167698; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGTT 2236
Db 13 AAAGTTATTTGTT 1

RESULT 143
ABF14297/c
ID ABF14297 standard; DNA; 13 BP.
XX
AC ABF14297;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 114294 for detecting SNP TSC0028617.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 114294; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
Db 13 AGTTAAATTTG 1

RESULT 144
ABH22578
ID ABH22578 standard; DNA; 13 BP.
XX
AC ABH22578;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 222555 for detecting SNP TSC0054151.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
```


CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 3 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAGTGTACA 2232
 DB 13 ACCAAGTGTATA 1

RESULT 147
 ABC48258
 ID ABC48258 standard; DNA; 13 BP.
 XX
 AC ABC48258;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 48275 for detecting SNP TSC0013776.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 48275; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAGTTATATGTT 2236
 DB 1 AAGTTATATGTT 13

RESULT 148
 ABC73508/C
 ID ABC73508 standard; DNA; 13 BP.
 XX
 AC ABC73508;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 73525 for detecting SNP TSC0018934.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 73525; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAGTGTACA 2232
 DB 13 ACCAAGTGTATA 1

RESULT 149
 ABC98510/C
 ID ABC98510 standard; DNA; 13 BP.
 XX
 AC ABC98510;
 XX
 DT 21-FEB-2002 (first entry)
 XX

```
DE Oligonucleotide SEQ ID NO 98527 for detecting SNP TSC0024492.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 98527; 28pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABR00010-ABR82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB 13 ACCAAACCTACA 1
RESULT 150
ABC24648/C
ID ABC24648 standard; DNA; 13 BP.
XX AC ABC24648;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 24665 for detecting SNP TSC0005912.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 98527; 28pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABR00010-ABR82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB 13 ACCAAACCTACA 1
RESULT 150
ABC24648/C
ID ABC24648 standard; DNA; 13 BP.
XX AC ABC24648;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 24665 for detecting SNP TSC0005912.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 24665; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABR00010-ABR82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2221 CCAAAGTTTACAT 2233
DB 13 CCAAACTTACAT 1
RESULT 151
ABC78605/C
ID ABC78605 standard; DNA; 13 BP.
XX AC ABC78605;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 78622 for detecting SNP TSC0020009.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
```

PS Claim 1; SEQ ID NO 78622; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
DB 13 AGTTATGTTTG 1

RESULT 152
ABH10602
ID ABH10602 standard; DNA; 13 BP.
XX
AC ABH10602;
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 210579 for detecting SNP TSC0051414.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PI WO200177384-A2.
PN
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PT
XX
PS Claim 1; SEQ ID NO 210579; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
DB 1 AATTAAATGTTT 13

RESULT 153
ABH44355
ID ABH44355 standard; DNA; 13 BP.
XX
AC ABH44355;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 244332 for detecting SNP TSC0059632.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PI WO200177384-A2.
PN
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PT
XX
PS Claim 1; SEQ ID NO 244332; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 3 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTTACA 2232
DB 1 ACCAAAGTTTATA 13

```
RESULT 154
ABC58323/c
ID ABC58323 standard; DNA; 13 BP.
XX
XX ABC58323;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 58340 for detecting SNP TSC0015654.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 58340; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 6 C; 1 G; 4 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 6 C; 1 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.8%; Pred. NO. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2215 GTGTGACCAAAAG 2227
OY 13 GTGTGACGAAGG 1
Db
XX
XX RESULT 155
ABC83932
ID ABC83932 standard; DNA; 13 BP.
XX
XX ABC83932;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 83949 for detecting SNP TSC0021124.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 83949; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.8%; Pred. NO. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2226 AGTTACATGTTG 2238
OY 1 AGTTATGTTG 13
Db
XX
XX RESULT 156
ABC11550
ID ABC11550 standard; DNA; 13 BP.
XX
XX ABC11550;
AC
XX
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 11549 for detecting SNP TSC0002804.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX
```



```
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGTT 2236
Db 1 AAAGTTATTGTT 13

RESULT 159
ABH44352/c
ID ABH44352 standard; DNA; 13 BP.
XX AC ABH44352;
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 244329 for detecting SNP TSC0059632.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 244329; 299p + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI92073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTTACA 2232
Db 13 ACCAAAATTATA 1

RESULT 160
ADL09225/c
ID ADL09225 standard; DNA; 14 BP.
XX AC ADL09225;
```

```
XX 20-MAY-2004 (first entry)
DT SP6 promoter DNA fragment #4.
XX DE
XX DE amplification; primer; promoter; RNA polymerase; ds.
XX KW Enterobacteria phage SP6.
XX OS
XX XX
XX FN WO2004016757-A2.
XX PD 26-FEB-2004.
XX PF 15-AUG-2003; 2003WO-US025564.
XX PR 16-AUG-2002; 2002US-0404075P.
XX PA (REGC ) UNIV CALIFORNIA.
XX PI Karin M, Park JM;
XX DR WPI; 2004-203788/19.
XX PT Producing a nucleic acid sequence comprises amplifying double stranded
XX PT DNA sequence in the presence of first and second primers to produce a
XX PT first nucleic acid molecule having the double stranded DNA sequence in a
XX PT head to head orientation.
XX PS Disclosure; SEQ ID NO 41; 55pp; English.
XX CC This invention describes a novel method for producing a nucleic acid
XX CC sequence comprising amplifying the double stranded DNA sequence of
XX CC interest in the presence of the first primer and the second primer to
XX CC produce a first nucleic acid molecule comprising the double stranded DNA
XX CC sequence of interest flanked by at least a portion of the first promoter
XX CC in a head to head orientation. The method involves providing RNA
XX CC polymerase that specifically binds to the first promoter and contacting
XX CC the first nucleic acid molecule with the RNA polymerase to produce double
XX CC stranded RNA that is complementary to the double stranded DNA sequence of
XX CC interest. This method further comprises providing a third primer
XX CC complementary to at least a portion of the first promoter and amplifying
XX CC the first nucleic acid molecule produced in the presence of the third
XX CC primer to produce a second nucleic acid molecule comprising the double
XX CC stranded DNA sequence of interest flanked by the first promoter in a head
XX CC to head orientation. The method further comprises providing RNA
XX CC polymerase that specifically binds to the first promoter and contacting
XX CC the second nucleic acid molecule with the RNA polymerase to produce
XX CC double stranded RNA that is complementary to the double stranded DNA
XX CC sequence of interest. The second strand of the double-stranded DNA
XX CC sequence of interest comprises at least a portion of a second promoter.
XX CC The second promoter is different from the first promoter. The first
XX CC promoter comprises T7, T3 or SP6 promoter. The first strand of the double
XX CC stranded DNA comprises a nucleotide sequence linked to the 3' end of the
XX CC first promoter, and the first primer further comprises a second sequence
XX CC complementary to the nucleotide sequence, where the second sequence is
XX CC linked to the 3' end of the first sequence of the first primer. The first
XX CC primer comprises a sequence complementary to T7, T3 or SP6 promoter. The
XX CC first sequence comprises a second primer complementary to at least a
XX CC portion of a promoter. The methods and kits are useful for producing
XX CC nucleic acid sequences as powerful alternative tools for functional
XX CC genomics.
XX SQ Sequence 14 BP; 4 A; 2 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAAAA 2226
Db 14 AGTGTACCTAAA 2
```


RESULT 161
ADL09227/C
ID ADL09227 standard; DNA; 14 BP.
XX
AC ADL09227;
XX
AC
XX
DT 20-MAY-2004 (first entry)
XX
DE SP6 promoter DNA fragment #6.
XX
KW amplification; primer; promoter; RNA polymerase; ds.
XX
OS Enterobacteria phage SP6.
XX
PN WO2004016757-A2.
XX
PN
XX
PD 26-FEB-2004.
XX
PF 15-AUG-2003; 2003WO-US025556A.
XX
PR 16-AUG-2002; 2002US-0404075P.
XX
XX (REGC) UNIV CALIFORNIA.
XX
PA Karin M. Park JM;
XX
PI
XX
DR WPI; 2004-203788/19.
XX
XX
PT Producing a nucleic acid sequence comprises amplifying double stranded
PT DNA sequence in the presence of first and second primers to produce a
PT first nucleic acid molecule having the double stranded DNA sequence in a
PT head to head orientation.
XX
PS Disclosure; SEQ ID NO 43; 55pp; English.
XX
CC This invention describes a novel method for producing a nucleic acid
CC sequence comprising amplifying the double stranded DNA sequence of
CC interest in the presence of the first primer and the second primer to
CC produce a first nucleic acid molecule comprising the double stranded DNA
CC sequence of interest flanked by at least a portion of the first promoter
CC in a head to head orientation. The method involves providing RNA
CC polymerase that specifically binds to the first promoter and contacting
CC the first nucleic acid molecule with the RNA polymerase to produce double
CC stranded RNA that is complementary to the double stranded DNA sequence of
CC interest. This method further comprises providing a third primer
CC complementary to at least a portion of the first promoter and amplifying
CC the first nucleic acid molecule produced in the presence of the third
CC primer to produce a second nucleic acid molecule comprising the double
CC stranded DNA sequence of interest flanked by the first promoter in a head
CC to head orientation. The method further comprises providing RNA
CC polymerase that specifically binds to the first promoter and contacting
CC the second nucleic acid molecule with the RNA polymerase to produce
CC double stranded RNA that is complementary to the double stranded DNA
CC sequence of interest. The second strand of the double stranded DNA
CC sequence of interest comprises at least a portion of a second promoter.
CC The second promoter is different from the first promoter. The first
CC promoter comprises T7, T3 or SP6 promoter. The first strand of the double
CC stranded DNA comprises a nucleotide sequence linked to the 3' end of the
CC first promoter, and the first primer further comprises a second sequence
CC complementary to the nucleotide sequence, where the second sequence is
CC linked to the 3' end of the first sequence of the first primer. The first
CC primer comprises a sequence complementary to T7, T3 or SP6 promoter. The
CC first sequence comprises a second primer complementary to at least a
CC portion of a promoter. The methods and kits are useful for producing
CC nucleic acid sequences as powerful alternative tools for functional
CC genomics.
XX
SQ Sequence 14 BP; 4 A; 2 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2214 AGTGTGACCAAAA 2226
Db 13 AGTGTGACCTAAA 1
RESULT 162
AAH55111/C
ID AAH55111 standard; DNA; 11 BP.
XX
AC AAH55111;
XX
DT 03-SEP-2001 (first entry)
XX
DE Genomic DNA methylation parallel detection associated DNA fragment #13.
XX
KW DNA methylation; parallel detection; 5-umethylated cytosine; CpG; CpNpg;
KW amplification; transcription regulation; genetic imprinting;
KW tumorigenesis; primer; ss.
XX
OS Unidentified.
XX
PN WO200142493-A2.
XX
PN
XX
PD 14-JUN-2001.
XX
PF 06-DEC-2000; 2000WO-DE004381.
XX
PR 06-DEC-1999; 99DE-01059691.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A. Piepenbrock C;
XX
DR WPI; 2001-381705/40.
XX
PT Parallel detection of the methylation pattern of many genomic DNA
PT regions, useful for detecting aberrant methylation, includes multiple
PT amplification of chemically modified DNA.
XX
PS Claim 18; Page 19; 63pp; German.
XX
CC This invention describes a novel method for the parallel detection of the
CC methylation status of genomic DNA (I) which involves a (I) sample being
CC treated chemically to convert 5-umethylated cytosine to uracil,
CC thymidine or some other base having hybridization behavior different from
CC that of C, then amplifying simultaneously at least 10 different fragments
CC (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
CC primers are based on regulatory, transcribed and/or translated segments
CC present in the sample after chemical treatment. The sequence context of
CC all, or some, of the CpG and CpNpg motifs in the amplified products is
CC then determined. The method is used to detect aberrant methylation
CC patterns in the genome, these are implicated in regulation of
CC transcription, genetic imprinting and tumorigenesis. Many target regions
CC in the genome can be analyzed simultaneously and it is not essential to
CC know the sequence context of all targeted regions. Primers may be
CC designed for preferential amplification of particular segments of
CC interest (e.g. promoters and exons)
XX
SQ Sequence 11 BP; 3 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 2223 AAAAGTTACAT 2233
Db 11 AAAAATTACAT 1
RESULT 163
AAH55112
ID AAH55112 standard; DNA; 11 BP.
XX

```

AC AAH55112;
XX
XX DT 03-SEP-2001 (first entry)
XX
XX DE Genomic DNA methylation parallel detection associated DNA fragment #14.
XX
XX KW DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX amplification; transcription regulation; genetic imprinting;
XX tumorigenesis; primer; ss.
XX
XX OS Unidentified.
XX
XX PN WO200142493-A2.
XX
XX PD 14-JUN-2001.
XX
XX PF 06-DEC-2000; 2000WO-DE004381.
XX
XX PR 06-DEC-1999; 99DE-01059691.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C;
XX
XX DR WPI; 2001-381705/40.
XX
XX PT Parallel detection of the methylation pattern of many genomic DNA
XX regions, useful for detecting aberrant methylation, includes multiple
XX amplification of chemically modified DNA.
XX
XX PS Claim 18; page 19; 63pp; German.
XX
XX CC This invention describes a novel method for the parallel detection of the
XX methylation status of genomic DNA (I) which involves a (1) sample being
XX treated chemically to convert 5-unmethylated cytosine to uracil,
XX thymidine or some other base having hybridization behavior different from
XX that of C, then amplifying simultaneously at least 10 different fragments
XX (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX primers are based on regulatory, transcribed and/or translated segments
XX present in the sample after chemical treatment. The sequence context of
XX all, or some, of the CpG and CpNpG motifs in the amplified products is
XX then determined. The method is used to detect aberrant methylation
XX patterns in the genome, these are implicated in regulation of
XX transcription, genetic imprinting and tumorigenesis. Many target regions
XX in the genome can be analyzed simultaneously and it is not essential to
XX know the sequence context of all targeted regions. Primers may be
XX designed for preferential amplification of particular segments of
XX interest (e.g. promoters and exons)
XX
XX SQ Sequence 11 BP; 7 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 11;
XX Best Local Similarity 90.9%; Pred. No. 1.7e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTACAT 2233
XX
XX DB 1 AAAAATTACAT 11
XX
XX RESULT 164
XX ABV67983/C
XX ID ABV67983 standard; cDNA; 11 BP.
XX
XX AC ABV67983;
XX
XX XX 21-OCT-2002 (first entry)
XX
XX DE Human skin EST 5769.
XX
XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX

```

```

XX Homo sapiens.
XX OS
XX PN WO200253774-A2.
XX
XX PD 11-JUL-2002.
XX
XX PF 20-DEC-2001; 2001WO-EP015179.
XX
XX PR 03-JAN-2001; 2001DE-01000127.
XX
XX PA (HENK ) HENKEL KGAA.
XX
XX PI Petersohn D, Conradt M, Hofmann K;
XX
XX DR WPI; 2002-590638/63.
XX
XX PT In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX PS Disclosure; Page 185; 1345pp; German.
XX
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
XX SQ Sequence 11 BP; 2 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 11;
XX Best Local Similarity 90.9%; Pred. No. 1.7e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTACA 2232
XX
XX DB 11 CAAAAGTTACA 1
XX
XX RESULT 165
XX ABV69864/C
XX ID ABV69864 standard; cDNA; 11 BP.
XX
XX AC ABV69864;
XX
XX XX 21-OCT-2002 (first entry)
XX
XX DE Human skin EST 7650.
XX
XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200253774-A2.
XX
XX PD 11-JUL-2002.
XX
XX PF 20-DEC-2001; 2001WO-EP015179.
XX
XX PR 03-JAN-2001; 2001DE-01000127.
XX
XX PA (HENK ) HENKEL KGAA.
XX

```

PI Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX Claim 24; Page 242; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX Sequence 11 BP; 2 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
DB 11 AAAAGTCACAT 1
RESULT 166
ABV70995/C
ID ABV70995 standard; cDNA; 11 BP.
XX AC ABV70995;
XX 21-OCT-2002 (first entry)
XX Human skin EST 8781.
XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253774-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015179.
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX Claim 24; Page 281; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)

CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
DB 11 ACCAAAGTAA 1
RESULT 167
ABV62443/C
ID ABV62443 standard; cDNA; 11 BP.
XX AC ABV62443;
XX 21-OCT-2002 (first entry)
XX Human skin EST 229.
XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253774-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015179.
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX Disclosure; Page 32; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX Sequence 11 BP; 2 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 11;

```
Best Local Similarity 90.9%; Pred. No. 1.7e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 10; Conservative 0;

QY 2223 AAAAGTTACAT 2233
DB 11 AAAAGTCACAT 1

RESULT 168
ABV63574/c
ID ABV63574 standard; cDNA; 11 BP.
XX AC ABV63574;
XX
XX 21-OCT-2002 (first entry)
XX Human skin EST 1360.
XX
XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK ) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Disclosure; Page 62; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
XX Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 11;
XX Best Local Similarity 90.9%; Pred. No. 1.7e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTA 2230
DB 11 ACCAAAAGTTAA 1

RESULT 169
ABH76664/c
ID ABH76664 standard; DNA; 12 BP.
XX AC ABH76664;
XX
```

```
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 276657 for detecting SNP TSC0004255.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A., Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 276657; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI99989
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234
DB 12 AAAGTTATATG 2

RESULT 170
ABI31743
ID ABI31743 standard; DNA; 12 BP.
XX AC ABI31743;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 331716 for detecting SNP TSC0036427.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
```


CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTG 2238
 DB 1 TTATATGTTG 11
 RESULT 173
 ABH1066/C
 ID ABH1066 standard; DNA; 12 BP.
 XX AC
 XX ABH1066;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 381039 for detecting SNP TSC0064140.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 381039; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAGTTTACA 2232
 DB 1 TTATATGTTG 11
 RESULT 175
 ABH71906/C
 ID ABH71906 standard; DNA; 12 BP.
 XX AC ABH71906;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 271883 for detecting SNP TSC0002643.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 271883; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

Db 11 CAAATTTACA 1
 RESULT 174
 ABH67812/C
 ID ABH67812 standard; DNA; 12 BP.
 XX AC ABH67812;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 267789 for detecting SNP TSC0000529.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 267789; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 6 A; 1 C; 1 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 DB 12 GTTACATATT 2
 RESULT 175
 ABH71906/C
 ID ABH71906 standard; DNA; 12 BP.
 XX AC ABH71906;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 271883 for detecting SNP TSC0002643.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 267789; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 271883; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
DB 11 AAAACTATACAT 1
RESULT 176
ABI27613/c
ID ABI27613 standard; DNA; 12 BP.
XX ABI27613;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 327586 for detecting SNP TSC0033749.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 327586; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTACAT 2232
DB 11 CAAAATATACA 1
RESULT 177
ABI78288
ID ABI78288 standard; DNA; 12 BP.
XX ABI78288;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 378261 for detecting SNP TSC0062696.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 378261; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligonucleotides are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0;

Qy 2228 TTACATGTTTG 2238
Db 1 TTACATGTTTG 11

RESULT 178
ABI19684
ID ABI19684 standard; DNA; 12 BP.
AC ABI19684;
XX
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 319657 for detecting SNP TSC0029347.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 319657; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0;

Qy 2227 GTTACATGTTT 2237
Db 1 GTTACATGTTT 11

RESULT 179
ABI29884/c
ID ABI29884 standard; DNA; 12 BP.
XX
XX ABI29884;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 329857 for detecting SNP TSC0035199.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 329857; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0;

Qy 2222 CAAAAGTTACA 2232
Db 11 CAAAAGTTACA 11

RESULT 180
ABI35542/c


```

ID XX ABI35542 standard; DNA; 12 BP.
AC XX
XX AC ABI35542;
XX
DT DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 335515 for detecting SNP TSC0038870.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX DR WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 335515; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. NO. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2226 AGTACATGTT 2236
XX
XX DB 11 AGTATATGTT 1
XX
XX RESULT 181
XX ABI15399
XX ID ABI15399 standard; DNA; 12 BP.
XX
XX AC ABI15399;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 315372 for detecting SNP TSC0026873.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.

```

```

XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 315372; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. NO. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2220 ACCAAAAGTTA 2230
XX
XX DB 2 ACCAAAATTTA 12
XX
XX RESULT 182
XX ABI77265
XX ID ABI77265 standard; DNA; 12 BP.
XX
XX AC ABI77265;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 377238 for detecting SNP TSC0010490.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX

```

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 377238; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTG 2238
 Db 1 TTATATGTTG 11
 RESULT 183
 ABI30122/c
 ID ABI30122 standard; DNA; 12 BP.
 XX
 AC ABI30122;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 330095 for detecting SNP TSC0035335.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 330095; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTG 2238
 Db 1 TTATATGTTG 11
 RESULT 183
 ABI30122/c
 ID ABI30122 standard; DNA; 12 BP.
 XX
 AC ABI30122;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 330095 for detecting SNP TSC0035335.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 330095; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACAT 2233
 Db 11 AAAAATTACAT 1
 RESULT 184
 ABI78505
 ID ABI78505 standard; DNA; 12 BP.
 XX
 AC ABI78505;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 378478 for detecting SNP TSC0062797.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 378478; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 294295; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 1 AAAATTACAT 11
 RESULT 188
 ABH85219/c
 ID ABH85219 standard; DNA; 12 BP.
 XX
 AC ABH85219;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285212 for detecting SNP TSC0012196.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

XX Claim 1; SEQ ID NO 285212; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTTG 2238
 DB 11 TTACATGTTTG 1
 RESULT 189
 ABH90151
 ID ABH90151 standard; DNA; 12 BP.
 XX
 AC ABH90151;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 290144 for detecting SNP TSC0014233.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 290144; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2225 AGTTACATGT 2235

Db 2 AAGTTATATGT 12

RESULT 190

ABI22109
ID ABI22109 standard; DNA; 12 BP.

XX AC ABI22109;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 322082 for detecting SNP TSC0030647.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 322082; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 2 CAAAATTACA 12

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 2 CAAAATTACA 12

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

RESULT 191

ABH83316
ID ABH83316 standard; DNA; 12 BP.

XX AC ABH83316;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 283309 for detecting SNP TSC0011256.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 283309; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 1 CAAAATTACA 11

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
PN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 284053; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
DB 1 AAAAATTACAT 11
RESULT 193
ABI40875/C
ID ABI40875 standard; DNA; 12 BP.
AC ABI40875;
XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 340848 for detecting SNP TSC0041713.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS WO200177384-A2.
PN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 340848; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
DB 11 TTACATGTTTG 1
RESULT 194
ABI42569/C
ID ABI42569 standard; DNA; 12 BP.
AC ABI42569;
XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 342542 for detecting SNP TSC0042592.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS WO200177384-A2.
PN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 342542; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 12 AAAATTACAT 2
 RESULT 195
 ABI37195/C
 ID ABI37195 standard; DNA; 12 BP.
 XX
 AC ABI37195;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 337168 for detecting SNP TSC0039711.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 337168; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 11 AAAATTACAT 1
 RESULT 196
 ABI54798
 ID ABI54798 standard; DNA; 12 BP.
 XX
 AC ABI54798;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354771 for detecting SNP TSC0049282.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 354771; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 1 AAAATTACAT 11
 RESULT 197
 ABH93701/c
 ID ABH93701 standard; DNA; 12 BP.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 340756; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233

Db 11 AAAATTACAT 1

RESULT 200

ABI78290/c

ID ABI78290 standard; DNA; 12 BP.

XX AC ABI78290;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 378263 for detecting SNP TSC0062696.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 378263; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238

Db 12 TTAGATGTTTG 2

RESULT 201

ABI78637

ID ABI78637 standard; DNA; 12 BP.

XX AC ABI78637;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 378610 for detecting SNP TSC0062866.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 378610; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238

```

Db      ||| ||| ||| ||| |||
        2 TTAGATGTTG 12

RESULT 202
ABH93832/c
ID      ABH93832 standard; DNA; 12 BP.
XX
XX      ABH93832;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 293825 for detecting SNP TSC0015810.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 293825; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX      Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX      Best Local Similarity 90.9%; Pred. No. 2e+02;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 1; Gaps 0;
XX
XX      QY      2222 CAAGACTTACA 2232
XX      ||| ||| ||| ||| |||
XX      11 CAAGACTTACA 1
XX
XX      RESULT 203
XX      ABH83231
XX      ID      ABH83231 standard; DNA; 12 BP.
XX
XX      AC      ABH83231;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 283224 for detecting SNP TSC0011213.

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 283224; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX      Best Local Similarity 90.9%; Pred. No. 2e+02;
XX      Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX      QY      2223 AAAAGTTACAT 2233
XX      ||| ||| ||| ||| |||
XX      2 AAAAATTACAT 12
XX
XX      RESULT 204
XX      AB109796/c
XX      ID      AB109796 standard; DNA; 12 BP.
XX
XX      AC      AB109796;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 309769 for detecting SNP TSC0023664.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.

```

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 309769; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
Db 12 CAAAATTACA 2
RESULT 205
ABI12365/C
ID ABI12365 standard; DNA; 12 BP.
XX AC ABI12365;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 312338 for detecting SNP TSC0025007.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 312338; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACAT 2233
Db 12 AAAAATTACAT 2
RESULT 206
ABH88948
ID ABH88948 standard; DNA; 12 BP.
XX AC ABH88948;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 288941 for detecting SNP TSC0013739.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 288941; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX


```

DT 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 330096 for detecting SNP TSC0035335.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
CS WO200177384-A2.
PN
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330096; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGCTTACAT 2233
Db 11 AAAAATTACAT 1

RESULT 215
ABH86927
ID ABH86927 standard; DNA; 12 BP.
AC
XX ABH86927;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 286920 for detecting SNP TSC0012877.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 286920; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGCTTACAT 2233
Db 11 AAAAATTACAT 1

RESULT 215
ABH86927
ID ABH86927 standard; DNA; 12 BP.
AC
XX ABH86927;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 286920 for detecting SNP TSC0012877.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
XX

```

```

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 286920; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 1 GTTAGATGTTT 11

RESULT 216
ABH87335/C
ID ABH87335 standard; DNA; 12 BP.
XX
XX ABH87335;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 287328 for detecting SNP TSC0013044.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT

```

PT methylation status.
PS Claim 1; SEQ ID NO 287328; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
DB 11 ACCAAATTGA 1
RESULT 217
ABI40400/C
ID ABI40400 standard; DNA; 12 BP.
AC ABI40400;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 340373 for detecting SNP TSC0041493.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
XX Claim 1; SEQ ID NO 340373; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
DB 11 ACCAAATTGA 1
RESULT 218
ABI58632
ID ABI58632 standard; DNA; 12 BP.
XX
XX AC ABI58632;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 358605 for detecting SNP TSC0006593.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
XX Claim 1; SEQ ID NO 358605; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTACA 2232
DB 1 CAAAATTACA 11


```
RESULT 219
ABH72035/c
ID ABH72035 standard; DNA; 12 BP.
XX
AC ABH72035;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 272014 for detecting SNP TSC0002685.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piegenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 272014; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2223 AAAAGTTACAT 2233
|||||
DB 12 AAAACTTACAT 2
XX
RESULT 220
ABH29882/c
ID ABH29882 standard; DNA; 12 BP.
XX
XX ABH29882;
AC
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 329855 for detecting SNP TSC00035199.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piegenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 329855; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2222 CAAAAGTTACA 2232
|||||
DB 11 CAAAATTACA 1
XX
RESULT 221
ABH14679
ID ABH14679 standard; DNA; 12 BP.
XX
XX ABH14679;
AC
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 314652 for detecting SNP TSC0026478.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
```

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 314652; 29pp + Sequence Listing; German.
 PS
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 YQ 2227 GTTACATGTTT 2237
 DB 2 GTTAAATGTTT 12
 RESULT 222
 ABI71311
 ID ABI71311 standard; DNA; 12 BP.
 XX
 AC ABI71311;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 371284 for detecting SNP TSC0058693.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 371284; 29pp + Sequence Listing; German.
 PS
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 YQ 2228 TTACATGTTT 2238
 DB 1 TTAAATGTTT 11
 RESULT 223
 ABS64496/C
 ID ABS64496 standard; DNA; 12 BP.
 XX
 AC ABS64496;
 XX
 XX 15-NOV-2002 (first entry)
 DT
 XX Human Goodpasture binding protein, GPPBdelta26, intron/exon boundary #1.
 DE
 XX ds; Goodpasture antigen binding protein; Goodpasture syndrome; human;
 KW chromosome 5q13; neuroprotective; dermatological; immunosuppressive;
 KW autoimmune condition; phosphorylation; myelin basic protein; MBP;
 KW alpha3 type IV collagen non-collagenous domain; NCI; multiple sclerosis;
 KW systemic lupus erythematosus; cutaneous lupus erythematosus; pemphigus;
 KW pemphigoid; lichen planus.
 XX
 OS Homo sapiens.
 XX
 WO200261430-A2.
 PN
 XX 08-AUG-2002.
 PD
 XX 31-JAN-2002; 2002WO-EP001010.
 PF
 XX 31-JAN-2001; 2001US-0265249P.
 PR
 XX (SAUS/) SAUS J.
 PA
 XX Saus J;
 PI
 XX WPI; 2002-619280/66.
 DR
 XX Identifying candidate compounds for treating autoimmune conditions, e.g.
 PT Goodpasture syndrome or lupus, comprises identifying compounds that
 PT reduce phosphorylation of, or formation of conformational isomers of,
 PT target proteins.
 XX
 PS Example 2; Fig 8; 217pp; English.
 XX
 CC The invention relates to identifying candidate compounds to treat an
 CC autoimmune condition by identifying compounds that reduce phosphorylation
 CC of a first target protein (I) (which is selected from Goodpasture antigen
 CC binding protein (GPBP), an alpha3 type IV collagen non-collagenous (NCI)
 CC domain polypeptide comprising Lys-Gly-Lys-Arg-Gly-Asp-Ser-Gly-Ser-Pro-
 CC Ala-Thr-Trp-Thr-Arg-Gly-Phe-Val-Phe-Thr, and a polypeptide comprising
 CC Gln-Lys-Arg-Pro-Ser-Gln-Arg-His-Gly), or reduce formation of
 CC conformational isomers of the second target protein (II) (selected from
 CC an alpha3 type IV collagen NCI domain polypeptide and myelin basic
 CC protein, MBP). Also included are (1) an isolated type IV collagen alpha3

CC NCl domain conformational isomer, which has an amino acid sequence
 CC identical to the wild type alpha3 type IV collagen NCl domain, is
 CC stabilised by disulphide bonds, and has a molecular weight in a non-
 CC reducing sodium dodecyl sulphate gel of 22, 23, 25, 27, or 28 kD, and in
 CC a reducing sodium dodecyl sulphate gel of 29 kDa; and (2) an isolated
 CC type IV collagen alpha3 NCl domain. The human gene for GPBP is located on
 CC chromosome 5q13. The method is useful for treating autoimmune conditions,
 CC such as Goodpasture Syndrome, multiple sclerosis, systemic and cutaneous
 CC lupus erythematosus, pemphigus, pemphigoid and lichen planus. The present
 CC sequence represents an intron/exon boundary of the GPBP gene
 XX
 SQ Sequence 12 BP; 3 A; 2 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2216 TGTGACCAAAA 2226
 Db 11 TGTGACTAAAA 1

RESULT 224
 ADF69380/C
 ID ADF69380 standard; DNA; 12 BP.
 XX
 AC ADF69380;

DT 12-FEB-2004 (first entry)

XX Human Goodpasture antigen binding protein related oligonucleotide #1.

KW Human; Goodpasture antigen binding protein; GPBP; ss;
 KW autoimmune disorder; apoptosis; cancer; tumour; cytostatic;
 KW immunosuppressive.

XX Homo sapiens.

PN US2003054488-A1.

XX 20-MAR-2003.

PF 11-OCT-2002; 2002US-00270837.

XX 24-FEB-2000; 2000US-00512563.

XX (SAUS/) SAUS J.

XX Saus J;

XX WPI; 2003-585167/55.

XX New nucleic acid, useful for preparing a composition for treating tumor
 PT or autoimmune disorder or for preventing cell apoptosis.

XX Disclosure; SEQ ID NO 55; 105pp; English.

XX The invention relates to Goodpasture antigen binding proteins (GPBP), the
 CC nucleic acids encoding them and GPBP variants. The invention also relates
 CC to an antibody that selectively binds to a protein of the invention,
 CC detecting the presence of the protein, detecting in a sample a sequence
 CC that is similar to the isolated nucleic acid, detecting an autoimmune
 CC condition in a patient, detecting cells undergoing apoptosis or cancer
 CC transformation in a tissue or body fluid sample, treating a patient with
 CC a tumour or an autoimmune disorder and preventing cell apoptosis. The
 CC nucleic acid is useful for preparing a composition for treating tumour or
 CC autoimmune disorders, or for preventing cell apoptosis. This sequence
 CC represents a GPBP-related oligonucleotide of the invention.

XX Sequence 12 BP; 3 A; 2 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 2216 TGTGACCAAAA 2226
 Db 11 TGTGACTAAAA 1

RESULT 225
 ADK15494
 ID ADK15494 standard; DNA; 12 BP.

XX AC ADK15494;

XX 06-MAY-2004 (first entry)

XX GUS2 primer, seq id 29.

XX Pesticide; virucide; gene therapy; promoter; transcribable DNA; chimeric;
 KW Badnavirus; plant; Taro bacilliform virus; TaBV; PCR; primer; ss.

XX Unidentified.

PN WO2004007729-A1.

XX 22-JAN-2004.

XX 17-JUL-2003; 2003WO-AU000919.

XX 17-JUL-2002; 2002US-0396912P.

XX (UYQU-) UNIV QUEENSLAND TECHNOLOGY.

XX Dale JL, Harding RM, Becker DK, Hafner GJ, Yang I;
 PI WPI; 2004-122959/12.

XX New isolated DNA molecule comprising a promoter that is located upstream
 PT of a transcribable DNA sequence that hybridizes to a nucleic acid probe,
 PT useful for treating or preventing Badnaviral infection in plants.

XX Example 12; SEQ ID NO 29; 105pp; English.

XX The invention relates to an isolated DNA molecule comprising a promoter
 CC or its biologically active fragment, where the promoter is located
 CC upstream of a transcribable DNA sequence that hybridizes to a nucleic
 CC acid probe derived from the polynucleotide sequence of 6523 bp fully
 CC defined in the specification under at least low stringency conditions.
 CC Also disclosed is a chimeric DNA construct comprising the isolated
 CC promoter, its fragment or variant that is operably linked to a foreign or
 CC endogenous DNA sequence to be transcribed. The DNA molecule, polypeptide,
 CC agents and methods are useful for treating or preventing Badnaviral
 CC infection of a plant. The chimeric DNA construct is useful for the
 CC production of a transformed plant cell, plant or plant part. The current
 CC sequence represents a primer used in an example from the invention in the
 CC analysis of transgenic plants.

XX Sequence 12 BP; 1 A; 2 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2228 TTACATGTTTG 2238
 Db 1 TTACTGTTTG 11

RESULT 226
 AAV11048
 ID AAV11048 standard; RNA; 13 BP.

XX AC AAV11048;

DT 25-MAR-2003 (revised)
 DT 14-JUL-1998 (first entry)
 DE Human ribozyme target sequence from HLA-DQB 03DQB #1.
 DE
 XX Ribozyme; target; human lymphocyte antigen; HLA-DQB; MHC allele;
 KW major histocompatibility complex; cleavage; suppression; transplant;
 KW incompatibility; autoimmune disease; juvenile diabetes;
 KW rheumatoid arthritis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9704087-A1.
 XX
 PD 06-FEB-1997.
 XX
 PF 18-JUL-1996; 96WO-EP0031173.
 XX
 PR 18-JUL-1995; 95EP-00111256.
 XX
 PA (KRUPP/) KRUPP G.
 PA (MARG/) MARGET M.
 PA (WEST/) WESTPHAL E.
 PA (MUEL/) MUELLER-RUCHHOLTZ W.
 XX
 PI Krupp G, Marget M, Westphal E, Mueller-Ruchholtz W;
 XX
 DR WPI; 1997-132628/12.
 XX
 XX Ribozyme that cleaves specific MHC allele(s) - used to inhibit graft
 PT versus host reactions, to overcome blood incompatibility and to treat
 PT auto-immune disease.
 XX
 PS Claim 5; Fig 1; 76pp; German.
 XX
 CC AAV10915-V11123 are target sequences for a novel ribozyme which cleaves
 CC specific alleles from the major histocompatibility complex (MHC). This
 CC ribozyme contains a catalytic region and a hybridisation region which is
 CC complementary to all mRNA transcribed from vertebrate genes of a specific
 CC family of closely related MHC alleles or to mRNA from a single MHC
 CC allele, and is able to cleave such mRNA. The mRNA has a target region
 CC which in case is essentially conserved in all genes of the family but
 CC differs from genes of all other MHC alleles to such a degree that no
 CC cleavage of mRNA transcribed from these other alleles occurs. This allows
 CC the selective reduction or inhibition of expression of all genes of a
 CC family or of a single gene. This ribozyme can be used for permanent or
 CC transient suppression of expression of MHC alleles, in vivo or in vitro.
 CC Specific applications are to prevent guest vs. host or host vs. guest
 CC reactions, to prevent blood incompatibilities (partic. of the ABO, thesus
 CC and Kell systems) and to treat autoimmune diseases such as juvenile
 CC diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
 CC need for immunosuppressants in transplant patients. It provides very
 CC specific reduction of particular HLA molecules that cause incompatibility
 CC between donor and recipient. (Updated on 25-MAR-2003 to correct PA
 CC field.) (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 13 BP; 2 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 72.7%; Pred. NO. 2.2e+02;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACCA 2223
 Db 2 GCGUGUGACCA 12
 RESULT 227
 AAV42299/C
 ID AAV42299 standard; cDNA; 13 BP.
 XX
 AC AAV42299;
 XX

DT 23-SEP-1998 (first entry)
 XX
 DE Clone F4.1.3 kappa light chain transcript segemnt J-kappa.
 XX
 KW Human; immunoglobulin; Ig; transgenic; non-human mammal;
 KW inactivated endogenous Ig locus; B-cell development;
 KW human heavy chain Ig locus; micro constant region; J-H; D-H; V-H gene;
 KW kappa light chain Ig locus; kappa constant region; J-kappa gene; V-kappa;
 KW production; antibody; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9824893-A2.
 XX
 PD 11-JUN-1998.
 XX
 PF 03-DEC-1997; 97WO-US023091.
 XX
 PR 03-DEC-1996; 96US-00759620.
 XX
 PA (ABGE-) ABGENIX INC.
 XX
 PI Jakobovits A, Kucherlapati R, Klapholz S, Mendez M, Green L;
 XX
 DR WPI; 1998-333314/29.
 XX
 XX New transgenic non-human mammals - having an inactivated immunoglobulin
 PT locus and a near complete human immunoglobulin locus, used for production
 PT of human antibodies.
 XX
 PS Example 8; Page 39; 128pp; English.
 XX
 CC AAV42284-99 represent human kappa light chain immunoglobulin (Ig)
 CC transcripts expressed in XenoMouse II strains. The Xenomice were produced
 CC using the method of the invention. The specification describes a
 CC transgenic non-human mammal which has genome modifications that comprise
 CC an inactivated endogenous Ig locus, so that the mammal does not display
 CC normal B-cell development. The modified genome also has an inserted human
 CC heavy chain Ig locus in germline configuration, the human heavy chain Ig
 CC locus comprising a human micro constant region and regulatory and switch
 CC sequences, human J-H genes, human D-H genes, and human V-H genes and an
 CC inserted human kappa light chain Ig locus in germline configuration, the
 CC human kappa light chain Ig locus comprising a human kappa constant
 CC region, J-kappa genes, and V-kappa genes, where the number of V-H and V-
 CC kappa genes inserted are selected to restore normal B-cell development in
 CC the mammal. The transgenic animals have a near complete human Ig locus,
 CC including both a human heavy chain locus and a human kappa light chain
 CC locus. They can be used for the production of human antibodies when
 CC exposed to particular antigens e.g. when exposed to human IL-8, EGFR or
 CC TNF- alpha the mice will produce antibodies to IL-8, EGFR or TNF- alpha
 CC respectively
 XX
 SQ Sequence 13 BP; 2 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. NO. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAGT 2228
 Db 12 TGGCAAAAGT 2
 RESULT 228
 ABC92353/C
 ID ABC92353 standard; DNA; 13 BP.
 XX
 AC ABC92353;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 92370 for detecting SNP TSC0023086.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 92370; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2237
Db 13 GTTACATGTTT 3
RESULT 229
ABC74081/C
ID ABC74081 standard; DNA; 13 BP.
XX
XX AC ABC74081;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 74098 for detecting SNP TSC0019057.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 74099; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2238
Db 12 TTATATGTTT 2
RESULT 230
ABC27364
ID ABC27364 standard; DNA; 13 BP.
XX
XX AC ABC27364;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 27381 for detecting SNP TSC0007524.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 27381; 29pp + Sequence Listing; German.

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 152981; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 Db 12 AAAAATTACAT 2
 RESULT 236
 ABF52985
 ID ABF52985 standard; DNA; 13 BP.
 AC ABF52985;
 AC ABF52985;
 XX 21-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 152982 for detecting SNP TSC0038667.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 152982; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 Db 2 AAAAATTACAT 12
 RESULT 237
 ABH42366/c
 ID ABH42366 standard; DNA; 13 BP.
 XX
 XX ABH42366;
 AC
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 242343 for detecting SNP TSC0059100.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 242343; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic. Oligonucleotide SEQ ID NO 87035 for detecting SNP TSC00218/3.

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 87035; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTT 2236
 Db 1 AGTTAAATGTT 11
 RESULT 241
 ABH19351
 ID ABH19351 standard; DNA; 13 BP.
 AC ABH19351;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 219328 for detecting SNP TSC0053332.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 219328; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 Db 1 AAAAATTACAT 11
 RESULT 242
 ABF72689/C
 ID ABF72689 standard; DNA; 13 BP.
 AC ABF72689;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 172686 for detecting SNP TSC0043037.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 172686; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

```
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
Db 13 AAAAGTTATAT 3

RESULT 243
ABH03654/c
ID ABH03654 standard; DNA; 13 BP.
XX
AC ABH03654;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 203631 for detecting SNP TSC0049990.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 203631; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 1 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGTTT 2237
Db 13 RAATTACATATT 1

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTTG 2238
Db 3 TTACATGTTTG 13

RESULT 245
ABH35161/c
ID ABH35161 standard; DNA; 13 BP.
XX
AC ABH35161;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 235138 for detecting SNP TSC0057422.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS WO200177384-A2.
PN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 235138; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTT 2236
DB 13 AGTTACGTTG 3
RESULT 246
ABF89734
ID ABF89734 standard; DNA; 13 BP.
XX AC ABF89734;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 189731 for detecting SNP TSC0046680.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 216622; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTT 2236
DB 13 AGTTACGTTG 3
RESULT 247
ABH16645
ID ABH16645 standard; DNA; 13 BP.
XX AC ABH16645;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 216622 for detecting SNP TSC0052664.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 216622; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTG 2238
DB 3 TTACGTTG 13
RESULT 247
ABH16645
ID ABH16645 standard; DNA; 13 BP.
XX AC ABH16645;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 216622 for detecting SNP TSC0052664.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 216622; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTG 2238
DB 3 TTACGTTG 13

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 3 AAAATTACAT 13

RESULT 248
 ABH52425/C
 ID ABH52425 standard; DNA; 13 BP.
 XX
 AC ABH52425;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 252402 for detecting SNP TSC0061571.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 252402; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 1 C; 0 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 11 AAAAGTTATAT 1

RESULT 249
 ABH59440/C
 ID ABH59440 standard; DNA; 13 BP.
 XX
 AC ABH59440;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 259417 for detecting SNP TSC0063001.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 259417; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 12 AAAAATTACAT 2

RESULT 250
 ABH61415/C
 ID ABH61415 standard; DNA; 13 BP.
 XX

```

AC ABH61415;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 261392 for detecting SNP TSC0063448.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPITG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 261392; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 1 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 76.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2224 AAGTTTACATGTT 2236
DB 13 AATGTTAAATGTY 1
XX
RESULT 251
ABC19842/C
ID ABC19842 standard; DNA; 13 BP.
XX
XX ABC19842;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 19859 for detecting SNP TSC0004100.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

```

```

XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPITG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 19859; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2222 CAAAGATTAC 2232
DB 12 CAAATTTACA 2
XX
RESULT 252
ABC57080/C
ID ABC57080 standard; DNA; 13 BP.
XX
XX ABC57080;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 57097 for detecting SNP TSC0015441.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPITG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 57097; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAAGTTTACA 2
RESULT 253
ABC60017/C
ID ABC60017 standard; DNA; 13 BP.
XX
AC ABC60017;
XX
AC ABC60017;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 60034 for detecting SNP TSC0016041.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 60034; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAAGTTTACA 2

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 3 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACAT 2233
DB 12 AAAAGTTTACGT 2
RESULT 254
ABF12588
ID ABF12588 standard; DNA; 13 BP.
XX
AC ABF12588;
XX
AC ABF12588;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 112585 for detecting SNP TSC0028146.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 112585; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 2 G; 4 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAAGTTTACATTT 2236

```

Db      1 AAAAGTAATATGTY 13
|||||
RESULT 255
ABF13161
ID ABF13161 standard; DNA; 13 BP.
XX
AC ABF13161;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 113158 for detecting SNP TSC0028332.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 113158; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAAGTTTAC 2231
|||||
Db 3 CCAAAAATTATC 13
|||||
RESULT 256
ABC90277/c
ID ABC90277 standard; DNA; 13 BP.
XX
AC ABC90277;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 90294 for detecting SNP TSC0022619.
XX

```

```

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 90294; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 1 C; 0 G; 8 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2223 AAAAGTTTACAT 2233
|||||
Db 13 AAAAGTTTATAT 3
|||||
RESULT 257
ABF22036
ID ABF22036 standard; DNA; 13 BP.
XX
AC ABF22036;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 122033 for detecting SNP TSC0030510.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX

```



```

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 122033; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 2 GTTATAGTTT 12
|||||
2 GTTACATGTTT 12

RESULT 258
ABF22040
ID ABF22040 standard; DNA; 13 BP.
XX
AC ABF22040;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 122037 for detecting SNP TSC0030510.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 122037; 29pp + Sequence Listing; German.

```

```

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 2 GTTACGTTT 12
|||||
2 GTTACGTTT 12

RESULT 259
ABF32562/c
ID ABF32562 standard; DNA; 13 BP.
XX
AC ABF32562;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 132559 for detecting SNP TSC0033063.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 132559; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```

```
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
Db 11 AAAACTTACAT 1

RESULT 260
ABH23614/C
ID ABH23614 standard; DNA; 13 BP.
XX AC ABH23614;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 223591 for detecting SNP TSC0054424.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX FA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 223591; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACA 2232
Db 11 CAAAANTTACA 1

RESULT 261
ABH23614/C
ID ABH23614 standard; DNA; 13 BP.
XX AC ABH23614;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 153021 for detecting SNP TSC0038680.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
ABF98926
ID ABF98926 standard; DNA; 13 BP.
XX AC ABF98926;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 198923 for detecting SNP TSC0048966.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX FA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 198923; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGTTT 2237
Db 1 AATTATATGTTT 13

RESULT 262
ABF53024
ID ABF53024 standard; DNA; 13 BP.
XX AC ABF53024;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 153021 for detecting SNP TSC0038680.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 153021; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 DB 1 GTTACATGTTT 11
 RESULT 263
 ABH04240
 ID ABH04240 standard; DNA; 13 BP.
 XX ABH04240;
 AC ABH04240;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 204217 for detecting SNP TSC0050100.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 204217; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2238
 DB 1 TTACATGTTT 11
 RESULT 264
 ABF88892/c
 ID ABF88892 standard; DNA; 13 BP.
 XX ABF88892;
 AC ABF88892;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 188889 for detecting SNP TSC0046500.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 188889; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAGTT 2229

Db 13 RTCACCAAAATT 1

RESULT 265

ABC47954

ID ABC47954 standard; DNA; 13 BP.

AC ABC47954;

XX

XX

DT 21-FEB-2002 (first entry)

XX

XX

DE Oligonucleotide SEQ ID NO 47971 for detecting SNP TSC0013728.

XX

XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

FN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

XX

PA (EPIG-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WPI; 2001-657177/75.

XX

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

XX

PS Claim 1; SEQ ID NO 47971; 29pp + Sequence Listing; German.

XX

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 Db 1 GTTAAATGTTT 11

RESULT 266

ABC26270/C

ID ABC26270 standard; DNA; 13 BP.

XX

AC ABC26270;

XX

DT 20-FEB-2002 (first entry)

XX

XX

DE Oligonucleotide SEQ ID NO 26287 for detecting SNP TSC0006896.

XX

XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

FN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

XX

PA (EPIG-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WPI; 2001-657177/75.

XX

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

XX

PS Claim 1; SEQ ID NO 26287; 29pp + Sequence Listing; German.

XX

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

XX

SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 90.9%; Pred. No. 2.2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 13 CAAAATTACA 3

RESULT 267

ABF22037/C

ID ABF22037 standard; DNA; 13 BP.

XX

XX

AC ABF22037;

XX

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;

PT methylation status.

XX Claim 1; SEQ ID NO 170170; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 90.9%; Pred. No. 2.2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238

DB 13 TTATATGTTTG 3

RESULT 270

ABH08735

ID ABH08735 standard; DNA; 13 BP.

XX AC ABH08735;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 208712 for detecting SNP TSC0000598.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 208712; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 90.9%; Pred. No. 2.2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238

DB 13 TTATATGTTTG 3

RESULT 271

ABH35883

ID ABH35883 standard; DNA; 13 BP.

XX AC ABH35883;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 235860 for detecting SNP TSC0057581.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 235860; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 90.9%; Pred. No. 2.2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACAT 2233

DB 2 AAAAATTACAT 12

RESULT 272

ABH35883

ID ABH35883 standard; DNA; 13 BP.

XX AC ABH35883;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 235860 for detecting SNP TSC0057581.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 235860; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 90.9%; Pred. No. 2.2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACAT 2233

DB 2 AAAAATTACAT 12

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 190880; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTTACA 2232
 DB 2 CAAAAGTTTACA 12
 RESULT 275
 ID ABC17571/C
 XX ABC17571 standard; DNA; 13 BP.
 AC ABC17571;
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 17578 for detecting SNP TSC0003772.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 17578 for detecting SNP TSC0003772.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 06-APR-2001; 2001WO-IB000713.
 DE (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 17578; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 6 C; 1 G; 3 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2212 AGAGTGTGACC 2222
 DB 13 AGAGTGTGAGC 3
 RESULT 276
 ID ABC18565/C
 XX ABC18565 standard; DNA; 13 BP.
 AC ABC18565;
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 18572 for detecting SNP TSC0003919.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 06-APR-2001; 2001WO-IB000713.
 DE (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 18572; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 2 C; 1 G; 3 T; 0 U; 1 Other;


```

PN WO200177384-A2.
PD
PP 18-OCT-2001.
PP
PR 06-APR-2001; 2001WO-IB000713.
PR
PR 07-APR-2000; 2000DE-01019173.
PR
PA (EPIG-) EPIGENOMICS AG.
PA
PI Olek A, Piepenbrock C, Berlin K;
PI
DR WPI; 2001-657177/75.
DR
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
PS Claim 1; SEQ ID NO 17155; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 2219 GACCAAAAGTTAC 2231
DB 13 RACCACAAATTAC 1
:|||||
RESULT 280
ABF32563
ID ABF32563 standard; DNA; 13 BP.
AC
AC ABF32563;
AC
DT 21-FEB-2002 (first entry)
DT
DE Oligonucleotide SEQ ID NO 132560 for detecting SNP TSC0033063.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
OS
XX WO200177384-A2.
XX
XX ABF32563;
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 132560; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTACAT 2233
DB 3 AAAACTTACAT 13
:|||||
RESULT 281
ABF77176/C
ID ABF77176 standard; DNA; 13 BP.
AC
AC ABF77176;
AC
DT 22-FEB-2002 (first entry)
DT
DE Oligonucleotide SEQ ID NO 177173 for detecting SNP TSC0043935.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
OS
XX WO200177394-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 177173; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX

```

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
DB 12 AAACTTACAT 2

RESULT 282
ABH30878
ID ABH30878 standard; DNA; 13 BP.
XX
AC ABH30878;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 230855 for detecting SNP TSC0056292.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 230855; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 1 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
DB 3 GTTACGTTT 13

RESULT 283
ABH30879/C
ID ABH30879 standard; DNA; 13 BP.
XX
AC ABH30879;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 230856 for detecting SNP TSC0056292.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 230856; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
DB 11 GTTACGTTT 1

RESULT 284
ABF82059
ID ABF82059 standard; DNA; 13 BP.
XX
AC ABF82059;
XX
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide SEQ ID NO 182056 for detecting SNP TSC0045007.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 182056; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTT 2229
DB 3 GACCAAAAGTT 13
RESULT 285
ABH42367
ID ABH42367 standard; DNA; 13 BP.
XX AC ABH42367;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 242344 for detecting SNP TSC0059100.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 242344; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB 1 RCCAAAGTTTAAA 13
RESULT 286
ABC29311
ID ABC29311 standard; DNA; 13 BP.
XX AC ABC29311;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 29328 for detecting SNP TSC0008653.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX 06-APR-2001; 2001WO-IB000713.

PS Claim 1; SEQ ID NO 29328; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 1 CAAAATTACA 11
RESULT 287
ABCS5033
ID ABCS5033 standard; DNA; 13 BP.
XX
AC ABCS5033;
XX
AC ABCS5033;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 55050 for detecting SNP TSC0015064.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 55050; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 3 CAAAATTACA 13
RESULT 288
ABCS7078/C
ID ABCS7078 standard; DNA; 13 BP.
XX
AC ABCS7078;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 57095 for detecting SNP TSC0015441.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 57095; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTACA 2

```

RESULT 289
ABH17681
ID ABH17681 standard; DNA; 13 BP.
XX
AC ABH17681;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 217658 for detecting SNP TSC0052951.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 217658; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
Dd 2 ACCAAATTTA 12
|||||
RESULT 290
ABF70172
ID ABF70172 standard; DNA; 13 BP.
XX
AC ABF70172;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 170169 for detecting SNP TSC0009903.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 170169; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTG 2238
Dd 1 TTATATGTTG 11
|||||
RESULT 291
ABF53025/c
ID ABF53025 standard; DNA; 13 BP.
XX
AC ABF53025;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 153022 for detecting SNP TSC0038680.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX

```

PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 153022; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligonucleotides are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2227 GTTACATGTTT 2237
 DB 13 GTTACATGTTT 3
 XX
 RESULT 292
 ABF55461/C
 ID ABF55461 standard; DNA; 13 BP.
 XX
 AC ABF55461;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 155458 for detecting SNP TSC0039254.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 155458; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2228 TTACATGTTT 2238
 DB 13 TTACATGTTT 3
 XX
 RESULT 293
 ABF65415
 ID ABF65415 standard; DNA; 13 BP.
 XX
 AC ABF65415;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 165412 for detecting SNP TSC0041486.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 165412; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC

Best Local Similarity 90.9%; Pred. No. 2.2e+02; Mismatches 0; Indels 1; Gaps 0;

Qy 2220 ACCAAAGTTA 2230
 Db 2 ACCAAATTTA 12

RESULT 294
 ABH16644/C
 ID ABH16644 standard; DNA; 13 BP.
 XX AC ABH16644;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 216621 for detecting SNP TSC0052664.
 XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 216621; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences

Qy 2223 AAAAGTTACAT 2233
 Db 11 AAAATTTACAT 1

RESULT 295
 ABH46083/C
 ID ABH46083 standard; DNA; 13 BP.
 XX AC ABH46083;

XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 246060 for detecting SNP TSC0060121.
 XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 246060; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences

Qy 2223 AAAAGTTACAT 2233
 Db 12 AAAAGTTATAT 2

RESULT 296
 ABC60089
 ID ABC60089 standard; DNA; 13 BP.
 XX AC ABC60089;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 60106 for detecting SNP TSC0016063.
 XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.

PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 60106; 29pp + Sequence Listing; German.
 PS
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2220 ACCAAAAGTTA 2230
 Db 3 ACCAAAAGTTA 13
 RESULT 297
 ABC17149
 ID ABC17149 standard; DNA; 13 BP.
 AC
 AC ABC17149;
 XX
 XX 20-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 17156 for detecting SNP TSC0003709.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX (EPiG-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 17156; 29pp + Sequence Listing; German.
 PS
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;
 SQ
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTTAC 2231
 Db 1 RACCAAAAGTTAC 13
 RESULT 298
 ABF23828
 ID ABF23828 standard; DNA; 13 BP.
 AC
 AC ABF23828;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 123825 for detecting SNP TSC0030956.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 123825; 29pp + Sequence Listing; German.
 PS
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTATATGTTTG 2238
 ||| |||||

Db 3 TTATATGTTTG 13

RESULT 299
 ABE23829/C
 ID ABE23829 standard; DNA; 13 BP.
 AC ABE23829;
 XX 21-FEB-2002 (first entry)
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 123826 for detecting SNP TSC0030956.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 FN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 123826; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTATATGTTTG 2238
 ||| |||||

Db 3 TTATATGTTTG 13

RESULT 300
 ABE24341/C
 ID ABE24341 standard; DNA; 13 BP.
 AC ABE24341;
 XX 21-FEB-2002 (first entry)
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 124338 for detecting SNP TSC0031086.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 FN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 124338; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTATATGTTTG 2238
 ||| |||||

Db 12 TTATATGTTTG 2

RESULT 301
 ABE2560/C
 ID ABE2560 standard; DNA; 13 BP.
 AC ABE2560;
 XX 21-FEB-2002 (first entry)
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 132557 for detecting SNP TSC0033063.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 132557; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2223 AAAAGTTACAT 2233
 DB 11 AAAATTACAT 1
 RESULT 302
 ABF36213/c
 ID ABF36213 standard; DNA; 13 BP.
 XX AC ABF36213;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 136210 for detecting SNP TSC0034016.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 136210; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2226 AGTTACATGTT 2236
 DB 13 AGTTAGATGTT 3
 RESULT 303
 ABF39058
 ID ABF39058 standard; DNA; 13 BP.
 XX AC ABF39058;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 139055 for detecting SNP TSC0034834.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 139055; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATATGTTG 2238
 ||| |||||
 Db 2 TTATATGTTG 12
 ||| |||||
 RESULT 304
 ABF39059/c
 ID ABF39059 standard; DNA; 13 BP.
 AC ABF39059;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 139056 for detecting SNP TSC0034834.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 139056; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATATGTTG 2238
 ||| |||||
 Db 12 TTATATGTTG 2
 ||| |||||
 RESULT 305
 ABH19350/c
 ID ABH19350 standard; DNA; 13 BP.
 AC ABH19350;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 219327 for detecting SNP TSC0053332.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 219327; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAACTTACAT 2233
 ||| |||||
 Db 13 AAAAATTACAT 3
 ||| |||||
 RESULT 306
 ABF95142/c

ID ABF95142 standard; DNA; 13 BP.
 XX AC ABF95142;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 195139 for detecting SNP TSC0048013.
 XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 195139; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACA 2232
 DB 13 CAAAAGTTACA 3
 RESULT 307
 ABF72688
 ID ABF72688 standard; DNA; 13 BP.
 XX AC ABF72688;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 172685 for detecting SNP TSC0043037.
 XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

XX WO200177384-A2.
 XX 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 172685; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACAT 2233
 DB 1 AAAAGTTTATAT 11
 RESULT 308
 ABF98927/C
 ID ABF98927 standard; DNA; 13 BP.
 XX AC ABF98927;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 198924 for detecting SNP TSC0048966.
 XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 198924; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTACATGTTT 2237
 DB 13 AATTATATGTTT 1
 RESULT 309
 ABH03815
 ID ABH03815 standard; DNA; 13 BP.
 AC ABH03815;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 203792 for detecting SNP TSC0050027.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 203792; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTACATGTTT 2237
 DB 13 AATTATATGTTT 1
 RESULT 310
 ABH35882/c
 ID ABH35882 standard; DNA; 13 BP.
 AC ABH35882;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 235859 for detecting SNP TSC0057581.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 235859; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY      2223 AAAAGTTACAT 2233
Db      12 AAAATTACAT 2
        |||||
RESULT 311
ABF60969
ID      ABF60969 standard; DNA; 13 BP.
XX      AC
XX      ABF60969;
XX      22-FEB-2002 (first entry)
DT      XX
DE      Oligonucleotide SEQ ID NO 160966 for detecting SNP TSC0005250.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      OS
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      22-FEB-2002 (first entry)
DT      XX
DE      Oligonucleotide SEQ ID NO 160966 for detecting SNP TSC0005250.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      OS
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIG-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX      Claim 1; SEQ ID NO 160966; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX      Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX      Best Local Similarity 76.9%; Pred. No. 2.2e+02;
XX      Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY      2219 GACCAAAAGTTAC 2231
Db      1 RACCAAAATATAC 13
        :|||||
RESULT 312
ABC49582
ID      ABC49582 standard; DNA; 13 BP.
XX      AC
XX      ABC49582;
XX      21-FEB-2002 (first entry)
DT      XX

```

```

XX      Oligonucleotide SEQ ID NO 49599 for detecting SNP TSC0014013.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      OS
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIG-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX      Claim 1; SEQ ID NO 49599; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX      Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX      Best Local Similarity 76.9%; Pred. No. 2.2e+02;
XX      Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY      2224 AAAGTTACATGT 2235
Db      1 AAATTATATGTY 13
        |||||
RESULT 313
ABC31733
ID      ABC31733 standard; DNA; 13 BP.
XX      AC
XX      ABC31733;
XX      20-FEB-2002 (first entry)
DT      XX
DE      Oligonucleotide SEQ ID NO 31750 for detecting SNP TSC0009892.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      OS
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.

```

PF 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 31750; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP),
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGCTTAC 2231
 Db 3 CCAAAAGCTTAC 13
 RESULT 314
 ABF22041/C
 ID ABF22041 standard; DNA; 13 BP.
 XX AC ABF22041;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 122038 for detecting SNP TSC0030510.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 122038; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 Db 12 GTTACGTTT 2
 RESULT 315
 ABF96440
 ID ABF96440 standard; DNA; 13 BP.
 XX AC ABF96440;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 196437 for detecting SNP TSC0048351.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 196437; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAAGTTACATGTT 2236
|||||
Db 1 AAACTTATATTT 13
RESULT 316
ID ABF77177 standard; DNA; 13 BP.
XX
AC ABF77177;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 177174 for detecting SNP TSC0043935.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO2001.77384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 177174; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
|||||
Db 2 AAAACTTACAT 12

RESULT 317
ID ABF55460 standard; DNA; 13 BP.
XX
AC ABF55460;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 155457 for detecting SNP TSC0039254.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO2001.77384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 155457; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
|||||
Db 1 TTATATGTTTG 11
RESULT 318
ID ABF82251/c standard; DNA; 13 BP.
XX
AC ABF82251;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 182248 for detecting SNP TSC0045045.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 182248; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2228 TTATATGTTG 2238
 DB 12 TTATATGTTG 2
 XX
 RESULT 319
 ABF65414/c
 ID ABF65414 standard; DNA; 13 BP.
 XX
 AC ABF65414;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 165411 for detecting SNP TSC0041486.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 165411; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2228 TTATATGTTG 2238
 DB 12 TTATATGTTG 2
 XX
 RESULT 319
 ABF65414/c
 ID ABF65414 standard; DNA; 13 BP.
 XX
 AC ABF65414;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 165411 for detecting SNP TSC0041486.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 165411; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2220 ACCAAAGCTTA 2230
 DB 12 ACCAAAGCTTA 2
 XX
 RESULT 320
 ABC18564
 ID ABC18564 standard; DNA; 13 BP.
 XX
 AC ABC18564;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 18571 for detecting SNP TSC0003919.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 18571; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 13 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACGTTT 2237
 Db 1 AAGTTACGTTT 13
 RESULT 321
 ABC23308
 ID ABC23308 standard; DNA; 13 BP.
 XX AC ABC23308;
 XX
 XX 20-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 23325 for detecting SNP TSC0004828.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 23325; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATCATGTTG 2238
 Db 3 TTATCATGTTG 13
 RESULT 322
 ABC05974/c
 ID ABC05974 standard; DNA; 13 BP.
 XX AC ABC05974;
 XX 20-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 5965 for detecting SNP TSC0001904.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 5965; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAGCTTACA 2232
 Db 13 CAAAGCTTACA 3
 RESULT 323
 ABC05975
 ID ABC05975 standard; DNA; 13 BP.
 XX

```

AC ABC05975;
XX
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 5966 for detecting SNP TSC0001904.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 5966; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2222 CAAAGTTTACA 2232
DB 1 CAAAGTTTACA 11
RESULT 324
ABF06917/C
ID ABE06917 standard; DNA; 13 BP.
AC
AC ABE06917;
XX
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 106914 for detecting SNP TSC0026765.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX

```

```

XX
XX 19-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 106914; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2228 TTACATGTTTG 2238
DB 13 TTAATGTTTG 3
RESULT 325
ABC82012
ID ABC82012 standard; DNA; 13 BP.
XX
XX
XX ABC82012;
XX
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 82029 for detecting SNP TSC0020739.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX
XX 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 82029; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTT 2236
DB 2 AGTTAGATGTT 12
RESULT 326
ABC82015/C
ID ABC82015 standard; DNA; 13 BP.
XX
AC ABC82015;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 82032 for detecting SNP TSC0020739.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 82032; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTT 2236
DB 2 AGTTAGATGTT 12
RESULT 326
ABC82015/C
ID ABC82015 standard; DNA; 13 BP.
XX
AC ABC82015;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 82032 for detecting SNP TSC0020739.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 82032; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTT 2236
DB 12 AGTTATAGTT 2
RESULT 327
ABF08266
ID ABF08266 standard; DNA; 13 BP.
XX
AC ABF08266;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 108263 for detecting SNP TSC0027110.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 108263; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2227 GTTACATGTT 2237

```

Db      2 GTTATATGTTT 12
||||| |||||
RESULT 328
ABC60088/c
ID ABC60088 standard; DNA; 13 BP.
XX
AC ABC60088;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 60105 for detecting SNP TSC0016063.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 60105; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2220 ACCAAAGTTA 2230
||||| |||||
Db 11 ACCAAAGTTA 1
RESULT 329
ABF24340
ID ABF24340 standard; DNA; 13 BP.
XX
AC ABF24340;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 124337 for detecting SNP TSC0031086.
XX

```

```

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 124337; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2228 TTACATGTTT 2238
||||| |||||
Db 2 TTACATGTTT 12
RESULT 330
ABH04241/c
ID ABH04241 standard; DNA; 13 BP.
XX
AC ABH04241;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 204218 for detecting SNP TSC0050100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX

```

```

PR 07-APR-2000; 2000DE-01019173.
PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 204218; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred.No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2228 TTACATGTTG 2238
XX
XX Db 13 TTACATGTTG 3
XX
XX RESULT 331
XX ABF05020
XX ID ID ABF05020 standard; DNA; 13 BP.
XX AC ABF05020;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE DE
XX DE DE
XX DE DE
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 105017; 29pp + Sequence Listing; German.
XX

```

XX	CC	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC000010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX	CC	Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX	CC	Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX	CC	Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX	CC	Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	Db	2228 TTACATGTTTG 2238 2 TTAATGTTTG 12
RESULT 332		
ABC82014		
ID	ABC82014	standard; DNA; 13 BP.
XX	AC	ABC82014;
XX	XX	
DT	21-FEB-2002	(first entry)
DE	Oligonucleotide SEQ ID NO 82031	for detecting SNP TSC0020739.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX	Homo sapiens.	
XX	WO200177384-A2.	
XX	18-OCT-2001.	
PD	06-APR-2001;	2001WO-IB000713.
XX	07-APR-2000;	2000DE-01019173.
PR	(EPIG-) EPIGENOMICS AG.	
XX	Olek A, Piepenbrock C, Berlin K;	
XX	WPI; 2001-657177/75.	
DR	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
XX	Claim 1; SEQ ID NO 82031; 29pp + Sequence Listing; German.	
XX	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC000010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences	

OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 112091; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTAC 2231
 Db 12 CCAAAAGTTAC 2
 RESULT 336
 ABF33254
 ID ABF33254 standard; DNA; 13 BP.
 AC ABF33254;
 XX 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 133251 for detecting SNP TSC0033247.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 133251; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTTG 2238
 Db 2 TTACATGTTTG 12
 RESULT 337
 ABF75257/C
 ID ABF75257 standard; DNA; 13 BP.
 AC ABF75257;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 175254 for detecting SNP TSC0043552.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 175254; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2227 GTTACATGTTT 2237
 Db 13 GTTATATGTTT 3

RESULT 338
 ABH08734/C
 ID ABH08734 standard; DNA; 13 BP.

XX AC ABH08734;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 208711 for detecting SNP TSC0000598.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 208711; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2223 AAAAGTTACAT 2233
 Db 12 AAAAATTACAT 2

RESULT 339
 ABH34747/C
 ID ABH34747 standard; DNA; 13 BP.

XX AC ABH34747;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 234724 for detecting SNP TSC0057295.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 234724; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2228 TTACATGTTTG 2238
 Db 11 TTAGATGTTTG 1

RESULT 340
 ABC57081
 ID ABC57081 standard; DNA; 13 BP.

XX AC ABC57081;
 XX

PT methylation status.
 XX Claim 1; SEQ ID NO 113692; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2228 TTATATGTTTG 2238
 Db 13 TTATATGTTTG 3
 RESULT 343
 ABC16210
 ID ABC16210 standard; DNA; 13 BP.
 AC ABC16210;
 XX
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 16217 for detecting SNP TSC0003547.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 PS Claim 1; SEQ ID NO 16217; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2228 TTATATGTTTG 2238
 Db 2 TTATATGTTTG 12
 RESULT 344
 ABH17680/C
 ID ABH17680 standard; DNA; 13 BP.
 AC ABH17680;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 217657 for detecting SNP TSC0052951.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 PS Claim 1; SEQ ID NO 217657; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2220 ACCAAAGTTA 2230
 Db 12 ACCAAAGTTA 2

RESULT 345

ABH19289 ID ABH19289 standard; DNA; 13 BP.
 XX AC ABH19289;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 219266 for detecting SNP TSC0053321.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 219266; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;
 XX
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAAGTTACATGTT 2236
 DB 1 RAATATCATTTT 13
 XX
 RESULT 346
 ABF96441/C
 ID ABF96441 standard; DNA; 13 BP.
 XX AC ABF96441;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 196438 for detecting SNP TSC0048351.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 196438; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 1 Other;
 XX
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAAGTTACATGTT 2236
 DB 13 AAAGTTATATTTT 1
 XX
 RESULT 347
 ABH03655
 ID ABH03655 standard; DNA; 13 BP.
 XX AC ABH03655;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 203632 for detecting SNP TSC0049990.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 203632; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 2225 AAGTACATGTTT 2237
 DB 1 RAATTACATATT 13
 : ||||| |||

RESULT 348
 ABH31181
 ID ABH31181 standard; DNA; 13 BP.
 AC ABH31181;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 231158 for detecting SNP TSC0056372.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPiG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 231158; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTACAT 2233
 DB 2 AAAACTTACAT 12
 : ||||| |||

RESULT 349
 ABH52424
 ID ABH52424 standard; DNA; 13 BP.
 AC ABH52424;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 252401 for detecting SNP TSC0061571.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPiG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 252401; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

```

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
DB 3 AAAAGTTATAT 13

RESULT 350
ABC92352
ID ABC92352 standard; DNA; 13 BP.
XX AC
XX AC ABC92352;
XX XX
DT 21-FEB-2002 (first entry)
XX XX
DE Oligonucleotide SEQ ID NO 92369 for detecting SNP TSC0023086.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
OS Homo sapiens.
XX XX
PN WO200177384-A2.
XX XX
PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIC-) EPIGENOMICS AG.
XX XX
PI Olek A, Piepenbrock C, Berlin K;
XX XX
DR WPI; 2001-657177/75.
XX XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX XX
PS Claim 1; SEQ ID NO 92369; 29pp + Sequence Listing; German.
XX XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;
XX XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
DB 1 GTTACATGTTT 11

RESULT 351
ABC17570
ID ABC17570 standard; DNA; 13 BP.

```

```

XX ABC17570;
XX AC
XX DT 20-FEB-2002 (first entry)
XX XX
DE Oligonucleotide SEQ ID NO 17577 for detecting SNP TSC0003772.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
OS Homo sapiens.
XX XX
PN WO200177384-A2.
XX XX
PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIC-) EPIGENOMICS AG.
XX XX
PI Olek A, Piepenbrock C, Berlin K;
XX XX
DR WPI; 2001-657177/75.
XX XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX XX
PS Claim 1; SEQ ID NO 17577; 29pp + Sequence Listing; German.
XX XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX XX
SQ Sequence 13 BP; 3 A; 1 C; 6 G; 2 T; 0 U; 1 Other;
XX XX
CC Query Match      34.8%; Score 9.4; DB 1; Length 13;
CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
CC QY 2212 AGAGTGTGACC 2222
CC DB 1 AGAGTGTGACC 11
CC
CC RESULT 352
CC ABC5032/c
CC ID ABC5032 standard; DNA; 13 BP.
XX XX
XX AC ABC5032;
XX XX
DT 21-FEB-2002 (first entry)
XX XX
DE Oligonucleotide SEQ ID NO 55049 for detecting SNP TSC0015064.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
OS Homo sapiens.
XX XX

```


CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2227 GTTATGTTT 2237
 Db 12 GTTATGTTT 2

RESULT 355
 ABF32561
 ID ABF32561 standard; DNA; 13 BP.

XX
 AC ABF32561;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 132558 for detecting SNP TSC0033063.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 132558; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTTACAT 2233
 Db 3 AAAATTTACAT 13

RESULT 356

ABF72397
 ID ABF72397 standard; DNA; 13 BP.

XX
 AC ABF72397;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 172394 for detecting SNP TSC0042980.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 172394; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 4 A; 5 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2221 CCAAAAGTTTAC 2231

Db 2 CCAACGTTAC 12

RESULT 357

ABF98925/c
 ID ABF98925 standard; DNA; 13 BP.

XX
 AC ABF98925;

XX 22-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 198922 for detecting SNP TSC0048966.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 198922; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 1 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 76.9%; Pred. No. 2.2e+02; Mismatches 2; Indels 0; Gaps 0;

Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

DB 13 AATTAAATGTTT 1

RESULT 358

ABF75256

ID ABF75256 standard; DNA; 13 BP.

AC ABF75256;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 175253 for detecting SNP TSC0043552.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 175253; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 90.9%; Pred. No. 2.2e+02; Mismatches 1; Indels 0; Gaps 0;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237

DB 1 GTTATAATGTTT 11

RESULT 359

ABF60279/c

ID ABF60279 standard; DNA; 13 BP.

AC ABF60279;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 160276 for detecting SNP TSC0040359.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 160276; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
|||||
Db 11 AAAAGTTACAT 1

RESULT 360

ABF89730

XX ID ABF89730 standard; DNA; 13 BP.

XX AC ABF89730;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 189727 for detecting SNP TSC0045680.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX PS Claim 1; SEQ ID NO 189727; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTATATGTTTG 2238
|||||
Db 3 TTATATGTTTG 13

RESULT 361

ABH16643

XX ID ABH16643 standard; DNA; 13 BP.

XX AC ABH16643;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 216620 for detecting SNP TSC0052664.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX PS Claim 1; SEQ ID NO 216620; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
|||||
Db 3 AAAAGTTACAT 13

```

RESULT 362
ABC19844/c
ID ABC19844 standard; DNA; 13 BP.
XX
AC ABC19844;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 19861 for detecting SNP TSC0004100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19861; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
Db 12 CAAAATTACA 2

RESULT 363
ABC19845
ID ABC19845 standard; DNA; 13 BP.
XX
AC ABC19845;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 19862 for detecting SNP TSC0004100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19862; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
Db 12 CAAAATTACA 2

RESULT 364
ABC31732/c
ID ABC31732 standard; DNA; 13 BP.
XX
AC ABC31732;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31749 for detecting SNP TSC0009892.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19862; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
Db 2 CAAAATTACA 12

RESULT 365
ABC31732/c
ID ABC31732 standard; DNA; 13 BP.
XX
AC ABC31732;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31749 for detecting SNP TSC0009892.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19862; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
Db 2 CAAAATTACA 12

```



```

Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTT 2236
DB 12 AGTTAGATGTT 2

RESULT 367
ABF13160/c
ID ABF13160 standard; DNA; 13 BP.
XX AC ABF13160;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 113157 for detecting SNP TSC0028332.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 113157; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTAC 2231
DB 11 CCAAAAGTTAC 1

RESULT 368
ABC90276
ID ABC90276 standard; DNA; 13 BP.
XX AC ABC90276;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 135559 for detecting SNP TSC0033840.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 113157; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 0 C; 1 G; 4 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
DB 1 AAAAGTTATAT 11

RESULT 369
ABF35562
ID ABF35562 standard; DNA; 13 BP.
XX AC ABF35562;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 135559 for detecting SNP TSC0033840.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 90293; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 0 C; 1 G; 4 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

PD 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 135559; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATATGTTTG 2238
 DB 2 TTATATGTTTG 12
 RESULT 370
 ID ABF99477/C
 XX ABF99477 standard; DNA; 13 BP.
 AC ABF99477;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 199474 for detecting SNP TSC0049079.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 135559; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATATGTTTG 2238
 DB 2 TTATATGTTTG 12

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 199474; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 DB 13 GTTAAATGTTT 3
 RESULT 371
 ID ABF82250
 XX ABF82250 standard; DNA; 13 BP.
 AC ABF82250;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 182247 for detecting SNP TSC0045045.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 182247; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 DB 13 GTTAAATGTTT 3

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
 |||||
 DB 2 TTATATGTTTG 12
 |||||

RESULT 372
 ABF60278
 ID ABF60278 standard; DNA; 13 BP.
 XX
 AC ABF60278;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 160275 for detecting SNP TSC0040359.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 160275; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACAT 2233
 |||||

DB 3 AAAAGTTTAT 13
 |||||

RESULT 373
 ABF89735/C
 ID ABF89735 standard; DNA; 13 BP.
 XX
 AC ABF89735;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 189732 for detecting SNP TSC0046680.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 189732; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 7 A; 4 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
 |||||
 DB 11 TTACGTTGTTG 1
 |||||

RESULT 374
 ABF90884/C
 ID ABF90884 standard; DNA; 13 BP.
 XX
 AC ABF90884;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 190881 for detecting SNP TSC0007930.
 XX
 OS

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 190881; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC000010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACA 2232
 Db 12 CAAAATTACA 2
 RESULT 375
 ABH51983/c
 ID ABH51983 standard; DNA; 13 BP.
 XX AC ABH51983;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 251960 for detecting SNP TSC0061476.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 251960; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC000010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTG 2238
 Db 11 TTAATGTTG 1
 RESULT 376
 ABC23309/c
 ID ABC23309 standard; DNA; 13 BP.
 XX AC ABC23309;
 XX 20-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 23326 for detecting SNP TSC0004828.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 23326; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
Db 11 TTACATGTTTG 1
RESULT 377
ABC74080
ID ABC74080 standard; DNA; 13 BP.
XX
AC ABC74080;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 74097 for detecting SNP TSC0019057.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
FA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
Claim 1; SEQ ID NO 74097; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
Db 2 TTATATGTTTG 12
RESULT 378
ABF72396/C
ID ABF72396 standard; DNA; 13 BP.
XX
AC ABF72396;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172393 for detecting SNP TSC0042980.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
FA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
Claim 1; SEQ ID NO 172393; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2221 CCACAAAGTTAC 2231
Db 12 CCACACGTTAC 2
RESULT 379
ABF98924

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 182055; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 2 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTT 2229
 DB 11 GACCAAAAGTT 1
 RESULT 382
 ID ABF89731/C
 XX ABF89731 standard; DNA; 13 BP.
 XX ABF89731;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 189728 for detecting SNP TSC0046680.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 189728; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 2 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTT 2229
 DB 11 GACCAAAAGTT 1
 RESULT 382
 ID ABF89731/C
 XX ABF89731 standard; DNA; 13 BP.
 XX ABF89731;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 189728 for detecting SNP TSC0046680.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 189728; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTTG 2238
 DB 11 TTATATGTTTG 1
 RESULT 383
 ID ABC27365/C
 XX ABC27365 standard; DNA; 13 BP.
 XX ABC27365;
 XX 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 27382 for detecting SNP TSC0007524.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 27382; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 190882; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTTACA 2232
 DB ||||| |||||
 2 CAAAAGTTTACA 12
 RESULT 392
 ABH16642/C
 ID ABH16642 standard; DNA; 13 BP.
 XX ABH16642;
 AC 22-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 216619 for detecting SNP TSC0052664.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 216619; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACAT 2233
 DB ||||| |||||
 11 AAAAGTTTACAT 1
 RESULT 393
 ABH46082
 ID ABH46082 standard; DNA; 13 BP.
 XX ABH46082;
 AC 22-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 246059 for detecting SNP TSC0060121.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 246059; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 Db 2 AAAAGTTATAT 12
 RESULT 394
 ABH59441
 ID ABH59441 standard; DNA; 13 BP.
 AC ABH59441;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 259418 for detecting SNP TSC0063001.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 259418; 29pp + Sequence Listing; German.
 XX
 This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 Db 2 AAAAATTACAT 12
 RESULT 395
 ABH61414
 ID ABH61414 standard; DNA; 13 BP.
 AC ABH61414;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 261391 for detecting SNP TSC0063448.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 261391; 29pp + Sequence Listing; German.
 XX
 This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAAGTTACATGTT 2236
 Db 1 AATGTTAAATGTY 13
 RESULT 396
 ABC26271
 ID ABC26271 standard; DNA; 13 BP.
 XX

AC ABC26271;
 XX
 XX DT 20-FEB-2002 (first entry)
 XX DE
 XX DE Oligonucleotide SEQ ID NO 26288 for detecting SNP TSC0006896.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF
 XX PR 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PR (EPIG-) EPIGENOMICS AG.
 XX PA Olek A, Piepenbrock C, Berlin K;
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX PI WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 26288; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACA 2232
 DB 1 CAAAATTACA 11
 RESULT 397
 ABC29310/C
 ID ABC29310 standard; DNA; 13 BP.
 XX AC ABC29310;
 XX AC
 XX DT 20-FEB-2002 (first entry)
 XX DE
 XX DE Oligonucleotide SEQ ID NO 29327 for detecting SNP TSC0008653.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF
 XX PR 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PR (EPIG-) EPIGENOMICS AG.
 XX PA Olek A, Piepenbrock C, Berlin K;
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX PI WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 29327; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACA 2232
 DB 1 CAAAATTACA 11
 RESULT 398
 ABF05021/C
 ID ABF05021 standard; DNA; 13 BP.
 XX AC ABF05021;
 XX AC
 XX DT 21-FEB-2002 (first entry)
 XX DE
 XX DE Oligonucleotide SEQ ID NO 105018 for detecting SNP TSC0026297.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF
 XX PR 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PR (EPIG-) EPIGENOMICS AG.
 XX PA Olek A, Piepenbrock C, Berlin K;
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX PI WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 29327; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACA 2232
 DB 13 CAAAATTACA 3

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 105018; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTG 2238

Db 12 TTAATGTTG 2

RESULT 399

ABC5256
 ID ABC5256 standard; DNA; 13 BP.

AC ABC5256;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 55273 for detecting SNP TSC0015107.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 55273; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACAT 2233

Db 3 AAAAGTTTAT 13

RESULT 400

ABF08270

ID ABF08270 standard; DNA; 13 BP.

AC ABF08270;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 108267 for detecting SNP TSC0027110.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 108267; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237

PR 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
DR designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT methylation status.
XX Claim 1; SEQ ID NO 13252; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTG 2238
Db 12 TTACATGTTG 2
RESULT 404
ABF36212
ID ABF36212 standard; DNA; 13 BP.
XX
AC ABF36212;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 136209 for detecting SNP TSC0034016.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT methylation status.
XX Claim 1; SEQ ID NO 136209; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTT 2236
Db 1 AGTTACATGTT 11
RESULT 405
ABH31180/C
ID ABH31180 standard; DNA; 13 BP.
XX
AC ABH31180;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 231157 for detecting SNP TSC0056372.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT methylation status.
XX Claim 1; SEQ ID NO 231157; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```

XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AARAGTTACAT 2233
DB 12 AAAACTTACAT 2
|||||
|||||

RESULT 406
ABF88893
ID ABF88893 standard; DNA; 13 BP.
XX AC ABF88893;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 188890 for detecting SNP TSC0046500.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 188890; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences
XX PS Claim 1; SEQ ID NO 188890; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAGTT 2229
DB 1 RTCACCAAAATT 13
|||||
|||||

RESULT 407
ABH51982
ID ABH51982 standard; DNA; 13 BP.
XX AC ABH51982;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 251959 for detecting SNP TSC0061476.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 251959; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
DB 3 TTAATGTTTG 13
|||||
|||||

RESULT 408
ACA62425
ID ACA62425 standard; DNA; 13 BP.
XX AC ACA62425;
XX DT 13-AUG-2003 (first entry)
XX DE Hepatitis B virus epsilon element priming reaction product.
XX KW HBV; hepatitis B virus core particle; ss; viral replication;
XX KW reverse transcript; antiviral agent; RNase H; epsilon element.
XX OS Hepatitis B virus.

```

XX US6518014-B1.
XX 11-FEB-2003.
XX 11-JUL-1997; 97US-00890735.
XX 11-JUL-1996; 96US-0021561P.
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX
XX Seifer M, Hamatake R, Standring DN;
XX WPI; 2003-465600/44.
XX
XX Non-infectious, recombinant hepadnavirus core particle composition,
XX comprises isolated hepadnavirus core particles, and template nucleic acid
XX and hepadnavirus polymerase, both encapsidated in core particles.
XX
XX Disclosure; Col 16; 25pp; English.
XX
XX The invention relates to a non-infectious, recombinant hepadnavirus core
XX particle composition, comprising isolated hepadnavirus core particles
XX (HC), a template nucleic acid (TN) encapsidated in HC and hepadnavirus
XX polymerase (HP) encapsidated in HC. Addition of deoxynucleoside
XX triphosphates to the hepadnavirus core particle, HP incorporates
XX deoxynucleotides into reverse transcripts (RTs) of TN beginning within
XX the hepadnavirus core particle. Also included is the preparation (M) of
XX the hepadnavirus core particle, which involves transfecting/infecting a
XX cell with one or more nucleic acid vectors that (i) encode hepadnavirus
XX polymerase and express hepadnavirus polymerase in the transfected or
XX infected cell and (ii) encode hepadnavirus core protein and express
XX hepadnavirus protein in the transfected or infected cell, and (iii)
XX contain a template nucleic acid, isolating core particles formed from the
XX expressed hepadnavirus core protein, hepadnavirus polymerase and the
XX template nucleic acid, which is derived from one of the nucleic acid
XX vectors. The hepadnavirus core particle is useful for identifying
XX bioactive agents that interrupt or inhibit hepadnavirus replication or
XX characterising the potency of antiviral agents in interrupting or
XX inhibiting hepadnavirus replication, by adding one or more
XX deoxynucleoside triphosphates and a bioactive agent to the hepadnavirus
XX core particle and either detecting formation of nucleic acids or
XX or measuring an RNase H activity exhibited by the hepadnavirus core particle,
XX detecting sizes of nucleic acids found in the hepadnavirus core particle,
XX or particle and further involves measuring the priming reaction. The
XX hepadnavirus core particle is useful for discovering or further
XX characterising antiviral agents. The hepadnavirus core particle is useful
XX for assaying for inhibitors of hepadnavirus replication, including
XX inhibitors of one or more of the priming reaction, the translocation
XX reaction, the (-) strand reaction, the elongation reaction, the (+)
XX strand elongation reaction and RNase H reaction. The human hepatitis B
XX virus (HBV, a hepadnavirus) strain ayw, was analysed and used to produce
XX the recombinant hepadnavirus core particles of the invention. The HBV
XX epsilon element is thought to form a stem-loop bulge and form the
XX template for earliest priming step of reverse transcription. The present
XX sequence is the priming product from the epsilon element
XX
XX Sequence 13 BP; 6 A; 1 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
Db 3 AAAAGTTGCAT 13
RESULT 409
AAZ78143/c
ID AAZ78143 standard; DNA; 10 BP.
XX
XX AAZ78143;

XX
DT 10-APR-2000 (first entry)
XX
XX Human dendritic cell SAGE tag, SEQ ID NO:571.
XX
XX SAGE tag; serial analysis of gene expression; antigen-presenting cell;
XX APC; monocyte-derived dendritic cell; differential gene expression;
XX immunostimulatory cofactor; costimulatory factor; CTL;
XX cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.
XX
XX Homo sapiens.
XX
XX WO965924-A2.
XX
XX 23-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US013800.
XX
XX 19-JUN-1998; 98US-0089833P.
XX 19-JUN-1998; 98US-0089844P.
XX 19-JUN-1998; 98US-0089853P.
XX 19-JUN-1998; 98US-0089878P.
XX 19-JUN-1998; 98US-0089911P.
XX 19-JUN-1998; 98US-0089922P.
XX 19-JUN-1998; 98US-0089931P.
XX 19-JUN-1998; 98US-0089934P.
XX 19-JUN-1998; 98US-0089977P.
XX 19-JUN-1998; 98US-0089999P.
XX 19-JUN-1998; 98US-0090000P.
XX 19-JUN-1998; 98US-0090035P.
XX 19-JUN-1998; 98US-0090036P.
XX 19-JUN-1998; 98US-0090039P.
XX 19-JUN-1998; 98US-0090040P.
XX 19-JUN-1998; 98US-0090041P.
XX 19-JUN-1998; 98US-0090042P.
XX 19-JUN-1998; 98US-0090043P.
XX 19-JUN-1998; 98US-0090044P.
XX 19-JUN-1998; 98US-0090045P.
XX 19-JUN-1998; 98US-0090047P.
XX 19-JUN-1998; 98US-0090048P.
XX 19-JUN-1998; 98US-0090072P.
XX 19-JUN-1998; 98US-0090076P.
XX 19-JUN-1998; 98US-0090077P.
XX 19-JUN-1998; 98US-0090078P.
XX 19-JUN-1998; 98US-0090079P.
XX 19-JUN-1998; 98US-0090080P.
XX 08-DEC-1998; 98US-0111715P.
XX
XX (GENZ) GENZYME CORP.
XX (ROBE) ROBERTS B L.
XX (SHAN) SHANKARA S.
XX
XX Roberts BL, Shankara S;
XX
XX WPI; 2000-106077/09.
XX
XX Isolated polynucleotides differentially expressed in antigen-presenting
XX cells, useful in gene vaccines against cancer.
XX
XX Claim 1; Page 81; 130pp; English.
XX
XX Sequences AAZ7573-279709 represent SAGE (serial analysis of gene
XX expression) tags used to identify mRNA transcripts encoding
XX immunostimulatory cofactor proteins which are preferentially or
XX differentially expressed in monocyte-derived dendritic cells compared
XX with monocytes. Some of the transcripts correspond to known genes or ESTs
XX (expressed sequence tags) which were previously unknown to be
XX preferentially or differentially expressed in dendritic cells, while
XX other transcripts correspond to novel genes. Antigen-presenting cell
XX (APC)-associated costimulatory factors play an important role in the
XX activation of the cytotoxic immune response, particularly against tumour
XX cells. Tumour antigen presentation via the MHC (major histocompatibility
XX complex) and subsequent recognition by T-cell receptors is alone

CC insufficient to activate a robust cytotoxic immune response that can lyse
 CC the tumour cells, immunostimulatory cofactors also being required for
 CC efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid
 CC sequences identified using the SAGE tags have several potential uses.
 CC They may be used in vaccines to induce an immune response, particularly
 CC against a tumour antigen; to modulate the genotype of an APC; to screen
 CC for agents that modulate expression of differentially expressed genes in
 CC an APC; and as hybridisation probes/amplification primers for the
 CC diagnosis, prognosis and monitoring of diseases related to abnormal
 CC expression of these genes. Detection of the dendritic cell differentially
 CC expressed genes, or of their encoded proteins, can be used to identify
 CC cells as belonging to the monocyte lineage. Cells containing these genes
 CC can be used in active immunotherapy (or to stimulate production of a
 CC population of antigen-specific effector cells) and vectors containing
 CC them are used in gene therapy. Co-administration of tumour antigens and
 CC APC-associated costimulatory factors ensures adequate antigen
 CC presentation to endogenous APCs and upregulates the APCs for the
 CC presentation of co-stimulatory signals, migration to T cell-rich sites,
 CC secretion of T cell growth factors and secretion of chemokines for
 CC recruitment of immune effector cells
 CC
 SQ Sequence 10 BP; 3 A; 3 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222

Db 9 AGTGTGACC 1

RESULT 410

AAZ83777/C

ID AAZ83777 standard; DNA; 10 BP.

XX AC AAZ83777;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #3011.

XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.

OS Homo sapiens.

XX WO9965928-A2.

PN 23-DEC-1999.

PD 18-JUN-1999; 99WO-US013647.

PF 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089997P.

PR 19-JUN-1998; 98US-0090039P.

PR 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.

XX (GENZ) GENZYME CORP.

PA (ROBE) ROBERTS B L.

PA (SHAN) SHANKARA S.

XX Roberts BL, Shankara S;

PI WPI; 2000-106079/09.

DR Isolated polynucleotides differentially expressed between metastatic and

XX non-metastatic breast cancer cells, useful for diagnosis, prevention and

PT treatment of cancer.

XX Claim 1; Page 139; 219pp; English.

PS

XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 CC
 SQ Sequence 10 BP; 2 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGTT 2229

Db 9 CCAAAAGTT 1

RESULT 411

AAF36621

ID AAF36621 standard; DNA; 10 BP.

XX AC AAF36621;

DT 23-MAR-2001 (first entry)

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3360.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

PN 21-DEC-2000.

PF 14-JUN-2000; 2000WO-US016223.

PR 16-JUN-1999; 99US-00335032.

PR (UYJO) UNIV JOHNS HOPKINS.

PA Velulescu V, Vogelstein B, Kinzler K;

PI WPI; 2001-061874/07.

DR Yeast gene coding sequences comprising NORF genes with serial analysis of

XX gene expression (SAGE) tags, useful for studying, monitoring and

PT affecting phases of the cell cycle.

XX Example; Page 120; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a

CC coding sequence of a yeast gene selected from a group of 745 NORF (not

CC previously assigned open reading frame, or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2217 GTGACCAA 2225
 DB 2 GTGACCAA 10
 |||||

RESULT 412
 AAF36059
 ID AAF36059 standard; DNA; 10 BP.

AC AAF36059;
 XX 23-MAR-2001 (first entry)
 DT
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2798.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 99; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGTT 2229
 DB 2 CCAAAAGTT 10
 |||||

RESULT 413
 AAF34702/C
 ID AAF34702 standard; DNA; 10 BP.

AC AAF34702;
 XX 23-MAR-2001 (first entry)
 DT
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:1441.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and

PT affecting phases of the cell cycle.

Example: Page 51: 419pp; English.

The present invention describes an isolated DNA molecule comprising a coding sequence of a yeast gene selected from a group of 745 NORF (not previously assigned open reading frame; or nonannotated ORF) genes comprising a SAGE (serial analysis of gene expression) tag. Also described are: (1) a method (M1) of using NORF genes to affect the cell cycle comprising administering a NORF gene whose expression varies by at least 10% between any two phases of the cell cycle selected from log phase, S phase and G2/M; (2) a method (M2) for screening candidate antifungal drugs comprising: (a) contacting a test substance with a yeast cell; and (b) monitoring expression of a NORF gene whose expression varies as in M1, where a test substance which modifies the expression of the yeast gene is a candidate antifungal drug; (3) a method (M3) for identifying human genes which are involved in cell cycle progression comprising contacting human DNA with a probe which comprises at least 10 contiguous nucleotides of a NORF gene whose expression varies as in M1; and (4) a method (M4) for identifying a candidate drug as a member of a class of drugs having a characteristic effect on gene expression in a yeast cell comprising contacting a yeast cell with a candidate drug and monitoring expression in the yeast cell of at least 1 NORF gene whose expression is affected by the class of drugs. The NORF genes may be used to study, monitor and affect phases of the cell cycle, the differentially expressed genes may be used as markers of phases of the cell cycle. The methods may be used to identify candidate drugs which affect the cell cycle and for identification of antifungal drugs. AAF33269 to AAF44064 represent SAGE tags used in the exemplification of the present invention. AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE method. In the exemplification of the present invention

Sequence 10 BP: 3 A: 1 C: 2 G: 4 T: 0 U: 0 Other: 0

```
Query Match      33.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Ov . 2221 CCAAAGTT 2229

```

      10 CCAAAAGTT 2
      |||||
      10 CCAAAAGTT 2

```

RESULT 414

AAF35200/c
ID AAF35200 standard: DNA: 10 BP.

XX
AC AAF35200:

AA	23-MAR-2001	(first entry)
DT		

XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:1939.

Yeast; *Saccharomyces cerevisiae*; characterisation; cell cycle; NORF;
nor previously assigned open reading frame; nonannotated ORF; SAGE;
serial analysis of gene expression; antifungal; tag; identification;
linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX PN WO200077214-A2.

21-DEC-2000.

14-JUN-2000: 2000WO-US016223.

16-JUN-1999: 99US-00335032.

(UYJO) UNIV JOHNS HOPKINS.

PI velculescu V, Vogelstein B, Kinzler K;

DR WPI; 2001-061874/07.

XX yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.

Example: Page 69: 419pp; English.

The present invention describes an isolated DNA molecule comprising a coding sequence of a yeast gene selected from a group of 745 NORF (not previously assigned open reading frame; or nonannotated ORF) genes comprising a SAGE (serial analysis of gene expression) tag. Also described are: (1) a method (M1) of using NORF genes to affect the cell cycle comprising administering a NORF gene whose expression varies by at least 10% between any two phases of the cell cycle selected from log phase, S phase and G2/M; (2) a method (M2) for screening candidate antifungal drugs comprising: (a) contacting a test substance with a yeast cell; and (b) monitoring expression of a NORF gene whose expression varies as in M1, where a test substance which modifies the expression of the yeast gene is a candidate antifungal drug; (3) a method (M3) for identifying human genes which are involved in cell cycle progression comprising contacting human DNA with a probe which comprises at least 10 contiguous nucleotides of a NORF gene whose expression varies as in M1; and (4) a method (M4) for identifying a candidate drug as a member of a class of drugs having a characteristic effect on gene expression in a yeast cell comprising contacting a yeast cell with a candidate drug and monitoring expression in the yeast cell of at least 1 NORF gene whose expression is affected by the class of drugs. The NORF genes may be used to study, monitor and affect phases of the cell cycle, the differentially expressed genes may be used as markers of phases of the cell cycle. The methods may be used to identify candidate drugs which affect the cell cycle and for identification of antifungal drugs. AAF33268 to AAF44064 represent SAGE tags used in the exemplification of the present invention. AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE method in the exemplification of the present invention.

XX
Sequence 10 BP: 2 A: 2 C: 2 G: 4 T: 0 U: 0 Other:

Query Match 33.3%: Score 9; DB 1: Length 10;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

```

: Matches 9; Conservative 0; Mismatches 0; Indels

```

Ov 2221 CCAAAGTT 2229

D**b** 9 CCAAAAGTT 1

RESULT 415

ABK70543

ID ABK70543 standard; DNA; 10 BP.

AC ABK70543:

AA	DT	15-JUL-2002	(first entry)

Human G protein-coupled receptor 7 allele-specific primer #3.

Human; G protein-coupled receptor 7; GPR7; haplotyping; SNP; psychological disorder; neurological disorder; primer; PCR; ss; single nucleotide polymorphism.

XX Homo sapiens.

AA
PN
W020022644-AA1

XX
PD 21-MAR-2002

XX
PF
17-SEP-2001: 2001WO-US029207.XX
PR 15-SEP-2000: 2000US-0232900P.

XX PA (GENA-) GENATISSANCE PHARM INC.

xx
PI
Koshy B, Sanchis A, Tirrell C;

XX WPI; 2002-383121/41.
 XX Novel genetic variants of G protein-coupled receptor 7 gene useful for
 XX therapeutic purposes and for expressing GPR7 protein useful in
 XX identifying drugs to treat psychological and neurological disorders.
 XX PS
 XX Claim 18; Page 13; 69pp; English.
 XX
 XX The invention relates to an isolated polynucleotide (I) comprising a
 XX nucleotide sequence which is a polymorphic variant of a reference
 XX sequence for G-protein coupled receptor 7 (GPR7) gene or its fragment, or
 XX a polymorphic variant of a reference sequence for a GPR7 cDNA or its
 XX fragment. The encoded polypeptide (II) is useful for screening for drugs
 XX targeting the polypeptide. (I) is useful for identifying an association
 XX between a trait such as a clinical response to a drug targeting GPR7 and
 XX a haplotype or haplotype pair of GPR7 gene. Such methods have
 XX applicability in developing diagnostic tests and therapeutic treatments
 XX psychological and neurological disorders. (I) is useful for studying the
 XX expression and function of GPR7 and expressing GPR7 protein for use in
 XX screening for candidate drugs to treat diseases related to GPR7 activity.
 XX The polymorphism and haplotype data are useful for validating whether
 XX GPR7 is a suitable target for drugs to treat psychological and
 XX neurological disorders, screening for such drugs and reducing bias in
 XX clinical trials of such drugs. (I) is useful for therapeutic purposes.
 XX Establishing the GPR7 haplotype or haplotype pair of an individual is
 XX useful for improving the efficiency and reliability of several steps in
 XX the discovery and development of drugs for treating diseases associated
 XX with GPR7 activity psychological and neurological disorders. The
 XX haplotyping method is useful to validate GPR7 as a candidate target for
 XX treating a specific condition or disease predicted to be associated with
 XX GPR7 activity. The method is also useful in screening for compounds
 XX targeting GPR7 to treat a specific condition or disease predicted to be
 XX associated with GPR7 activity, e.g. detecting which of the GPR7
 XX haplotypes or haplotype pairs present in individual members of a
 XX population with the specific disease of interest enables one to screen
 XX for compounds that display the highest desired agonist or antagonist
 XX activity for each of the most frequent GPR7 isoforms present in the
 XX disease population. A polymorphic variant of GPR7 is useful in studying
 XX the effect of the variation on the biological activity of GPR7, on the
 XX binding affinity of candidate drugs targeting GPR7 for the treatment of
 XX psychological and neurological disorders and in assays to measure the
 XX binding affinities of one or more candidate drugs targeting the GPR7
 XX protein. (I) is useful for studying expression of the GPR7 isoforms in
 XX vivo, for in vivo screening and testing of drugs against GPR7 protein and
 XX for testing the efficacy of therapeutic agents and compounds for
 XX psychological and neurological disorders in a biological system. Antibody
 XX to (II) is useful for diagnostic and prognostic formats and therapeutic
 XX methods, for immunoprecipitating (II) from solution, for detecting GPR7
 XX protein isoforms in biological samples, frozen tissue sections, cells
 XX which have been fixed or unfixed and prepared on slides, for use in
 XX immunocytochemical, immunohistochemical and immunofluorescence
 XX techniques. ABX70517-ABX70558 represent human GPR7 allele-specific probes
 XX and primers used in haplotyping of human GPR7 as described in the
 XX invention
 XX
 XX Sequence 10 BP; 5 A; 1 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2224 AAGATTACA 2232
 Db 2 AAGATTACA 10
 |||||
 RESULT 416
 ABV69773
 ID ABV69773 standard; cDNA; 11 BP.
 XX
 XX AC ABV69773;
 XX

DT 21-OCT-2002 (first entry)
 XX Human skin EST 7559.
 XX
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
 XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638//63.
 XX In vitro identification of skin-expressed genes, useful for determining
 XX homeostasis and identifying cosmetic or pharmaceutical agents against
 XX e.g. skin cancer.
 XX
 XX Claim 24; Page 239; 1345pp; German.
 XX
 XX The invention relates to in vitro identification (M1) of genes expressed
 XX in the skin of humans or animals by subjecting a mixture of genetically
 XX encoded factors from skin, to serial analysis of gene expression (SAGE)
 XX so as to identify skin-expressed genes and quantify their expression.
 XX (M1) is useful for identifying genes involved in skin homeostasis; to
 XX determine skin homeostasis and to test agent (A) that maintains or
 XX promotes skin homeostasis or that can be used for treating skin
 XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 XX skin. The present sequence is that of a human expressed sequence tag
 XX (EST) of the invention
 XX
 XX Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 33.3%; Score 9; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2212 AGAGTGGA 2220
 Db 3 AGAGTGGA 11
 |||||
 RESULT 417
 ABV66253/c
 ID ABV66253 standard; cDNA; 11 BP.
 XX
 XX AC ABV66253;
 XX
 XX 21-OCT-2002 (first entry)
 XX Human skin EST 4039.
 XX
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
 XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX

XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX Disclosure; Page 137; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 3 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 33.3%; Score 9; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 2221 CCAAAAGTT 2229
 DB 11 CCAAAAGTT 3
 RESULT 418
 ABV62352
 ID ABV62352 standard; cDNA; 11 BP.
 AC ABV62352;
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 138.
 DE Human; skin; dermatological; vulnery; antipsoriatic; antiseborrheic;
 XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS WO200253774-A2.
 PN 11-JUL-2002.
 PD 20-DEC-2001; 2001WO-EP015179.
 PF 03-JAN-2001; 2001DE-01000127.
 PR (HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against

PT e.g. skin cancer.
 XX Disclosure; Page 30; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 33.3%; Score 9; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 2212 AGAGTGTC A 2220
 DB 3 AGAGTGTC A 11
 RESULT 419
 ABL91964
 ID ABL91964 standard; cDNA; 11 BP.
 XX AC ABL91964;
 XX 30-MAY-2002 (first entry)
 DT Human Pan-Endothelial Marker SEQ ID NO 62.
 DE Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
 KW normal endothelial marker; pan-endothelial marker; immunostimulant;
 KW antiangiogenic; tumour; neovascularisation; vascularised tumour;
 KW polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
 KW psoriasis; ss.
 XX Homo sapiens.
 OS WO200210217-A2.
 PN 07-FEB-2002.
 PD 01-AUG-2001; 2001WO-US024031.
 PF 02-AUG-2000; 2000US-0222599P.
 PR 11-AUG-2000; 2000US-0224360P.
 PR 11-APR-2001; 2001US-0282850P.
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA St Croix B, Kinzler KW, Vogelstein B;
 XX WPI; 2002-291856/33.
 DR An isolated molecule comprising an antibody variable region which
 PT specifically binds to an extracellular domain of a tumor endothelial
 PT marker (TEM) protein, useful for inhibiting tumor growth.
 XX Example 4; Page 325; 331pp; English.
 XX The invention relates to an isolated molecule comprising an antibody
 CC variable region which specifically binds to an extracellular domain of a
 CC tumour endothelial marker (TEM) protein selected from ABB90732, ABB90740,
 CC ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
 CC proteins have cytostatic, immunostimulant and antiangiogenic activity.

CC They are useful for inhibiting tumour growth, neoangiogenesis in subjects
CC bearing a vascularised tumour, polycystic kidney disease, diabetic
CC retinopathy, rheumatoid arthritis and psoriasis. Human, mouse and rat TEM
CC genes and the encoded proteins (ABL92075-ABL92141 and ABB90721-ABB90789)
CC are disclosed, as are marker oligonucleotide sequences: tumour
CC endothelial markers (TEM) ABL91996-ABL92041 and ABL92143-ABL92191; normal
CC endothelial markers (NEM) ABL92042-ABL92074; and pan-endothelial markers
CC (PEM) ABL91903-ABL91995. The present sequence is that of an
CC oligonucleotide marker useful to the invention
XX
SQ Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2212 AGAGTGTGA 2220
Db 3 AGAGTGTGA 11
RESULT 420
ID ABX71889 standard; DNA; 11 BP.
XX AC ABX71889;
XX DT 12-MAR-2003 (first entry)
XX DE DNA tag used to identify human gene encoding PEM 62.
XX KW Human; endothelial cell; EC; tumour endothelial cell; TEM; NEM;
XX KW Tumour endothelial marker; normal endothelial marker; PEM;
XX KW pan-endothelial marker; polycystic kidney disease; psoriasis;
XX KW diabetic retinopathy; rheumatoid arthritis; tumour angiogenesis;
XX KW neoangiogenesis; immune response; cytostatic; antidiabetic;
XX KW ophthalmological; antirheumatic; antiarthritic; antipsoriatic; ds.
XX OS Homo sapiens.
XX PN WO200283874-A2.
XX PD 24-OCT-2002.
XX PF 10-APR-2002; 2002WO-US008253.
XX PR 11-APR-2001; 2001US-0282850P.
XX PR 06-FEB-2002; 2002US-0354262P.
XX PA (UJVO) UNIV JOHNS HOPKINS.
XX PI Carson-Walter E, St Croix B, Kinzler KW, Vogelstein B;
XX DR WPI; 2003-093016/08.
XX PT New purified human transmembrane protein, designated as tumor endothelial
XX marker (TEM) 3, useful for detecting, diagnosing or treating tumors,
XX PT polycystic kidney disease, diabetic retinopathy, rheumatoid arthritis or
XX PT psoriasis.
XX PS Disclosure; Page 96; 374pp; English.
XX CC The present invention relates to a novel method for the isolation of
XX CC endothelial cells (ECs), and the identification of genes expressed in
XX CC normal and tumour ECs. Tumour endothelial marker (TEM), normal
XX CC endothelial marker (NEM), and pan-endothelial marker (PEM) genes are
XX CC identified in human ECs. The human EC marker proteins and the
XX CC polynucleotide sequences encoding them are useful for detecting,
XX CC diagnosing or treating tumours as well as polycystic kidney disease,
XX CC diabetic retinopathy, rheumatoid arthritis, and psoriasis. They are also
XX CC useful for inhibiting neoangiogenesis or tumour angiogenesis, for
XX CC inducing an immune response to tumour endothelial cells in a patient, or
XX CC for identifying candidate drugs for treating tumours. ABX71828-ABX71999

CC represent DNA tags for human PEM, TEM or NEM genes
XX Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
SQ Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2212 AGAGTGTGA 2220
Db 3 AGAGTGTGA 11
RESULT 421
ID ADQ34600 standard; DNA; 11 BP.
XX AC ADQ34600;
XX DT 23-SEP-2004 (first entry)
XX DE Human facial skin-associated DNA fragment SEQ ID NO 2690.
XX KW facial skin; human; serial analysis of gene expression; SAGE;
XX KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX OS Homo sapiens.
XX PN DE10260928-A1.
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060928.
XX PR 20-DEC-2002; 2002DE-01060928.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518855/50.
XX PT In vitro identification of genes important for facial skin, useful for
XX PT assessing homeostasis and in screening for pharmaceutical or cosmetic
XX PT agents, based on differential expression analysis.
XX PS Claim 4; SEQ ID NO 2690; 577pp; German.
XX CC This invention describes a novel in vitro method for identifying genes
XX CC that are significant for facial skin in humans. The method comprises
XX CC recovering, from facial skin, a first mixture of genetically expressed
XX CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
XX CC their fragments), recovering a second, similar mixture from some other
XX CC human tissue, preferably skin from a protected area, especially from the
XX CC breast and subjecting the mixtures to serial analysis of gene expression
XX CC (SAGE) to identify those genes for which expression is markedly different
XX CC between facial skin and the other tissue. The invention also describes an
XX CC in vitro method for determining homeostasis of human facial skin; a test
XX CC kit which comprises a solid support (flexible or rigid) on which are
XX CC immobilised probes that bind specifically to the factors of interest and
XX CC a biochip for determining homeostasis of human facial skin. The products
XX CC of the invention are also used in a method which determines activity of
XX CC cosmetic and pharmaceutical agents for use against disorders or
XX CC disturbances of the homeostasis of human skin and a screening method for
XX CC identifying cosmetic and pharmaceutical agents. The method allows
XX CC identification of as many as possible of the genes important for facial
XX CC skin and thus of a very wide range of potential therapeutic and cosmetic
XX CC agents. ADQ34600-ADQ35111 represent human DNA tag fragments used to
XX CC identify the facial skin-associated genes described in the invention.
XX Sequence 11 BP; 2 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2221 CCAAAGTT 2229
DB 9 CCAAAGTT 1

RESULT 422

ADQ32402
ID ADQ32402 standard; DNA; 11 BP.

XX AC ADQ32402;

XX 23-SEP-2004 (first entry)

XX Human facial skin-associated DNA fragment SEQ ID NO 492.

XX facial skin; human; serial analysis of gene expression; SAGE;
XX homeostasis; biochip; cosmetic; pharmaceutical; ds.

XX Homo sapiens.

XX DE10260928-AL.

XX 08-JUL-2004.

XX 20-DEC-2002; 2002DE-01060928.

XX 20-DEC-2002; 2002DE-01060928.

XX (HENK) HENKEL KGAA.

XX Petersohn D, Schlottmann K, Gassenmeier T, Holtkoetter O;

XX Conrad M, Hofmann K;

XX WPI; 2004-518855/50.

XX In vitro identification of genes important for facial skin, useful for
XX assessing homeostasis and in screening for pharmaceutical or cosmetic
XX agents, based on differential expression analysis.

XX Claim 6; SEQ ID NO 492; 577bp; German.

XX This invention describes a novel in vitro method for identifying genes
XX that are significant for facial skin in humans. The method comprises
XX recovering, from facial skin, a first mixture of genetically expressed
XX (transcribed and optionally translated) factors (i.e. proteins, mRNA or
XX their fragments), recovering a second, similar mixture from some other
XX human tissue, preferably skin from a protected area, especially from the
XX breast and subjecting the mixtures to serial analysis of gene expression
XX (SAGE) to identify those genes for which expression is markedly different
XX between facial skin and the other tissue. The invention also describes an
XX in vitro method for determining homeostasis of human facial skin; a test
XX kit which comprises a solid support (flexible or rigid) on which are
XX immobilised probes that bind specifically to the factors of interest and
XX a biochip for determining homeostasis of human facial skin. The products
XX of the invention are also used in a method which determines activity of
XX cosmetic and pharmaceutical agents for use against disorders or
XX disturbances of the homeostasis of human skin and a screening method for
XX identifying cosmetic and pharmaceutical agents. The method allows
XX identification of as many as possible of the genes important for facial
XX skin and thus of a very wide range of potential therapeutic and cosmetic
XX agents. ADQ31911-ADQ31511 represent human DNA Tag fragments used to
XX identify the facial skin-associated genes described in the invention.

XX Sequence 11 BP; 6 A; 3 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2218 TGACCAAAA 2226
DB 1 TGACCAAAA 9

RESULT 423

AB167341
ID AB167341 standard; DNA; 12 BP.

XX AC AB167341;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 367314 for detecting SNP TSC0006849.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 367314; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX The oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, cardiovascular and metabolic disorders. The
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2212 ACAGGTGTGA 2220

DB 2 ACAGGTGTGA 10

RESULT 424

AB151628
ID AB151628 standard; DNA; 12 BP.

XX AC AB151628;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 351601 for detecting SNP TSC0047395.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 351601; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 33.3%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2212 AGAGTGTCGA 2220
DB 3 AGAGTGTCGA 11
RESULT 425
ABI19573
ID ABI19573 standard; DNA; 12 BP.
AC ABI19573;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 319546 for detecting SNP TSC0029290.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 319546; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 3 A; 0 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 33.3%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2212 AGAGTGTCGA 2220
DB 3 AGAGTGTCGA 11
RESULT 426
ABI68656/C
ID ABI68656 standard; DNA; 12 BP.
XX ABI68656;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 368629 for detecting SNP TSC0057125.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX


```

Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTTG 2238
Db 1 GTTATATTTTG 12

RESULT 434
ABI61564
ID ABI61564 standard; DNA; 12 BP.
XX AC
XX ABI61564;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 361537 for detecting SNP TSC0052684.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 361537; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTTACA 2232
Db 1 CCAAAAATACA 12

RESULT 435
ABI63012
ID ABI63012 standard; DNA; 12 BP.
XX AC
XX ABI63012;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 379632 for detecting SNP TSC0063394.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 361537; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 362985 for detecting SNP TSC0053575.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 362985; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2213 GAGTGTGACCAA 2224
Db 1 GAGTGTGAGGAA 12

RESULT 436
ABI79659
ID ABI79659 standard; DNA; 12 BP.
XX AC
XX ABI79659;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 379632 for detecting SNP TSC0063394.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 362985; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 379632; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCRAAAGTTTACA 2232
 Db 1 CAAAAATTTACA 12
 RESULT 437
 ABH69606/c
 ID ABH69606 standard; DNA; 12 BP.
 XX
 AC ABH69606;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 269583 for detecting SNP TSC0001812.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 273224; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCRAAAGTTTACA 2232
 Db 1 CAAAAATTTACA 12
 RESULT 437
 ABH69606/c
 ID ABH69606 standard; DNA; 12 BP.
 XX
 AC ABH69606;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 269583 for detecting SNP TSC0001812.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 273224; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTTAC 2231
 Db 12 ACCAATTTTAC 1
 RESULT 438
 ABH73239/c
 ID ABH73239 standard; DNA; 12 BP.
 XX
 AC ABH73239;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 273224 for detecting SNP TSC0003096.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 273224; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTTAC 2231
 Db 12 ACCAATTTTAC 1

PT designed to detect single-nucleotide polymorphisms and cytosine.
 PT methylation status.

XX Claim 1; SEQ ID NO 269583; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTTAC 2231
 Db 12 ACCAATTTTAC 1

RESULT 438
 ABH73239/c
 ID ABH73239 standard; DNA; 12 BP.

XX AC ABH73239;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 273224 for detecting SNP TSC0003096.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 273224; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2225 AAGTTACATGTT 2236
Db 12 AAGTTACATGTT 1
RESULT 439
ABI01684
ID ABI01684 standard; DNA; 12 BP.
XX AC
AC ABI01684;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 301657 for detecting SNP TSC0019597.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPT; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 301657; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2225 AAGTTACATGTT 2236
Db 12 AAGTTACATGTT 1

Db 1 AAGTTTAAATGTT 12
RESULT 440
ABI06155
ID ABI06155 standard; DNA; 12 BP.
XX AC
AC ABI06155;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 306128 for detecting SNP TSC0021818.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPT; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 306128; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2226 AGTTACATGTT 2237
Db 1 AGTTACATGTT 12
RESULT 441
ABI33010/C
ID ABI33010 standard; DNA; 12 BP.
XX AC
AC ABI33010;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 332983 for detecting SNP TSC0037310.
XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 332983; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAAGTTTACATCT 2235
 Db 12 AAAGTTTATTTT 1
 RESULT 442
 ABI12796/C
 ID ABI12796 standard; DNA; 12 BP.
 AC ABI12796;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 312769 for detecting SNP TSC0025278.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 344198; 29pp + Sequence Listing; German.

XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 312769; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2238
 Db 12 GTTAAATATTT 1
 RESULT 443
 ABI44225/C
 ID ABI44225 standard; DNA; 12 BP.
 AC ABI44225;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 344198 for detecting SNP TSC0043438.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 344198; 29pp + Sequence Listing; German.


```

ID  ABI77494 standard; DNA; 12 BP.
XX
AC  ABI77494;
XX
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 377467 for detecting SNP TSC0062347.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIG-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX
XX  Claim 1; SEQ ID NO 377467; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  central nervous system, cardiovascular and metabolic disorders. The
XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX  represent the oligomers described in the invention. NOTE: The sequence
XX  data for this patent did not form part of the printed specification, but
XX  was obtained in electronic format from WIPO at
XX  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX  Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY  2216 TGTGACCAAAAG 2227
DB  12 TGTGAAAAAAAG 1
XX
RESULT 447
ID  ABH97775/C
XX
AC  ABH97775 standard; DNA; 12 BP.
XX
XX  ABH97775;
XX
XX  22-FEB-2002 (first entry)
XX
XX  Oligonucleotide primer SEQ ID NO 297768 for detecting SNP TSC0017751.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIG-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX
XX  Claim 1; SEQ ID NO 297768; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  central nervous system, cardiovascular and metabolic disorders. The
XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX  represent the oligomers described in the invention. NOTE: The sequence
XX  data for this patent did not form part of the printed specification, but
XX  was obtained in electronic format from WIPO at
XX  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX  Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY  2216 TGTGACCAAAAG 2227
DB  12 TGTGAAAAAAAG 1
XX
RESULT 447
ID  ABH97775/C
XX
AC  ABH97775 standard; DNA; 12 BP.
XX
XX  ABH97775;
XX
XX  22-FEB-2002 (first entry)
XX
XX  Oligonucleotide primer SEQ ID NO 297768 for detecting SNP TSC0017751.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS

```


DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 299919; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2222 CAAGAAGTTACAT 2233
DB 12 CAATAATTACT 1
RESULT 449
ABI11682/c
ID ABI11682 standard; DNA; 12 BP.
AC
AC ABI11682;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 311655 for detecting SNP TSC0024599.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
DE Oligonucleotide primer SEQ ID NO 311655 for detecting SNP TSC0024599.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 311655; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2222 CAAGAAGTTACAT 2233
DB 12 CAATAATTACT 1
RESULT 449
ABI11682/c
ID ABI11682 standard; DNA; 12 BP.
AC
AC ABI11682;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 311655 for detecting SNP TSC0024599.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 311655; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAAGTTTAC 2231
DB 12 AACAAAATTTC 1
RESULT 450
ABI40821/c
ID ABI40821 standard; DNA; 12 BP.
XX
AC ABI40821;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 340794 for detecting SNP TSC0006025.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 340794; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 357294; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2226 AGTTACATGTT 2237
Db 1 AGTTAAATGTT 12

RESULT 454
ABI62405
ID ABI62405 standard; DNA; 12 BP.
XX
XX ABI62405;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 362378 for detecting SNP TSC0053191.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPiG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 362378; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2224 AAAGTTACATGT 2235
Db 1 AAAGTTATATAT 12

RESULT 455
ABH71095/c
ID ABH71095 standard; DNA; 12 BP.
XX
XX ABH71095;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 271072 for detecting SNP TSC0002388.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPiG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 271072; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

```

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match      32.6%; Score 8.8; DB 1; Length 12;
  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233
Db 12 CAAAAGTTACAT 1

RESULT 456
AB100641
ID AB100641 standard; DNA; 12 BP.
XX
AC AB100641;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 300614 for detecting SNP TSC0019116.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 300614; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match      32.6%; Score 8.8; DB 1; Length 12;
  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2220 ACCAAAGTTAC 2231
Db 1 AACAAAGTTAC 12

RESULT 457
ABH81103
ID ABH81103 standard; DNA; 12 BP.
XX
AC ABH81103;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 281096 for detecting SNP TSC0009436.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 281096; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match      32.6%; Score 8.8; DB 1; Length 12;
  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTG 2238
Db 1 GTTACATGTTG 12

RESULT 458
AB106822
ID AB106822 standard; DNA; 12 BP.
XX
AC AB106822;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306795 for detecting SNP TSC0022172.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 306795; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2226 AGTTACATGTTT 2237
DB 1 AGTTATTTGTTT 12
RESULT 459
ABI35155
ID ABI35155 standard; DNA; 12 BP.
XX
XX ABI35155;
AC
XX
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 335128 for detecting SNP TSC0038616.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 335128; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2226 AGTTACATGTTT 2237
DB 1 AGTTATTTGTTT 12
RESULT 460
ABI10551
ID ABI10551 standard; DNA; 12 BP.
XX
XX ABI10551;
AC
XX
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 310524 for detecting SNP TSC0024021.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 310524; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligonucleotides are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: the sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
 Db 1 AGATATATGTTT 12
 |||||

RESULT 461
 ABH89652
 ID ABH89652 standard; DNA; 12 BP.
 XX AC ABH89652;
 XX 22-FEB-2002 (first entry)
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 289645 for detecting SNP TSC0014029.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 289645; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAGCTTAC 2231
 Db 1 AACAAACTTAC 12
 |||||

RESULT 462
 ABI50659
 ID ABI50659 standard; DNA; 12 BP.
 XX AC ABI50659;
 XX 22-FEB-2002 (first entry)
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 350632 for detecting SNP TSC0046788.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 350632; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTT 2236
 Db 1 AAGTTATTTGTT 12
 |||||

RESULT 463
 ABI54006/C
 ID ABI54006 standard; DNA; 12 BP.
 XX

```
AC ABI54006;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 353979 for detecting SNP TSC0048830.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 353979; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTT 2237
DB 12 AGTTAAATTTT 1
XX
RESULT 464
ABI70902
ID ABI70902 standard; DNA; 12 BP.
XX
AC ABI70902;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 370875 for detecting SNP TSC0058443.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
```

```
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 370875; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTT 2237
DB 1 AGTTACGTGATT 12
XX
RESULT 465
ABI62037
ID ABI62037 standard; DNA; 12 BP.
XX
AC ABI62037;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362010 for detecting SNP TSC0052990.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 362010; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234

Db 1 AAAAGTTAAGG 12

RESULT 466

ABH93579

ID ABH93579 standard; DNA; 12 BP.

AC ABH93579;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 293572 for detecting SNP TSC0015681.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 293572; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233

Db 1 CAAAAGTTATAT 12

RESULT 467

ABH94835/C

ID ABH94835 standard; DNA; 12 BP.

XX ABH94835;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 294828 for detecting SNP TSC0016298.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 294828; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233

XX	Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;	
SQL		
	Query Match 32.6%; Score 8.8; DB 1; Length 12;	
	Best Local Similarity 83.3%; Pred. No. 2.7e+02;	
	Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	2221 CCATAAGTTTACA 2232	
DB	12 CTATAAATTACA 1	
	RESULT 473	
	ABI48638/c	
XX	ID ABI48638 standard; DNA; 12 BP.	
XX	AC ABI48638;	
XX	AC	
XX	DT 22-FEB-2002 (first entry)	
XX	DE Oligonucleotide primer SEQ ID NO 348611 for detecting SNP TSC0006026.	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX	Homo sapiens.	
XX	WO200177384-A2.	
XX	18-OCT-2001.	
XX	06-APR-2001; 2001WO-IB000713.	
XX	07-APR-2000; 2000DE-01019173.	
XX	(EPIG-) EPIGENOMICS AG.	
XX	Olek A, Piepenbrock C, Berlin K;	
XX	WPI; 2001-657177/75.	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is	
XX	designed to detect single-nucleotide polymorphisms and cytosine	
XX	methylation status.	
XX	Claim 1; SEQ ID NO 348611; 29pp + Sequence Listing; German.	
XX	This invention describes novel oligonucleotide primers or peptide nucleic	
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
XX	and cytosine methylation status in chemically pretreated genomic DNA. The	
XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
XX	range of diseases including immune system, gastrointestinal, respiratory,	
XX	central nervous system, cardiovascular and metabolic disorders. The	
XX	oligonucleotides are also used for detecting cell type differentiation. ABC00010	
XX	-ABC99989, ABF00010-ABF99989, ABH0010-ABH99989 and ABT00010-ABT82073	
XX	represent the oligomers described in the invention. NOTE: The sequence	
XX	data for this patent did not form part of the printed specification, but	
XX	was obtained in electronic format from WIPO at	
XX	ftp.wipo.int/pub/published_pat_sequences	
XX	Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;	
SQL		
	Query Match 32.6%; Score 8.8; DB 1; Length 12;	
	Best Local Similarity 83.3%; Pred. No. 2.7e+02;	
	Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	2215 GTGTACCAAAA 2226	
DB	12 GTCTAACCAAAA 1	
	RESULT 474	

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGT 2235
 |||||
 Db 12 AAAATTACATAT 1

RESULT 478
 ABI71978
 ID ABI71978 standard; DNA; 12 BP.
 XX
 AC ABI71978;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 371951 for detecting SNP TSC0059080.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 371951; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGT 2235
 |||||
 Db 12 AAAATTACATAT 1

Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACAT 2233
 |||||
 Db 1 CAAAATTTCAT 12
 RESULT 479
 ABI73808/C
 ID ABI73808 standard; DNA; 12 BP.
 XX
 AC ABI73808;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 373781 for detecting SNP TSC0060316.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 373781; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTAC 2231
 |||||
 Db 12 ACCAAATTTCAC 1

RESULT 480
 ABI60517
 ID ABI60517 standard; DNA; 12 BP.
 XX
 AC ABI60517;
 XX

The following information was obtained from electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0

QY 2226 AGTTCATCTTT 2237
DB 1 ATTACATTTTT 12
||||| |||||
1 ATTCATTTTT 12

RESULT 484
ABH74578/C
ID ABH74578 standard; DNA; 12 BP.
XX AC ABH74578;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 274563 for detecting SNP TSC0003596.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
PA (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PS Claim 1; SEQ ID NO 274563; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0

QY 2222 CAAGGTTCATCAT 2233
DB 1 CAATTTCATCAT 12
||||| |||||
1 CAATTTCATCAT 12

RESULT 483
ABI233994
ID ABI233994 standard; DNA; 12 BP.
XX AC ABI233994;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 323967 for detecting SNP TSC0031695.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
PA (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 323967; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

methylation status.

Claim 1; SEQ ID NO 297906; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0

QY 2222 CAAGGTTCATCAT 2233
DB 1 CAATTTCATCAT 12
||||| |||||
1 CAATTTCATCAT 12

RESULT 483
ABI233994
ID ABI233994 standard; DNA; 12 BP.
XX AC ABI233994;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 323967 for detecting SNP TSC0031695.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
PA (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 323967; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

methylation status.

Claim 1; SEQ ID NO 297906; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0

QY 2226 AGTTCATCTTT 2237
DB 1 ATTACATTTTT 12
||||| |||||
1 ATTCATTTTT 12

RESULT 484
ABH74578/C
ID ABH74578 standard; DNA; 12 BP.
XX AC ABH74578;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 274563 for detecting SNP TSC0003596.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
PA (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PS Claim 1; SEQ ID NO 274563; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0

QY 2219 GACCAAAAGTTA 2230
DB 12 GACCAAAAATAACTA 1
||||| |||||
12 GACCAAAAATAACTA 1

peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.
Homo sapiens.	Homo sapiens.
WO200177384-A2.	WO200177384-A2.
18-OCT-2001.	18-OCT-2001.
06-APR-2001; 2001WO-IB000713.	06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.	07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.	(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;	Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.	WPI; 2001-657177/75.
Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.	Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
Claim 1; SEQ ID NO 276551; 29pp + Sequence Listing; German.	Claim 1; SEQ ID NO 276551; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010-ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010-ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
Sequence 12 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 0 Other;	Sequence 12 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;	Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;	Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0	Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0
QY 2225 AAGTTACATGTT 2236	QY 2225 AAGTTACATGTT 2236
Db 12 AGTTAAGGTT 1	Db 12 AGTTAAGGTT 1
RESULT 487	RESULT 487
ABI08258	ABI08258
ID ID ABI08258 standard; DNA; 12 BP.	ID ID ABI08258 standard; DNA; 12 BP.
XX AC	XX AC
XX ABI08258;	XX ABI08258;
XX	XX
DT 22-FEB-2002 (first entry)	DT 22-FEB-2002 (first entry)
XX	XX
DE Oligonucleotide primer SEQ ID NO 308231 for detecting SNP TSC0022918.	DE Oligonucleotide primer SEQ ID NO 308231 for detecting SNP TSC0022918.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.	KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	XX
OS Homo sapiens.	OS Homo sapiens.
XX	XX
WO200177384-A2.	WO200177384-A2.
XX	XX
18-OCT-2001.	18-OCT-2001.
XX	XX
06-APR-2001; 2001WO-IB000713.	06-APR-2001; 2001WO-IB000713.
XX	XX
07-APR-2000; 2000DE-01019173.	07-APR-2000; 2000DE-01019173.
XX	XX

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 308231; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 PS
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. NO. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2227 GTTACATGTTTG 2238
 DB 1 GTTATAGTTTG 12
 RESULT 488
 ABH88907
 ID ABH88907 standard; DNA; 12 BP.
 XX
 AC ABH88907;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 288900 for detecting SNP TSC0013725.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 288900; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 PS
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. NO. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2222 CAAAAGTTTACAT 2233
 DB 1 CAAAAAATACAT 12
 RESULT 489
 ABI47584
 ID ABI47584 standard; DNA; 12 BP.
 XX
 AC ABI47584;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 347557 for detecting SNP TSC0045161.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 347557; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

```

Query Match          32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2218 TGACCAAAAGTT 2229
Db 1 TTACCAAAATTT 12
|||||
RESULT 490
ABI53872/c
ID ABI53872 standard; DNA; 12 BP.
XX AC
XX AB153872;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 353845 for detecting SNP TSC0048761.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 353845; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match          32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGTT 2236
Db 12 AAGTTATAGTT 1
|||||
RESULT 491
ABI68385
ID ABI68385 standard; DNA; 12 BP.
XX AC
XX AB168385
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 356192 for detecting SNP TSC0050005.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 368358; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX Query Match          32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX Qy 2221 CCAAAAGTTACA 2232
XX Db 1 CCAAAATCACA 12
XX RESULT 492
XX ABI56219/c
XX ID ABI56219 standard; DNA; 12 BP.
XX AC
XX AB156219;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 356192 for detecting SNP TSC0050005.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 368358; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

```

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 356192; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTTA 2230
DB 12 GAACAAAATTA 1
RESULT 493
ABI61542
ID ABI61542 standard; DNA; 12 BP.
XX
AC ABI61542;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 361515 for detecting SNP TSC0052678.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 356192; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTTA 2230
DB 12 GAACAAAATTA 1
RESULT 493
ABI61542
ID ABI61542 standard; DNA; 12 BP.
XX
AC ABI61542;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 361515 for detecting SNP TSC0052678.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 361515; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATGT 2235
DB 1 AAATTTATATGT 12
RESULT 494
ABI20408/C
ID ABI20408 standard; DNA; 12 BP.
XX
AC ABI20408;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 320381 for detecting SNP TSC0029678.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 320381; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC Oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2222 CAAAGTTACAT 2233
 Db 12 CAAATTCACAT 1

RESULT 495
 ABH85618/c
 ID ABH85618 standard; DNA; 12 BP.
 AC
 XX
 AC ABH85618;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285611 for detecting SNP TSC0012377.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 285611; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2222 CAAAGTTACAT 2233
 Db 12 CAAATTCACAT 1

RESULT 495
 ABH85618/c
 ID ABH85618 standard; DNA; 12 BP.
 AC
 XX
 AC ABH85618;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285611 for detecting SNP TSC0012377.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

OY 2225 AAGTTACATGTT 2236
 Db 12 AAGTTATATTTT 1

RESULT 496
 ABI10848/c
 ID ABI10848 standard; DNA; 12 BP.
 AC
 XX
 AC ABI10848;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 310821 for detecting SNP TSC0024131.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 310821; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2226 AGTTACATGTTT 2237
 Db 12 AGTGAGATGTTT 1

RESULT 497
 ABH86904/c
 ID ABH86904 standard; DNA; 12 BP.
 AC
 XX
 AC ABH86904;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285611 for detecting SNP TSC0012377.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 285611; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
DE Oligonucleotide primer SEQ ID NO 286897 for detecting SNP TSC0012870.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 286897; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2222 CAAAGCTTACAT 2233
DB 12 CATACTTACAT 1
RESULT 498
ABI37828
ID ABI37828 standard; DNA; 12 BP.
XX
XX ABI37828;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 337801 for detecting SNP TSC0040080.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
PF
```

```
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 337801; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTTA 2230
DB 1 GACCAAAATATA 12
RESULT 499
ABH91107/c
ID ABH91107 standard; DNA; 12 BP.
XX
XX ABH91107;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 291100 for detecting SNP TSC0014633.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
```

PS Claim 1; SEQ ID NO 291100; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTAC 2231

Db 12 ACCAAAGTTAC 1

RESULT 500

ABI46624/C
 ID ABI46624 standard; DNA; 12 BP.

AC ABI46624;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 346597 for detecting SNP TSC0044666.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 346597; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACAT 2233

Db 12 CAAAAGTTACAT 1

RESULT 501

ABI56299
 ID ABI56299 standard; DNA; 12 BP.

AC ABI56299;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 356272 for detecting SNP TSC0050039.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX Claim 1; SEQ ID NO 356272; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTG 2238

Db 1 GTTACATGTTG 12

RESULT 502
ABI59543
ID ABI59543 standard; DNA; 12 BP.
XX AC ABI59543;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 359516 for detecting SNP TSC0010776.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 359516; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2220 ACCAAAAGTTAC 2231
XX 1 ACCATAATTAC 12
XX
RESULT 503
ABI80453/C
ID ABI80453 standard; DNA; 12 BP.
XX AC ABI80453;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 380426 for detecting SNP TSC0063919.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 380426; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2219 GACCAAAAGTTA 2230
XX 12 GACCATTAATTA 1
XX
RESULT 504
ABH68117
ID ABH68117 standard; DNA; 12 BP.
XX AC ABH68117;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 268094 for detecting SNP TSC0000870.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX

PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 268094; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTACAT 2233
 DB 1 CAAAATTATAT 12
 RESULT 505
 ABH73023/C
 ID ABH73023 standard; DNA; 12 BP.
 AC ABH73023;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 273008 for detecting SNP TSC0003011.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 273008; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTACAT 2233
 DB 1 CAAAATTATAT 12
 RESULT 505
 ABH73023/C
 ID ABH73023 standard; DNA; 12 BP.
 AC ABH73023;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 273008 for detecting SNP TSC0003011.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 273008; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 2225 AAGTTACATGTT 2236
 DB 12 AATTAGATGTT 1
 RESULT 506
 ABH83888/C
 ID ABH83888 standard; DNA; 12 BP.
 AC ABH83888;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 283981 for detecting SNP TSC0011547.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 283981; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;


```
Best Local Similarity 83.3%; Pred. No. 2.7e+02; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 2;

QY 2223 AAAAGTTACATG 2234
Db 12 AAAAATTATATG 1

RESULT 507
ABH90635/c
ID ABH90635 standard; DNA; 12 BP.
XX AC ABH90635;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 290628 for detecting SNP TSC0014446.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 290628; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
Db 12 AGTATTATGTTT 1

RESULT 508
ABH91770/c
ID ABH91770 standard; DNA; 12 BP.
XX AC ABH91770;
XX
```

```
XX
DT
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 291763 for detecting SNP TSC0014924.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 291763; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTT 2236
Db 12 AAGTAAATGTTT 1

RESULT 509
ABI60352
ID ABI60352 standard; DNA; 12 BP.
XX
XX AC ABI60352;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 360325 for detecting SNP TSC0006977.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
```

PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 360325; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2225 AAGTTACATGTT 2236
 XX |||||
 XX 1 AAGTTAAATTT 12
 XX
 XX RESULT 510
 XX ABI74908
 XX ID ABI74908 standard; DNA; 12 BP.
 XX
 XX AC ABI74908;
 XX
 XX DT 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide primer SEQ ID NO 374881 for detecting SNP TSC0060951.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPIG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 374881; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2225 AAGTTACATGTT 2236
 XX |||||
 XX 1 AAGTTAAATTT 12
 XX
 XX RESULT 510
 XX ABI74908
 XX ID ABI74908 standard; DNA; 12 BP.
 XX
 XX AC ABI74908;
 XX
 XX DT 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide primer SEQ ID NO 374881 for detecting SNP TSC0060951.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPIG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 374881; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2225 AAGTTACATGTT 2236
 XX |||||
 XX 1 AAGTTAAATTT 12
 XX
 XX RESULT 511
 XX ABI76096
 XX ID ABI76096 standard; DNA; 12 BP.
 XX
 XX AC ABI76096;
 XX
 XX DT 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide primer SEQ ID NO 376069 for detecting SNP TSC0061599.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPIG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 376069; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2218 TGACCAAAAGTT 2229
 XX |||||
 XX 1 TCAAAAAAAGTT 12
 XX
 XX Db

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 374881; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2218 TGACCAAAAGTT 2229
 XX |||||
 XX 1 TCAAAAAAAGTT 12
 XX
 XX Db

RESULT 511
 ABI76096
 ID ABI76096 standard; DNA; 12 BP.
 XX
 XX AC ABI76096;
 XX
 XX DT 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide primer SEQ ID NO 376069 for detecting SNP TSC0061599.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPIG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 376069; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 2218 TGACCAAAAGTT 2229
 XX |||||
 XX 1 TCAAAAAAAGTT 12
 XX
 XX Db

CC represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTAC 2231

DB 1 AAAAAAATTAC 12

RESULT 512

ID AB165524/C
 ID AB165524 standard; DNA; 12 BP.

AC AB165524;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 365497 for detecting SNP TSC0055166.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 365497; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTG 2238

|||||

DB 12 GTTAAATGTTG 1

RESULT 513

ID AB165731
 ID AB165731 standard; DNA; 12 BP.

XX AB165731;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 365704 for detecting SNP TSC0055288.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 365704; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGT 2235

DB 1 AAAGTTACATGT 12

RESULT 514

ID ABH77539
 ID ABH77539 standard; DNA; 12 BP.

XX ABH77539;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 277532 for detecting SNP TSC0004498.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 277532; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTTG 2238
 DB |||||
 1 GGTATATGTTTG 12
 RESULT 515
 ABH83514
 ID ABH83514 standard; DNA; 12 BP.
 XX
 AC ABH83514;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 283507 for detecting SNP TSC0011350.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 339195; 29pp + Sequence Listing; German.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 283507; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 SQ Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTTACA 2232
 DB |||||
 1 CCAAAATTATA 12
 RESULT 516
 ABI39222/c
 ID ABI39222 standard; DNA; 12 BP.
 XX
 AC ABI39222;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 339195 for detecting SNP TSC0040893.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 339195; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2226 AGTTACATGTTT 2237
Db 12 ATTTATGTTT 1
RESULT 517
ABI48414/C
ID ABI48414 standard; DNA; 12 BP.
XX AC ABI48414;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 348387 for detecting SNP TSC0045573.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 348387; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2227 GTTACATGTTTG 2238
Db 12 GTTTATGTTT 1
RESULT 518
ABI73304/C
ID ABI73304 standard; DNA; 12 BP.
XX AC ABI73304;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 373277 for detecting SNP TSC0059941.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 373277; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2222 CAAAAGTTACAT 2233
Db 12 CAAAAGTTACAT 1
RESULT 519
ABI74430

```

ID  ABI74430 standard; DNA; 12 BP.
XX  AC
XX  ABI74430;
DT  22-FEB-2002 (first entry)
XX  DE
XX  Oligonucleotide primer SEQ ID NO 374403 for detecting SNP TSC0060671.
XX  KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  OS Homo sapiens.
XX  PN WO200177384-A2.
XX  PD 18-OCT-2001.
XX  PF 06-APR-2001; 2001WO-IB000713.
XX  PR 07-APR-2000; 2000DE-01019173.
XX  PA (EPIG-) EPIGENOMICS AG.
XX  PI Olek A, Piepenbrock C, Berlin K;
XX  DR WPI; 2001-657177/75.
XX  PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  PT designed to detect single-nucleotide polymorphisms and cytosine
XX  PT methylation status.
XX  PS Claim 1; SEQ ID NO 374403; 29pp + Sequence Listing; German.
XX  CC This invention describes novel oligonucleotide primers or peptide nucleic
XX  CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX  CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  CC range of diseases including immune system, gastrointestinal, respiratory,
XX  CC central nervous system, cardiovascular and metabolic disorders. The
XX  CC oligomers are also used for detecting cell type differentiation. ABC00010
XX  CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX  CC represent the oligomers described in the invention. NOTE: The sequence
XX  CC data for this patent did not form part of the printed specification, but
XX  CC was obtained in electronic format from WIPO at
XX  CC ftp.wipo.int/pub/published_pct_sequences
XX  SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
XX  Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  OY 2224 AAAGTTACATCT 2235
XX  DB 1 AAATTTAAATCT 12
XX  RESULT 520
XX  ABH77088/c
XX  ID ABH77088 standard; DNA; 12 BP.
XX  AC ABH77088;
XX  DT 22-FEB-2002 (first entry)
XX  DE Oligonucleotide primer SEQ ID NO 277081 for detecting SNP TSC0004378.
XX  KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  OS Homo sapiens.

```

```

XX  WO200177384-A2.
XX  PN 18-OCT-2001.
XX  PD 06-APR-2001; 2001WO-IB000713.
XX  PR 07-APR-2000; 2000DE-01019173.
XX  PA (EPIG-) EPIGENOMICS AG.
XX  PI Olek A, Piepenbrock C, Berlin K;
XX  DR WPI; 2001-657177/75.
XX  PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  PT designed to detect single-nucleotide polymorphisms and cytosine
XX  PT methylation status.
XX  PS Claim 1; SEQ ID NO 277081; 29pp + Sequence Listing; German.
XX  CC This invention describes novel oligonucleotide primers or peptide nucleic
XX  CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX  CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  CC range of diseases including immune system, gastrointestinal, respiratory,
XX  CC central nervous system, cardiovascular and metabolic disorders. The
XX  CC oligomers are also used for detecting cell type differentiation. ABC00010
XX  CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX  CC represent the oligomers described in the invention. NOTE: The sequence
XX  CC data for this patent did not form part of the printed specification, but
XX  CC was obtained in electronic format from WIPO at
XX  CC ftp.wipo.int/pub/published_pct_sequences
XX  SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX  Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  OY 2221 CCAAAAGTTACA 2232
XX  DB 12 CTAATAACTTACA 1
XX  RESULT 521
XX  AB103021
XX  ID AB103021 standard; DNA; 12 BP.
XX  AC AB103021;
XX  DT 22-FEB-2002 (first entry)
XX  DE Oligonucleotide primer SEQ ID NO 302994 for detecting SNP TSC0020264.
XX  KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  OS Homo sapiens.
XX  PN WO200177384-A2.
XX  PD 18-OCT-2001.
XX  PF 06-APR-2001; 2001WO-IB000713.
XX  PR 07-APR-2000; 2000DE-01019173.
XX  PA (EPIG-) EPIGENOMICS AG.
XX  PI Olek A, Piepenbrock C, Berlin K;
XX  DR

```

DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 302994; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2225 AAGTTACATGTT 2236
Db 1 AAGTTAGTTGTT 12
RESULT 522
ABH81621/c
ID ABH81621 standard; DNA; 12 BP.
XX
AC ABH81621;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 281614 for detecting SNP TSC00009939.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 281614; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2226 AGTTACATGTT 2237
Db 12 AGTTATGTTT 1
RESULT 523
ABH82934/c
ID ABH82934 standard; DNA; 12 BP.
XX
AC ABH82934;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 282927 for detecting SNP TSC0011060.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 282927; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTTACA 2232
DB 12 CCAAAATTTTAA 1

RESULT 524
ABI09379/C
ID ABI09379 standard; DNA; 12 BP.
XX
AC ABI09379;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 309352 for detecting SNP TSC0023494.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 309352; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX

QY 2220 ACCAAAGTTTAC 2231
DB 12 ACCAAATTTTTC 1

RESULT 525
ABI13600/C
ID ABI13600 standard; DNA; 12 BP.
XX
AC ABI13600;
XX
DT 22-FEB-2002 (first entry)
XX

XX Oligonucleotide primer SEQ ID NO 313573 for detecting SNP TSC0025845.
DE
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 313573; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX

QY 2225 AGTTTACATGTT 2236
DB 12 AGTTTACGTTT 1

RESULT 526
ABH91463
ID ABH91463 standard; DNA; 12 BP.
XX
AC ABH91463;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 291456 for detecting SNP TSC0014801.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX


```
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 291456; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2221 CCAAAAGCTTACA 2232
Db 1 CTAATAATTACA 12
RESULT 527
ABH91653/C
ID ABH91653 standard; DNA; 12 BP.
XX
AC ABH91653;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 291456 for detecting SNP TSC0014871.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
```

```
XX
PS Claim 1; SEQ ID NO 291646; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2227 GTTACATCTTGG 2238
Db 12 GTTATTCTTGG 1
RESULT 528
ABI55743/C
ID ABI55743 standard; DNA; 12 BP.
XX
AC ABI55743;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 355716 for detecting SNP TSC0049786.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 355716; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2227 GTTACATCTTGG 2238
Db 12 GTTATTCTTGG 1
```

```
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234
    |||||
Db 12 AAAAGTTGTATG 1

RESULT 529
ABI69810/C
ID ABI69810 standard; DNA; 12 BP.
XX
AC ABI69810;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 369783 for detecting SNP TSC0057823.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 369783; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTTG 2238
    |||||
Db 12 GTTAGGTTTG 1

RESULT 530
ABI70259
ID ABI70259 standard; DNA; 12 BP.
XX
AC ABI70259;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 370232 for detecting SNP TSC0058063.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 370232; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233
    |||||
Db 1 CCAAACCTTACAT 12

RESULT 531
ABI74416
ID ABI74416 standard; DNA; 12 BP.
XX
AC ABI74416;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 374389 for detecting SNP TSC0060667.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 374399; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 0 C; 2 G; 4 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAGTTACATGT 2235
DB 1 AAGTTAGATAT 12
RESULT 532
ABI75308/C
ID ABI75308 standard; DNA; 12 BP.
XX AC ABI75308;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 375281 for detecting SNP TSC0000856.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 375281; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2225 AAGTTACATGTT 2236
DB 12 AAGTTAGATTT 1
RESULT 533
ABI76464/C
ID ABI76464 standard; DNA; 12 BP.
XX AC ABI76464;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 376437 for detecting SNP TSC0061814.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 376437; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2227 GTTACATGTTTG 2238
Db 12 GTTATATTTTG 1

RESULT 534
ABH70658
ID ABH70658 standard; DNA; 12 BP.

XX AC ABH70658;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 270635 for detecting SNP TSC0002209.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 270635; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: the sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2223 AAAAGTTACATG 2234
Db 1 AAAAGATATATG 12

RESULT 535
ABH99406
ID ABH99406 standard; DNA; 12 BP.

XX AC ABH99406;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 299399 for detecting SNP TSC0018556.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 299399; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2225 AAGTTACATGTT 2236
Db 1 AAGTATATGTT 12

RESULT 536
ABH74790/C
ID ABH74790 standard; DNA; 12 BP.

XX

```
AC ABH74790;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 274775 for detecting SNP TSC0003672.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 274775; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e-02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2225 AAGTTACATGTT 2236
DB 12 AAATTACATTT 1
XX
XX RESULT 537
XX ABI25180
XX ID ABI25180 standard; DNA; 12 BP.
XX
XX AC ABI25180;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 325153 for detecting SNP TSC0032421.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
```

```
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 325153; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e-02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAGTTTACA 2232
DB 1 CCAAAATTAAACA 12
XX
XX RESULT 538
XX ABI03377/C
XX ID ABI03377 standard; DNA; 12 BP.
XX
XX AC ABI03377;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 303350 for detecting SNP TSC0020448.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 303350; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAGTTACAT 2233

DB 12 CATAAATTACAT 1

RESULT 539

ABH78775/C
 ID ABH78775 standard; DNA; 12 BP.

AC ABH78775;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 278768 for detecting SNP TSC0006367.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 278768; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGT 2235

DB 12 AAAGTTAGATAT 1

RESULT 540

ABI29999
 ID ABI29999 standard; DNA; 12 BP.

AC ABI29999;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 329972 for detecting SNP TSC0035257.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 329972; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAGTTACAT 2233

```
Db      ||||| ||||| 1 CAAAAATTACT 12
RESULT 541
ABI13012/C
ID      ABI13012 standard; DNA; 12 BP.
AC      ABI13012;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 312985 for detecting SNP TSC0025413.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DE      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 312985 for detecting SNP TSC0025413.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 312985; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX
Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      2221 CCAAAAGTTTACA 2232
Db      12 CTAAATTATTA 1
XX
RESULT 542
ABI66523/C
ID      ABI66523 standard; DNA; 12 BP.
XX
AC      ABI66523;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 366496 for detecting SNP TSC0006059.
XX
```

```
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DE      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 366496; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
XX
Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      2225 AAGTTACATGTT 2236
Db      12 AAATTAATGTT 1
XX
RESULT 543
ABI81819/C
ID      ABI81819 standard; DNA; 12 BP.
XX
AC      ABI81819;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 381792 for detecting SNP TSC0064552.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
```

PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 381792; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTT 2237
 DB 12 AGTTAAATATT 1
 |||||
 |||||
 RESULT 544
 ABH77349
 ID ABH77349 standard; DNA; 12 BP.
 AC ABH77349;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 277342 for detecting SNP TSC0004444.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 277342; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAGTT 2229
 DB 1 TTACCAAAATTT 12
 |||||
 |||||
 RESULT 545
 ABI07835
 ID ABI07835 standard; DNA; 12 BP.
 AC ABI07835;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 307808 for detecting SNP TSC0022698.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 307808; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

ABI08943/C	
ID	ABI08943 standard; DNA; 12 BP.
XX	XX
AC	ABI08943;
XX	XX
DT	22-FEB-2002 (first entry)
XX	XX
DE	Oligonucleotide primer SEQ ID NO 308916 for detecting SNP TSC0023278.
DE	XX
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	XX
OS	Homo sapiens.
XX	XX
PN	WO200177384-A2.
XX	XX
PD	18-OCT-2001.
XX	XX
XX	06-APR-2001; 2001WO-IB000713.
XX	XX
PR	07-APR-2000; 2000DE-01019173.
XX	XX
PA	(EPIG-) EPIGENOMICS AG.
XX	XX
PI	Olek A, Piepenbrock C, Berlin K;
PI	WPI; 2001-657177/75.
DR	XX
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	XX
PS	Claim 1; SEQ ID NO 308916; 23pp + Sequence Listing; German.
XX	XX
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-AEC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	XX
SQ	Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
Query Match	32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity	83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative	0; Mismatches 2; Indels 0; Gaps 0
Qy	2227 GTTACATGTTTG 2238
Db	12 GTTAGATTTTG 1
RESULT 548	
ABH86758/C	
ID	ABH86758 standard; DNA; 12 BP.
XX	XX
AC	ABH86758;
XX	XX
DT	22-FEB-2002 (first entry)
XX	XX
DE	Oligonucleotide primer SEQ ID NO 286751 for detecting SNP TSC0012809.
XX	XX
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	XX

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTG 2238
Db 12 GGTATATGTTG 1
|||||
RESULT 551
ABI50778/C
ID ABI50778 standard; DNA; 12 BP.
XX
AC ABI50778;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 350751 for detecting SNP TSC0046859.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 350751; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTT 2237
Db 12 ACTTATATTTT 1
|||||
RESULT 552
ABI53415
ID ABI53415 standard; DNA; 12 BP.
XX
AC ABI53415;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 353388 for detecting SNP TSC0048496.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 353388; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 2 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234
Db 1 AAAATTACACG 12
|||||
RESULT 553
ABH93581
ID ABH93581 standard; DNA; 12 BP.
XX
AC ABH93581;
XX

DT 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 293574 for detecting SNP TSC0015683.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 293574; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 XX
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2226 AGTTACATGTTT 2237
 DB 1 AGTTATATGATT 12
 XX
 RESULT 554
 ABH70836
 ID ABH70836 standard; DNA; 12 BP.
 AC ABH70836;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 270813 for detecting SNP TSC0002288.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 270813; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 XX
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2226 AGTTACATGTTT 2237
 DB 1 AGTTATATGATT 12
 XX
 RESULT 554
 ABH70836
 ID ABH70836 standard; DNA; 12 BP.
 AC ABH70836;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 270813 for detecting SNP TSC0019073.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 270813; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2222 CAAAGATTACAT 2233
 DB 1 CAAATTTTAAAT 12
 XX
 RESULT 555
 ABI00546
 ID ABI00546 standard; DNA; 12 BP.
 AC ABI00546;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 300519 for detecting SNP TSC0019073.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PT methylation status.
 XX Claim 1; SEQ ID NO 300519; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 2222 CAAAGTACAT 2233
 1 CAAACATACAT 12
 Db
 RESULT 556
 ABH79073/C
 ID ABH79073 standard; DNA; 12 BP.
 XX
 AC ABH79073;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 279066 for detecting SNP TSC0006840.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 279066; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 2227 GTTACATGTTTG 2238
 12 GTTAAATTTTG 1
 Db
 RESULT 557
 ABI29888
 ID ABI29888 standard; DNA; 12 BP.
 XX
 AC ABI29888;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 329861 for detecting SNP TSC0035200.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 329861; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 2220 ACCAAAGTAC 2231
 1 ACCAAACATAC 12
 Db

PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 349666; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2214 AGTGTGACCAAA 2225
Db 1 AGTGTGATAAA 12
XX
RESULT 561
ABI74720
ID ABI74720 standard; DNA; 12 BP.
XX
AC ABI74720;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 374693 for detecting SNP TSC0060844.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 374693; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2217 GTGACCAAAAGT 2228
Db 1 GTGAGTAAAAGT 12
XX
RESULT 562
ABI62368
ID ABI62368 standard; DNA; 12 BP.
XX
AC ABI62368;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362341 for detecting SNP TSC0053169.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 362341; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234
Db 1 AGAAGTTAAATG 12

RESULT 563

ABI76317
ID ABI76317 standard; DNA; 12 BP.

XX AC ABI76317;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 376290 for detecting SNP TSC0061715.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 376290; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTG 2238

Db 1 GTTATTGTTG 12

RESULT 564

ABI65421
ID ABI65421 standard; DNA; 12 BP.

XX

AC ABI65421;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 365394 for detecting SNP TSC005090.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 365394; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGTT 2236

Db 1 AATTAAATGTT 12

RESULT 565

ABH79752
ID ABH79752 standard; DNA; 12 BP.

XX ABH79752;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 279745 for detecting SNP TSC0007781.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACATG 2234
 DB 1 AAAAGATAGTG 12
 RESULT 568
 ABI02621
 ID ABI02621 standard; DNA; 12 BP.
 XX
 AC ABI02621;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 302594 for detecting SNP TSC0020074.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 302594; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTACATG 2232
 DB 12 CCAAAATATTACA 1
 RESULT 570
 ABI08371
 ID ABI08371 standard; DNA; 12 BP.
 XX
 AC ABI08371;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 281990 for detecting SNP TSC0010237.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 281990; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACAT 2233
 DB 1 CAAAATTTTCAT 12
 RESULT 569
 ABH81997/C
 ID ABH81997 standard; DNA; 12 BP.
 XX
 AC ABH81997;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 281990 for detecting SNP TSC0010237.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 281990; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CAAAAGTTACAT 2232
 DB 12 CCAAAATATTACA 1
 RESULT 570
 ABI08371
 ID ABI08371 standard; DNA; 12 BP.
 XX
 AC ABI08371;
 XX
 DT 22-FEB-2002 (first entry)
 XX

```
DE Oligonucleotide primer SEQ ID NO 308344 for detecting SNP TSC0022964.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 308344; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF99989, ABH0010-ABH99989 and ABIC0010-ABIS2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2227 GTTACATGTTTG 2238
DB 1 GTTGTATGTTTG 12
RESULT 571
ABIO9674
ID ABIO9674 standard; DNA; 12 BP.
XX ABIO9674;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 309647 for detecting SNP TSC0023602.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 308344; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF99989, ABH0010-ABH99989 and ABIC0010-ABIS2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2227 GTTACATGTTTG 2238
DB 1 GTTGTATGTTTG 12
RESULT 571
ABIO9674
ID ABIO9674 standard; DNA; 12 BP.
XX ABIO9674;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 309647 for detecting SNP TSC0023602.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
```

```
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 309647; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF99989, ABH0010-ABH99989 and ABIC0010-ABIS2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2220 ACCAAAAGTTAC 2231
DB 1 ACTAAAAATTAC 12
RESULT 572
ABH87275/c
ID ABH87275 standard; DNA; 12 BP.
XX ABH87275;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 287268 for detecting SNP TSC0013021.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
```

PS Claim 1; SEQ ID NO 287268; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the invention. NOTE: The sequence CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
Db 12 AGTTAAGTTT 1
|||||

RESULT 573
ABI47891/C
ID ABI47891 standard; DNA; 12 BP.

XX AC ABI47891;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 347864 for detecting SNP TSC0045309.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single-nucleotide polymorphisms and cytosine PT methylation status.

XX Claim 1; SEQ ID NO 347864; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the invention. NOTE: The sequence CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATG 2234
Db 12 ATAAGTTATATG 1
|||||

RESULT 574
ABI62180/C
ID ABI62180 standard; DNA; 12 BP.

XX AC ABI62180;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 362153 for detecting SNP TSC0053039.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single-nucleotide polymorphisms and cytosine PT methylation status.

XX Claim 1; SEQ ID NO 362153; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the invention. NOTE: The sequence CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATG 2234
Db 12 ATAAGTTATATG 1
|||||

```
RESULT 575
ABi63029/c
ID ABi63029 standard; DNA; 12 BP.
XX AC ABi63029;
XX AC
XX XX 22-FEB-2002 (first entry)
XX DT
XX XX Oligonucleotide primer SEQ ID NO 363002 for detecting SNP TSC0053586.
XX DE
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPiG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 363002; 29pp + Sequence Listing; German.
XX XX
XX XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTT 2237
DB 12 ATTAGATGTTT 1
RESULT 576
ABX15954/c
ID ABX15954 standard; DNA; 12 BP.
XX AC ABX15954;
XX AC
XX XX 31-MAR-2003 (first entry)
XX DT
XX DE Antisense oligonucleotide for the E. coli acpP gene #4.
XX DE AcpP; antisense; ss; protein nucleic acid; PNA; bacterial infection;
XX KW genetically modified micro-organism.
XX XX
XX XX Escherichia coli.
XX XX
```

```
OS Escherichia coli.
XX Key Location/Qualifiers
FE modified_base 1
FT /*tag= a
FT /mod_base= OTHER
FT /note= "T is covalently linked to a Lysine residue"
XX XX
XX PN WO200279467-A2.
XX XX
XX PD 10-OCT-2002.
XX XX
XX PF 26-MAR-2002; 2002WO-DK000208.
XX XX
XX PR 29-MAR-2001; 2001DK-00000523.
XX XX
XX PA (UYKO-) UNIV KOBENHAVNS.
XX XX
XX PI Nielsen PE, Good L;
XX XX
XX DR WPI; 2003-103273/09.
XX XX
XX PT Selecting genetically modified cells useful for isolation and industrial
XX PT growth of transformed organisms comprises treating the modified cells
XX PT with an antisense or antigen construct directed against the essential
XX PT gene X of the cells.
XX PS
XX PS Claim 24; Page 52; 92pp; English.
XX XX
XX CC The invention relates to selecting genetically modified cells comprising:
XX CC (a) modifying cells containing a growth essential gene X, with a vector
XX CC containing gene Y; and (b) treating the modified cells with an antisense
XX CC or antigen construct directed against the essential gene X of the cells
XX CC to obtain preferential growth of the modified cells over other non-
XX CC modified cells. Also included is a product manufactured fully or
XX CC partially by use of the new method. The method is useful for selecting
XX CC genetically modified cells and manufacturing a product. It is useful for
XX CC research the isolation and industrial growth maintenance of transforming
XX CC organisms. The new method has the advantage of selecting and maintaining
XX CC a plasmid containing bacterial culture without the use of antibiotics.
XX CC This has a wide variety of applications in research, development, and
XX CC industrial production involving genetically modified micro-organisms. The
XX CC method inhibits bacterial infections in eukaryotic cell cultures. The
XX CC present sequence is an antisense oligonucleotide (incorporated into a
XX CC peptide nucleic acid (PNA) molecule) which targets the E. coli acpP gene
XX CC (gene X in this example)
XX XX
XX SQ Sequence 12 BP; 2 A; 4 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2212 AGAGTGTGACCA 2223
DB 12 AGAGTATGAGCA 1
RESULT 577
ABX16005/c
ID ABX16005 standard; DNA; 12 BP.
XX AC ABX16005;
XX AC
XX XX 31-MAR-2003 (first entry)
XX DT
XX DE Antisense oligonucleotide for the E. coli AcpP gene, SP146.
XX DE AcpP; antisense; ss; protein nucleic acid; PNA; bacterial infection;
XX KW genetically modified micro-organism.
XX XX
XX XX Escherichia coli.
XX XX
```


PN US5686242-A.
 XX
 PD 11-NOV-1997.
 XX
 PF 27-OCT-1994; 94US-00330000.
 XX
 PR 05-SEP-1991; 91US-00755485.
 PR
 PR 04-SEP-1992; 92WO-US007489.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Lima WF, Bruice TW;
 PI
 DR WPI; 1997-558135/51.
 XX
 PT Determination of oligo-nucleotide with specific activity for target bio-
 PT molecule - using set of randomised oligo-nucleotide(s).
 XX
 PS Example 12; Col 29-30; 22pp; English.
 XX
 CC The present sequence was used in the development of a method of
 CC determining an oligonucleotide having specific activity for a target
 CC biomolecule. The method comprises assaying a set of randomised
 CC oligonucleotides for activity against a target biomolecule, separating
 CC active from inactive oligonucleotides and recovering, amplifying and
 CC determining the nucleic acid sequence of the active oligonucleotides. The
 CC oligonucleotides can be used for therapeutic, diagnostic and research
 CC purposes
 XX
 SQ Sequence 10 BP; 2 A; 4 C; 1 G; 0 T; 3 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2215 GTGTGACCAA 2224
 Db ||||| |||||
 10 GTGTGACCAA 1
 RESULT 580
 ID AAZ82626/c
 XX AAZ82626 standard; DNA; 10 BP.
 AC AAZ82626;
 XX
 DT 07-APR-2000 (first entry)
 XX
 DE Metastatic breast tumour cell upregulated transcript tag #1860.
 XX
 KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 XX antimetastatic; vaccine; diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9965928-A2.
 XX
 PD 23-DEC-1999.
 XX
 PF 18-JUN-1999; 99WO-US013647.
 XX
 PR 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089997P.
 PR 19-JUN-1998; 98US-0090039P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 XX
 PA (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B.L.
 PA (SHAN/) SHANKARA S.
 XX
 PI Roberts BL, Shankara S;

XX WPI; 2000-106079/09.
 DR
 XX
 PT Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX
 PS Claim 1; Page 109; 219pp; English.
 XX
 CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 2 A; 4 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2215 GTGTGACCAA 2224
 Db ||||| |||||
 10 GTGTGACCAA 1
 RESULT 581
 ID AAZ86089
 XX AAZ86089 standard; DNA; 10 BP.
 AC AAZ86089;
 XX
 DT 07-APR-2000 (first entry)
 XX
 DE Metastatic breast tumour cell downregulated transcript tag #5323.
 XX
 KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 XX antimetastatic; vaccine; diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9965928-A2.
 XX
 PD 23-DEC-1999.
 XX
 PF 18-JUN-1999; 99WO-US013647.
 XX
 PR 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089997P.
 PR 19-JUN-1998; 98US-0090039P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 XX
 PA (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B.L.
 PA (SHAN/) SHANKARA S.

XX Roberts BL, Shankara S;
 PI
 XX
 DR WPI; 2000-106079/09.
 XX
 XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX
 XX
 PS Claim 1; Page 200; 219pp; English.
 XX
 CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 4 A; 3 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGT 2228
 |||||
 Db 1 GACCAACAGT 10
 RESULT 582
 AAZ81055/c
 ID AAZ81055 standard; DNA; 10 BP.
 AC AAZ81055;
 XX
 DT 07-APR-2000 (first entry)
 XX
 XX Metastatic breast tumour cell upregulated transcript tag #289.
 DE Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9965928-A2.
 XX
 XX 23-DEC-1999.
 XX
 XX 18-JUN-1999; 99WO-US013647.
 XX
 XX 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089997P.
 PR 19-JUN-1998; 98US-0090039P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 XX
 XX (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 PI Roberts BL, Shankara S;
 XX
 XX WPI; 2000-106079/09.
 XX
 XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX
 XX
 PS Claim 1; Page 65; 219pp; English.
 XX
 CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 3 A; 1 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 |||||
 Db 10 AAAAGTTTCA 1
 RESULT 583
 AAZ88682/c
 ID AAZ88682 standard; RNA; 10 BP.
 AC AAZ88682;
 XX
 DT 11-MAY-2000 (first entry)
 XX
 XX Ras RNA binding 2'-O-methyl oligonucleotide #3.
 DE Primer; detection; diagnosis; ras gene; RNA binding; 2'-O-methyl; ss.
 KW Unidentified.
 OS
 XX
 XX Key Location/Qualifiers
 PH misc_RNA 1..10
 FT /*tag= a
 FT /note= "2'-O-methyl nucleotides"
 XX
 XX US6022691-A.
 XX
 XX 08-FEB-2000.
 PD
 XX 07-NOV-1997; 97US-00965908.
 PF
 XX 05-SEP-1991; 91US-00755485.
 PR
 XX 04-SEP-1992; 92WO-US007489.
 PR

PR 27-OCT-1994; 94US-00330000.
XX (ISIS-) ISIS PHARM INC.
XX Lima WF, Bruce TW;
XX WPI; 2000-170669/15.
DR Assay for a chemical or drug in a sample comprises detecting binding of
PT an oligonucleotide selected from a set of randomized oligonucleotides.
XX Example 12; Col 29-30; 20pp; English.
XX This invention describes a novel method (I) for specifically detecting a
CC chemical or drug in a sample comprises contacting the sample with an
CC oligonucleotide having specific activity for a target biomolecule and
CC detecting the presence or absence of binding where the presence of
CC binding indicates the presence of the chemical or drug in the sample. The
CC oligonucleotide is identified by: (a) assaying a prepared set of
CC randomized oligonucleotides for activity against a target biomolecule;
CC (b) separating active from inactive oligonucleotides; (c) recovering the
CC active oligonucleotides; and (d) characterizing the recovered
CC oligonucleotides by microanalytical structure determination. The method
CC can be used for diagnostic or research purposes
XX
XX Sequence 10 BP; 2 A; 4 C; 1 G; 0 T; 3 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2215 GTGTGACCAA 2224
DB 10 GTGTGAGCAA 1
RESULT 584
AAH63248
ID AAH63248 standard; cDNA; 10 BP.
XX AC AAH63248;
XX 20-SEP-2001 (first entry)
XX Human colon epithelium specific transcriptome sequence SEQ ID NO: 88.
XX Human; transcriptome; gene expression pattern; cancer; drug screening;
XX cancer diagnosis; cell specific gene expression; ss.
XX Homo sapiens.
XX WO200138577-A2.
XX 31-MAY-2001.
XX 21-NOV-2000; 2000WO-US031922.
XX 24-NOV-1999; 99US-00448480.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Velculescu VE, Vogelstein B, Kinzler KW;
XX WPI; 2001-367706/38.
XX Claim 1; Page 41; 94pp; English.
XX The present invention describes a method of identifying the type of cell
XX in a sample, involving determining which of the sequences AAH63161-
XX AAH64724 is expressed by the cell. The transcriptomes described in the
XX invention are cell-type specific, cancer specific or ubiquitously
XX expressed in humans. They can also be used to screen for drugs, reduce
XX cancer specific gene expression, standardise expression and restore the
XX function of a diseased cell or tissue. The present sequence is one of the
XX transcriptomes described in the exemplification of the invention
XX
XX Sequence 10 BP; 2 A; 4 C; 1 G; 0 T; 3 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2215 GTGTGACCAA 2224
DB 10 GTGTGAGCAA 1
RESULT 584
AAH63248
ID AAH63248 standard; cDNA; 10 BP.
XX AC AAH63248;
XX 20-SEP-2001 (first entry)
XX Human colon epithelium specific transcriptome sequence SEQ ID NO: 88.
XX Human; transcriptome; gene expression pattern; cancer; drug screening;
XX cancer diagnosis; cell specific gene expression; ss.
XX Homo sapiens.
XX WO200138577-A2.
XX 31-MAY-2001.
XX 21-NOV-2000; 2000WO-US031922.
XX 24-NOV-1999; 99US-00448480.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Velculescu VE, Vogelstein B, Kinzler KW;
XX WPI; 2001-367706/38.
XX Claim 1; Page 41; 94pp; English.
XX The present invention describes a method of identifying the type of cell
XX in a sample, involving determining which of the sequences AAH63161-

CC AAH64724 is expressed by the cell. The transcriptomes described in the
CC invention are cell-type specific, cancer specific or ubiquitously
CC expressed in humans. They can also be used to screen for drugs, reduce
CC cancer specific gene expression, standardise expression and restore the
CC function of a diseased cell or tissue. The present sequence is one of the
CC transcriptomes described in the exemplification of the invention
XX
XX Sequence 10 BP; 6 A; 1 C; 1 G; 2 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2221 CCAAAAGTTA 2230
DB 1 CAAAAAGTTA 10
RESULT 585
AAH63310
ID AAH63310 standard; cDNA; 10 BP.
XX AC AAH63310;
XX 20-SEP-2001 (first entry)
XX Human colon epithelium specific transcriptome sequence SEQ ID NO: 150.
XX Human; transcriptome; gene expression pattern; cancer; drug screening;
XX cancer diagnosis; cell specific gene expression; ss.
XX Homo sapiens.
XX WO200138577-A2.
XX 31-MAY-2001.
XX 21-NOV-2000; 2000WO-US031922.
XX 24-NOV-1999; 99US-00448480.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Velculescu VE, Vogelstein B, Kinzler KW;
XX WPI; 2001-367706/38.
XX New isolated polynucleotides, useful for identifying specific cell type,
XX such as cancer cell, comprises transcriptomes expressed in particular
XX cell types.
XX Claim 11; Page 42; 94pp; English.
XX The present invention describes a method of identifying the type of cell
XX in a sample, involving determining which of the sequences AAH63161-
XX AAH64724 is expressed by the cell. The transcriptomes described in the
XX invention are cell-type specific, cancer specific or ubiquitously
XX expressed in humans. They can also be used to screen for drugs, reduce
XX cancer specific gene expression, standardise expression and restore the
XX function of a diseased cell or tissue. The present sequence is one of the
XX transcriptomes described in the exemplification of the invention
XX
XX Sequence 10 BP; 4 A; 2 C; 2 G; 2 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2218 TGACCAAAAG 2227
DB 1 TGACCAATAG 10

RESULT 586
 AAH63362/C
 ID AAH63362 standard; cDNA; 10 BP.
 XX
 AC AAH63362;
 XX
 DT 20-SEP-2001 (first entry)
 XX
 DE Human melanocyte specific transcriptome sequence SEQ ID NO: 202.
 XX
 KW Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW cancer diagnosis; cell specific gene expression; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 DR WPI; 2001-367706/38.
 XX
 CC The present invention describes a method of identifying the type of cell
 CC in a sample, involving determining which of the sequences AAH63161-
 CC AAH64724 is expressed by the cell. The transcriptomes described in the
 CC invention are cell-type specific, cancer specific or ubiquitously
 CC expressed in humans. They can also be used to screen for drugs, reduce
 CC cancer specific gene expression, standardise expression and restore the
 CC function of a diseased cell or tissue. The present sequence is one of the
 CC transcriptomes described in the exemplification of the invention
 XX
 SQ Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2216 TGTGACCAAA 2225
 Db 10 TGTACCAAA 1
 XX
 RESULT 587
 AAH63364/C
 ID AAH63364 standard; cDNA; 10 BP.
 XX
 AC AAH63364;
 XX
 DT 20-SEP-2001 (first entry)
 XX
 DE Human melanocyte specific transcriptome sequence SEQ ID NO: 204.
 XX
 KW Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW cancer diagnosis; cell specific gene expression; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX

XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 DR WPI; 2001-367706/38.
 XX
 CC New isolated polynucleotides, useful for identifying specific cell type,
 CC such as cancer cell, comprises transcriptomes expressed in particular
 CC cell types.
 XX
 PS Claim 1; Page 43; 94pp; English.
 XX
 CC The present invention describes a method of identifying the type of cell
 CC in a sample, involving determining which of the sequences AAH63161-
 CC AAH64724 is expressed by the cell. The transcriptomes described in the
 CC invention are cell-type specific, cancer specific or ubiquitously
 CC expressed in humans. They can also be used to screen for drugs, reduce
 CC cancer specific gene expression, standardise expression and restore the
 CC function of a diseased cell or tissue. The present sequence is one of the
 CC transcriptomes described in the exemplification of the invention
 XX
 SQ Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2216 TGTGACCAAA 2225
 Db 10 TGTACCAAA 1
 XX
 RESULT 588
 AAH74044
 ID AAH74044 standard; DNA; 10 BP.
 XX
 AC AAH74044;
 XX
 DT 30-APR-2001 (first entry)
 XX
 DE Human SLC6A4 allele-specific oligonucleotide primer #164.
 XX
 KW Solute carrier family 6 neurotransmitter transporter; seotonin 4; SLC6A4;
 KW genotyping; allele specific oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200109161-A1.
 XX
 PD 08-FEB-2001.
 XX
 PF 31-JUL-2000; 2000WO-US020638.
 XX
 PR 29-JUL-1999; 99US-0146290P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Denton RR, Duda A, Mandabalan K, Sanchis A, Stephens JC;
 XX
 DR WPI; 2001-123317/13.
 XX
 CC New isolated polynucleotide comprising a polymorphic variant for the
 CC solute carrier family 6 neurotransmitter transporter, serotonin member 4
 CC gene for identifying drugs for treating disorders related to expression
 CC of the protein.
 XX
 PS Disclosure; Page 23; 152pp; English.
 XX

CC The present invention relates to a polymorphic variant of a reference
 CC sequence for the solute carrier family 6 neurotransmitter transporter,
 CC serotonin member 4 (SLC6A4) gene or a fragment of it or a sequence
 CC complementary to the first sequence. The invention is used in producing a
 CC recombinant organism that can be used to express SLC6A4 for protein
 CC structure analysis and binding studies. A composition comprising a
 CC genotyping oligonucleotide is used to detect a polymorphism in the SLC6A4
 CC gene

XX Sequence 10 BP; 6 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTTACA 2232
 Db |||||
 1 AAAAGTTTACA 10

RESULT 589
 AAF40439/c
 ID AAF40439 standard; DNA; 10 BP.
 XX AC AAF40439;
 XX DT 23-MAR-2001 (first entry)
 XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7178.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.
 OS WO200077214-A2.
 XX PN 21-DEC-2000.
 XX PD 14-JUN-2000; 2000WO-US016223.
 XX PF 16-JUN-1999; 99US-00335032.
 XX PR (UYJO) UNIV JOHNS HOPKINS.
 XX PA Veiculescu V, Vogelstein B, Kinzler K;
 XX PI WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 256; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a

CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

XX Sequence 10 BP; 5 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2229 TACATGTTTG 2238
 Db |||||
 1 TAAATGTTTG 1

RESULT 590
 AAF41011
 ID AAF41011 standard; DNA; 10 BP.
 XX AC AAF41011;
 XX DT 23-MAR-2001 (first entry)
 XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7750.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.
 OS WO200077214-A2.
 XX PN 21-DEC-2000.
 XX PD 14-JUN-2000; 2000WO-US016223.
 XX PF 16-JUN-1999; 99US-00335032.
 XX PR (UYJO) UNIV JOHNS HOPKINS.
 XX PA Veiculescu V, Vogelstein B, Kinzler K;
 XX PI WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 276; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression

CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 CC
 XX Sequence 10 BP; 4 A; 2 C; 1 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e-02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 221 CCACAAAGTTA 2230
 |||||
 Db 1 CCTAAAGTTA 10

RESULT 591
 AAF42006
 ID AAF42006 standard; DNA; 10 BP.
 XX
 AC AAF42006;
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:8745.

KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.

XX WO200077214-A2.
 XX
 XX 21-DEC-2000.
 XX
 XX 14-JUN-2000; 2000WO-US016223.
 XX
 XX 16-JUN-1999; 99US-00335032.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX
 XX Velculescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 DR

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 312; 419pp; English.
 XX
 XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression

CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 CC
 XX Sequence 10 BP; 5 A; 1 C; 3 G; 1 T; 0 U; 0 Other;
 SQ

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e-02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
 |||||
 Db 1 GAGCAAAAGT 10

RESULT 592
 AAF43317/c
 ID AAF43317 standard; DNA; 10 BP.

XX
 AC AAF43317;
 DT 23-MAR-2001 (first entry)
 XX

XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:11456.

KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 359; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression

CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF3262 to AAF3267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACA 2232
 Db 10 AAAAGTTTACA 1

RESULT 593
 AAF40798
 ID AAF40798 standard; DNA; 10 BP.

XX AAF40798;

XX 23-MAR-2001 (first entry)

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7537.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 269; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also

CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF3262 to AAF3267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTTA 2230
 Db 1 CCAAAAGTTTA 10

RESULT 594

AAF38269

ID AAF38269 standard; DNA; 10 BP.

XX AAF38269;

XX 23-MAR-2001 (first entry)

XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5008.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 178; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a

CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF3268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

XX Sequence 10 BP; 3 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 DB 1 TTAAATGTTT 10

RESULT 595
 AAF35345/C
 ID AAF35345 standard; DNA; 10 BP.
 XX AAF35345;
 AC AAF35345;
 XX 23-MAR-2001 (first entry)
 DT 23-MAR-2001 (first entry)
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2084.
 XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX Saccharomyces cerevisiae.
 OS Saccharomyces cerevisiae.
 XX WO200077214-A2.
 PN 21-DEC-2000.
 XX 14-JUN-2000; 2000WO-US016223.
 XX 16-JUN-1999; 99US-00335032.
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA Velculescu V, Vogelstein B, Kinzler K;
 PI WPI; 2001-061874/07.
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags; useful for studying, monitoring and
 PT affecting phases of the cell cycle.

Example; Page 74; 419pp; English.

PS The present invention describes an isolated DNA molecule comprising a
 XX coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF3268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

XX Sequence 10 BP; 2 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTAC 2231
 DB 10 CAAAAGTTAC 1

RESULT 596
 AAF43860/C
 ID AAF43860 standard; DNA; 10 BP.
 XX AAF43860;
 AC AAF43860;
 XX 23-MAR-2001 (first entry)
 DT 23-MAR-2001 (first entry)
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:11999.
 XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX Saccharomyces cerevisiae.
 OS Saccharomyces cerevisiae.
 XX WO200077214-A2.
 PN 21-DEC-2000.
 XX 14-JUN-2000; 2000WO-US016223.
 XX 16-JUN-1999; 99US-00335032.
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA Velculescu V, Vogelstein B, Kinzler K;
 PI WPI; 2001-061874/07.
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags; useful for studying, monitoring and
 PT affecting phases of the cell cycle.

gene expression (SAGE) tags, useful for studying, monitoring and affecting phases of the cell cycle.

Example; Page 378; 419pp; English.

The present invention describes an isolated DNA molecule comprising a coding sequence of a yeast gene selected from a group of 745 NORF (not previously assigned open reading frame; or nonannotated ORF) genes comprising a SAGE (serial analysis of gene expression) tag. Also described are: (1) a method (M1) of using NORF genes to affect the cell cycle comprising administering a NORF gene whose expression varies by at least 10% between any two phases of the cell cycle selected from log phase, S phase and G2/M; (2) a method (M2) for screening candidate antifungal drugs comprising: (a) contacting a test substance with a yeast cell; and (b) monitoring expression of a NORF gene whose expression varies as in M1, where a test substance which modifies the expression of identifying human genes which are involved in cell cycle progression comprising contacting human DNA with a probe which comprises at least 10 contiguous nucleotides of a NORF gene whose expression varies as in M1; and (4) a method (M4) for identifying a candidate drug as a member of a class of drugs having a characteristic effect on gene expression in a yeast cell comprising contacting a yeast cell with a candidate drug and monitoring expression in the yeast cell of at least 1 NORF gene whose expression is affected by the class of drugs. The NORF genes may be used to study, monitor and affect phases of the cell cycle, the differentially expressed genes may be used as markers of phases of the cell cycle. The methods may be used to identify candidate drugs which affect the cell cycle and for identification of antifungal drugs. AAF33268 to AAF4064 represent SAGE tags used in the exemplification of the present invention. CCAAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE method, in the exemplification of the present invention

Sequence 10 BP; 2 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 2.6e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232

DB 10 AAAAGTTTAAA 1

RESULT 597

AAF38462

ID AAF38462 standard; DNA; 10 BP.

AC AAF38462;

DT 23-MAR-2001 (first entry)

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5201.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;

KW nor previously assigned open reading frame; nonannotated ORF; SAGE;

KW serial analysis of gene expression; antifungal; tag; identification;

XX linker; PCR primer; ds.

OS Saccharomyces cerevisiae.

XX WO200077214-A2.

PN 21-DEC-2000.

PD 14-JUN-2000; 2000WO-US016223.

PF 16-JUN-1999; 99US-00335032.

PR (UYJO) UNIV JOHNS HOPKINS.

XX Velculescu V, Vogelstein B, Kinzler K;

PI

WPI; 2001-061874/07.

Yeast gene coding sequences comprising NORF genes with serial analysis of gene expression (SAGE) tags, useful for studying, monitoring and affecting phases of the cell cycle.

Example; Page 185; 419pp; English.

The present invention describes an isolated DNA molecule comprising a coding sequence of a yeast gene selected from a group of 745 NORF (not previously assigned open reading frame; or nonannotated ORF) genes comprising a SAGE (serial analysis of gene expression) tag. Also described are: (1) a method (M1) of using NORF genes to affect the cell cycle comprising administering a NORF gene whose expression varies by at least 10% between any two phases of the cell cycle selected from log phase, S phase and G2/M; (2) a method (M2) for screening candidate antifungal drugs comprising: (a) contacting a test substance with a yeast cell; and (b) monitoring expression of a NORF gene whose expression varies as in M1, where a test substance which modifies the expression of identifying human genes which are involved in cell cycle progression comprising contacting human DNA with a probe which comprises at least 10 contiguous nucleotides of a NORF gene whose expression varies as in M1; and (4) a method (M4) for identifying a candidate drug as a member of a class of drugs having a characteristic effect on gene expression in a yeast cell comprising contacting a yeast cell with a candidate drug and monitoring expression in the yeast cell of at least 1 NORF gene whose expression is affected by the class of drugs. The NORF genes may be used to study, monitor and affect phases of the cell cycle, the differentially expressed genes may be used as markers of phases of the cell cycle. The methods may be used to identify candidate drugs which affect the cell cycle and for identification of antifungal drugs. AAF33268 to AAF4064 represent SAGE tags used in the exemplification of the present invention. CCAAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE method, in the exemplification of the present invention

Sequence 10 BP; 6 A; 2 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 2.6e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232

DB 1 AAAAGTCACA 10

RESULT 598

AAF38459

ID AAF38459 standard; DNA; 10 BP.

AC AAF38459;

DT 23-MAR-2001 (first entry)

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5198.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;

KW nor previously assigned open reading frame; nonannotated ORF; SAGE;

KW serial analysis of gene expression; antifungal; tag; identification;

XX linker; PCR primer; ds.

OS Saccharomyces cerevisiae.

XX WO200077214-A2.

PN 21-DEC-2000.

PD 14-JUN-2000; 2000WO-US016223.

PF 16-JUN-1999; 99US-00335032.

PR (UYJO) UNIV JOHNS HOPKINS.

XX

PA

XX Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 XX
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX Example; Page 185; 419pp; English.
 XX
 XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 XX Sequence 10 BP; 6 A; 1 C; 2 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 Db 1 AAAAGGTACA 10
 RESULT 599
 AAF36865/C
 ID AAF36865 standard; DNA; 10 BP.
 AC AAF36865;
 XX
 XX 23-MAR-2001 (first entry)
 DT
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3604.
 XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX Saccharomyces cerevisiae.
 OS
 XX WO200077214-A2.
 PN
 XX 21-DEC-2000.
 PD
 XX 14-JUN-2000; 2000WO-US016223.
 PF
 XX

PR 16-JUN-1999; 99US-00335032.
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 XX Velulescu V, Vogelstein B, Kinzler K;
 PI WPI; 2001-061874/07.
 XX
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX Example; Page 128; 419pp; English.
 PS
 XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 XX Sequence 10 BP; 3 A; 1 C; 2 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2216 TGTGACCAAA 2225
 Db 10 TGTTACAAA 1
 RESULT 600
 AAF38454
 ID AAF38454 standard; DNA; 10 BP.
 AC AAF38454;
 XX
 XX 23-MAR-2001 (first entry)
 DT
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5193.
 XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX Saccharomyces cerevisiae.
 OS
 XX WO200077214-A2.
 PN
 XX 21-DEC-2000.
 PD
 XX


```

XX 14-JUN-2000; 2000WO-US016223.
XX
XX 16-JUN-1999; 99US-00335032.
XX
XX (UYJO ) UNIV JOHNS HOPKINS.
XX
XX Velulescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
XX Example; Page 185; 419pp; English.
XX
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
XX Sequence 10 BP; 6 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACA 2232
DB 1 AAAAGCTACA 10
|||||
RESULT 601
AAF37124/C
ID AAF37124 standard; DNA; 10 BP.
XX
XX AAF37124;
AC
XX
XX 23-MAR-2001 (first entry)
DT
XX
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3863.
DE
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.
OS
XX

```

```

PN W0200077214-A2.
XX
XX 21-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-US016223.
XX
XX 16-JUN-1999; 99US-00335032.
XX
XX (UYJO ) UNIV JOHNS HOPKINS.
XX
XX Velulescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
XX Example; Page 138; 419pp; English.
XX
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
XX Sequence 10 BP; 1 A; 3 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2219 GACCAAAAGT 2228
DB 10 GACCAGAAGT 1
|||||
RESULT 602
AAF39808
ID AAF39808 standard; DNA; 10 BP.
XX
XX AAF39808;
AC
XX
XX 23-MAR-2001 (first entry)
DT
XX
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:6547.
DE
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX

```

XX OS Saccharomyces cerevisiae.
 XX PN WO200077214-A2.
 XX PD 21-DEC-2000.
 XX PF 14-JUN-2000; 2000WO-US016223.
 XX PR 16-JUN-1999; 99US-00335032.
 XX PA (UYJO) UNIV JOHNS HOPKINS.
 XX PI Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 XX
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 XX Example; Page 233; 419pp; English.
 XX
 XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 XX Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2214 AGTGACCA 2223
 |||||
 Db 1 AGTGAGACCA 10
 RESULT 603
 AAF43316/C
 ID AAF43316 standard; DNA; 10 BP.
 XX
 XX AAF43316;
 XX
 XX 23-MAR-2001 (first entry)
 DT
 XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:11455.
 DE
 XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW

KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 XX Saccharomyces cerevisiae.
 XX OS WO200077214-A2.
 XX PN 21-DEC-2000.
 XX PD 14-JUN-2000; 2000WO-US016223.
 XX PF 16-JUN-1999; 99US-00335032.
 XX PR (UYJO) UNIV JOHNS HOPKINS.
 XX PA Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 XX
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 XX Example; Page 359; 419pp; English.
 XX
 XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 XX Sequence 10 BP; 2 A; 2 C; 1 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 |||||
 Db 10 AAAGTTACA 1
 RESULT 604
 ABV84769
 ID ABV84769 standard; cDNA; 10 BP.
 XX
 XX ABV84769;
 AC
 XX 12-DEC-2002 (first entry)
 DT
 XX

DE Chronic hepatitis C/HCC differentially expressed gene SAGE tag #579.
 XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
 KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
 KW expression pattern; differential expression; ss.
 XX Homo sapiens.
 OS
 XX JP2002209591-A.
 PN 30-JUL-2002.
 XX
 XX 19-JAN-2001; 2001JP-00012328.
 PF
 XX 19-JAN-2001; 2001JP-00012328.
 PR
 XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
 PA WPI; 2002-631294/68.
 DR
 XX Human chronic hepatitis C tissue expression exasperating gene group
 PT comprises 100 high-ranking genes.
 XX
 XX Claim 46; Page 26; 139pp; Japanese.
 PS
 XX The invention relates to SAGE (serial analysis of gene expression) tags
 CC representing groups of genes which are differentially expressed in human
 CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
 CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
 CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
 CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
 CC polyA region of cDNAs derived from a variety of genes. These tags serve
 CC to uniquely identify each transcript and can thus be used to analyse the
 CC pattern of gene expression in particular cell types. The invention also
 CC relates to proteins encoded by the genes expressed in chronic hepatitis C
 CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
 CC the expression of groups of genes that are overexpressed in chronic
 CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
 CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
 CC treatment of these diseases. Such genes, inhibitors of their expression
 CC or activity, and antibodies against the gene products may be used in the
 CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
 CC ABV84591-ABV84790 are SAGE tags representing the 100 least highly
 CC expressed genes out of those genes which are underexpressed in
 CC hepatocellular carcinoma compared with chronic hepatitis C liver tissue
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAG 2227
 DB 1 TGACCAAG 10
 RESULT 605
 ABV84230
 ID ABV84230 standard; cDNA; 10 BP.
 XX
 AC ABV84230;
 XX
 XX 12-DEC-2002 (first entry)
 DT
 XX Human chronic hepatitis C tissue overexpressed gene SAGE tag #40.
 DE
 XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
 KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
 KW expression pattern; differential expression; ss.
 XX Homo sapiens.
 OS
 XX JP2002209591-A.
 PN 30-JUL-2002.
 XX
 XX 19-JAN-2001; 2001JP-00012328.
 PF
 XX 19-JAN-2001; 2001JP-00012328.
 PR
 XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
 PA WPI; 2002-631294/68.
 DR
 XX Human chronic hepatitis C tissue expression exasperating gene group
 PT comprises 100 high-ranking genes.
 XX
 XX Claim 46; Page 26; 139pp; Japanese.
 PS
 XX The invention relates to SAGE (serial analysis of gene expression) tags
 CC representing groups of genes which are differentially expressed in human
 CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
 CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
 CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
 CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
 CC polyA region of cDNAs derived from a variety of genes. These tags serve
 CC to uniquely identify each transcript and can thus be used to analyse the
 CC pattern of gene expression in particular cell types. The invention also
 CC relates to proteins encoded by the genes expressed in chronic hepatitis C
 CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
 CC the expression of groups of genes that are overexpressed in chronic
 CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
 CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
 CC treatment of these diseases. Such genes, inhibitors of their expression
 CC or activity, and antibodies against the gene products may be used in the
 CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
 CC ABV84591-ABV84790 are SAGE tags representing the 100 least highly
 CC expressed genes out of those genes which are underexpressed in
 CC hepatocellular carcinoma compared with chronic hepatitis C liver tissue
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAG 2227
 DB 1 TGACCAAG 10
 RESULT 605
 ABV84230
 ID ABV84230 standard; cDNA; 10 BP.
 XX
 AC ABV84230;
 XX
 XX 12-DEC-2002 (first entry)
 DT
 XX Human chronic hepatitis C tissue overexpressed gene SAGE tag #40.
 DE
 XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
 KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
 KW expression pattern; differential expression; ss.
 XX Homo sapiens.
 OS
 XX JP2002209591-A.
 PN 30-JUL-2002.
 XX
 XX 19-JAN-2001; 2001JP-00012328.
 PF
 XX 19-JAN-2001; 2001JP-00012328.
 PR
 XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
 PA WPI; 2002-631294/68.
 DR
 XX Human chronic hepatitis C tissue expression exasperating gene group
 PT comprises 100 high-ranking genes.
 XX
 XX Claim 1; Page 10; 139pp; Japanese.
 PS
 XX The invention relates to SAGE (serial analysis of gene expression) tags
 CC representing groups of genes which are differentially expressed in human
 CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
 CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
 CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
 CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
 CC polyA region of cDNAs derived from a variety of genes. These tags serve
 CC to uniquely identify each transcript and can thus be used to analyse the
 CC pattern of gene expression in particular cell types. The invention also
 CC relates to proteins encoded by the genes expressed in chronic hepatitis C
 CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
 CC the expression of groups of genes that are overexpressed in chronic
 CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
 CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
 CC treatment of these diseases. Such genes, inhibitors of their expression
 CC or activity, and antibodies against the gene products may be used in the
 CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
 CC ABV84591-ABV84790 are SAGE tags representing the 100 most highly
 CC expressed genes out of those genes which are overexpressed in chronic
 CC hepatitis C liver tissue compared with normal liver tissue
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAG 2227
 DB 1 TGACCAAG 10
 RESULT 606
 ABK70750
 ID ABK70750 standard; DNA; 10 BP.
 XX
 AC ABK70750;
 XX
 XX 15-JUL-2002 (first entry)
 DT
 XX Primer-extension oligonucleotide #7 to detect human SCYA8 polymorphisms.
 DE
 XX Human; single nucleotide polymorphism; SNP; monocyte chemoattractant protein;
 KW small inducible cytokine subfamily A member 8; SCYA8; anti-HIV;
 KW haplotyping; genotyping; inflammatory disease; HIV infection;
 KW human immunodeficiency virus; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200222888-A1.
 XX
 XX 21-MAR-2002.
 PD
 XX 17-SEP-2001; 2001WO-US029332.
 PF
 XX 15-SEP-2000; 2000US-0232755P.
 PR

CC sequences given in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 3 A; 2 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2213 GAGTGTGACC 2222
 DB 1 GAGTGTGACC 10

RESULT 609
 ADE73174
 ID ADE73174 standard; DNA; 10 BP.

XX ADE73174;

XX 29-JAN-2004 (first entry)

XX Oligon #11 used to illustrate nucleic acid characterisation method.

XX Mutation detection; identification; ss.

XX Synthetic.

XX WO2003091408-A2.

XX 06-NOV-2003.

XX 25-APR-2003; 2003WO-US012962.

XX 26-APR-2002; 2002US-0375640P.

XX (UTAH) UNIV UTAH.

XX Wittwer CT, Dummer CW;

XX WPI; 2003-845591/78.

XX Characterizing single stranded nucleic acid, by combining nucleic acid
 PT with specific dye to form detectable complex, varying temperature to
 PT determine melting temperature for each secondary structures in complex.

XX Example 2; Fig 8; 94pp; English.

XX The present invention relates to a method (M1) for characterizing single
 CC stranded nucleic acid (SNA). The method involves combining SNA with
 CC double stranded nucleic acid-specific dye to form detectable complex
 CC between dye and one or more double strand secondary structures within
 CC SNA, and varying temperature of SNA to determine melting temperature (Tm)
 CC for each of the secondary structures in detectable complex, where Tm(s)
 CC define a Tm profile characterizing SNA. (M1) is useful for detecting a
 CC difference between the sequence of a first and a second single stranded
 CC nucleic acid which involves determining the Tm profile of a first single
 CC stranded nucleic acid using a double stranded nucleic acid-specific dye,
 CC and comparing the Tm profile of the first single stranded nucleic acid
 CC with the Tm profile of the second single stranded nucleic acid, where a
 CC difference in Tm profile between the first and the second single stranded
 CC nucleic acid indicates a difference in sequence between the first and
 CC second nucleic acids. The determining is by combining the first single
 CC stranded nucleic acid with a double stranded nucleic acid-specific dye to
 CC form a detectable complex between the dye and one or more double strand
 CC secondary structures within the first single stranded nucleic acid and
 CC measuring the fluorescence emission of the double strand nucleic acid-
 CC specific dye while varying the temperature of the combination. A change
 CC in fluorescence indicates a change in secondary structure of the single
 CC stranded nucleic acid. (M1) is useful for detecting a change (mutation)
 CC in the sequence of a sample nucleic acid as compared with a nucleic acid
 CC having a known sequence which involves determining the Tm profile of a
 CC single stranded nucleic acid sample using a double strands nucleic acid-
 CC specific dye, where a difference between the Tm profile of the nucleic

CC acid sample and the Tm profile of the nucleic acid having a known
 CC sequence indicates an alteration in the sequence of the sample nucleic
 CC acid as compared to the known sequence. (M1) is useful for identifying
 CC the species type of a cell (bacterial or plant cell) which involves
 CC determining the Tm profile of a sample rRNA or its fragment from a cell
 CC using a double stranded nucleic acid-specific dye, where a match between
 CC the determined Tm profile and the Tm profile of a corresponding rRNA or
 CC its fragment of a cell from a known species type indicates that the
 CC sample rRNA is from the known rRNA cell type. The sample rRNA or its
 CC fragment is an amplified rRNA gene or its fragment. The determining is by
 CC combining the rRNA gene or its fragment with a double stranded nucleic
 CC acid-specific dye to form a detectable complex between the dye and one or
 CC more double strand secondary structures within the amplified rRNA gene or
 CC its fragment and measuring the fluorescence emission of the double strand
 CC nucleic acid-specific dye while varying the temperature of the
 CC combination. In an example from the invention, a model oligonucleotide
 CC system was designed to (1) demonstrate secondary structure melting curves
 CC by monitoring fluorescence intensity of ds DNA specific nucleic acid dye
 CC SYBR Green 1, (2) empirically determine secondary structure melting
 CC temperature ranges, (3) demonstrate multiple domain melting using SYBR
 CC Green I fluorescence and, (4) demonstrate sequence specific melting of
 CC secondary structures using SYBR Green I. The present sequence is an
 CC oligonucleotide used in the model system.

SQ Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 2.6e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTT 2229

DB 1 ACCAAAAGTT 10

RESULT 610

AAL56066/c

ID AAL56066 standard; DNA; 10 BP.

XX AAL56066;

XX 11-MAR-2004 (first entry)

XX Human BAGE 5 intron/exon junction #5.

XX BAGE; tumour antigen; melanoma; cancer; cytostatic; gene therapy; gene;
 XX ds.

XX Homo sapiens.

XX WO2003084990-A1.

XX 16-OCT-2003.

XX 05-APR-2002; 2002WO-EP003811.

XX 05-APR-2002; 2002WO-EP003811.

XX (CNRS) CENT NAT RECH SCI.

XX De Sario A, Ruault M;

XX WPI; 2003-804293/75.

XX New BAGE proteins useful for manufacturing a medicament for diagnosing
 XX and treating cancer, particularly melanoma.

XX Disclosure; Page 13; Opp; English.

XX The present invention provides the protein and coding sequences of a
 CC number of members of the BAGE family of proteins from humans. The
 CC proteins or their antibodies are useful for manufacturing a medicament
 CC for the treatment of pathologies (e.g. tumours such as melanomas) linked

CC to the expression, at the surface of the cells of the organism, of
CC complexes between the peptide fragments and HLA molecules. The methods
CC may also be used for treating a subject with a tumour, such as melanoma.
CC The nucleotide sequences, host cells, cytolytic cells or antibodies are
CC also useful for in vitro diagnosis of the disorders cited above. The
CC present sequence is a coding sequence/fragment of the invention
XX
XX
SQ Sequence 10 BP; 6 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 10 TTACATGTTT 1

RESULT 611
AAL56049/C
ID AAL56049 standard; DNA; 10 BP.
XX
XX AAL56049;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX Human BAGE 2 intron/exon junction #5.
DE
XX
XX BAGE; tumour antigen; melanoma; cancer; cytostatic; gene therapy; gene;
KW ds.
XX
XX Homo sapiens.
OS
XX
XX WO2003084990-A1.
PN
XX
XX 16-OCT-2003.
PD
XX
XX 05-APR-2002; 2002WO-EP003811.
PF
XX
XX 05-APR-2002; 2002WO-EP003811.
PR
XX
XX (CNRS) CENT NAT RECH SCI.
PA
XX
XX De Sario A, Ruault M;
PI
XX
XX WPI; 2003-804293/75.
DR
XX
XX New BAGE proteins useful for manufacturing a medicament for diagnosing
PT and treating cancer, particularly melanoma.
PT
XX
XX Disclosure; Page 13; Opp; English.
PS
XX
XX The present invention provides the protein and coding sequences of a
CC number of members of the BAGE family of proteins from humans. The
CC proteins or their antibodies are useful for manufacturing a medicament
CC for the treatment of pathologies (e.g. tumours such as melanomas) linked
CC to the expression, at the surface of the cells of the organism, of
CC complexes between the peptide fragments and HLA molecules. The methods
CC may also be used for treating a subject with a tumour, such as melanoma.
CC The nucleotide sequences, host cells, cytolytic cells or antibodies are
CC also useful for in vitro diagnosis of the disorders cited above. The
CC present sequence is a coding sequence/fragment of the invention
XX
XX
SQ Sequence 10 BP; 6 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 10 TTACATGTTT 1

RESULT 612
ADL96132/C
ID ADL96132 standard; DNA; 10 BP.
XX
XX ADL96132;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX CD15+ myeloid cell associated probe seqid 30.
DE
XX
XX cytostatic; gene therapy; microarray; gene expression characteristic;
KW haematopoietic cell; haematopoiesis; myeloid leukaemia; probe;
XX CD15+ myeloid cell; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003165949-A1.
PN
XX
XX 04-SEP-2003.
PD
XX
XX 23-DEC-2002; 2002US-00329465.
PF
XX
XX 27-DEC-2001; 2001US-0343826P.
PR
XX
XX (WANG/) WANG S M.
PA (LEES/) LEE S.
PA (CHEN/) CHEN J.
PA (ZHOU/) ZHOU G.
PA (ROWL/) ROWLEY J D.
XX
XX Wang SM, Lee S, Chen J, Zhou G, Rowley JD;
PI
XX
XX WPI; 2003-863699/80.
DR
XX
XX New microarray for measuring gene expression characteristics of
PT haematopoietic cells, useful for preparing a composition for diagnosing or
PT treating myeloid leukemia.
PT
XX
XX Claim 1; SEQ ID NO 30; 32pp; English.
PS
XX
XX The invention describes a microarray for measuring gene expression
CC characteristics of haematopoietic cells comprising at least 5
CC polynucleotides having distinct sequences. Also described are: a method
CC of diagnosing or treating an abnormality associated with haematopoiesis;
CC and diagnosing myeloid leukaemia in a patient. The microarray is useful
CC for preparing a composition for diagnosing or treating myeloid leukaemia.
CC This sequence represents a polynucleotide probe comprising a portion of
CC an expressed gene isolated from a population of CD15+ myeloid cells and
CC suitable for use in the microarray of the invention.
XX
XX
SQ Sequence 10 BP; 2 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 AGTGTGACCA 2223
Db 10 AGTGTGACCA 1

RESULT 613
ADH14478
ID ADH14478 standard; DNA; 10 BP.
XX
XX ADH14478;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX Human retinoblastoma 1 (RB1CC1) genomic DNA 3' border of exon 14.
DE
XX
XX cell nucleus; transcription; gene expression; retinoblastoma-1; RB1CC1;
KW

diagnosis; cancer; primer; ss.
 Homo sapiens.
 WO2003102028-A1.
 11-DEC-2003.
 30-JAN-2003; 2003WO-JP000882.
 03-JUN-2002; 2002JP-00161400.
 24-JUL-2002; 2002JP-00214978.
 (OKAB//) OKABE H.
 (IKEG//) IKEGAWA S.
 (CHAN//) CHANO T.
 Chano T;
 MPI; 2004-081932/08.
 Protein in the nuclei of human and animal cells associated with
 expression of retinoblastoma-1 gene for diagnosis of cancer.
 Disclosure; Page 11; 113pp; Japanese.
 The invention relates to a protein or polypeptide found in the nuclei of
 human and animal cells that are associated with transcription and/or
 induction of expression of retinoblastoma-1 gene (RB1CC1). The detection
 of RB1CC1 gene and its protein is useful for the diagnosis of cancer. The
 human RB1CC1 cDNA is 6.6 kb containing a 4782 bp ORF, encoding a 180 kD
 1594 amino acid protein. This sequence corresponds to the sequence at the
 junction between an intron and an exon in the human RB1CC1 genomic
 sequence.
 Sequence 10 BP; 6 A; 1 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. NO. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAG 2227
 ||| |||||
 DB 1 TGAACAAAAG 10
 RESULT 614
 ADK13337
 ID ADK13337 standard; DNA; 10 BP.
 AC ADK13337;
 XX 20-MAY-2004 (first entry)
 DT Human glioma endothelial marker (GEM) SAGE tag oligonucleotide.
 DE
 XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
 KW anticancer; antiglioma; immune response; cytostatic;
 KW multi-drug sensitive glioma; human; SAGE tag; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004016758-A2.
 XX 26-FEB-2004.
 XX 15-AUG-2003; 2003WO-US025614.
 PF 15-AUG-2002; 2002US-0403390P.
 PR 01-APR-2003; 2003US-0458978P.
 XX (GENZ) GENZYME CORP.

(UYJO) UNIV JOHNS HOPKINS.
 Madden SI, Wang CJ, Cook BP, Lattera J, Walter K;
 MPI; 2004-247973/23.
 Diagnosing glioma by detecting expression product of any one of 255
 genes, glioma endothelial markers, in brain tissue sample suspected of
 being neoplastic, and comparing the expression with expression in normal
 brain tissue sample.
 Example 10; Page 64; 114pp; English.
 The present invention describes a method (M1) for aiding in the diagnosis
 of glioma. (M1) involves detecting an expression product of at least one
 gene (I) in a first brain tissue sample (T) suspected of being
 neoplastic, where (I) is chosen from any one of 255 genes (Glioma
 endothelial markers (GEMs)) as given in specification, and comparing the
 expression of (I) in (T) with expression of (I) in a second normal brain
 tissue sample (R), where increased expression of (I) in (T) relative to
 (R) identifies (T) as likely to be neoplastic. Also described: (1)
 treating (M2) glioma involves contacting cells of the glioma with an
 antibody that specifically binds to a extracellular epitope; (2)
 identifying (M3) a test compound as potential anticancer or anti-glioma
 drug involves contacting a test compound with the cell which expresses
 (I), monitoring an expression product of the at least one gene and
 identifying test compound as a potential anticancer drug if it decreases
 the expression of at least one gene; (3) identifying (M4) a test compound
 as potential anticancer or anti-glioma drug involves contacting a test
 compound with the cell which expresses mRNA of at least one gene
 identified by a tag as described above, monitoring mRNA of the gene, and
 identifying the test compound as a potential anticancer drug if it
 decreases the expression of at least one gene; and (4) inducing (M5) an
 immune response to glioma involves administering to a mammal, a protein
 or (I). (I) have cytostatic activities, and can be used to trigger immune
 destruction of glioma cells, and as immune response inducers. (M1) is
 useful for aiding in diagnosing glioma. (M2) is useful for inducing multi
 -drug sensitive glioma in a human. (M5) is useful for inducing an immune
 response to a glioma in a mammal having glioma or in a mammal who has had
 a glioma surgically removed. The present sequence represents a human GEM
 SAGE tag oligonucleotide, which is used in the exemplification of the
 present invention.
 Sequence 10 BP; 3 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. NO. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACC 2222
 ||||| |||||
 DB 1 GAGTGAGACC 10
 RESULT 615
 ADK12886
 ID ADK12886 standard; DNA; 10 BP.
 AC ADK12886;
 XX 20-MAY-2004 (first entry)
 DT Human glioma endothelial marker (GEM) standard tag SEQ ID NO:64.
 DE
 XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
 KW anticancer; antiglioma; immune response; cytostatic;
 KW multi-drug sensitive glioma; human; standard tag; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004016758-A2.

PD 26-FEB-2004.
XX 15-AUG-2003; 2003WO-US025614.
XX 15-AUG-2002; 2002US-0403390P.
PR 01-APR-2003; 2003US-0458978P.
XX (GENZ) GENZYME CORP.
PA (UYJO) UNIV JOHNS HOPKINS.
XX Madden SI, Wang CJ, Cook BP, Lattera J, Walter K;
PI WPI; 2004-247973/23.
XX Diagnosing glioma by detecting expression product of any one of 255
PT genes, glioma endothelial markers, in brain tissue sample suspected of
PT being neoplastic, and comparing the expression with expression in normal
PT brain tissue sample.
XX Example 2; SEQ ID NO 64; 114pp; English.
XX The present invention describes a method (M1) for aiding in the diagnosis
CC of glioma. (M1) involves detecting an expression product of at least one
CC gene (I) in a first brain tissue sample (T) suspected of being
CC neoplastic, where (I) is chosen from any one of 255 genes (glioma
CC endothelial markers (GEMs)) as given in specification, and comparing the
CC expression of (I) in (T) with expression of (I) in a second normal brain
CC tissue sample (R), where increased expression of (I) in (T) relative to
CC (R), identifies (T) as likely to be neoplastic. Also described: (1)
CC treating (M2) glioma involves contacting cells of the glioma with an
CC antibody that specifically binds to a extracellular epitope; (2)
CC identifying (M3) a test compound as potential anticancer or anti-glioma
CC drug involves contacting a test compound with the cell which expresses
CC (I), monitoring an expression product of the at least one gene and
CC identifying test compound as a potential anticancer drug if it decreases
CC the expression of at least one gene; (3) identifying (M4) a test compound
CC as potential anticancer or anti-glioma drug involves contacting a test
CC compound with the cell which expresses mRNA of at least one gene
CC identified by a tag as described above, monitoring mRNA of the gene, and
CC identifying the test compound as a potential anticancer drug if it
CC decreases the expression of at least one gene; and (4) inducing (M5) an
CC immune response to glioma involves administering to a mammal, a protein
CC or (I). (I) have cytostatic activities, and can be used to trigger immune
CC destruction of glioma cells, and as immune response inducers. (M1) is
CC useful for aiding in diagnosing glioma. (M2) is useful for inducing an immune
CC -drug sensitive glioma in a human. (M5) is useful for inducing an immune
CC response to a glioma in a mammal having glioma or in a mammal who has had
CC a glioma surgically removed. The present sequence represents a human GEM
CC standard tag oligonucleotide, which is used in the exemplification of the
CC present invention.
XX Sequence 10 BP; 3 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 10;
XX Best Local Similarity 90.0%; Pred. No. 2.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX 2213 GAGTGTGACC 2222
XX |||||
XX 1 GAGTGAGACC 10
XX Db
XX RESULT 616
XX ADK13362
XX ID ADK13362 standard; DNA; 10 BP.
XX AC ADK13362;
XX XX
XX 20-MAY-2004 (first entry)
XX Human glioma endothelial marker (GEM) SAGE tag oligonucleotide.
XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEN;
KW anticancer; anti-glioma; immune response; cytostatic;
KW multi-drug sensitive glioma; human; SAGE tag; ss.
OS Homo sapiens.
OS Synthetic.
PN WC2004016758-A2.
XX 26-FEB-2004.
XX 15-AUG-2003; 2003WO-US025614.
XX 15-AUG-2002; 2002US-0403390P.
PR 01-APR-2003; 2003US-0458978P.
XX (GENZ) GENZYME CORP.
PA (UYJO) UNIV JOHNS HOPKINS.
XX Madden SI, Wang CJ, Cook BP, Lattera J, Walter K;
PI WPI; 2004-247973/23.
XX Diagnosing glioma by detecting expression product of any one of 255
PT genes, glioma endothelial markers, in brain tissue sample suspected of
PT being neoplastic, and comparing the expression with expression in normal
PT brain tissue sample.
XX Example 10; Page 66; 114pp; English.
XX The present invention describes a method (M1) for aiding in the diagnosis
CC of glioma. (M1) involves detecting an expression product of at least one
CC gene (I) in a first brain tissue sample (T) suspected of being
CC neoplastic, where (I) is chosen from any one of 255 genes (glioma
CC endothelial markers (GEMs)) as given in specification, and comparing the
CC expression of (I) in (T) with expression of (I) in a second normal brain
CC tissue sample (R), where increased expression of (I) in (T) relative to
CC (R), identifies (T) as likely to be neoplastic. Also described: (1)
CC treating (M2) glioma involves contacting cells of the glioma with an
CC antibody that specifically binds to a extracellular epitope; (2)
CC identifying (M3) a test compound as potential anticancer or anti-glioma
CC drug involves contacting a test compound with the cell which expresses
CC (I), monitoring an expression product of the at least one gene and
CC identifying test compound as a potential anticancer drug if it decreases
CC the expression of at least one gene; (3) identifying (M4) a test compound
CC as potential anticancer or anti-glioma drug involves contacting a test
CC compound with the cell which expresses mRNA of at least one gene
CC identified by a tag as described above, monitoring mRNA of the gene, and
CC identifying the test compound as a potential anticancer drug if it
CC decreases the expression of at least one gene; and (4) inducing (M5) an
CC immune response to glioma involves administering to a mammal, a protein
CC or (I). (I) have cytostatic activities, and can be used to trigger immune
CC destruction of glioma cells, and as immune response inducers. (M1) is
CC useful for aiding in diagnosing glioma. (M2) is useful for inducing an immune
CC -drug sensitive glioma in a human. (M5) is useful for inducing an immune
CC response to a glioma in a mammal having glioma or in a mammal who has had
CC a glioma surgically removed. The present sequence represents a human GEM
CC standard tag oligonucleotide, which is used in the exemplification of the
CC present invention.
XX Sequence 10 BP; 3 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 10;
XX Best Local Similarity 90.0%; Pred. No. 2.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX 2213 GAGTGTGACC 2222
XX |||||
XX 1 GAGTGAGACC 10
XX Db
XX RESULT 616
XX ADK13362
XX ID ADK13362 standard; DNA; 10 BP.
XX AC ADK13362;
XX XX
XX 20-MAY-2004 (first entry)
XX Human glioma endothelial marker (GEM) SAGE tag oligonucleotide.
XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEN;
KW anticancer; anti-glioma; immune response; cytostatic;
KW multi-drug sensitive glioma; human; SAGE tag; ss.
OS Homo sapiens.
OS Synthetic.
PN WC2004016758-A2.
XX 26-FEB-2004.
XX 15-AUG-2003; 2003WO-US025614.
XX 15-AUG-2002; 2002US-0403390P.
PR 01-APR-2003; 2003US-0458978P.
XX (GENZ) GENZYME CORP.
PA (UYJO) UNIV JOHNS HOPKINS.
XX Madden SI, Wang CJ, Cook BP, Lattera J, Walter K;
PI WPI; 2004-247973/23.
XX Diagnosing glioma by detecting expression product of any one of 255
PT genes, glioma endothelial markers, in brain tissue sample suspected of
PT being neoplastic, and comparing the expression with expression in normal
PT brain tissue sample.
XX Example 10; Page 66; 114pp; English.
XX The present invention describes a method (M1) for aiding in the diagnosis
CC of glioma. (M1) involves detecting an expression product of at least one
CC gene (I) in a first brain tissue sample (T) suspected of being
CC neoplastic, where (I) is chosen from any one of 255 genes (glioma
CC endothelial markers (GEMs)) as given in specification, and comparing the
CC expression of (I) in (T) with expression of (I) in a second normal brain
CC tissue sample (R), where increased expression of (I) in (T) relative to
CC (R), identifies (T) as likely to be neoplastic. Also described: (1)
CC treating (M2) glioma involves contacting cells of the glioma with an
CC antibody that specifically binds to a extracellular epitope; (2)
CC identifying (M3) a test compound as potential anticancer or anti-glioma
CC drug involves contacting a test compound with the cell which expresses
CC (I), monitoring an expression product of the at least one gene and
CC identifying test compound as a potential anticancer drug if it decreases
CC the expression of at least one gene; (3) identifying (M4) a test compound
CC as potential anticancer or anti-glioma drug involves contacting a test
CC compound with the cell which expresses mRNA of at least one gene
CC identified by a tag as described above, monitoring mRNA of the gene, and
CC identifying the test compound as a potential anticancer drug if it
CC decreases the expression of at least one gene; and (4) inducing (M5) an
CC immune response to glioma involves administering to a mammal, a protein
CC or (I). (I) have cytostatic activities, and can be used to trigger immune
CC destruction of glioma cells, and as immune response inducers. (M1) is
CC useful for aiding in diagnosing glioma. (M2) is useful for inducing an immune
CC -drug sensitive glioma in a human. (M5) is useful for inducing an immune
CC response to a glioma in a mammal having glioma or in a mammal who has had
CC a glioma surgically removed. The present sequence represents a human GEM
CC standard tag oligonucleotide, which is used in the exemplification of the
CC present invention.
XX Sequence 10 BP; 3 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 10;
XX Best Local Similarity 90.0%; Pred. No. 2.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX 2213 GAGTGTGACC 2222
XX |||||
XX 1 GAGTGAGACC 10
XX Db
XX RESULT 617
XX AAV82624
XX ID AAV82624 standard; DNA; 11 BP.


```

XX AC AAV82624;
XX DT 11-FEB-1999 (first entry)
XX DE Target binding site for the polyamides of the invention.
XX KW Binding site; polyamide; hairpin turn; gamma-aminobutyric acid; GABA;
XX KW minor groove; (R)-2,4-diaminobutyric acid; R-DAB; gene expression;
XX KW inhibition; detection; ds.
XX OS Synthetic.
XX PN WO9845284-A1.
XX PD 15-OCT-1998.
XX PF 29-JAN-1998; 98WO-US003829.
XX PR 20-FEB-1997; 97WO-US003332.
XX PR 08-APR-1997; 97US-0043444P.
XX PR 16-APR-1997; 97US-0042022P.
XX PR 21-APR-1997; 97US-00837524.
XX PR 08-MAY-1997; 97US-00853522.
XX PR 21-JUL-1997; 97WO-US012722.
XX PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX PI Baird EE, Dervan PB;
XX WPI; 1998-594477/50.
XX New hairpin polyamides including R-2,4-diaminobutyric acid residue in the
XX hairpin - bind more tightly to complementary bases in the minor groove of
XX DNA, particularly of regulatory regions for therapeutic or diagnostic
XX inhibition of gene expression.
XX Example 9; Page 43; 79pp; English.
XX The present sequence represents a target binding site for the polyamides
XX of the invention. These polyamides have a hairpin turn derived from gamma
XX -aminobutyric acid (GABA) and bind specifically to base pairs in the
XX minor groove of DNA. The GABA in the hairpin of the polyamides is
XX replaced by the residue of (R)-2,4-diaminobutyric acid (R-DAB). The
XX polyamides are used to inhibit gene expression by sequence-specific
XX binding to the double-stranded regulatory region of the gene. They can be
XX used therapeutically or diagnostically, e.g. for detection or isolation
XX of target DNA
XX Sequence 11 BP; 2 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTT 2236
Db 2 GTTATATGTT 11

RESULT 618
AAH55107/c
ID AAH55107 standard; DNA; 11 BP.
XX AC AAH55107;
XX DT 03-SEP-2001 (first entry)
XX DE Genomic DNA methylation parallel detection associated DNA fragment #9.
XX KW DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX KW amplification; transcription regulation; genetic imprinting;
XX KW tumorigenesis; primer; ss.

XX AC AAV82624;
XX DT 11-FEB-1999 (first entry)
XX DE Target binding site for the polyamides of the invention.
XX KW Binding site; polyamide; hairpin turn; gamma-aminobutyric acid; GABA;
XX KW minor groove; (R)-2,4-diaminobutyric acid; R-DAB; gene expression;
XX KW inhibition; detection; ds.
XX OS Synthetic.
XX PN WO9845284-A1.
XX PD 15-OCT-1998.
XX PF 29-JAN-1998; 98WO-US003829.
XX PR 20-FEB-1997; 97WO-US003332.
XX PR 08-APR-1997; 97US-0043444P.
XX PR 16-APR-1997; 97US-0042022P.
XX PR 21-APR-1997; 97US-00837524.
XX PR 08-MAY-1997; 97US-00853522.
XX PR 21-JUL-1997; 97WO-US012722.
XX PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX PI Baird EE, Dervan PB;
XX WPI; 1998-594477/50.
XX New hairpin polyamides including R-2,4-diaminobutyric acid residue in the
XX hairpin - bind more tightly to complementary bases in the minor groove of
XX DNA, particularly of regulatory regions for therapeutic or diagnostic
XX inhibition of gene expression.
XX Example 9; Page 43; 79pp; English.
XX The present sequence represents a target binding site for the polyamides
XX of the invention. These polyamides have a hairpin turn derived from gamma
XX -aminobutyric acid (GABA) and bind specifically to base pairs in the
XX minor groove of DNA. The GABA in the hairpin of the polyamides is
XX replaced by the residue of (R)-2,4-diaminobutyric acid (R-DAB). The
XX polyamides are used to inhibit gene expression by sequence-specific
XX binding to the double-stranded regulatory region of the gene. They can be
XX used therapeutically or diagnostically, e.g. for detection or isolation
XX of target DNA
XX Sequence 11 BP; 2 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTT 2236
Db 2 GTTATATGTT 11

RESULT 618
AAH55107/c
ID AAH55107 standard; DNA; 11 BP.
XX AC AAH55107;
XX DT 03-SEP-2001 (first entry)
XX DE Genomic DNA methylation parallel detection associated DNA fragment #9.
XX KW DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX KW amplification; transcription regulation; genetic imprinting;
XX KW tumorigenesis; primer; ss.

```

```

XX OS Unidentified.
XX PN WO200142493-A2.
XX PD 14-JUN-2001.
XX PF 06-DEC-2000; 2000WO-DE004381.
XX PR 06-DEC-1999; 99DE-01059691.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C;
XX WPI; 2001-381705/40.
XX Parallel detection of the methylation pattern of many genomic DNA
XX regions, useful for detecting aberrant methylation, includes multiple
XX amplification of chemically modified DNA.
XX Claim 18; Page 19; 63pp; German.
XX This invention describes a novel method for the parallel detection of the
XX methylation status of genomic DNA (I) which involves a (I) sample being
XX treated chemically to convert 5-unmethylated cytosine to uracil,
XX thymidine or some other base having hybridization behavior different from
XX that of C, then amplifying simultaneously at least 10 different fragments
XX (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX primers are based on regulatory, transcribed and/or translated segments
XX present in the sample after chemical treatment. The sequence context of
XX all, or some, of the CpG and CpNpG motifs in the amplified products is
XX then determined. The method is used to detect aberrant methylation of
XX patterns in the genome, these are implicated in regulation of
XX transcription, genetic imprinting and tumorigenesis. Many target regions
XX in the genome can be analyzed simultaneously and it is not essential to
XX know the sequence context of all targeted regions. Primers may be
XX designed for preferential amplification of particular segments of
XX interest (e.g. promoters and exons)
XX Sequence 11 BP; 2 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
Db 11 AAAAATTACA 2

RESULT 619
AAH55108
ID AAH55108 standard; DNA; 11 BP.
XX AC AAH55108;
XX DT 03-SEP-2001 (first entry)
XX DE Genomic DNA methylation parallel detection associated DNA fragment #10.
XX KW DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX KW amplification; transcription regulation; genetic imprinting;
XX KW tumorigenesis; primer; ss.
XX OS Unidentified.
XX PN WO200142493-A2.
XX PD 14-JUN-2001.
XX PF 06-DEC-2000; 2000WO-DE004381.
XX

```

PR 06-DEC-1999; 99DE-01059691.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C;
 PI WPI; 2001-381705/40.
 XX
 XX Parallel detection of the methylation pattern of many genomic DNA
 PT regions, useful for detecting aberrant methylation, includes multiple
 PT amplification of chemically modified DNA.
 PS Claim 18; page 19; 63pp; German.
 XX
 XX This invention describes a novel method for the parallel detection of the
 CC methylation status of genomic DNA (I) which involves a (I) sample being
 CC treated chemically to convert 5-unmethylated cytosine to uracil,
 CC thymidine or some other base having hybridization behavior different from
 CC that of C, then amplifying simultaneously at least 10 different fragments
 CC (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
 CC primers are based on regulatory, transcribed and/or translated segments
 CC present in the sample after chemical treatment. The sequence context of
 CC all, or some, of the CpG and CpNpG motifs in the amplified products is
 CC then determined. The method is used to detect aberrant methylation
 CC patterns in the genome, these are implicated in regulation of
 CC transcription, genetic imprinting and tumorigenesis. Many target regions
 CC in the genome can be analyzed simultaneously and it is not essential to
 CC know the sequence context of all targeted regions. Primers may be
 CC designed for preferential amplification of particular segments of
 CC interest (e.g. promoters and exons)
 XX
 SQ Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 1 AAAAATTACA 10
 RESULT 620
 ABQ86506/c
 ID ABQ86506 standard; cDNA; 11 BP.
 XX
 AC ABQ86506;
 XX
 XX 10-SEP-2002 (first entry)
 DT Human skin stress/ageing related EST SEQ ID NO 261.
 DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS
 XX WC200253773-A2.
 XX
 XX 11-JUL-2002.
 PD
 XX 20-DEC-2001; 2001WO-EP015178.
 XX
 XX 03-JAN-2001; 2001DE-01000121.
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Conradt M, Hofmann K;
 PI WPI; 2002-528865/56.
 XX
 XX Identifying genes involved in skin stress and aging, useful e.g. in
 PT screening for cosmetic or therapeutic agents, based on differential gene
 PT expression.

XX Claim 8; Page 47; 325pp; German.
 PS
 XX The invention relates to identifying (M1) genes in vitro that, in humans
 CC or animals, are important for skin ageing and/or skin stress by serial
 CC analysis of gene expression between mixtures of transcribed and
 CC optionally translated, genetically encoded factors (A) obtained from
 CC young and aged skin, to identify that genes that show strong differential
 CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 CC useful for: identifying markers of skin ageing and/or stress; determining
 CC skin ageing and/or stress; and identifying or determining the effects of
 CC pharmaceutical or cosmetic agents for control of skin ageing. The present
 CC sequence is one of a group of human skin ageing/stress related expressed
 CC sequence tags (ABQ86246-ABQ87680) of the invention
 XX
 SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 11 AAAAGATACA 2
 RESULT 621
 ABQ87043/c
 ID ABQ87043 standard; cDNA; 11 BP.
 XX
 AC ABQ87043;
 XX
 XX 10-SEP-2002 (first entry)
 DT Human skin stress/ageing related EST SEQ ID NO 798.
 DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS
 XX WC200253773-A2.
 XX
 XX 11-JUL-2002.
 PD
 XX 20-DEC-2001; 2001WO-EP015178.
 XX
 XX 03-JAN-2001; 2001DE-01000121.
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Conradt M, Hofmann K;
 PI WPI; 2002-528865/56.
 XX
 XX Identifying genes involved in skin stress and aging, useful e.g. in
 PT screening for cosmetic or therapeutic agents, based on differential gene
 PT expression.
 XX
 XX Claim 8; Page 70; 325pp; German.
 PS
 XX The invention relates to identifying (M1) genes in vitro that, in humans
 CC or animals, are important for skin ageing and/or skin stress by serial
 CC analysis of gene expression between mixtures of transcribed and
 CC optionally translated, genetically encoded factors (A) obtained from
 CC young and aged skin, to identify that genes that show strong differential
 CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 CC useful for: identifying markers of skin ageing and/or stress; determining
 CC skin ageing and/or stress; and identifying or determining the effects of
 CC pharmaceutical or cosmetic agents for control of skin ageing. The present
 CC sequence is one of a group of human skin ageing/stress related expressed
 CC sequence tags (ABQ86246-ABQ87680) of the invention
 XX
 SQ Sequence 11 BP; 6 A; 2 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACAGTTT 2237
Db 11 TTACAGTTT 2

RESULT 622
ABQ87534/c
ID ABQ87534 standard; cDNA; 11 BP.
XX AC ABQ87534;
XX 10-SEP-2002 (first entry)
XX DE Human skin stress/ageing related EST SEQ ID NO 1289.
XX DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253773-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015178.
XX PR 03-JAN-2001; 2001DE-01000121.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-528865/56.
XX PT Identifying genes involved in skin stress and aging, useful e.g. in
XX PT screening for cosmetic or therapeutic agents, based on differential gene
XX PT expression.
XX PS Claim 8; Page 90; 325pp; German.
XX CC The invention relates to identifying (M1) genes in vitro that, in humans
XX CC or animals, are important for skin ageing and/or skin stress by serial
XX CC analysis of gene expression between mixtures of transcribed and
XX CC optionally translated, genetically encoded factors (A) obtained from
XX CC young and aged skin, to identify that genes that show strong differential
XX CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX CC useful for: identifying markers of skin ageing and/or stress; determining
XX CC skin ageing and/or stress; and identifying or determining the effects of
XX CC pharmaceutical or cosmetic agents for control of skin ageing. The present
XX CC sequence is one of a group of human skin ageing/stress related expressed
XX CC sequence tags (ABQ86246-ABQ87680) of the invention
XX SQ Sequence 11 BP; 3 A; 2 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTCA 2232
Db 10 AAAAGTTTCA 1

RESULT 623
ABQ87282/c
ID ABQ87282 standard; cDNA; 11 BP.
XX AC ABQ87282;
XX

10-SEP-2002 (first entry)
XX DE Human skin stress/ageing related EST SEQ ID NO 1037.
XX DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253773-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015178.
XX PR 03-JAN-2001; 2001DE-01000121.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-528865/56.
XX PT Identifying genes involved in skin stress and aging, useful e.g. in
XX PT screening for cosmetic or therapeutic agents, based on differential gene
XX PT expression.
XX PS Claim 8; Page 80; 325pp; German.
XX CC The invention relates to identifying (M1) genes in vitro that, in humans
XX CC or animals, are important for skin ageing and/or skin stress by serial
XX CC analysis of gene expression between mixtures of transcribed and
XX CC optionally translated, genetically encoded factors (A) obtained from
XX CC young and aged skin, to identify that genes that show strong differential
XX CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX CC useful for: identifying markers of skin ageing and/or stress; determining
XX CC skin ageing and/or stress; and identifying or determining the effects of
XX CC pharmaceutical or cosmetic agents for control of skin ageing. The present
XX CC sequence is one of a group of human skin ageing/stress related expressed
XX CC sequence tags (ABQ86246-ABQ87680) of the invention
XX SQ Sequence 11 BP; 1 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
Db 11 GCCCAAAAGT 2

RESULT 624
ABV64034
ID ABV64034 standard; cDNA; 11 BP.
XX AC ABV64034;
XX 21-OCT-2002 (first entry)
XX DE Human skin EST 1820.
XX DE Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX

```

PR 03-JAN-2001; 2001DE-01000127.
XX (HENK ) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Disclosure; Page 75; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
XX Sequence 11 BP; 6 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 11;
XX Best Local Similarity 90.0%; Pred. No. 3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2223 AAAAGTTACA 2232
DB 2 AAAAGTTACA 11
|||||
|||||

RESULT 625
ABV69946
ID ABV69946 standard; cDNA; 11 BP.
XX
XX AC ABV69946;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 7732.
XX
XX Human; skin; dermatological; vulvular; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK ) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Disclosure; Page 246; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 11;
XX Best Local Similarity 90.0%; Pred. No. 3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAAGTTA 2230
DB 1 CCAAAAAGTTA 10
|||||
|||||

RESULT 626
ABV67422/c
ID ABV67422 standard; cDNA; 11 BP.
XX
XX AC ABV67422;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 5208.
XX
XX Human; skin; dermatological; vulvular; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK ) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Disclosure; Page 169; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 11;
XX Best Local Similarity 90.0%; Pred. No. 3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAAGTTA 2230
DB 1 CCAAAAAGTTA 10
|||||
|||||

```

```

XX
SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
  Query Match      31.1%; Score 8.4; DB 1; Length 11;
  Best Local Similarity 90.0%; Pred. No. 3e+02;
  Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 11 AAAAGATACA 2
  |||||
  |||||

RESULT 627
ABV69109/c
ID ABV69109 standard; cDNA; 11 BP.
XX
AC ABV69109;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 6895.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
PT WPI; 2002-590638/63.
XX
DR WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
PT WPI; 2002-590638/63.
XX
DR In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
FS Disclosure; Page 217; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 1 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
  Query Match      31.1%; Score 8.4; DB 1; Length 11;
  Best Local Similarity 90.0%; Pred. No. 3e+02;
  Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
DB 11 GCAAAAGT 2
  |||||
  |||||

RESULT 628

```

```

ABV66433
ID ABV66433 standard; cDNA; 11 BP.
XX
AC ABV66433;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 4219.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
PT WPI; 2002-590638/63.
XX
DR In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
FS Disclosure; Page 141; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 7 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
  Query Match      31.1%; Score 8.4; DB 1; Length 11;
  Best Local Similarity 90.0%; Pred. No. 3e+02;
  Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
DB 1 GTACCAAAA 10
  |||||
  |||||

RESULT 629
ABV71455
ID ABV71455 standard; cDNA; 11 BP.
XX
AC ABV71455;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 9241.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX

```

OS Homo sapiens.
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Claim 24; Page 297; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 XX Sequence 11 BP; 6 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 2 AAAAGTTACA 11
 RESULT 630
 ABV62525 standard; cDNA; 11 BP.
 AC
 AC ABV62525;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 311.
 DE
 XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhoeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 PN
 XX 11-JUL-2002.
 PD
 XX
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 90; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 XX Sequence 11 BP; 6 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 2 AAAAGTTACA 11
 RESULT 630
 ABV62525 standard; cDNA; 11 BP.
 AC
 AC ABV62525;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 311.
 DE
 XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhoeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 PN
 XX 11-JUL-2002.
 PD
 XX
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 90; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 DB 1 CCAAAAGTTA 10
 RESULT 631
 ABV64573/c
 ID ABV64573 standard; cDNA; 11 BP.
 XX
 AC ABV64573;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 2359.
 DE
 XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhoeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 PN
 XX 11-JUL-2002.
 PD
 XX
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 90; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 DB 1 CCAAAAGTTA 10

XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 XX Disclosure; Page 34; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 DB 1 CCAAAAGTTA 10
 RESULT 631
 ABV64573/c
 ID ABV64573 standard; cDNA; 11 BP.
 XX
 AC ABV64573;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 2359.
 DE
 XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhoeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 PN
 XX 11-JUL-2002.
 PD
 XX
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 90; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 DB 1 CCAAAAGTTA 10

CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 1 A; 3 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 10 AAAAGGTACA 1
 RESULT 632
 ABV66821
 ID ABV66821 standard; cDNA; 11 BP.
 AC ABV66821;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 4607.
 DE
 XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaetic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX WO200253774-A2.
 PN 11-JUL-2002.
 XX
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX 03-JAN-2001; 2001DE-01000127.
 PR
 XX (HENK) HENKEL KGAA.
 PA
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 152; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 6 A; 2 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGT 2228
 DB 1 GACCAAAAGT 10
 RESULT 633
 ABV65066/c
 ID ABV65066 standard; cDNA; 11 BP.
 XX
 XX AC ABV65066;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 2852.
 DE
 XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaetic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX WO200253774-A2.
 PN 11-JUL-2002.
 XX
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX 03-JAN-2001; 2001DE-01000127.
 PR
 XX (HENK) HENKEL KGAA.
 PA
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 104; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 2 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2217 GTGACCAAAA 2226
 DB 10 GTGACCAAAA 1
 RESULT 634
 ABV71994/c
 ID ABV71994 standard; cDNA; 11 BP.
 XX
 XX AC ABV71994;
 XX

PT e.g. skin cancer.
 PS Disclosure; Page 126; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 2 A; 3 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2217 GTGACCAAAA 2226
 Db 11 GTGGCCAAA 2
 RESULT 637
 ABV66721/c
 ID ABV66721 standard; cDNA; 11 BP.
 AC ABV66721;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 4507.
 DE
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
 XX immunosuppressive; antiinflammatory; cyostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 PN 11-JUL-2002.
 PD
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX 03-JAN-2001; 2001DE-01000127.
 PR (HENK) HENKEL KGAA.
 PA Petersohn D, Conradt M, Hofmann K;
 PI WPI; 2002-590638/63.
 DR
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 149; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;

CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 6 A; 2 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACAGGTTT 2237
 Db 11 TTACAGGTTT 2
 RESULT 638
 ABV67158
 ID ABV67158 standard; cDNA; 11 BP.
 XX
 AC ABV67158;
 XX
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 4944.
 DE
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cyostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 PN 11-JUL-2002.
 PD
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX 03-JAN-2001; 2001DE-01000127.
 PR (HENK) HENKEL KGAA.
 PA Petersohn D, Conradt M, Hofmann K;
 PI WPI; 2002-590638/63.
 DR
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 161; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 3 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACC 2222
 Db 1 GAGTGTGACC 10

RESULT 639
 ID ABLV66189 standard; CDNA; 11 BP.
 AC ABLV66189;
 XX
 XX 21-OCT-2002 (first entry)
 XX
 XX Human skin EST 3975.
 XX
 XX Human; skin; dermatological; vulvular; antipsoriatic; antiseborrheic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200253774-A2.
 PN
 XX 11-JUL-2002.
 XX
 XX 20-DEC-2001; 2001WO-EP015179.
 XX
 XX 03-JAN-2001; 2001DE-01000127.
 XX
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Conradt M, Hofmann K;
 PI
 XX WPI; 2002-590638/63.
 DR
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 PT
 XX Disclosure; Page 135; 1345pp; German.
 PS
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 3 A; 2 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02; Mismatches 0; Gaps 0;
 Matches 9; Conservative 0; Indels 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 Db 10 AAAAGTTTCA 1
 RESULT 640
 ID ABLV66189 standard; CDNA; 11 BP.
 AC ABLV66189;
 XX
 XX 30-MAY-2002 (first entry)
 XX
 XX Short human Tumour Endothelial Marker SEQ ID NO 106.
 DE Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
 KW

KW normal endothelial marker; pan-endothelial marker; immunostimulant;
 KW antiangiogenic; tumour; neovascularisation; vascularised tumour;
 KW polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
 KW psoriasis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200210217-A2.
 PN
 XX 07-FEB-2002.
 XX
 XX 01-AUG-2001; 2001WO-US024031.
 XX
 XX 02-AUG-2000; 2000US-0222599P.
 PR
 XX 11-AUG-2000; 2000US-0224360P.
 PR
 XX 11-APR-2001; 2001US-0282850P.
 PR
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA
 XX St Croix B, Kinzler KW, Vogelstein B;
 PI
 XX WPI; 2002-291856/33.
 DR
 XX An isolated molecule comprising an antibody variable region which
 PT specifically binds to an extracellular domain of a tumor endothelial
 PT marker (TEM) protein, useful for inhibiting tumor growth.
 PT
 XX Example 5; Page 20; 331pp; English.
 PS
 XX The invention relates to an isolated molecule comprising an antibody
 CC variable region which specifically binds to an extracellular domain of a
 CC tumour endothelial marker (TEM) protein selected from ABB90732, ABB90740,
 CC ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
 CC proteins have cytostatic, immunostimulant and antiangiogenic activity.
 CC They are useful for inhibiting tumour growth, neovascularisation in subjects
 CC bearing a vascularised tumour, polycystic kidney disease, diabetic
 CC retinopathy, rheumatoid arthritis and psoriasis. Human, mouse and rat TEM
 CC genes and the encoded proteins (ABL92075-ABL92141 and ABB90721-ABB90789)
 CC are disclosed, as are marker oligonucleotide sequences: tumour
 CC endothelial markers (TEM) ABL91996-ABL92041 and ABL92143-ABL92191; normal
 CC endothelial markers (NEM) ABL92042-ABL92074; and pan-endothelial markers
 CC (PEM) ABL91903-ABL91995. The present sequence is that of an
 CC oligonucleotide marker useful to the invention
 XX
 SQ Sequence 11 BP; 3 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02; Mismatches 0; Gaps 0;
 Matches 9; Conservative 0; Indels 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACC 2222
 Db 1 GAGTGTGACC 10
 RESULT 641
 ID ABLV66189 standard; CDNA; 11 BP.
 AC ABLV66189;
 XX
 XX 23-JUL-2003 (first entry)
 XX
 XX Modified promoter associated DNA #3.
 DE Promoter; Bacillus genus microbe; protein production; ds.
 KW
 XX Synthetic.
 OS
 XX JP2002272466-A.
 PN
 XX 24-SEP-2002.
 PD
 XX

PF 15-MAR-2001; 2001JP-00074780.
XX
PR 15-MAR-2001; 2001JP-00074780.
XX
PA (SHOS) SHOWA SANGYO CO.
XX
XX WPI; 2003-345599/33.
DR
XX A modified promoter, an expression cassette, an expression vector, a
PT recombinant microbe, preparation of a protein.
XX
XX Example 5; Page 8; 15pp; Japanese.
PS
XX The invention describes a promoter which can function in a Bacillus genus
CC microbe in which the ratio of adenine to cytosine in the sequence near
CC the 3'-end of said promoter is 0.5 to 2 and the activity of the promoter
CC is higher than that of a natural promoter. The promoter is useful in the
CC preparation of a protein. This sequence represents a modified promoter
CC associated DNA
XX
SQ Sequence 11 BP; 2 A; 4 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2213 GAGTGTGACC 2222
DB 11 GAGAGTGACC 2
RESULT 642
ABX71933
ID ABX71933 standard; DNA; 11 BP.
XX
AC ABX71933;
XX
DT 12-MAR-2003 (first entry)
XX
DE DNA tag used to identify human gene encoding TEM 13.
XX
KW Human; endothelial cell; EC; tumour endothelial cell; TEM; NEM;
KW Tumour endothelial marker; normal endothelial marker; PEM;
KW pan-endothelial marker; polycystic kidney disease; psoriasis;
KW diabetic retinopathy; rheumatoid arthritis; tumour angiogenesis;
KW neocangiogenesis; immune response; cytostatic; antidiabetic;
KW ophthalmological; antirheumatic; antiarthritic; antipsoriatic; ds.
XX
OS Homo sapiens.
XX
PN WO200283874-A2.
XX
PD 24-OCT-2002.
XX
PF 10-APR-2002; 2002WO-US008253.
XX
XX 11-APR-2001; 2001US-0282850P.
PR 06-FEB-2002; 2002US-0354262P.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
PA
XX Carson-Walter E, St Croix B, Kinzler KW, Vogelstein B;
PI WPI; 2003-093016/08.
XX
XX New purified human transmembrane protein, designated as tumor endothelial
PT marker (TEM) 3, useful for detecting, diagnosing or treating tumors,
PT polycystic kidney disease, diabetic retinopathy, rheumatoid arthritis or
PT psoriasis.
XX
PS Disclosure; Page 102; 374pp; English.
XX
XX The present invention relates to a novel method for the isolation of

CC endothelial cells (ECs), and the identification of genes expressed in
CC normal and tumour ECs. Tumour endothelial marker (TEM), normal
CC endothelial marker (NEM), and pan-endothelial marker (PEM) genes are
CC identified in human ECs. The human EC marker proteins and the
CC polynucleotide sequences encoding them are useful for detecting,
CC diagnosing or treating tumours as well as polycystic kidney disease,
CC diabetic retinopathy, rheumatoid arthritis, and psoriasis. They are also
CC useful for inhibiting neocangiogenesis or tumour angiogenesis, for
CC inducing an immune response to tumour endothelial cells in a patient, or
CC for identifying candidate drugs for treating tumours. ABX71828-ABX71999
CC represent DNA tags for human PEM, TEM or NEM genes
XX
SQ Sequence 11 BP; 3 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2213 GAGTGTGACC 2222
DB 1 GAGTGTGACC 10
RESULT 643
ADQ29874
ID ADQ29874 standard; DNA; 11 BP.
XX
AC ADQ29874;
XX
DT 09-SEP-2004 (first entry)
XX
DE Human VRI exon la transcription factor binding fragment #1.
XX
KW ds; VRI receptor; vanilloid receptor type 1; modulator;
KW pain transmission; primary sensory neuron; transcription factor;
KW detection; MZF1; NFKappaB; NFAT; GATA1; sensitivity disorder; analgesia;
KW hypalgesia; hyperalgesia; neuralgia; myalgia; human.
XX
OS Homo sapiens.
XX
PN WO2004053120-A2.
XX
PD 24-JUN-2004.
XX
PF 01-DEC-2003; 2003WO-EP013522.
XX
XX 09-DEC-2002; 2002DE-01057421.
PR
XX (CHEF) GRUENTHAL GMBH.
XX
XX Weihe E, Bieller A, Schaefer MKH;
PI WPI; 2004-468866/44.
XX
XX New nucleic acid that modulates expression of the vanilloid receptor-1,
PT useful for control of pain or sensitivity disorders, comprises sequences
PT from control regions of the receptor gene.
XX
XX Disclosure; Page 44; 68pp; German.
XX
XX This invention describes a novel nucleic acid containing a specific
CC segment having at least one region that modulates expression of the VRI
CC (vanilloid receptor type 1) receptor, or a functional derivative, allele
CC or fragment of this region, or a sequence that hybridises to it under
CC standard conditions. The VRI modulator is derived from one or more of
CC positions 221931-223344 of GenBank AF570399, 31673-36359 of AF63116, or
CC 44731-44231 or 36616-33151 of AF168787 and is involved in transmission of
CC pain, particularly in primary sensory neurons. The invention also
CC describes a vector that contains the VRI modulator, host cells containing
CC this vector (other than human germ or embryonal stem cells) and a method
CC for modulating expression of the VRI receptor by introducing the
CC modulator or the vector into a cell that contains the VRI gene. The
CC products of the invention are used for detecting a transcription factor

mcgarry191-19.rng

Thu Nov 18 12:41:57 2004

CC from its binding to a regulatory sequence (or a double-stranded
CC oligonucleotide fragment of it), e.g. by Western blotting or enzyme-
CC linked immunosorbent assay, particularly for diagnosis of diseases
CC associated with overexpression or underexpression of the transcription
CC factor. The region that modulates VRL receptor expression includes a
CC binding site for a transcription factor, e.g. MZF1, NFKappaB, NFAT or
CC GATA1. The nucleic acids of the invention, or vectors containing them,
CC are used for prevention or treatment of pain, also for treating
CC sensitivity disorders, e.g. analgesia, hyperalgesia or hyperalgesia, also
CC neuralgia and myalgia, that are associated with activity of the VRL
CC receptor. This sequence represents a fragment of human VRL exon 1a DNA
CC which is capable of binding to a transcription factor.

XX
XX
SQ Sequence 11 BP; 5 A; 2 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
DQ 2 GTGACCAGAA 11
|||||

RESULT 644
ADQ29856
ID ADQ29856 standard; DNA; 11 BP.
XX
XX
AC ADQ29856;
XX
DT 09-SEP-2004 (first entry)
XX
DE Murine VRL exon 1a transcription factor binding fragment #52.
XX
KW ds; VRL receptor; vanilloid receptor type 1; modulator;
KW pain transmission; primary sensory neuron; transcription factor;
KW detection; MZF1; NFKappaB; NFAT; GATA1; sensitivity disorder; analgesia;
KW hyperalgesia; hyperalgesia; neuralgia; myalgia; murine.
XX
XX
OS Mus sp.
XX
XX WO2004053120-A2.
XX
XX 24-JUN-2004.
XX
XX 01-DEC-2003; 2003WO-EP013522.
XX
XX 09-DEC-2002; 2002DE-01057421.
XX
XX (CHEF) GRUENENTHAL GMBH.
XX
XX Weihe E, Bieller A, Schaefer MKH;
XX
XX WPI; 2004-468868/44.
XX
XX
XX New nucleic acid that modulates expression of the vanilloid receptor-1,
XX useful for control of pain or sensitivity disorders, comprises sequences
XX from control regions of the receptor gene.
XX
XX
XX Disclosure; Page 43; 68pp; German.

CC This invention describes a novel nucleic acid containing a specific
CC segment having at least one region that modulates expression of the VRL
CC (vanilloid receptor type 1) receptor, or a functional derivative, allele
CC or fragment of this region, or a sequence that hybridizes to it under
CC standard conditions. The VRL modulator is derived from one or more of
CC positions 22191-223344 of GenBank AL670399, 31673-36359 of AL663116, or
CC 4731-4231 or 36116-33131 of AF168787 and is involved in transmission of
CC pain, particularly in primary sensory neurons. The invention also
CC describes a vector that contains the VRL modulator, host cells containing
CC this vector (other than human germ or embryonal stem cells) and a method
CC for modulating expression of the VRL receptor by introducing the
CC modulator or the vector into a cell that contains the VRL gene. The

CC products of the invention are used for detecting a transcription factor
CC from its binding to a regulatory sequence (or a double-stranded
CC oligonucleotide fragment of it), e.g. by Western blotting or enzyme-
CC linked immunosorbent assay, particularly for diagnosis of diseases
CC associated with overexpression or underexpression of the transcription
CC factor. The region that modulates VRL receptor expression includes a
CC binding site for a transcription factor, e.g. MZF1, NFKappaB, NFAT or
CC GATA1. The nucleic acids of the invention, or vectors containing them,
CC are used for prevention or treatment of pain, also for treating
CC sensitivity disorders, e.g. analgesia, hyperalgesia or hyperalgesia, also
CC neuralgia and myalgia, that are associated with activity of the VRL
CC receptor. This sequence represents a fragment of murine VRL exon 1a DNA
CC which is capable of binding to a transcription factor.

XX
XX
SQ Sequence 11 BP; 5 A; 2 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2218 TGACCAAAAG 2227
DQ 1 TGACCAATAG 10
|||||

RESULT 645
ADQ35599/c
ID ADQ35599 standard; DNA; 11 BP.
XX
XX
AC ADQ35599;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 416.
XX
KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
XX
XX Homo sapiens.
XX
XX DE10260931-A1.
XX
XX 08-JUL-2004.
XX
XX 20-DEC-2002; 2002DE-01060931.
XX
XX 20-DEC-2002; 2002DE-01060931.
XX
XX (HENKEL) HENKEL KGAA.
XX
XX Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX Conradt M, Hofmann K;
XX
XX WPI; 2004-518857/50.
XX
XX In vitro identification of genes important for hair-bearing skin, useful
XX for assessing homeostasis and in screening for pharmaceutical or cosmetic
XX agents, based on differential expression analysis.
XX
XX
XX Claim 5; SEQ ID NO 416; 350pp; German.

CC This invention describes a novel in vitro method for identifying genes
CC that are significant for hair-bearing skin in humans. The method
CC comprises recovering, from hair-bearing skin, a first mixture of
CC genetically expressed (transcribed and optionally translated) factors
CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
CC mixture from skin on which hair does not grow and subjecting both
CC mixtures to serial analysis of gene expression (SAGE) to identify those
CC genes for which expression is markedly different between the two types of
CC skin. The invention also describes in vitro methods for determining
CC homeostasis of human hair-bearing skin and for determining activity of
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human hair-bearing skin. A biochip and

CC a test kit comprising a solid support (flexible or rigid) with
CC immobilised probes are also described for determining homeostasis. The
CC hair-bearing skin is from the scalp and the other skin is from the face.
CC The method allows identification of as many as possible of the genes
CC important for hair-bearing skin, and therefore, of a very wide range of
CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
CC human DNA tag fragments used to identify genes associated with hair-
CC bearing skin.
SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
D5 11 AAAAGATACA 2

RESULT 646
ADQ35819
ID ADQ35819 standard; DNA; 11 BP.
XX AC ADQ35819;
XX DT 23-SEP-2004 (first entry)
XX DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 636.
XX KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
XX KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
XX OS Homo sapiens.
XX PN DE10260931-A1.
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060931.
XX PR 20-DEC-2002; 2002DE-01060931.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518857/50.

In vitro identification of genes important for hair-bearing skin, useful
PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
PT agents, based on differential expression analysis.
PS Claim 5; SEQ ID NO 636; 250pp; German.

This invention describes a novel in vitro method for identifying genes
CC that are significant for hair-bearing skin in humans. The method
CC comprises recovering, from hair-bearing skin, a first mixture of
CC genetically expressed (transcribed and optionally translated) factors
CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
CC mixture from skin on which hair does not grow and subjecting both
CC mixtures to serial analysis of gene expression (SAGE) to identify those
CC genes for which expression is markedly different between the two types of
CC skin. The invention also describes in vitro methods for determining
CC homeostasis of human hair-bearing skin and for determining activity of
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
CC a test kit comprising a solid support (flexible or rigid) with
CC immobilised probes are also described for determining homeostasis. The
CC hair-bearing skin is from the scalp and the other skin is from the face.
CC The method allows identification of as many as possible of the genes
CC important for hair-bearing skin, and therefore, of a very wide range of

CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
CC human DNA tag fragments used to identify genes associated with hair-
CC bearing skin.
SQ Sequence 11 BP; 4 A; 3 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
D5 1 GACCAACAGT 10

RESULT 647
ADQ36261/C
ID ADQ36261 standard; DNA; 11 BP.
XX AC ADQ36261;
XX DT 23-SEP-2004 (first entry)
XX DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 1078.
XX KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
XX KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
XX OS Homo sapiens.
XX PN DE10260931-A1.
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060931.
XX PR 20-DEC-2002; 2002DE-01060931.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518857/50.

In vitro identification of genes important for hair-bearing skin, useful
PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
PT agents, based on differential expression analysis.
PS Claim 4; SEQ ID NO 1078; 250pp; German.

This invention describes a novel in vitro method for identifying genes
CC that are significant for hair-bearing skin in humans. The method
CC comprises recovering, from hair-bearing skin, a first mixture of
CC genetically expressed (transcribed and optionally translated) factors
CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
CC mixture from skin on which hair does not grow and subjecting both
CC mixtures to serial analysis of gene expression (SAGE) to identify those
CC genes for which expression is markedly different between the two types of
CC skin. The invention also describes in vitro methods for determining
CC homeostasis of human hair-bearing skin and for determining activity of
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
CC a test kit comprising a solid support (flexible or rigid) with
CC immobilised probes are also described for determining homeostasis. The
CC hair-bearing skin is from the scalp and the other skin is from the face.
CC The method allows identification of as many as possible of the genes
CC important for hair-bearing skin, and therefore, of a very wide range of
CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
CC human DNA tag fragments used to identify genes associated with hair-
CC bearing skin.
SQ Sequence 11 BP; 4 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

QY 2215 GTGTGACCAA 2224 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 10 GTTGACCAA 1

RESULT 648
 ADQ36457
 ID ADQ36457 standard; DNA; 11 BP.
 XX
 AC ADQ36457;
 DT 23-SEP-2004 (first entry)
 XX Human hair-bearing skin-associated DNA fragment SEQ ID NO 1274.
 DE hair-bearing skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
 XX Homo sapiens.
 OS
 PN DE10260931-A1.
 XX
 PD 08-JUL-2004.
 XX
 PF 20-DEC-2002; 2002DE-01060931.
 XX
 PR 20-DEC-2002; 2002DE-01060931.
 XX (HENK) HENKEL KGAA.
 PA
 PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 XX WPI; 2004-518857/50.
 XX
 PT In vitro identification of genes important for hair-bearing skin, useful
 PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 XX
 PS Claim 4; SEQ ID NO 1274; 250pp; German.
 XX
 CC This invention describes a novel in vitro method for identifying genes
 CC that are significant for hair-bearing skin in humans. The method
 CC comprises recovering, from hair-bearing skin, a first mixture of
 CC genetically expressed (transcribed and optionally translated) factors
 CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
 CC mixture from skin on which hair does not grow and subjecting both
 CC mixtures to serial analysis of gene expression (SAGE) to identify those
 CC genes for which expression is markedly different between the two types of
 CC skin. The invention also describes in vitro methods for determining
 CC homeostasis of human hair-bearing skin and for determining activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
 CC a test kit comprising a solid support (flexible or rigid) with
 CC immobilised probes are also described for determining homeostasis. The
 CC hair-bearing skin is from the scalp and the other skin is from the face.
 CC The method allows identification of as many as possible of the genes
 CC important for hair-bearing skin, and therefore, of a very wide range of
 CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
 CC human DNA tag fragments used to identify genes associated with hair-
 CC bearing skin.
 XX
 SQ Sequence 11 BP; 6 A; 2 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAACT 2228
 Db 1 GACCAAACT 10

RESULT 649
 ADQ35882/c
 ID ADQ35882 standard; DNA; 11 BP.
 XX
 AC ADQ35882;
 DT 23-SEP-2004 (first entry)
 XX Human hair-bearing skin-associated DNA fragment SEQ ID NO 699.
 DE hair-bearing skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
 XX Homo sapiens.
 OS
 PN DE10260931-A1.
 XX
 PD 08-JUL-2004.
 XX
 PF 20-DEC-2002; 2002DE-01060931.
 XX
 PR 20-DEC-2002; 2002DE-01060931.
 XX (HENK) HENKEL KGAA.
 PA
 PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 XX WPI; 2004-518857/50.
 XX
 PT In vitro identification of genes important for hair-bearing skin, useful
 PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 XX
 PS Claim 5; SEQ ID NO 699; 250pp; German.
 XX
 CC This invention describes a novel in vitro method for identifying genes
 CC that are significant for hair-bearing skin in humans. The method
 CC comprises recovering, from hair-bearing skin, a first mixture of
 CC genetically expressed (transcribed and optionally translated) factors
 CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
 CC mixture from skin on which hair does not grow and subjecting both
 CC mixtures to serial analysis of gene expression (SAGE) to identify those
 CC genes for which expression is markedly different between the two types of
 CC skin. The invention also describes in vitro methods for determining
 CC homeostasis of human hair-bearing skin and for determining activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
 CC a test kit comprising a solid support (flexible or rigid) with
 CC immobilised probes are also described for determining homeostasis. The
 CC hair-bearing skin is from the scalp and the other skin is from the face.
 CC The method allows identification of as many as possible of the genes
 CC important for hair-bearing skin, and therefore, of a very wide range of
 CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
 CC human DNA tag fragments used to identify genes associated with hair-
 CC bearing skin.
 XX
 SQ Sequence 11 BP; 2 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
 Db 10 GTGACCAAAA 1

```
RESULT 650
ADQ34842/c
ID ADQ34842 standard; DNA; 11 BP.
XX
AC ADQ34842;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human facial skin-associated DNA fragment SEQ ID NO 2932.
XX
KW facial skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX
OS Homo sapiens.
XX
PN DE10260928-A1.
XX
PD 08-JUL-2004.
XX
PF 20-DEC-2002; 2002DE-01060928.
XX
PR 20-DEC-2002; 2002DE-01060928.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
PI Conradt M, Hofmann K;
XX
DR WPI; 2004-518855/50.
XX
PT In vitro identification of genes important for facial skin, useful for
PT assessing homeostasis and in screening for pharmaceutical or cosmetic
PT agents, based on differential expression analysis.
XX
PS Claim 4; SEQ ID NO 2932; 577bp; German.
XX
CC This invention describes a novel in vitro method for identifying genes
CC that are significant for facial skin in humans. The method comprises
CC recovering, from facial skin, a first mixture of genetically expressed
CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
CC their fragments), recovering a second, similar mixture from some other
CC human tissue, preferably skin from a protected area, especially from the
CC breast and subjecting the mixtures to serial analysis of gene expression
CC (SAGE) to identify those genes for which expression is markedly different
CC between facial skin and the other tissue. The invention also describes an
CC in vitro method for determining homeostasis of human facial skin; a test
CC kit which comprises a solid support (flexible or rigid) on which are
CC immobilised probes that bind specifically to the factors of interest and
CC a biochip for determining homeostasis of human facial skin. The products
CC of the invention are also used in a method which determines activity of
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human skin and a screening method for
CC identifying cosmetic and pharmaceutical agents. The method allows
CC identification of as many as possible of the genes important for facial
CC skin and thus of a very wide range of potential therapeutic and cosmetic
CC agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
CC identify the facial skin-associated genes described in the invention.
XX
SQ Sequence 11 BP; 6 A; 2 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 11 TTACAGGTTT 2

RESULT 651
ADQ32411/c
ID ADQ32411 standard; DNA; 11 BP.
XX
```

```
AC ADQ32411;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human facial skin-associated DNA fragment SEQ ID NO 501.
XX
KW facial skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX
OS Homo sapiens.
XX
PN DE10260928-A1.
XX
PD 08-JUL-2004.
XX
PF 20-DEC-2002; 2002DE-01060928.
XX
PR 20-DEC-2002; 2002DE-01060928.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
PI Conradt M, Hofmann K;
XX
DR WPI; 2004-518855/50.
XX
PT In vitro identification of genes important for facial skin, useful for
PT assessing homeostasis and in screening for pharmaceutical or cosmetic
PT agents, based on differential expression analysis.
XX
PS Claim 6; SEQ ID NO 501; 577bp; German.
XX
CC This invention describes a novel in vitro method for identifying genes
CC that are significant for facial skin in humans. The method comprises
CC recovering, from facial skin, a first mixture of genetically expressed
CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
CC their fragments), recovering a second, similar mixture from some other
CC human tissue, preferably skin from a protected area, especially from the
CC breast and subjecting the mixtures to serial analysis of gene expression
CC (SAGE) to identify those genes for which expression is markedly different
CC between facial skin and the other tissue. The invention also describes an
CC in vitro method for determining homeostasis of human facial skin; a test
CC kit which comprises a solid support (flexible or rigid) on which are
CC immobilised probes that bind specifically to the factors of interest and
CC a biochip for determining homeostasis of human facial skin. The products
CC of the invention are also used in a method which determines activity of
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human skin and a screening method for
CC identifying cosmetic and pharmaceutical agents. The method allows
CC identification of as many as possible of the genes important for facial
CC skin and thus of a very wide range of potential therapeutic and cosmetic
CC agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
CC identify the facial skin-associated genes described in the invention.
XX
SQ Sequence 11 BP; 1 A; 3 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
DB 11 GGCCAAAAGT 2

RESULT 652
ADQ32947/c
ID ADQ32947 standard; DNA; 11 BP.
XX
AC ADQ32947;
XX
DT 23-SEP-2004 (first entry)
XX
```

DE Human facial skin-associated DNA fragment SEQ ID NO 1037.
 XX facial skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
 XX Homo sapiens.
 OS
 XX DE10260928-A1.
 PN
 XX 08-JUL-2004.
 PD
 XX 20-DEC-2002; 2002DE-01060928.
 PF
 XX 20-DEC-2002; 2002DE-01060928.
 PR
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 PI
 XX WPI; 2004-518855/50.
 DR
 XX In vitro identification of genes important for facial skin, useful for
 PT assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 PT
 XX Claim 5; SEQ ID NO 1037; 577pp; German.
 PS
 XX This invention describes a novel in vitro method for identifying genes
 CC that are significant for facial skin in humans. The method comprises
 CC recovering from facial skin, a first mixture of genetically expressed
 CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
 CC their fragments), recovering a second, similar mixture from some other
 CC human tissue, preferably skin from a protected area, especially from the
 CC breast and subjecting the mixtures to serial analysis of gene expression
 CC (SAGE) to identify those genes for which expression is markedly different
 CC between facial skin and the other tissue. The invention also describes an
 CC in vitro method for determining homeostasis of human facial skin; a test
 CC kit which comprises a solid support (flexible or rigid) on which are
 CC immobilised probes that bind specifically to the factors of interest and
 CC a biochip for determining homeostasis of human facial skin. The products
 CC of the invention are also used in a method which determines activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human skin and a screening method for
 CC identifying cosmetic and pharmaceutical agents. The method allows
 CC identification of as many as possible of the genes important for facial
 CC skin and thus of a very wide range of potential therapeutic and cosmetic
 CC agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
 CC identify the facial skin-associated genes described in the invention.
 XX Sequence 11 BP; 6 A; 1 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 DB 11 TTACCTGTTT 2
 RESULT 653
 ADQ33099/c
 ID ADQ33099 standard; DNA; 11 BP.
 XX
 AC ADQ33099;
 XX
 DT 23-SEP-2004 (first entry)
 DE Human facial skin-associated DNA fragment SEQ ID NO 1189.
 XX facial skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
 XX Homo sapiens.
 OS
 PN DE10260928-A1.

XX Homo sapiens.
 OS
 XX DE10260928-A1.
 PN
 XX 08-JUL-2004.
 PD
 XX 20-DEC-2002; 2002DE-01060928.
 PF
 XX 20-DEC-2002; 2002DE-01060928.
 PR
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 PI
 XX WPI; 2004-518855/50.
 DR
 XX In vitro identification of genes important for facial skin, useful for
 PT assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 PT
 XX Claim 5; SEQ ID NO 1189; 577pp; German.
 PS
 XX This invention describes a novel in vitro method for identifying genes
 CC that are significant for facial skin in humans. The method comprises
 CC recovering from facial skin, a first mixture of genetically expressed
 CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
 CC their fragments), recovering a second, similar mixture from some other
 CC human tissue, preferably skin from a protected area, especially from the
 CC breast and subjecting the mixtures to serial analysis of gene expression
 CC (SAGE) to identify those genes for which expression is markedly different
 CC between facial skin and the other tissue. The invention also describes an
 CC in vitro method for determining homeostasis of human facial skin; a test
 CC kit which comprises a solid support (flexible or rigid) on which are
 CC immobilised probes that bind specifically to the factors of interest and
 CC a biochip for determining homeostasis of human facial skin. The products
 CC of the invention are also used in a method which determines activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human skin and a screening method for
 CC identifying cosmetic and pharmaceutical agents. The method allows
 CC identification of as many as possible of the genes important for facial
 CC skin and thus of a very wide range of potential therapeutic and cosmetic
 CC agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
 CC identify the facial skin-associated genes described in the invention.
 XX Sequence 11 BP; 1 A; 2 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
 DB 11 AAAAGTTACA 2
 RESULT 654
 ADQ33003
 ID ADQ33003 standard; DNA; 11 BP.
 XX
 AC ADQ33003;
 XX
 DT 23-SEP-2004 (first entry)
 DE Human facial skin-associated DNA fragment SEQ ID NO 1093.
 XX facial skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
 XX Homo sapiens.
 OS
 PN DE10260928-A1.


```
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060928.
XX PR 20-DEC-2002; 2002DE-01060928.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518855/50.
XX PT In vitro identification of genes important for facial skin, useful for
XX PT assessing homeostasis and in screening for pharmaceutical or cosmetic
XX PT agents, based on differential expression analysis.
XX PS Claim 5; SEQ ID NO 1093; 577bp; German.
XX CC This invention describes a novel in vitro method for identifying genes
XX CC that are significant for facial skin in humans. The method comprises
XX CC recovering, from facial skin, a first mixture of genetically expressed
XX CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
XX CC their fragments), recovering a second, similar mixture from some other
XX CC human tissue, preferably skin from a protected area, especially from the
XX CC breast and subjecting the mixtures to serial analysis of gene expression
XX CC (SAGE) to identify those genes for which expression is markedly different
XX CC between facial skin and the other tissue. The invention also describes an
XX CC in vitro method for determining homeostasis of human facial skin; a test
XX CC kit which comprises a solid support (flexible or rigid) on which are
XX CC immobilised probes that bind specifically to the factors of interest and
XX CC a biochip for determining homeostasis of human facial skin. The products
XX CC of the invention are also used in a method which determines activity of
XX CC cosmetic and pharmaceutical agents for use against disorders or
XX CC disturbances of the homeostasis of human skin and a screening method for
XX CC identifying cosmetic and pharmaceutical agents. The method allows
XX CC identification of as many as possible of the genes important for facial
XX CC skin and thus of a very wide range of potential therapeutic and cosmetic
XX CC agents. ADQ31911-ADQ35111 represent human DNA Tag fragments used to
XX CC identify the facial skin-associated genes described in the invention.
XX SQ Sequence 11 BP; 7 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2221 CCAAAAGTTA 2230
Db 1 CCAAAGTAA 10
RESULT 655
ADQ32752
ID ADQ32752 standard; DNA; 11 BP.
XX AC ADQ32752;
XX DT 23-SEP-2004 (first entry)
XX DE Human facial skin-associated DNA fragment SEQ ID NO 842.
XX KW facial skin; human; serial analysis of gene expression; SAGE;
XX KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX OS Homo sapiens.
XX PN DE10260928-A1.
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060928.
```

```
XX PR 20-DEC-2002; 2002DE-01060928.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518855/50.
XX PT In vitro identification of genes important for facial skin, useful for
XX PT assessing homeostasis and in screening for pharmaceutical or cosmetic
XX PT agents, based on differential expression analysis.
XX PS Claim 5; SEQ ID NO 842; 577bp; German.
XX CC This invention describes a novel in vitro method for identifying genes
XX CC that are significant for facial skin in humans. The method comprises
XX CC recovering, from facial skin, a first mixture of genetically expressed
XX CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
XX CC their fragments), recovering a second, similar mixture from some other
XX CC human tissue, preferably skin from a protected area, especially from the
XX CC breast and subjecting the mixtures to serial analysis of gene expression
XX CC (SAGE) to identify those genes for which expression is markedly different
XX CC between facial skin and the other tissue. The invention also describes an
XX CC in vitro method for determining homeostasis of human facial skin; a test
XX CC kit which comprises a solid support (flexible or rigid) on which are
XX CC immobilised probes that bind specifically to the factors of interest and
XX CC a biochip for determining homeostasis of human facial skin. The products
XX CC of the invention are also used in a method which determines activity of
XX CC cosmetic and pharmaceutical agents for use against disorders or
XX CC disturbances of the homeostasis of human skin and a screening method for
XX CC identifying cosmetic and pharmaceutical agents. The method allows
XX CC identification of as many as possible of the genes important for facial
XX CC skin and thus of a very wide range of potential therapeutic and cosmetic
XX CC agents. ADQ31911-ADQ35111 represent human DNA Tag fragments used to
XX CC identify the facial skin-associated genes described in the invention.
XX SQ Sequence 11 BP; 3 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2216 TGTGACCAAA 2225
Db 2 TGTGTCCAAA 11
RESULT 656
AAC93147
ID AAC93147 standard; DNA; 12 BP.
XX AC AAC93147;
XX DT 21-MAR-2001 (first entry)
XX DE Newcastle disease virus virulent strain F protein cDNA 3' end.
XX KW Newcastle disease virus; NDV; RT; reverse transcriptase; virucide;
XX KW vaccine; F protein; ss.
XX OS Newcastle disease virus.
XX PN WO200007218-A1.
XX PD 21-DEC-2000.
XX PF 05-JUN-2000; 2000WO-IB000748.
XX PR 10-JUN-1999; 99ZA-00003896.
XX PA (AGRI-) AGRIC RES COUNCIL.
```

XX	Cohen AS, Viljoen GJ;
PI	WPI; 2001-071275/08.
XX	
DR	
XX	Novel vaccine comprising recombinant DNA molecule coding for F protein of
PT	virulent strain of Newcastle disease virus or its portion, or
PT	bioprecursor, useful for treating diseases caused by Newcastle disease
PT	virus.
PT	
XX	Claim 10; Page 12; 21pp; English.
XX	
CC	The present sequence is claimed in a specification relating to a gene
CC	coding for the F protein of a virulent strain of Newcastle disease virus
CC	(NDV). The F protein is useful for treating diseases caused by virulent
CC	NDV. Serotype sequence specific probes are useful for diagnosing or
CC	detecting virulent NDV in animals. A vaccine including a recombinant
CC	plasmid nucleic acid coding for the F protein of a virulent NDV strain is
CC	capable of raising satisfactory levels of antibody against the F protein
XX	
XX	Sequence 12 BP; 5 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
SQ	
	Query Match 31.1%; Score 8.4; DB 1; Length 12;
	Best Local Similarity 90.0%; Pred. No. 3.3e+02;
	Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2218 TGACCAAAAG 2227
DB	
	3 TGACCAAAAG 12
RESULT 657	
ABH94949/C	
ID	ABH94949 standard; DNA; 12 BP.
XX	
AC	ABH94949;
AC	
XX	22-FEB-2002 (first entry)
DT	
XX	Oligonucleotide primer SEQ ID NO 294942 for detecting SNP TSC0016361.
DE	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
XX	
XX	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB000713.
PF	
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
XX	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
XX	WPI; 2001-657177/75.
DR	
XX	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PT	
XX	
XX	Claim 1; SEQ ID NO 294942; 29pp + Sequence Listing; German.
PS	
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The

```
OY 2228 TTACATGTTT 2237
Db 3 TTAATGTTT 12
RESULT 659
ABH70818
XX ID ABH70818 standard; DNA; 12 BP.
XX AC ABH70818;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 270795 for detecting SNP TSC0002280.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
XX Oligonucleotide primer SEQ ID NO 270795 for detecting SNP TSC0002280.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 270795; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 2227 GTTACATGTTT 2236
Db 2 GTTATGTTT 11
RESULT 660
ABI21917
XX ID ABI21917 standard; DNA; 12 BP.
XX AC ABI21917;
XX
XX 22-FEB-2002 (first entry)
XX
```

```
DE Oligonucleotide primer SEQ ID NO 321890 for detecting SNP TSC0030548.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 321890; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 2 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 2228 TTACATGTTT 2237
Db 1 TTACATTTT 10
RESULT 661
ABH74210
XX ID ABH74210 standard; DNA; 12 BP.
XX AC ABH74210;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 274195 for detecting SNP TSC0003472.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
```


CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 11 TTATATGTTT 2

RESULT 664
ABH84898
ID ABH84898 standard; DNA; 12 BP.
AC ABH84898;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 284891 for detecting SNP TSC0012044.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 284891; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABIO0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTAC 2231
DB 1 CAAAATTAC 10

RESULT 665
ABI10267/C
ID ABI10267 standard; DNA; 12 BP.
XX
AC ABI10267;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 310240 for detecting SNP TSC003881.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 310240; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABIO0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 12 TTATATGTTT 3

RESULT 666
ABI15800
ID ABI15800 standard; DNA; 12 BP.
XX
AC ABI15800;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 315773 for detecting SNP TSC0027088.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIC-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 315773; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 1 TTATATGTTT 10
 RESULT 667
 ABI43356/C
 ID ABI43356 standard; DNA; 12 BP.
 XX AC ABI43356;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 343329 for detecting SNP TSC0043002.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIC-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 351297; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 Db 10 AAAGTTAAAT 1
 RESULT 668
 ABI51324
 ID ABI51324 standard; DNA; 12 BP.
 XX AC ABI51324;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 351297 for detecting SNP TSC0047213.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 05-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIC-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 351297; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 343329; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 Db 10 AAAGTTAAAT 1

RESULT 668
 ABI51324
 ID ABI51324 standard; DNA; 12 BP.
 XX AC ABI51324;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 351297 for detecting SNP TSC0047213.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 05-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIC-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 351297; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
Db 1 TAGATGTTTG 10
|||||

RESULT 669
ABI73035/c
ID ABI73035 standard; DNA; 12 BP.
XX
AC ABI73035;
XX
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 373008 for detecting SNP TSC0059784.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX

FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 373008; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2229 TACATGTTTG 2238
Db 11 TAAATGTTTG 2
|||||

RESULT 670
ABI60884
ID ABI60884 standard; DNA; 12 BP.
XX
AC ABI60884;
XX
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 360857 for detecting SNP TSC0052325.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX

FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 360857; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTT 2229
Db 2 ACCAAAATT 11
|||||

RESULT 671
ABI61879/c
ID ABI61879 standard; DNA; 12 BP.
XX
AC ABI61879;
XX

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 282359; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 0 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2228 TTACATGTTT 2237
XX 12 TTACATTTT 3
XX
XX RESULT 679
XX ABH83243
XX ID ABH83243 standard; DNA; 12 BP.
XX AC ABH83243;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 283236 for detecting SNP TSC0011220.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal, respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 282356; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2223 AAAAGTTTACA 2232
XX 2 AAAACTTACA 11
XX
XX RESULT 680
XX ABI39437/C
XX ID ABI39437 standard; DNA; 12 BP.
XX AC ABI39437;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 339410 for detecting SNP TSC0040990.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal, respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 339410; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

XX WO200177384-A2.
PN 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX Claim 1; SEQ ID NO 345811; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
DB 11 TTATATGTTT 2
RESULT 684
ABI55931/C
ID ABI55931 standard; DNA; 12 BP.
AC ABI55931;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 355904 for detecting SNP TSC0049863.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
PN 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX Claim 1; SEQ ID NO 355904; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
DB 11 TTATATGTTT 2
RESULT 684
ABI55931/C
ID ABI55931 standard; DNA; 12 BP.
AC ABI55931;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 355904 for detecting SNP TSC0049863.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
PN 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX Claim 1; SEQ ID NO 355904; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
DB 11 TTATATGTTT 2
RESULT 685
ABI56634/C
ID ABI56634 standard; DNA; 12 BP.
AC ABI56634;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 356607 for detecting SNP TSC0050219.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
PN 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX Claim 1; SEQ ID NO 356607; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTAC 2231
DB 11 CAAAATTAC 2
RESULT 685
ABI56634/C
ID ABI56634 standard; DNA; 12 BP.
AC ABI56634;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 356607 for detecting SNP TSC0050219.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
PN 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX Claim 1; SEQ ID NO 356607; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTAC 2231
DB 11 CAAAATTAC 2

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTAC 2231
 Db 12 CAAAAGTTAC 3
 ||||| |||||

RESULT 686

ABI70972
 ID ABI70972 standard; DNA; 12 BP.

XX AC
 XX ABI70972;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 370945 for detecting SNP TSC0058486.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 370945; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTAC 2231
 Db 3 CAAAAGTTAC 12
 ||||| |||||

RESULT 687

ABI73521/c
 ID ABI73521 standard; DNA; 12 BP.

XX AC
 XX ABI73521;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 373494 for detecting SNP TSC0060118.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 373494; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233
 Db 11 AAATTACAT 2
 ||||| |||||

RESULT 688

ABI75085/c
 ID ABI75085 standard; DNA; 12 BP.

XX AC
 XX ABI75085;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 375058 for detecting SNP TSC0061049.
DE
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
PA
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 375058; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: the sequence
CC data for this patent did not form part of the invention. NOTE: the sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e-02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2332
DB 11 AAAAATTACA 2

RESULT 689
ABI78626/c
ID ABI78626 standard; DNA; 12 BP.
XX
AC ABI78626;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 378599 for detecting SNP TSC0062862.
XX
KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 378599; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the invention. NOTE: The sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e-02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAAGTTTACAT 2233
DB 11 AAAAATTACAT 2

RESULT 690
ABH68239
ID ABH68239 standard; DNA; 12 BP.
XX
AC ABH68239;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 268216 for detecting SNP TSC0000987.
XX
KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX PS Claim 1; SEQ ID NO 268216; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 2 AAAAATTACA 11
|||||

RESULT 691

AB103629
ID ABI03629 standard; DNA; 12 BP.

XX AC AB103629;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 303602 for detecting SNP TSC0020547.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 303602; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 2 AAAAATTACA 11
|||||

RESULT 691

AB103629
ID ABI03629 standard; DNA; 12 BP.

XX AC AB103629;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 303602 for detecting SNP TSC0020547.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 303602; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAATTACAT 2233
Db 2 AAAATTATAT 11
|||||

RESULT 692

ABH79574/C
ID ABH79574 standard; DNA; 12 BP.

XX AC ABH79574;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 279567 for detecting SNP TSC0007512.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 279567; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 12 TTATATGTTT 3
|||||


```

RESULT 693
ABI07513
ID ABI07513 standard; DNA; 12 BP.
XX AC
XX ABI07513;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 307486 for detecting SNP TSC0022521.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS
XX Claim 1; SEQ ID NO 307486; 29pp + Sequence Listing; German.
XX CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2220 ACCAAAGCTT 2229
XX DB 2 ACCAAATTT 11
XX RESULT 694
ABI07790
ID ABI07790 standard; DNA; 12 BP.
XX AC
XX ABI07790;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 307763 for detecting SNP TSC0022574.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS
XX Claim 1; SEQ ID NO 307486; 29pp + Sequence Listing; German.
XX CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2220 ACCAAAGCTT 2229
XX DB 2 ACCAAATTT 11
XX RESULT 695
ABI48543/C
ID ABI48543 standard; DNA; 12 BP.
XX AC
XX ABI48543;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 348516 for detecting SNP TSC0045629.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.

```

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS
XX Claim 1; SEQ ID NO 307763; 29pp + Sequence Listing; German.
XX CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2223 AAAAGTTTACA 2232
XX DB 3 AAAAATTACA 12
XX RESULT 695
ABI48543/C
ID ABI48543 standard; DNA; 12 BP.
XX AC
XX ABI48543;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 348516 for detecting SNP TSC0045629.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.

```

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 348516; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGATTACAT 2233
 DB 11 AAGATTACAT 2
 RESULT 696
 AB153698/c
 ID AB153698 standard; DNA; 12 BP.
 AC AB153698;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 353671 for detecting SNP TSC0048648.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 353671; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2229 TACATGTTTG 2238
 DB 10 TAAATGTTTG 1
 RESULT 697
 ABI70210
 ID ABI70210 standard; DNA; 12 BP.
 XX AC ABI70210;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 370183 for detecting SNP TSC0058045.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 370183; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

OS Homo sapiens.
XX
PN WC00177384-A2.

XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 267604; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTT 2229
Db 12 ACCAAAGTT 3
RESULT 701
ABH70324/c
ID ABH70324 standard; DNA; 12 BP.
XX AC ABH70324;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 270301 for detecting SNP TSC0002082.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 270301; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
Db 10 TTACATGTTT 1
RESULT 702
ABH82215
ID ABH82215 standard; DNA; 12 BP.
XX AC ABH82215;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 282208 for detecting SNP TSC0010580.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 282208; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
SQ

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACA 2232
Db 1 AAAAATTACA 10

RESULT 703
ABH86310/c
ID ABH86310 standard; DNA; 12 BP.
XX
AC ABH86310;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 286303 for detecting SNP TSC0012663.
DE
DE SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 286303; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237

Db 10 TTACGTTT 1

RESULT 704
ABI12868/c
ID ABI12868 standard; DNA; 12 BP.
XX
AC ABI12868;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 312841 for detecting SNP TSC0025330.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 312841; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2229 TACATGTTT 2238
Db 11 TATATGTTT 2

RESULT 705
ABI41815
ID ABI41815 standard; DNA; 12 BP.
XX
AC ABI41815;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 341788 for detecting SNP TSC0042229.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 341788; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 DB 1 AAAATTACAT 10
 RESULT 706
 ID ABI49149/C
 AC
 AC ABI49149;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 349122 for detecting SNP TSC0045928.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX Claim 1; SEQ ID NO 369127; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 DB 1 AAAATTACAT 10
 RESULT 705
 ID ABI49149/C
 AC
 AC ABI49149;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 349122 for detecting SNP TSC0057460.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX Claim 1; SEQ ID NO 369127; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 12 TTACATGTTT 3
 RESULT 707
 ID ABI69154
 AC
 AC ABI69154;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 369127 for detecting SNP TSC0057460.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 369127; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 12 TTACATGTTT 3

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2228 TTACATGTTT 2237
Db 1 TTACATGTTT 10
|||||

RESULT 708
ABI74582/C
ID ABI74582 standard; DNA; 12 BP.
XX AC ABI74582;
XX AC ABI74582;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 374555 for detecting SNP TSC0007192.
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 374555; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2217 GTGACCAAAA 2226
Db 12 GTAACCAAAA 3
|||||

RESULT 709
ABH69592
ID ABH69592 standard; DNA; 12 BP.
XX AC ABH69592;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 269569 for detecting SNP TSC0001808.
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 269569; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2228 TTACATGTTT 2237
Db 1 TTACATGTTT 10
|||||

RESULT 710

ABH74068
ID ABH74068 standard; DNA; 12 BP.
AC ABH74068;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide primer SEQ ID NO 274053 for detecting SNP TSC0003410.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX W0200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 274053 for detecting SNP TSC0003579.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX W0200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 274053; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 1 G; 4 T; 0 U; 0 Other;
SQ
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 223 AAAAGTTTACA 2232
DB 3 AAAAGTTTAAA 12
RESULT 711
ABH74532/c
ID ABH74532 standard; DNA; 12 BP.
XX
XX
AC ABH74532;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 274517 for detecting SNP TSC0003579.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX W0200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 274053; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 223 AAAAGTTTACA 2232
DB 3 AAAAGTTTAAA 12
RESULT 711
ABH74532/c
ID ABH74532 standard; DNA; 12 BP.
XX
XX
AC ABH74532;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 274517 for detecting SNP TSC0003579.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX W0200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI

OS Homo sapiens.
XX W0200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 274517; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 223 AAAAGTTTACA 2232
DB 12 AAAAATTACA 3
RESULT 712
ABH99676/c
ID ABH99676 standard; DNA; 12 BP.
XX
XX
AC ABH99676;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 299669 for detecting SNP TSC0018671.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX W0200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI

XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 299669; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2232
 Db 10 AAAATTACAT 1
 RESULT 713
 ABH75004
 ID ABH75004 standard; DNA; 12 BP.
 AC ABH75004;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 274991 for detecting SNP TSC0003754.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 274991; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAAGTTACAT 2233
 Db 3 AAAATTACAT 12
 RESULT 714
 ABI25982
 ID ABI25982 standard; DNA; 12 BP.
 AC ABI25982;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 325955 for detecting SNP TSC0032823.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 325955; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTAC 2231
 ID ABI26700 standard; DNA; 12 BP.
 AC ABI26700;
 XX
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 326673 for detecting SNP TSC0033216.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 326673; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
 ID ABI44041/C
 AC ABI44041 standard; DNA; 12 BP.
 XX
 XX
 XX 12 AAAAGTTAGA 3
 DE
 XX
 XX RESULT 716
 ABI44041/C
 ID ABI44041 standard; DNA; 12 BP.
 XX
 XX
 XX ABI44041;
 XX 18-OCT-2001.

DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 344014 for detecting SNP TSC0043333.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 344014; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2220 ACCAAGTTT 2229
 Db 10 ACCAAGTTT 1
 DE
 XX
 XX RESULT 717
 ABI54160
 ID ABI54160 standard; DNA; 12 BP.
 XX
 XX
 XX ABI54160;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 354133 for detecting SNP TSC0001249.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB0000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 354133; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
Db 2 AAAAATTACA 11
|||||

RESULT 718
ABI55384
ID ABI55384 standard; DNA; 12 BP.
AC
AC ABI55384;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 355357 for detecting SNP TSC0006294.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB0000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PT methylation status.
XX
XX Claim 1; SEQ ID NO 355357; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
Db 1 CCAAAAGTTA 10
|||||

RESULT 719
ABI70168/C
ID ABI70168 standard; DNA; 12 BP.
XX
XX ABI70168;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 370141 for detecting SNP TSC0058018.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB0000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 370141; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237
 Db 11 TTACATGTTT 2

RESULT 720
 ABI59356/C

ID ABI59356 standard; DNA; 12 BP.

XX AC ABI59356;

XX XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 359329 for detecting SNP TSC0051569.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 359329; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2225 AAGTTACATG 2234
 Db 11 AAGTTAAATG 2

RESULT 721

ABI73271
 ID ABI73271 standard; DNA; 12 BP.

XX AC ABI73271;

XX XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 373244 for detecting SNP TSC0059921.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO:373244; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACA 2232
 Db 1 AAAAGTTTACA 10

RESULT 722

ABI22008
 ID ABI22008 standard; DNA; 12 BP.

XX AC ABI22008;

XX XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 321981 for detecting SNP TSC0030585.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 321981; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGT 2235
 Db 1 AGTTATATGT 10
 RESULT 723
 ABI07647
 ID ABI07647 standard; DNA; 12 BP.
 AC
 AC ABI07647;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 307620 for detecting SNP TSC0022594.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 307620; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 Db 3 AAAACTTACA 12
 RESULT 724
 ABH86376/c
 ID ABH86376 standard; DNA; 12 BP.
 AC
 AC ABH86376;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 286369 for detecting SNP TSC0012695.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 286369; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 11 TAGATGTTTG 2

RESULT 725
ABI44219
ID ABI44219 standard; DNA; 12 BP.
AC ABI44219;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 344192 for detecting SNP TSC0043435.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
AC
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 344192; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 1 TATATGTTTG 10

RESULT 726
ABI45183
ID ABI45183 standard; DNA; 12 BP.
AC ABI45183;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 345156 for detecting SNP TSC0043898.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
AC
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 345156; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
DB 3 CCAAAAGTTA 12

RESULT 727
ABI55245
ID ABI55245 standard; DNA; 12 BP.

```
XX AC ABI55245;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 355218 for detecting SNP TSC0008094.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 355218; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2221 CCAAAAGTTA 2230
XX DB ||||| |||
XX 2 CCAAAAATTA 11
XX RESULT 728
XX ABI63409/C
XX ID ABI63409 standard; DNA; 12 BP.
XX AC ABI63409;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 353382 for detecting SNP TSC0053815.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
```

```
PN WO200177384-A2.
XX 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 363382; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2223 AAAAGTTACA 2232
XX DB ||||| |||
XX 10 AAAACTTACA 1
XX RESULT 729
XX ABI80489/C
XX ID ABI80489 standard; DNA; 12 BP.
XX AC ABI80489;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 380462 for detecting SNP TSC0063834.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 380462; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
DB 10 GTTAGATGTT 1

RESULT 730
ABI25674
ID ABI25674 standard; DNA; 12 BP.
XX
AC ABI25674;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 325647 for detecting SNP TSC0032642.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 325647; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTG 2238
DB 2 TATATGTTG 11

RESULT 731
ABI27809
ID ABI27809 standard; DNA; 12 BP.
XX
AC ABI27809;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 327782 for detecting SNP TSC0033890.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 327782; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```

QY      2226 AGTACATGT 2235
Db      2 AGTTATATGT 11
|||||
RESULT 732
ABH78190/C
ID      ABH78190 standard; DNA; 12 BP.
XX      AC
XX      ABH78190;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 278183 for detecting SNP TSC0005767.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
FN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 278183 for detecting SNP TSC0005767.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
FN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPiG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
PI      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 278183; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACA 2232
Db      11 AAAACTTACA 2
|||||
RESULT 733
ABI30496/C
ID      ABI30496 standard; DNA; 12 BP.
XX      AC
XX      ABI30496;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 307745 for detecting SNP TSC0022660.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
FN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.

```

```

DE      Oligonucleotide primer SEQ ID NO 330469 for detecting SNP TSC0035544.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
FN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPiG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
PI      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 330469; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACA 2232
Db      12 AAAACTTACA 3
|||||
RESULT 734
ABI07772
ID      ABI07772 standard; DNA; 12 BP.
XX
AC      ABI07772;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 307745 for detecting SNP TSC0022660.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
FN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.

```

XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 307745; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 4 A; 1 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2212 AGAGTGAC 2221
 DB 3 AGAGTGAC 12
 |||||
 |||||
 RESULT 735
 ABI16233/C
 ID ABI16233 standard; DNA; 12 BP.
 XX
 XX ABI16233;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 316206 for detecting SNP TSC0027332.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 316206; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 10 TTACATGTTT 1
 |||||
 |||||
 RESULT 736
 ABI50633
 ID ABI50633 standard; DNA; 12 BP.
 XX
 XX ABI50633;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 350606 for detecting SNP TSC0010551.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 350606; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
	Query Match 31.1%; Score 8.4; DB 1; Length 12;
	Best Local Similarity 90.0%; Pred. No. 3.3e+02;
	Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	2224 AAAGTTACAT 2233
Dd	1 AAAAGTTATAT 10
RESULT 737	
ABI69035	
ID	ABI69035 standard; DNA; 12 BP.
XX	AC
XX	ABI69035;
DT	22-FEB-2002 (first entry)
DE	Oligonucleotide primer SEQ ID NO 369008 for detecting SNP TSC0057399.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
PV	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	(EPIG-) EPIGENOMICS AG.
PA	Olek A, Piepenbrock C, Berlin K;
PI	
XX	WPI; 2001-657177/75.
DR	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 369008; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
	Query Match 31.1%; Score 8.4; DB 1; Length 12;
	Best Local Similarity 90.0%; Pred. No. 3.3e+02;
	Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	2227 GTTACATGTT 2236
Dd	3 GTTAAATGTT 12
RESULT 739	
ABI94461/C	
ID	ABI94461 standard; DNA; 12 BP.
XX	AC
XX	ABI94461;
DT	22-FEB-2002 (first entry)
DE	Oligonucleotide primer SEQ ID NO 294454 for detecting SNP TSC0016128.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 294454; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABIO0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 2217 GTGACCAAAA 2236
 Db 11 GTACCAAAA 2
 RESULT 740
 ABI19759
 ID ABI19759 standard; DNA; 12 BP.
 XX AC ABI19759;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 319732 for detecting SNP TSC0029382.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 302095; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABIO0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 2217 GTGACCAAAA 2236
 Db 11 GTACCAAAA 2
 RESULT 740
 ABI19759
 ID ABI19759 standard; DNA; 12 BP.
 XX AC ABI19759;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 319732 for detecting SNP TSC0029382.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 319732; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABIO0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 2229 TACATGTTG 2238
 Db 1 TAAATGTTG 10
 RESULT 741
 ABI02122/c
 ID ABI02122 standard; DNA; 12 BP.
 XX AC ABI02122;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 302095 for detecting SNP TSC0019789.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 302095; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAACTTACAT 2233
DB 12 AAATTACAT 3

RESULT 742
ABI03729
ID ABI03729 standard; DNA; 12 BP.
XX
AC ABI03729;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 303702 for detecting SNP TSC0020611.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 303702; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 1 AAAAATTACA 10

RESULT 743
ABI31308
ID ABI31308 standard; DNA; 12 BP.
XX
AC ABI31308;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 331281 for detecting SNP TSC0036096.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 331281; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 3 AAAAATTACA 12

RESULT 744
ABI43477
ID ABI43477 standard; DNA; 12 BP.
XX
AC ABI43477;

XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 343450 for detecting SNP TSC0006453.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 343450; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Claim 1; SEQ ID NO 343450; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 DB 1 AAAAGTTAAA 10
 RESULT 745
 ABI44147
 ID ABI44147 standard; DNA; 12 BP.
 XX AC ABI44147;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 344120 for detecting SNP TSC0043393.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 344120; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 DB 1 AAAAGTTAAA 10
 RESULT 745
 ABI44147
 ID ABI44147 standard; DNA; 12 BP.
 XX AC ABI44147;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 344120 for detecting SNP TSC0043393.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 344120; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 TACATGTTTG 2238
 DB 3 TATATGTTTG 12
 RESULT 746
 ABI45966/c
 ID ABI45966 standard; DNA; 12 BP.
 XX AC ABI45966;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 345939 for detecting SNP TSC0044293.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 345939; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 0 C; 1 G; 2 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2228 TTACATGTTT 2237
DB 10 TTACATGTTT 1
XX
RESULT 747
ABI70868
ID ABI70868 standard; DNA; 12 BP.
XX
AC ABI70868;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 370841 for detecting SNP TSC0058426.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 370841; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2229 TACATGTTTG 2238
DB 1 TACATGTTTG 10
XX
RESULT 748
ABI57581
ID ABI57581 standard; DNA; 12 BP.
XX
AC ABI57581;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 357554 for detecting SNP TSC0007336.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 357554; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2228 TTACATGTTT 2237
DB 10 TTACATGTTT 10
XX

```

Db 2 TTACATGTTT 11

RESULT 749
ABI74058
ID ABI74058 standard; DNA; 12 BP.
XX AC ABI74058;
XX 22-FEB-2002 (first entry)
DT XX
DE XX
DE XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 374031; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2225 AAGTTACATG 2234
DB 3 AAGTTACATG 12
RESULT 750
ABI76381
ID ABI76381 standard; DNA; 12 BP.
XX AC ABI76381;
XX 22-FEB-2002 (first entry)
DT XX
DE XX
DE XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX Oligonucleotide primer SEQ ID NO 376354 for detecting SNP TSC0061749.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 376354; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2229 TACATGTTTG 2238
DB 1 TAAATGTTTG 10
RESULT 751
ABI63441
ID ABI63441 standard; DNA; 12 BP.
XX AC ABI63441;
XX 22-FEB-2002 (first entry)
DT XX
DE XX
DE XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX Oligonucleotide primer SEQ ID NO 363414 for detecting SNP TSC0053832.

XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 363414; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 1 C; 2 G; 3 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 Db 1 CGAAAAGTTA 10
 RESULT 752
 ABI80040/C
 ID ABI80040 standard; DNA; 12 BP.
 XX AC ABI80040;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 380013 for detecting SNP TSC0063595.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380013; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 Db 10 AAAATTACAT 1
 RESULT 753
 ABI80160
 ID ABI80160 standard; DNA; 12 BP.
 XX AC ABI80160;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 380133 for detecting SNP TSC0063654.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380133; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 Db 10 AAAATTACAT 1
 RESULT 753
 ABI80160
 ID ABI80160 standard; DNA; 12 BP.
 XX AC ABI80160;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 380133 for detecting SNP TSC0063654.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380133; 29pp + Sequence Listing; German.

XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 283882; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTT 2236
Db 1 GTTACATGTT 10
RESULT 758
ABI39196
ID ABI39196 standard; DNA; 12 BP.
XX AC ABI39196;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 339169 for detecting SNP TSC0040877.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 339169; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 300043; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2225 AAGTTACATG 2234
Db 12 AAGTTACATG 3
RESULT 757
ABH83889
ID ABH83889 standard; DNA; 12 BP.
XX AC ABH83889;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 283882 for detecting SNP TSC0011547.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 300043; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 2 TTACATGTTT 11
 RESULT 759
 ABI40471
 ID ABI40471 standard; DNA; 12 BP.
 AC ABI40471;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 340444 for detecting SNP TSC0041532.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 XX Claim 1; SEQ ID NO 340444; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 2 TTACATGTTT 11
 RESULT 761
 ABI49451
 ID ABI49451 standard; DNA; 12 BP.
 AC ABI49451;
 XX
 DT 22-FEB-2002 (first entry)

QY 2222 CAAAAGTTAC 2231
 Db 3 CAAAAGTTAC 12
 RESULT 760
 ABH92093/C
 ID ABH92093 standard; DNA; 12 BP.
 XX
 AC ABH92093;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 292086 for detecting SNP TSC0015079.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 XX Claim 1; SEQ ID NO 292086; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 Db 12 AAAAGTTTACA 3
 RESULT 761
 ABI49451
 ID ABI49451 standard; DNA; 12 BP.
 AC ABI49451;
 XX
 DT 22-FEB-2002 (first entry)

```

XX DE Oligonucleotide primer SEQ ID NO 349424 for detecting SNP TSC0046132.
XX DE
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX WO200177384-A2.
XX PN
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 349424; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTACA 2232
XX Db 3 AAAAGTTATA 12
XX
XX RESULT 762
XX ABI68097/C
XX ID ABI68097 standard; DNA; 12 BP.
XX AC
XX AC ABI68097;
XX DT
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 349424 for detecting SNP TSC0056733.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN
XX XX
XX PD 18-OCT-2001.
XX XX

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX XX WPI; 2001-657177/75.
XX
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 368070; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2220 ACCAAAAGTT 2229
XX Db 10 ACCAAAAGTT 1
XX
XX RESULT 763
XX ABI68747/C
XX ID ABI68747 standard; DNA; 12 BP.
XX AC
XX AC ABI68747;
XX DT
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 368720 for detecting SNP TSC0057183.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX XX WPI; 2001-657177/75.
XX
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

XX PS Claim 1; SEQ ID NO 368720; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2217 GTGACCAAAA 2226
 DB 10 GTAACCAAAA 1
 RESULT 764
 ABI56919/c
 ID ABI56919 standard; DNA; 12 BP.
 XX AC ABI56919;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 356892 for detecting SNP TSC0050363.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 356892; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2217 GTGACCAAAA 2226
 DB 10 GTAACCAAAA 1
 RESULT 764
 ABI56919/c
 ID ABI56919 standard; DNA; 12 BP.
 XX AC ABI56919;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 356892 for detecting SNP TSC0050363.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 356892; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 DB 12 AAAGTTACAT 3
 RESULT 765
 ABI62778/c
 ID ABI62778 standard; DNA; 12 BP.
 XX AC ABI62778;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 362751 for detecting SNP TSC0053419.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 362751; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 DB 10 CCAAAAGTTA 1

RESULT 766	
ABI77268	
ID	ABI77268 standard; DNA; 12 BP.
XX	AC
XX	ABI77268;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide primer SEQ ID NO 377241 for detecting SNP TSC0010490.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
XX	
DE	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
XX	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 365553; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
	Query Match 31.1%; Score 8.4; DB 1; Length 12;
	Best Local Similarity 90.0%; Pred. No. 3.3e+02;
	Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2221 CCAAAAGTTA 2230
Db	
	11 CCAAAAGTTA 2
RESULT 768	
ABI66101/c	
ID	ABI66101 standard; DNA; 12 BP.
XX	AC
XX	ABI66101;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide primer SEQ ID NO 366074 for detecting SNP TSC0055521.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	

XX PI Olek A, Piepenbrock C, Berlin K;
 XX WI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 366074; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, cardiovascular and metabolic disorders. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTACAT 2233
 Db 10 AAGTTAAAT 1
 RESULT 769
 ABI80039/C
 ID ABI80039 standard; DNA; 12 BP.
 AC ABI80039;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 380012 for detecting SNP TSC0063595.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380012; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTACAT 2233
 Db 10 AAGTTACAT 1
 RESULT 770
 ABH71218/C
 ID ABH71218 standard; DNA; 12 BP.
 AC ABH71218;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 271195 for detecting SNP TSC0002423.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 271195; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 302264; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2223 AAAAGTTACA 2232
 Db 3 AAAACTTACA 12
 RESULT 774
 AB103272/c
 ID AB103272 standard; DNA; 12 BP.
 AC AB103272;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 303245 for detecting SNP TSC0020406.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 302264; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 303245; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2221 CCAAAAGTTA 2230
 Db 11 CCAAAACTTA 2
 RESULT 775
 ABH78244/c
 ID ABH78244 standard; DNA; 12 BP.
 AC ABH78244;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 278237 for detecting SNP TSC0005824.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 278237; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAGAATTAC 2231
Db 11 CAATAATAC 2
|||||
|||||

RESULT 776
ABI30491
ID ABI30491 standard; DNA; 12 BP.
XX AC ABI30491;
XX AC ABI30491;
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 330464 for detecting SNP TSC0035540.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 330464 for detecting SNP TSC0035540.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330464; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2224 AAAGTTACAT 2233

Db 3 AAAATTACAT 12
|||||
|||||

RESULT 777
ABH80892
ID ABH80892 standard; DNA; 12 BP.
XX AC ABH80892;
XX AC ABH80892;
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 280885 for detecting SNP TSC0009196.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 280885; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACA 2232
Db 3 AAAAATTACA 12
|||||
|||||

RESULT 778
ABI08067/c
ID ABI08067 standard; DNA; 12 BP.
XX AC ABI08067;
XX AC ABI08067;
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 308040 for detecting SNP TSC0022851.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 DN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 308040; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 10 TTACGTTT 1
 RESULT 779
 ABH84767
 ID ABH84767 standard; DNA; 12 BP.
 AC ABH84767;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 284760 for detecting SNP TSC0011987.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 DN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 308040; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 10 TTACGTTT 1
 RESULT 779
 ABH84767
 ID ABH84767 standard; DNA; 12 BP.
 AC ABH84767;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 284760 for detecting SNP TSC0011987.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 DN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 308040; 29pp + Sequence Listing; German.
 XX

PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 284760; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 DB 1 AAAATTTTACA 10
 RESULT 780
 ABT37813/C
 ID ABT37813 standard; DNA; 12 BP.
 AC ABT37813;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 337786 for detecting SNP TSC0040076.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 DN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 337786; 29pp + Sequence Listing; German.
 XX

```
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
Db 11 TTAATGTTT 2
RESULT 781
ABI14259
XX ID ABI14259 standard; DNA; 12 BP.
XX AC ABI14259;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 314232 for detecting SNP TSC0026218.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 314232; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
```

```
XX SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2224 AAAGTTACAT 2233
Db 2 AAAATTACAT 11
RESULT 782
ABH90009/C
XX ID ABH90009 standard; DNA; 12 BP.
XX AC ABH90009;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 290002 for detecting SNP TSC0014182.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 290002; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2224 AAAGTTACAT 2233
Db 10 AAAATTACAT 1
RESULT 783
```

```

ABI49736/c
ID  ABI49736 standard; DNA; 12 BP.
XX
AC  ABI49736;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 349709 for detecting SNP TSC0046267.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 349709; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABIS2073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2227 GTTACATGTT 2236
DB  |||||
   10 GTTAAATGTT 1

RESULT 784
ABI49736/c
ID  ABI49736 standard; DNA; 12 BP.
XX
AC  ABI49736;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 349709 for detecting SNP TSC0046267.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;

```

```

OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 374856; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABIS2073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2228 TTACATGTTT 2237
DB  |||||
   10 TTAATGTTT 1

RESULT 785
ABI18050/c
ID  ABI18050 standard; DNA; 12 BP.
XX
AC  ABI18050;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 318023 for detecting SNP TSC0028398.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;

```

```

XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 318023; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGT 2235
DB 11 AGTTAAATGT 2
RESULT 786
ABH93224/c
ID ABH93224 standard; DNA; 12 BP.
XX
XX ABH93224;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 293217 for detecting SNP TSC0015548.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 293217; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

```

```

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2221 CCAAAAGTTA 2230
DB 10 CCAAAATTA 1
RESULT 787
ABH68672
ID ABH68672 standard; DNA; 12 BP.
XX
XX ABH68672;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 268649 for detecting SNP TSC0001276.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 268649; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;

```

```
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
Db 1 TTAAATGTTT 10

RESULT 788
ABH74218/C
ID ABH74218 standard; DNA; 12 BP.
XX
AC ABH74218;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 274203 for detecting SNP TSC0003475.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 274203; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2236
Db 10 GTTAAATGTTT 1

RESULT 789
ABH99975/C
ID ABH99975 standard; DNA; 12 BP.
XX
AC ABH99975;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275352 for detecting SNP TSC0003869.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 274203; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2236
Db 10 GTTAAATGTTT 1

RESULT 789
ABH99975/C
ID ABH99975 standard; DNA; 12 BP.
XX
AC ABH99975;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275352 for detecting SNP TSC0003869.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 299968; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2236
Db 12 GTTAGATGTTT 3

RESULT 790
ABH75361
ID ABH75361 standard; DNA; 12 BP.
XX
AC ABH75361;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275352 for detecting SNP TSC0003869.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
```

```
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 299968 for detecting SNP TSC0018823.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 299968; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2236
Db 12 GTTAGATGTTT 3

RESULT 790
ABH75361
ID ABH75361 standard; DNA; 12 BP.
XX
AC ABH75361;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275352 for detecting SNP TSC0003869.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
```


CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTTACA 2232
 DB 1 AAAAATTACA 10

RESULT 793

ABI07539
 ID ABI07539 standard; DNA; 12 BP.

XX AC ABI07539;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 307512 for detecting SNP TSC0022534.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS Claim 1; SEQ ID NO 307512; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 9 A; 0 C; 1 G; 2 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTTACA 2232
 DB 2 AAAAGTTTAA 11

RESULT 794

ABH86141
 ID ABH86141 standard; DNA; 12 BP.

XX AC ABH86141;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 286134 for detecting SNP TSC0013595.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS Claim 1; SEQ ID NO 286134; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTT 2229

DB 3 ACCAAAGTTT 12

RESULT 795

ABI17314
 ID ABI17314 standard; DNA; 12 BP.

XX AC ABI17314;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 317287 for detecting SNP TSC0027908.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237
 Db 2 TTAAATGTTT 11
 |||||
 |||||

RESULT 798
 ABI54181/c
 ID ABI54181 standard; DNA; 12 BP.
 XX
 AC ABI54181;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354154 for detecting SNP TSC0048938.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 354154; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTA 2230
 Db 11 CCAAAATTA 2
 |||||
 |||||

RESULT 799
 ABI54184
 ID ABI54184 standard; DNA; 12 BP.
 XX
 AC ABI54184;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354157 for detecting SNP TSC0048942.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 354157; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237
 Db 1 TTACATATT 10
 |||||
 |||||

RESULT 800
 ABI68709
 ID ABI68709 standard; DNA; 12 BP.

XX AC ABI68709;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 368682 for detecting SNP TSC0057150.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 368682; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2223 AAAAGTTACA 2232
XX Db 2 AAAAGTTATA 11
XX RESULT 801
XX ABI68786/C
XX ID ABI68786 standard; DNA; 12 BP.
XX AC ABI68786;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 368759 for detecting SNP TSC0057206.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 368759; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2220 ACCAAAAGCTT 2229
XX Db 10 ACCAAAAGCTT 1
XX RESULT 802
XX ABI56803/C
XX ID ABI56803 standard; DNA; 12 BP.
XX AC ABI56803;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 356776 for detecting SNP TSC0007348.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 356776; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 2 C; 0 G; 7 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACA 2232
DB 12 AAAAGTTATA 3
RESULT 803
ABI73769
ID ABI73769 standard; DNA; 12 BP.
XX
XX ABI73769;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 373742 for detecting SNP TSC0060298.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 373742; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
DB 1 TTACATGTTT 10
RESULT 804
ABI78563
ID ABI78563 standard; DNA; 12 BP.
XX
XX ABI78563;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 378536 for detecting SNP TSC0010844.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 378536; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
|||||
Db 3 GTTATAGTT 12

RESULT 805
AB167192/c
ID AB167192 standard; DNA; 12 BP.
AC
AC AB167192;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367165 for detecting SNP TSC0056206.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367165 for detecting SNP TSC0056206.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 367165; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
|||||
Db 12 CCAAAATTTA 3

RESULT 806
ABH67895/c
ID ABH67895 standard; DNA; 12 BP.
XX
AC ABH67895;
XX
XX
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 267872 for detecting SNP TSC0000618.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 267872; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
|||||
Db 12 TTATAGTTT 3

RESULT 807
ABH77338
ID ABH77338 standard; DNA; 12 BP.
XX
XX ABH77338;
XX
XX 22-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide primer SEQ ID NO 277331 for detecting SNP TSC0004440.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX

XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 277331; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 2 AAAAATTACA 11
 RESULT 808
 ABI34133/C
 ID ABI34133 standard; DNA; 12 BP.
 AC ABI34133;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 334106 for detecting SNP TSC0037943.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 334106; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 2 AAAAATTACA 11
 RESULT 809
 ABI36475/C
 ID ABI36475 standard; DNA; 12 BP.
 AC ABI36475;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 336448 for detecting SNP TSC0039364.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 336448; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences


```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 5 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2213 GAGTGTGACC 2222
Db 12 GAGTGTGAAC 3

RESULT 810
ABI43240/C
ID ABI43240 standard; DNA; 12 BP.
XX
AC ABI43240;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 343213 for detecting SNP TSC0042951.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
AC
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 343213; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
Db 10 AAAACTTACA 1
```

```
RESULT 811
ABI44537
ID ABI44537 standard; DNA; 12 BP.
XX
AC ABI44537;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 344510 for detecting SNP TSC0043590.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
AC
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 344510; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 1 TTAATGTTT 10

RESULT 812
ABI45007/C
ID ABI45007 standard; DNA; 12 BP.
XX
AC ABI45007;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 344980 for detecting SNP TSC0043808.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```


CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 DB 1 TTAATGTTT 10
 ||| |||||

RESULT 815
 ABI76427/C
 ID ABI76427 standard; DNA; 12 BP.
 XX
 AC ABI76427;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide primer SEQ ID NO 376400 for detecting SNP TSC0061795.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 AC 18-OCT-2001.
 XX

PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WIPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 376400; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;

QY 2223 AAAAGTTTACA 2232
 DB 12 AAAATTACA 3
 ||| |||||

RESULT 817
 ABI79156/C
 ID ABI79156 standard; DNA; 12 BP.
 XX
 AC ABI79156;
 XX

DE Oligonucleotide primer SEQ ID NO 378241 for detecting SNP TSC0062685.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 AC 18-OCT-2001.
 XX

PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WIPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 378241; 29pp + Sequence Listing; German.
 XX

Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
 DB 11 GTTAGATGTT 2
 ||| |||||

RESULT 816
 ABI78268/C
 ID ABI78268 standard; DNA; 12 BP.
 XX
 AC ABI78268;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide primer SEQ ID NO 378241 for detecting SNP TSC0062685.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 AC 18-OCT-2001.
 XX

PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WIPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 378241; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
 DB 12 AAAATTACA 3
 ||| |||||

RESULT 817
 ABI79156/C
 ID ABI79156 standard; DNA; 12 BP.
 XX
 AC ABI79156;
 XX

DE Oligonucleotide primer SEQ ID NO 378241 for detecting SNP TSC0062685.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 AC 18-OCT-2001.
 XX

PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WIPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 378241; 29pp + Sequence Listing; German.
 XX

XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 379129 for detecting SNP TSC0063097.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 379129; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 DB |||||
 10 AAAATTTACA 1
 RESULT 818
 ABI79510/c.
 ID ABI79510 standard; DNA; 12 BP.
 XX AC ABI79510;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 379483 for detecting SNP TSC0000821.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 379129; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 DB |||||
 10 AAAATTTACA 1
 RESULT 818
 ABI79510/c.
 ID ABI79510 standard; DNA; 12 BP.
 XX AC ABI79510;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 379483 for detecting SNP TSC0000821.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 379483; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTTACAT 2233
 DB |||||
 12 AAAGTTTACAT 3
 RESULT 819
 ABI65753
 ID ABI65753 standard; DNA; 12 BP.
 XX AC ABI65753;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 365726 for detecting SNP TSC0055297.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PD 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 379483; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTTACAT 2233
 DB |||||
 12 AAAGTTTACAT 3
 RESULT 819
 ABI65753
 ID ABI65753 standard; DNA; 12 BP.
 XX AC ABI65753;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 365726 for detecting SNP TSC0055297.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 365726; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2223 AAAAGTTACA 2322
Db 2 AAAAATTACA 11
RESULT 820
ABH73741/C
ID ABH73741 standard; DNA; 12 BP.
XX
AC ABH73741;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 273726 for detecting SNP TSC0003286.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 273726; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2223 AAAAGTTACA 2322
Db 2 AAAAATTACA 11
RESULT 821
ABI02843/C
ID ABI02843 standard; DNA; 12 BP.
XX
AC ABI02843;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 302816 for detecting SNP TSC0020175.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 302816; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2219 GACCAAACT 2228
Db 11 AAAAATTACA 2

Db 10 GACCAAACT 1

RESULT 822

ABH78716

ID ABH78716 standard; DNA; 12 BP.

XX AC ABH78716;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 278709 for detecting SNP TSC0006283.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 278709; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;

XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;

XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237

Db 3 TTACATGTTT 12

RESULT 823

ABH78834

ID ABH78834 standard; DNA; 12 BP.

XX AC ABH78834;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 278827 for detecting SNP TSC0006455.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 278827; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;

XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;

XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACA 2232

Db 1 AAAAATTACA 10

RESULT 824

ABH82209

ID ABH82209 standard; DNA; 12 BP.

XX AC ABH82209;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 282202 for detecting SNP TSC0010577.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

```

XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 282202; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2220 ACCAAAGCTT 2229
XX |||||
XX 3 ACCAAAGCTT 12
XX
XX RESULT 825
XX ABH82461
XX ID ABH82461 standard; DNA; 12 BP.
XX AC
XX ABH82461;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 282454 for detecting SNP TSC0010786.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 282454; 29pp + Sequence Listing; German.
XX

```

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2224 AAAGTTACAT 2233
XX |||||
XX 2 AAAGTTAGAT 11
XX
XX RESULT 826
XX ABI08226/c
XX ID ABI08226 standard; DNA; 12 BP.
XX AC
XX ABI08226;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 308199 for detecting SNP TSC0022910.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 308199; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

```


XX WO200177384-A2.
PN
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 370877; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAAGTT 2229
Db 12 ACCAAAAGTT 3
RESULT 830
ABI62344
ID ABI62344 standard; DNA; 12 BP.
AC ABI62344;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 362317 for detecting SNP TSC0053155.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX

DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 362317; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 12 BP; 6 A; 0 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2224 AAAAGTTACAT 2233
Db 3 AAAAGTTATAT 12
RESULT 831
ABI65740
ID ABI65740 standard; DNA; 12 BP.
AC ABI65740;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 365713 for detecting SNP TSC0055295.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
FN
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 365713; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2228 TTACATGTTT 2237
 DB 2 TTACATATT 11
 RESULT 832
 ABH67811/c
 ID ABH67811 standard; DNA; 12 BP.
 AC ABH67811;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 267788 for detecting SNP TSC0000529.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 267788; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2228 TTACATGTTT 2237
 DB 2 TTACATATT 11
 RESULT 833
 ABH7811/c
 ID ABH7811 standard; DNA; 12 BP.
 AC ABH7811;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 267788 for detecting SNP TSC0000529.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 267788; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2228 TTACATGTTT 2237
 DB 2 TTACATATT 11
 RESULT 834
 ABH74722
 ID ABH74722 standard; DNA; 12 BP.
 AC ABH74722;
 XX
 XX 22-FEB-2002 (first entry)
 DT

OY 2228 TTACATGTTT 2237
 DB 11 TTACATATT 2
 RESULT 833
 ABI19419/c
 ID ABI19419 standard; DNA; 12 BP.
 XX
 AC ABI19419;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 319392 for detecting SNP TSC0029191.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 319392; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2220 ACCAAAAGTT 2229
 DB 10 ACCAAAATT 1
 RESULT 834
 ABH74722
 ID ABH74722 standard; DNA; 12 BP.
 AC ABH74722;
 XX
 XX 22-FEB-2002 (first entry)
 DT

```
XX DE Oligonucleotide primer SEQ ID NO 274707 for detecting SNP TSC0003650.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 274707; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC000010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2212 AGAGTGTGAC 2221
XX DB ||||| |||||
XX 2 AGAGTTTGAC 11
XX
XX RESULT 835
XX ABH99973/C
XX ID ABH99973 standard; DNA; 12 BP.
XX AC ABH99973;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 299966 for detecting SNP TSC0018823.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
```

```
PF 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 239966; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC000010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2227 GTTACATGTT 2236
XX DB ||||| |||||
XX 12 GTTACATGTT 3
XX
XX RESULT 836
XX ABI26971
XX ID ABI26971 standard; DNA; 12 BP.
XX AC ABI26971;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 326944 for detecting SNP TSC0033363.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
```

XX PS Claim 1; SEQ ID NO 326944; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 1 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237

DB 3 TTACATGTTT 12

RESULT 837

ID ABH77510/C

XX ID ABH77510 standard; DNA; 12 BP.

XX AC ABH77510;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 277503 for detecting SNP TSC0004488.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 277503; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230

DB 10 CCAAAAGTTA 1

RESULT 838

ID ABI03900/C

XX ID ABI03900 standard; DNA; 12 BP.

XX AC ABI03900;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 303873 for detecting SNP TSC0020682.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 303873; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGT 2235

DB 11 AGTTACATGT 2

```
central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

Homo sapiens.
WO200177384-A2.
18-OCT-2001.

06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.

Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 333487; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABCO0010-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0

OY 2220 ACCAAAGTT 2229
|||||
Db 1 ACCAAACGTT 10

RESULT 841
ABI42680/c
ID ID ABI42680 standard; DNA; 12 BP.
XX AC ABI42680;
XX CC
DT 22-FEB-2002 (first entry)
XX DE
DE DE Oligonucleotide primer SEQ ID NO 342653 for detecting SNP TSC0010690.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
PN XX
PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 342653; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2228 TTACATGTTT 2237
XX ||| |||||
XX 10 TTATATGTTT 1
XX
XX RESULT 842
XX ABI4148
XX ID ABI414148 standard; DNA; 12 BP.
XX AC ABI414148;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 344121 for detecting SNP TSC0043393.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 344121; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2229 TACATGTTTG 2238
XX ||| |||||
XX 3 TATATGTTTG 12
XX
XX RESULT 843
XX ABI55912
XX ID ABI55912 standard; DNA; 12 BP.
XX AC ABI55912;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 355885 for detecting SNP TSC0049846.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 355885; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

```
Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
   |||||
Db 1 AAAAATTACA 10

RESULT 846
ABI56477/C
ID ABI56477 standard; DNA; 12 BP.
XX
AC ABI56477;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 356450 for detecting SNP TSC0050119.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 356450; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
   |||||
Db 11 CCAAAAATTAA 2

RESULT 845
ABI71747/C
ID ABI71747 standard; DNA; 12 BP.
XX
```

```
AC ABI71747;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 371720 for detecting SNP TSC0058938.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 371720; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
   |||||
Db 11 TTAATGTTT 2

RESULT 846
ABI72421/C
ID ABI72421 standard; DNA; 12 BP.
XX
AC ABI72421;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 372394 for detecting SNP TSC0059365.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
```

```

XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 372394; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Oy 2222 CAAAAGTTTAC 2231
Db 11 CAAAATTTAC 2
RESULT 847
ABH161602/c
ID ABH161602 standard; DNA; 12 BP.
AC ABH161602;
XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 361575 for detecting SNP TSC0052702.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 375940; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 2 C; 0 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Oy 2223 AAAAGTTTACA 2232
Db 10 AAAAGTTTAAA 1
RESULT 848
ABH75967/c
ID ABH75967 standard; DNA; 12 BP.
AC ABH75967;
XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 375940 for detecting SNP TSC0061535.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 375940; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

```


XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 286650; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 1 TTAAATGTTT 10
 RESULT 852
 ABH77024/C
 ID ABH77024 standard; DNA; 12 BP.
 XX ABH77024;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 277017 for detecting SNP TSC0004360.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 304961; 29pp + Sequence Listing; German.

PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 277017; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTT 2229
 Db 11 ACCAAAGTTT 2
 RESULT 853
 ABI04988/C
 ID ABI04988 standard; DNA; 12 BP.
 XX ABI04988;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 304961 for detecting SNP TSC0021190.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 304961; 29pp + Sequence Listing; German.

```
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACA 2232
Db 12 AAAATTTTACA 3
RESULT 854
ABI05944/C
XX AC ABI05944;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 305917 for detecting SNP TSC0021700.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 305917; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
```

```
XX SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTT 2236
Db 10 GTTATATGTT 1
RESULT 855
ABI07069
XX ID ABI07069 standard; DNA; 12 BP.
XX AC ABI07069;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 307042 for detecting SNP TSC0022311.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 307042; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACA 2232
Db 1 AAAAATTTACA 10
RESULT 856
```

OS	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	(EPIC-) EPIGENOMICS AG.
XX	Olek A, Piepenbrock C, Berlin K;
XX	WPI; 2001-657177/75.
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
XX	designed to detect single-nucleotide polymorphisms and cytosine
XX	methylation status.
XX	Claim 1; SEQ ID NO 284139; 29pp + Sequence Listing; German.
XX	This invention describes novel oligonucleotide primers or peptide nucleic
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX	and cytosine methylation status in chemically pretreated genomic DNA. The
XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX	range of diseases including immune system, gastrointestinal, respiratory,
XX	central nervous system, cardiovascular and metabolic disorders. The
XX	oligomers are also used for detecting cell type differentiation. ABC000010
XX	-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI2073
XX	represent the oligomers described in the invention. NOTE: The sequence
XX	data for this patent did not form part of the printed specification, but
XX	was obtained in electronic format from WIPO at
XX	ftp.wipo.int/pub/published_pct_sequences
XX	Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
XX	Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX	Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX	Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2223 AAAAGTTACA 2232
DB	10 AAAATTACA 1
RESULT 858	
ABH87939/c	
ID	ABH87939 standard; DNA; 12 BP.
XX	AC ABH87939;
XX	22-FEB-2002 (first entry)
XX	oligonucleotide primer SEQ ID NO 287932 for detecting SNP TSC0013313.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	(EPIC-) EPIGENOMICS AG.
XX	Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 287932; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2224 AAGTTACAT 2233
Db 11 AATTACAT 2
RESULT 859
ABH89692/c
ID ABH89692 standard; DNA; 12 BP.
XX ABH89692;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 289685 for detecting SNP TSC0014043.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 289685; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACA 2232
Db 12 AAAAATTACA 3
RESULT 860
ABI44215/c
ID ABI44215 standard; DNA; 12 BP.
XX ABI44215;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 344188 for detecting SNP TSC0043433.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 344188; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAGTTTACAT 2233
 |||||
 10 AAGTTTAAAT 1

Db

RESULT 861
 ABI67950/c
 ID ABI67950 standard; DNA; 12 BP.

XX AC ABI67950;
 XX
 XX

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 367923 for detecting SNP TSC0056652.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 367923; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAGTTTACAT 2233
 |||||
 12 AACGTTACAT 3

Db

RESULT 862
 ABI70580
 ID ABI70580 standard; DNA; 12 BP.

XX AC ABI70580;
 XX
 XX

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 374983 for detecting SNP TSC0061022.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX

XX 18-OCT-2001.

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 370553 for detecting SNP TSC0006739.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 370553; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
 |||||
 2 GTTACATGTT 11

Db

RESULT 863
 ABI75010/c
 ID ABI75010 standard; DNA; 12 BP.

XX AC ABI75010;
 XX
 XX

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 374983 for detecting SNP TSC0061022.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 374983; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2229 TACATGTTG 2238
 DB 12 TAATGTTG 3
 RESULT 864
 ABI67100/c
 ID ABI67100 standard; DNA; 12 BP.
 XX AC ABI67100;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 367073 for detecting SNP TSC0056139.
 XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
 XX Claim 1; SEQ ID NO 367073; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2236 AGTTACATGT 2235
 DB 10 AGTTAAATGT 1
 RESULT 865
 ABH92370/c
 ID ABH92370 standard; DNA; 12 BP.
 XX AC ABH92370;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 292363 for detecting SNP TSC0015185.
 XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 292363; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 10 TTAAATGTTT 1

RESULT 866
ABH68307/c
ID ABH68307 standard; DNA; 12 BP.
XX
AC ABH68307;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 268284 for detecting SNP TSC0001037.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 268284; 29pp + Sequence Listing; German.
XX
SQ This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233
Db 11 AAAATACAT 2

RESULT 868
ABH97542
ID ABH97542 standard; DNA; 12 BP.
XX
AC ABH97542;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 297535 for detecting SNP TSC0017621.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

RESULT 867
ABH18919
ID ABH18919 standard; DNA; 12 BP.
XX
AC ABH18919;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 318992 for detecting SNP TSC0028936.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 318992; 29pp + Sequence Listing; German.
XX
SQ This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233
Db 2 AAAATTAAT 11

RESULT 868
ABH97542
ID ABH97542 standard; DNA; 12 BP.
XX
AC ABH97542;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 297535 for detecting SNP TSC0017621.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 297535; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATATGTTT 2237
 Db 2 TTATATGTTT 11
 RESULT 869
 ABH74170
 ID ABH74170 standard; DNA; 12 BP.
 XX
 AC ABH74170;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 274155 for detecting SNP TSC0003451.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 274155; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 Db 1 AAAAGTTTACA 10
 RESULT 870
 ABH74595/c
 ID ABH74595 standard; DNA; 12 BP.
 XX
 AC ABH74595;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 274580 for detecting SNP TSC0003600.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 274580; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
 Db 12 GTCACCAAAA 3

RESULT 871
 ABI33653/c
 ID ABI33653 standard; DNA; 12 BP.
 XX
 AC ABI33653;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 333626 for detecting SNP TSC0037648.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 333626; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 Db 10 TTAGAIGTTT 1

RESULT 872
 ABI09881
 ID ABI09881 standard; DNA; 12 BP.
 XX
 AC ABI09881;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 309854 for detecting SNP TSC0023708.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 309854; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
 Db 3 CCAAAACCTA 12

RESULT 873
 ABH84928/c
 ID ABH84928 standard; DNA; 12 BP.

```
XX ABH84928;
XX AC
XX DD
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 284921 for detecting SNP TSC0012055.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 284921; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2219 GACCAAAAGT 2228
XX Db 12 GACCAAAAGT 3
XX RESULT 874
XX ABI36547
XX ID ABI36547 standard; DNA; 12 BP.
XX AC
XX AC ABI36547;
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 336520 for detecting SNP TSC0039399.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX OS Homo sapiens.
```

```
PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 336520; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2229 TACATGTTTG 2238
XX Db 3 TATATGTTTG 12
XX RESULT 875
XX ABI14909/c
XX ID ABI14909 standard; DNA; 12 BP.
XX AC
XX AC ABI14909;
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 314882 for detecting SNP TSC0026600.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 314882; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2229 TACATGTTTG 2238
DB 12 TACATGTTTG 3
RESULT 876
ABI40947/C
ID ABI40947 standard; DNA; 12 BP.
XX
XX ABI40947;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 340920 for detecting SNP TSC0007216.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 340920; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACA 2232
DB 10 AAAAATTACA 1
RESULT 877
ABI16868/C
ID ABI16868 standard; DNA; 12 BP.
XX
XX ABI16868;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 316841 for detecting SNP TSC0027631.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 316841; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
 Db 12 GTTATATGTT 3
 RESULT 878
 ABI151360/C
 ID ABI151360 standard; DNA; 12 BP.
 XX AC ABI151360;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 351333 for detecting SNP TSC0047229.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 351333; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 Db 10 AAAATTATACA 1
 RESULT 879
 ABI151468/C
 ID ABI151468 standard; DNA; 12 BP.
 XX AC ABI151468;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 376028 for detecting SNP TSC0061572.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.

DE Oligonucleotide primer SEQ ID NO 351441 for detecting SNP TSC0047327.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 351441; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 8 A; 0 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 11 TTACATATTT 2
 RESULT 880
 ABI176055/C
 ID ABI176055 standard; DNA; 12 BP.
 XX AC ABI176055;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 376028 for detecting SNP TSC0061572.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 376028; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 DB 12 CCAAAAGTTA 3
 RESULT 881
 ABI64981
 ID ABI64981 standard; DNA; 12 BP.
 AC ABI64981;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 364954 for detecting SNP TSC0054825.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 364954; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 1 TTAATGTTT 10
 RESULT 882
 ABI66823/C
 ID ABI66823 standard; DNA; 12 BP.
 XX AC ABI66823;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 366796 for detecting SNP TSC0055977.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 366796; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 2 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match      31.1%; Score 8.4; DB 1; Length 12;
  Best Local Similarity 90.0%; Pred. No. 3.3e+02;
  Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 11 AAAAGTTTACA 2

RESULT 883
AB180759/c
ID AB180759 standard; DNA; 12 BP.
XX
AC AB180759;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 380732 for detecting SNP TSC0063954.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 380732; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match      31.1%; Score 8.4; DB 1; Length 12;
  Best Local Similarity 90.0%; Pred. No. 3.3e+02;
  Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 12 AAAAGTTTACA 3

RESULT 884
AB234313/c
ID AB234313 standard; DNA; 12 BP.
XX
AC AB234313;
XX
DT 31-JAN-2003 (first entry)
XX
DE HIV-1 reverse transcriptase mutation detection probe SEQ ID NO:555.
XX
XX Human immunodeficiency virus; HIV; reverse transcriptase; RT; enzyme;
KW detection; mutation; anti-HIV drug resistance; polymorphism; resistance;
KW probe; ss.
XX
XX Human immunodeficiency virus 1.
OS Synthetic.
XX
XX WO200255741-A2.
XX
XX 18-JUL-2002.
XX
XX 09-JAN-2002; 2002WO-EP000153.
XX
XX 11-JAN-2001; 2001EP-00870005.
XX
XX 20-APR-2001; 2001EP-00870085.
XX
XX 24-APR-2001; 2001US-0286102P.
XX
XX (INNO-) INNOGENETICS NV.
XX
XX De Smet K, Stuyver L;
XX
XX WPI; 2002-590680/63.
XX
XX Detecting mutations associated with anti-HIV drug resistance comprises
PT detecting at least one of the mutations in the HIV reverse transcriptase
PT gene by using probes optimized to function together in a reverse-
PT hybridization assay.
XX
XX Claim 2; Page 32; 117pp; English.
XX
XX The present invention describes a method for detecting mutations
CC associated with anti-HIV drug resistance in a patient by detecting at
CC least one of the mutations K103N/R, V106A/I/L, Y181C/I, M184V/I, Y188L,
CC G190A/S/R, T215Y/F/D/S/A and/or Q151M/L in the reverse transcriptase (RT)
CC of HIV strains in a biological sample using a specific set of probes
CC optimised to function together in a reverse-hybridisation assay. The
CC method and the nucleic acid sequences used in the method are useful for
CC determining viral mutations and/or polymorphisms in the HIV RT gene
CC associated with resistance. The probes are useful for the genetic
CC detection, preferably in vitro detection of the mutations K103N/R,
CC V106A/I/L, Y181C/I, M184V/I, Y188L, G190A/S/R and/or
CC T215Y/F/D/S/A in the RT of HIV strains in a biological sample, where the
CC mutation is associated with anti-HIV drug resistance. The method provides
CC a rapid, reliable and precise assay or determination and monitoring of
CC antiviral drug resistance or mutations associated with drug resistance of
CC viruses containing RT genes. AB233759 to AB234642 represent HIV RT
CC sequences and probes which are used in the exemplification of the present
CC invention
XX
SQ Sequence 12 BP; 3 A; 3 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match      31.1%; Score 8.4; DB 1; Length 12;
  Best Local Similarity 90.0%; Pred. No. 3.3e+02;
  Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2224
Db 12 GTGTGACCAA 3

RESULT 885
ADF78584
ID ADF78584 standard; DNA; 12 BP.
```

XX AC ADF78584;
XX DT 26-FEB-2004 (first entry)
XX DE Chromosomal abnormality detection-related PCR primer 165.
XX KW Chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW mutation; translocation; transversion; monosomy; trisomy 21;
KW chromosome 21; Down's Syndrome; aneuploidies; chromosome deletion;
KW chromosome addition; chromosome amplification; chromosome translocation;
KW chromosome rearrangement; single nucleotide polymorphism detection;
KW SNP detection; pregnant female; PCR; primer; ss.
XX OS Homo sapiens.
XX PN WO2003074723-A2.
XX PD 12-SEP-2003.
XX PF 28-FEB-2003; 2003WO-US006198.
XX PR 01-MAR-2002; 2002US-0360232P.
XX PR 11-MAR-2002; 2002US-00093618.
XX PR 08-MAY-2002; 2002US-0378354P.
XX PA (DHALLAN R.
XX PI Dhallan R;
XX DR WPI; 2003-845073/78.
XX PT Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
PT invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT a locus of interest and a different heterozygous locus.
XX PS Example 11; Page 227; 164pp; English.
XX CC This invention relates to a novel method of detecting chromosomal
CC abnormalities by determining the sequence of alleles of a locus of
CC interest from template DNA, determining which alleles are present and
CC comparing to amounts of alleles at a different, selected heterozygous
CC locus (for example on another chromosome or a maternal locus); relative
CC amounts are expressed as a ratio indicating presence or absence of the
CC abnormality. The method is useful for the detection of genetic disorders,
CC especially in a foetus, including chromosomal abnormalities and
CC mutations, for example translocations, transversions, monosomies,
CC trisomies (for example trisomy 21 in which an additional copy of
CC chromosome 21 results in Down's Syndrome) and other aneuploidies,
CC deletions, additions, amplifications, translocations and rearrangements.
CC It can be used to detect any alterations in a gene sequence, especially
CC single nucleotide polymorphisms (SNPs), and may be used to detect
CC numerous abnormalities simultaneously, for example if several SNPs are
CC associated with a particular disease. The method provides a rapid, non-
CC invasive method for determining the sequence of DNA from a foetus using a
CC sample from a pregnant female, for example to detect genetic disorders as
CC above or to determine if a foetus is a carrier of a disease or
CC predisposed to a disease.
XX SQ Sequence 12 BP; 4 A; 2 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2229 TACATGTTG 2238
| | | | |
Db 1 TACATCATTG 10
RESULT 886
ADF78619
ID ADF78619 standard; DNA; 12 BP.

XX AC ADF78619;
XX DT 26-FEB-2004 (first entry)
XX DE Chromosomal abnormality detection-related PCR primer 200.
XX KW Chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW mutation; translocation; transversion; monosomy; trisomy 21;
KW chromosome 21; Down's Syndrome; aneuploidies; chromosome deletion;
KW chromosome addition; chromosome amplification; chromosome translocation;
KW chromosome rearrangement; single nucleotide polymorphism detection;
KW SNP detection; pregnant female; PCR; primer; ss.
XX OS Homo sapiens.
XX PN WO2003074723-A2.
XX PD 12-SEP-2003.
XX PF 28-FEB-2003; 2003WO-US006198.
XX PR 01-MAR-2002; 2002US-0360232P.
XX PR 11-MAR-2002; 2002US-00093618.
XX PR 08-MAY-2002; 2002US-0378354P.
XX PA (DHALLAN R.
XX PI Dhallan R;
XX DR WPI; 2003-845073/78.
XX PT Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
PT invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT a locus of interest and a different heterozygous locus.
XX PS Example 11; Page 232; 164pp; English.
XX CC This invention relates to a novel method of detecting chromosomal
CC abnormalities by determining the sequence of alleles of a locus of
CC interest from template DNA, determining which alleles are present and
CC comparing to amounts of alleles at a different, selected heterozygous
CC locus (for example on another chromosome or a maternal locus); relative
CC amounts are expressed as a ratio indicating presence or absence of the
CC abnormality. The method is useful for the detection of genetic disorders,
CC especially in a foetus, including chromosomal abnormalities and
CC mutations, for example translocations, transversions, monosomies,
CC trisomies (for example trisomy 21 in which an additional copy of
CC chromosome 21 results in Down's Syndrome) and other aneuploidies,
CC deletions, additions, amplifications, translocations and rearrangements.
CC It can be used to detect any alterations in a gene sequence, especially
CC single nucleotide polymorphisms (SNPs), and may be used to detect
CC numerous abnormalities simultaneously, for example if several SNPs are
CC associated with a particular disease. The method provides a rapid, non-
CC invasive method for determining the sequence of DNA from a foetus using a
CC sample from a pregnant female, for example to detect genetic disorders as
CC above or to determine if a foetus is a carrier of a disease or
CC predisposed to a disease.
XX SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2228 TTACATGTTT 2237
| | | | |
Db 1 TTAAATGTTT 10

Search completed: November 18, 2004, 08:16:21
Job time : 4 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:17:36 ; Search time 0.001 Seconds
(without alignments)
19.278 Million cell updates/sec

Title: US-10-006-191-19
Perfect score: 27
Sequence: 1 agagtgtgacaaaagtacattgttg 27

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 35 seqs, 357 residues

Total number of hits satisfying chosen parameters: 70

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 35 summaries

Database : rni19.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	11.4	42.2	15	1	US-09-081-646-31
C 2	9.4	34.8	12	1	US-09-512-563C-55
C 3	9.4	34.8	13	1	US-08-990-735C-4
C 4	8.4	31.1	10	1	US-08-330-000-5
C 5	8.4	31.1	10	1	US-08-965-908-5
C 6	8.4	31.1	10	1	US-09-322-484-2
C 7	8.4	31.1	12	1	US-08-068-945A-33
C 8	8.4	31.1	12	1	US-08-442-806-33
C 9	8	29.6	8	1	US-08-859-954-20
C 10	8	29.6	10	1	US-08-623-428B-34
C 11	8	29.6	10	1	US-09-508-753B-219
C 12	8	29.6	11	1	US-09-249-155A-122
C 13	7.8	28.9	11	1	US-09-157-257-42
C 14	7.8	28.9	11	1	US-09-404-912-12
C 15	7.4	27.4	9	1	US-08-360-051A-45
C 16	7.4	27.4	9	1	US-08-360-051A-48
C 17	7.4	27.4	9	1	US-08-375-151-5
C 18	7.4	27.4	9	1	US-09-425-072-5
C 19	7.4	27.4	9	1	US-09-194-842A-21
C 20	7.4	27.4	9	1	US-10-096-596-12
C 21	7.4	27.4	9	1	US-09-982-658A-4
C 22	7.4	27.4	9	1	PCT-US94-08023-39
C 23	7.4	27.4	10	1	US-08-631-755A-15
C 24	7.4	27.4	10	1	US-08-388-353-115
C 25	7.4	27.4	10	1	US-08-388-353-116
C 26	7.4	27.4	10	1	US-08-488-551B-115
C 27	7.4	27.4	10	1	US-08-488-551B-116
C 28	7.4	27.4	10	1	US-09-180-903-14
C 29	7.4	27.4	10	1	US-09-171-759-20
C 30	7.4	27.4	10	1	US-09-083-235A-40
C 31	7.4	27.4	10	1	US-09-083-235A-41
C 32	7.4	27.4	10	1	US-09-083-235A-42
C 33	7.4	27.4	10	1	US-09-693-467A-13

ALIGNMENTS

RESULT 1
US-09-081-646-31/c
; Sequence 31, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; PRIOR FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-31

Query Match 42.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.2;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACATG 2234
DB 13 CAAAATTACATG 1

RESULT 2
US-09-512-563C-55/c
; Sequence 55, Application US/09512563C
; Patent No. 6579969
; GENERAL INFORMATION:
; APPLICANT: Saus, Juan
; TITLE OF INVENTION: Goodpasture Binding Protein
; FILE REFERENCE: 98-723-A
; CURRENT APPLICATION NUMBER: US/09/512,563C
; CURRENT FILING DATE: 2000-02-24
; PRIOR FILING DATE: 1999-02-24
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-512-563C-55

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 5;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
DB 11 TGTGACTAAA 1

RESULT 3
US-08-890-735C-4
; Sequence 4, Application US/08890735C
; Patent No. 6518014

Sequence 16, Appl
Sequence 17, Appl

APPLICANT: Desmond MASARENHAS
APPLICANT: David PASSMORE
APPLICANT: Stephen DANKO
TITLE OF INVENTION: INSULIN-LIKE GROWTH FACTOR BINDING
TITLE OF INVENTION: PROTEIN VARIANTS
FILE REFERENCE: 22095209100
CURRENT APPLICATION NUMBER: US/09/322.484
CURRENT FILING DATE: 1999-05-27
PRIOR APPLICATION NUMBER: 60/087.559
PRIOR FILING DATE: 1998-06-01
NUMBER OF SEQ ID NOS: 6
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 10
TYPE: DNA
ORGANISM: Saccharomyces cerevisiae
US-09-322-484-2

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 10;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGT 2235
Db 10 AATTACATGT 1

RESULT 7
US-08-068-945A-33
Sequence 33, Application US/08068945A
Patent No. 5616483

GENERAL INFORMATION:
APPLICANT: Bjursell, Gunnar
APPLICANT: Carlsson, Peter
APPLICANT: Enerback, Sven
APPLICANT: Hansson, Lennart
APPLICANT: Lidberg, Ulf
APPLICANT: Nilsson, Jeanette
APPLICANT: Tornell, Jan
TITLE OF INVENTION: New DNA Sequences
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESS:
ADDRESSEE: White & Case
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: United States
ZIP: 10036-2787
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/068,945A
FILING DATE: 27-MAY-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9201809-2
FILING DATE: 11-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9201826-6
FILING DATE: 12-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9202088-2
FILING DATE: 03-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9300902-5
FILING DATE: 19-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Sterner, Richard J.
REGISTRATION NUMBER: 35,372
REFERENCE/DOCKET NUMBER: 1103326-052

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)819-8783
TELEFAX: (212)354-8113
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-068-945A-33

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 8.7;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
Db 1 GGTACATGTT 10

RESULT 8
US-08-442-806-33
Sequence 33, Application US/08442806
Patent No. 5716817
GENERAL INFORMATION:
APPLICANT: Bjursell, Gunnar
APPLICANT: Carlsson, Peter
APPLICANT: Enerback, Sven
APPLICANT: Hansson, Lennart
APPLICANT: Lidberg, Ulf
APPLICANT: Nilsson, Jeanette
APPLICANT: Tornell, Jan
TITLE OF INVENTION: Genomic DNA Sequences
TITLE OF INVENTION: Encoding Human BSS/L/CEL
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESS:
ADDRESSEE: White & Case
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: United States
ZIP: 10036-2787
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/442,806
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/068,945
FILING DATE: 27-MAY-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9201809-2
FILING DATE: 11-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9201826-6
FILING DATE: 12-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9202088-2
FILING DATE: 03-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: SE 9300902-5
FILING DATE: 19-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Sterner, Richard J.
REGISTRATION NUMBER: 35,372
REFERENCE/DOCKET NUMBER: 1103326-052
TELECOMMUNICATION INFORMATION:

TELEPHONE: (212)819-8783
TELEFAX: (212)354-8113
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-442-806-33

Query Match 31.18; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.08; Pred. No. 8.7;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTT 2236
| | | | |
Db 1 GGTACATGTT 10

RESULT 9
US-08-859-954-20/c
Sequence 20, Application US/08859954
Patent No. 6083695

GENERAL INFORMATION:
APPLICANT: Hardin, Susan H.
APPLICANT: Hcmayouni, Ramin
APPLICANT: Hardin, Paul E.
TITLE OF INVENTION: Design and Optimized Primer Library for
NUMBER OF SEQUENCES: 566
TITLE OF INVENTION: Gene Sequencing and Method Thereof
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski L.L.P.
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/859,954
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/632,782
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5900
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5325
TELEFAX: 713/651-5246
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "oligonucleotide"
HYPOTHETICAL: YES
ANTI-SENSE: YES
US-08-859-954-20

Query Match 29.6%; Score 8; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2214 AGTGAGAC 2221
| | | | |
Db 8 AGTGAGAC 1

RESULT 10
US-08-623-428D-34/c
Sequence 34, Application US/08623428D
Patent No. 6312890
GENERAL INFORMATION:
APPLICANT: W. MARSTON LINEHAN, MICHAEL
LERMAN, FARIDA LATIF AND BERTON
ZBAR

TITLE OF INVENTION: PARTIAL INTRON SEQUENCE
OF VHL DISEASE GENE AND ITS USE IN DIAGNOSIS
OF DISEASE CARRIERS
NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154

COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MICROSOFT WORD 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/623,428D
FILING DATE: 03-Sep-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/623,428
FILING DATE: MARCH 28, 1996
APPLICATION NUMBER: 08/061,889
FILING DATE: May 14, 1993

ATTORNEY/AGENT INFORMATION:
NAME: Kathryn M. Brown
REGISTRATION NUMBER: 34,556
REFERENCE/DOCKET NUMBER: 2026-4078US3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
TELEX: 421792

INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-08-623-428D-34

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2217 GTGACCAA 2224
| | | | |
Db 10 GTGACCAA 3

RESULT 11
US-09-508-753B-219/c
Sequence 219, Application US/09508753B
Patent No. 6544736
GENERAL INFORMATION:
APPLICANT: Akira SHIMAMOTO
APPLICANT: Yasuhiro FURUICHI
APPLICANT: Yuko SHIBATA
APPLICANT: HIROKO FUNAKI

; APPLICANT: Eiji OHARA
 ; APPLICANT: Masanori WATAHAKI
 ; TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
 ; FILE REFERENCE: 00162/HG
 ; CURRENT APPLICATION NUMBER: US/09/508,753B
 ; CURRENT FILING DATE: 2000-06-16
 ; PRIOR APPLICATION NUMBER: JP 9/270324
 ; PRIOR FILING DATE: 1997-09-18
 ; NUMBER OF SEQ ID NOS: 472
 ; SEQ ID NO 219
 ; LENGTH: 10
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer
 US-09-508-753B-219

Query Match 29.6%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCRAAAGT 2228
 Db 8 CCRAAAGT 1

RESULT 12
 US-09-249-155A-122
 ; Sequence 122, Application US/09249155A
 ; Patent No. 6538173
 ; GENERAL INFORMATION:
 ; APPLICANT: Heber-Katz, Ellen
 ; TITLE OF INVENTION: Compositions and Methods for Wound
 ; TITLE OF INVENTION: Healing
 ; FILE REFERENCE: 00486.78503
 ; CURRENT APPLICATION NUMBER: US/09/249,155A
 ; CURRENT FILING DATE: 1999-02-12
 ; PRIOR APPLICATION NUMBER: US 60/074,737
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: US 60/097,937
 ; PRIOR FILING DATE: 1998-08-26
 ; PRIOR APPLICATION NUMBER: US 60/102,051
 ; PRIOR FILING DATE: 1998-09-28
 ; NUMBER OF SEQ ID NOS: 346
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 122
 ; LENGTH: 11
 ; TYPE: DNA
 ; ORGANISM: Mus musculus
 US-09-249-155A-122

Query Match 29.6%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGTGACCA 2223
 Db 3 TGTGACCA 10

RESULT 13
 US-09-157-257-42/c
 ; Sequence 42, Application US/09157257
 ; Patent No. 6375954
 ; GENERAL INFORMATION:
 ; APPLICANT: DUTTA, Sukanta K.
 ; APPLICANT: BISWAS, Biswajit
 ; APPLICANT: VEMULAPALLI, Ramesh
 ; TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
 ; TITLE OF INVENTION: POTOMAC HORSE FEVER
 ; FILE REFERENCE: 8172-9016
 ; CURRENT APPLICATION NUMBER: US/09/157,257
 ; CURRENT FILING DATE: 1998-09-18

; EARLIER APPLICATION NUMBER: 60/059,252
 ; EARLIER FILING DATE: 1997-09-18
 ; NUMBER OF SEQ ID NOS: 48
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 42
 ; LENGTH: 11
 ; TYPE: DNA
 ; ORGANISM: Ehrlichia risticii
 US-09-157-257-42

Query Match 28.9%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 13;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
 Db 11 AAGTTACCGT 1

RESULT 14
 US-09-404-912-12
 ; Sequence 12, Application US/09404912
 ; Patent No. 6703228
 ; GENERAL INFORMATION:
 ; APPLICANT: John Landers
 ; APPLICANT: David Houseman
 ; APPLICANT: Barbara Jordan
 ; APPLICANT: Alain Charest
 ; TITLE OF INVENTION: Methods and Products Related to
 ; TITLE OF INVENTION: Genotyping and DNA Analysis
 ; FILE REFERENCE: M0856/7045 (HCL/NAT)
 ; CURRENT APPLICATION NUMBER: US/09/404,912
 ; CURRENT FILING DATE: 1999-09-24
 ; PRIOR APPLICATION NUMBER: US 60/101,757
 ; PRIOR FILING DATE: 1998-09-25
 ; PRIOR APPLICATION NUMBER: PCT/US99/22283
 ; PRIOR FILING DATE: 1999-09-24
 ; NUMBER OF SEQ ID NOS: 691
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 12
 ; LENGTH: 11
 ; TYPE: DNA
 ; ORGANISM: Homo Sapiens
 US-09-404-912-12

Query Match 28.9%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 13;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
 Db 1 AAATTAATGT 11

RESULT 15
 US-08-360-051A-45/c
 ; Sequence 45, Application US/08360051A
 ; Patent No. 5891881
 ; GENERAL INFORMATION:
 ; APPLICANT: Maillet, Francois
 ; APPLICANT: Guillo-Bonnici, Francoise
 ; APPLICANT: Cleuziat, Philippe
 ; APPLICANT: Levasseur, Pierre
 ; TITLE OF INVENTION: MODIFIED PROMOTER FOR RNA POLYMERASE,
 ; TITLE OF INVENTION: ITS PREPARATION AND ITS APPLICATIONS
 ; NUMBER OF SEQUENCES: 65
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: OLIFF & BERRIDGE
 ; STREET: 700 South Washington Street, Suite 300
 ; CITY: Alexandria
 ; STATE: VA
 ; COUNTRY: USA
 ; ZIP: 22314

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/360,051A
FILING DATE: 20-DEC-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 36049
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-08-360-051A-45

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222
|||||
Db 9 AGTGTGACC 1

RESULT 16
US-08-360-051A-48/c
Sequence 48, Application US/08360051A
Patent No. 5891681
GENERAL INFORMATION:
APPLICANT: Mallet, Francois
APPLICANT: Guillon-Bonnici, Francoise
APPLICANT: Cleuziat, Philippe
APPLICANT: Levasseur, Pierre
TITLE OF INVENTION: MODIFIED PROMOTER FOR RNA POLYMERASE,
TITLE OF INVENTION: ITS PREPARATION AND ITS APPLICATIONS
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: OLIFF & BERRIDGE
STREET: 700 South Washington Street, Suite 300
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/360,051A
FILING DATE: 20-DEC-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 36049
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787
INFORMATION FOR SEQ ID NO: 48:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-08-360-051A-48

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222
|||||
Db 9 AGTGTGACC 1

RESULT 17
US-08-375-151-5/c
Sequence 5, Application US/08375151
Patent No. 6060237
GENERAL INFORMATION:
APPLICANT: Hakan Nygren and Manne
APPLICANT: Stenberg
TITLE OF INVENTION: Devices and Methods for
TITLE OF INVENTION: Optical Detection of Nucleic
TITLE OF INVENTION: Acid Hybridization
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
SOFTWARE: Wordperfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/375,151
FILING DATE: January 17, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 07/965,661
FILING DATE: September 17, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/215
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 9
TYPE: nucleic
STRANDEDNESS: single
TOPOLOGY: linear
US-08-375-151-5

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
|||||
Db 9 TACATGTTT 1

```
RESULT 18
US-09-425-072-5/c
; Sequence 5, Application US/09425072
; Patent No. 6355429
; GENERAL INFORMATION:
; APPLICANT: Hakan Nygren and Manne
; APPLICANT: Stenberg
; TITLE OF INVENTION: Devices and Methods for
; TITLE OF INVENTION: Optical Detection of Nucleic
; TITLE OF INVENTION: Acid Hybridization
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/425,072
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/375,151
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9
; TYPE: nucleic
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-425-072-5

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
Db 9 TACATCTTT 1

RESULT 19
US-09-194-842A-21/c
; Sequence 21, Application US/09194842A
; Patent No. 6416948
; GENERAL INFORMATION:
; APPLICANT: Pilarski, Linda M.
; APPLICANT: Belch, Andrew R.
; APPLICANT: Szczepek, Agnieszka J.
; TITLE OF INVENTION: METHODS FOR DETECTION OF REARRANGED DNA
; FILE REFERENCE: SPI-008USCPA
; CURRENT APPLICATION NUMBER: US/09/194,842A
; CURRENT FILING DATE: 1999-01-04
; PRIOR APPLICATION NUMBER: US 60/019,106
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: PCT/US97/09534
; PRIOR FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Patentin Ver. 2.0
```

```
; SEQ ID NO 21
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-194-842A-21

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCA 2223
Db 9 GTGTGACA 1

RESULT 20
US-10-096-596-12
; Sequence 12, Application US/10096596
; Patent No. 6746845
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth W
; APPLICANT: Vogelstein, Bert
; APPLICANT: Velculescu, Victor
; APPLICANT: Zhang, Lin
; TITLE OF INVENTION: METHOD FOR SERIAL ANALYSIS OF GENE EXPRESSION
; FILE REFERENCE: 001107.00242
; CURRENT APPLICATION NUMBER: US/10/096,596
; CURRENT FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: US 08/527,154
; PRIOR FILING DATE: 1995-09-12
; PRIOR APPLICATION NUMBER: US 08/544,861
; PRIOR FILING DATE: 1995-10-18
; PRIOR APPLICATION NUMBER: US 09/107,228
; PRIOR FILING DATE: 1998-06-30
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 12
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-096-596-12

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCA 2223
Db 1 GCGTGACCA 9

RESULT 21
US-09-982-658A-4/c
; Sequence 4, Application US/09982658A
; Patent No. 6783938
; GENERAL INFORMATION:
; APPLICANT: HAKAN, NYGREN
; APPLICANT: MANNE, STENBERG
; TITLE OF INVENTION: DEVICES AND METHODS FOR OPTICAL DETECTION OF NUCLEIC ACID
; FILE REFERENCE: 074022/2305
; CURRENT APPLICATION NUMBER: US/09/982,658A
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/425,072
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: 08/375,151
; PRIOR FILING DATE: 1995-01-17
; PRIOR APPLICATION NUMBER: 07/965,661
; PRIOR FILING DATE: 1992-09-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Patentin version 2.1
; SEQ ID NO 4
; LENGTH: 9
```

```

; TYPE: DNA
; ORGANISM: Bacteriophage M13mpl8
; FEATURE:
; OTHER INFORMATION: 9-mer
US-09-982-658A-4

Query Match      27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2229 TACATGTTT 2237
Db      9 TACATCTTT 1

RESULT 22
PCT-US94-08023-39/c
; Sequence 39, Application PC/TUS9408023
; GENERAL INFORMATION:
; APPLICANT: de Kloet, Siwo R.
; TITLE OF INVENTION: Sex-Specific DNA Probe For Parrots,
; TITLE OF INVENTION: Methods And Kits
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSEE: Russell, P.A.
; STREET: 200 East Broadway Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/08023
; FILING DATE: 15-JUL-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/093,198
; FILING DATE: 15-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: FL20979-34
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 305-527-2498
; TELEFAX: 305-764-4986
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US94-08023-39

Query Match      27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2220 ACCAAAGCT 2228
Db      9 ACCAAAGAT 1

RESULT 23
US-08-631-751A-15/c
; Sequence 15, Application US/08631751A
; Patent No. 5843767
; GENERAL INFORMATION:
; APPLICANT: Beattie, Kenneth L.
; TITLE OF INVENTION: Microfabricated, Flowthrough Porous
; TITLE OF INVENTION: Apparatus for Discrete Detection of Binding Reactions
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Vinson & Elkins
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20004-1008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/631,751A
; FILING DATE: 11-April-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sanzo, Michael A.
; REGISTRATION NUMBER: 36,912
; REFERENCE/DOCKET NUMBER: HARC0001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)639-6500
; TELEFAX: (202)639-6604
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: linear
US-08-631-751A-15

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2230 ACATGTTTG 2238
Db      10 ACAAGTTTG 2

RESULT 24
US-08-388-353-115/C
; Sequence 115, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:

```


NAME: DiGiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 115:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-115

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
DB 10 TCCATGTTT 2

RESULT 25
US-08-388-353-116/c
; Sequence 116, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Leamont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: DiGiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 116:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-116

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
DB 9 TCCATGTTT 1

RESULT 26
US-08-488-551B-115/c
; Sequence 115, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 115:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-115

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
DB 10 TCCATGTTT 2

RESULT 27
US-08-488-551B-116/c
; Sequence 116, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee

APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 116:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-116

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2229 TACATGTTT 2237
DB 9 TCCATGTTT 1

RESULT 28
US-09-180-903-14
Sequence 14, Application US/09180903
Patent No. 6316190
GENERAL INFORMATION:
APPLICANT: Rein, Alan
Casas-Finet, Jose
Fisher, Robert
Fivash, Matthew
Henderson, Louis E.
TITLE OF INVENTION: Oligonucleotides Which Specifically Bind
Retroviral Nucleocapsid Proteins
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/180,903
FILING DATE: 12-JUL-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/017,128
FILING DATE: 20-MAY-1996
APPLICATION NUMBER: WO PCT/US97/08936
FILING DATE: 19-MAY-1997
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Kathleen L.
REGISTRATION NUMBER: 43,433
REFERENCE/DOCKET NUMBER: 015280-279100US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-180-903-14

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAG 2227
DB 1 GACTAAAG 9

RESULT 29
US-09-171-759-20
Sequence 20, Application US/09171759
Patent No. 6346415
GENERAL INFORMATION:
APPLICANT: Feldhaus, Andrew
TITLE OF INVENTION: TRANSCRIPTIONALLY-ACTIVATED
AAV INVERTED TERMINAL REPEATS (ITRs) FOR USE WITH RECOMBINant
AAV VECTORS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 755 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/171,759
FILING DATE: 20-Oct-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: <Unknown>
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Dylan, Tyler M
REGISTRATION NUMBER: 37,612
REFERENCE/DOCKET NUMBER: 22627-20038.01

```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-09-171-759-20

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTT 2229
Db 1 CCGAAGTT 9

RESULT 30
US-09-083-235A-40/c
; Sequence 40, Application US/09083235A
; Patent No. 6632919
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Peter E
; APPLICANT: Haaima, Gerald
; APPLICANT: Eldrup, Anne B
; TITLE OF INVENTION: Peptide Nucleic Acid Monomers and Oligomers
; FILE REFERENCE: ISIS3044
; CURRENT APPLICATION NUMBER: US/09/083,235A
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 08/862,629
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 40
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6632919el Sequence
US-09-083-235A-40

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2212 AGAGTGTGA 2220
Db 10 AGAGTTTGA 2

RESULT 31
US-09-083-235A-41/c
; Sequence 41, Application US/09083235A
; Patent No. 6632919
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Peter E
; APPLICANT: Haaima, Gerald
; APPLICANT: Eldrup, Anne B
; TITLE OF INVENTION: Peptide Nucleic Acid Monomers and Oligomers
; FILE REFERENCE: ISIS3044
; CURRENT APPLICATION NUMBER: US/09/083,235A
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 08/862,629
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6632919el Sequence
US-09-083-235A-41

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2212 AGAGTGTGA 2220
Db 10 AGAGTTTGA 2

RESULT 32
US-09-083-235A-42
; Sequence 42, Application US/09083235A
; Patent No. 6632919
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Peter E
; APPLICANT: Haaima, Gerald
; APPLICANT: Eldrup, Anne B
; TITLE OF INVENTION: Peptide Nucleic Acid Monomers and Oligomers
; FILE REFERENCE: ISIS3044
; CURRENT APPLICATION NUMBER: US/09/083,235A
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 08/862,629
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6632919el Sequence
US-09-083-235A-42

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2212 AGAGTGTGA 2220
Db 1 AGAGTTTGA 9

RESULT 33
US-09-693-467A-13/c
; Sequence 13, Application US/09693467A
; Patent No. 6686513
; GENERAL INFORMATION:
; APPLICANT: Albert, Henrik H.
; APPLICANT: Wei, Hairong
; TITLE OF INVENTION: PLANT PROMOTER SEQUENCES AND METHODS OF USE THEREOF
; FILE REFERENCE: UH-04331
; CURRENT APPLICATION NUMBER: US/09/693,467A
; CURRENT FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/270,976
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Saacharum Hybrid Cultivar H32-8560
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)
; OTHER INFORMATION: The "n" at position 9 is any nucleotide.
US-09-693-467A-13
```

mcgarry191-19.rni

Thu Nov 18 12:41:58 2004

Search completed: November 18, 2004, 08:17:36
Job time : 0.001 secs

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 80.0%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAARAGTT 2229
| | | | | | | | | |
Db 10 ANCAAAACTT 1

RESULT 34
US-09-693-467A-16/c
; Sequence 16 Application US/09693467A
; Patent No. 668513
; GENERAL INFORMATION:
; APPLICANT: Albert, Henrik H.
; APPLICANT: Wei, Haihong
; TITLE OF INVENTION: PLANT PROMOTER SEQUENCES AND METHODS OF USE THEREOF
; FILE REFERENCE: UH-04331
; CURRENT APPLICATION NUMBER: US/09/693,467A
; CURRENT FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/270,976
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 16
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Saccharum Hybrid Cultivar H32-8560
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)
; OTHER INFORMATION: The "n" at position 9 is any nucleotide.
US-09-693-467A-16

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 80.0%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAARAGTT 2229
| | | | | | | | | |
Db 10 ANCAAAACTT 1

RESULT 35
US-09-822-250A-17/c
; Sequence 17 Application US/09822250A
; Patent No. 6706477
; GENERAL INFORMATION:
; APPLICANT: Zauderer, Maurice
; TITLE OF INVENTION: Methods for Producing Polynucleotide Libraries in Vaccinia Virus
; FILE REFERENCE: 1821.0010001
; CURRENT APPLICATION NUMBER: US/09/822,250A
; CURRENT FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 08/935,377
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MP_9 primer
US-09-822-250A-17

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCA 2224
| | | | | | | | | |
Db 9 TGTGACCGA 1

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 09:18:59 ; Search time 0.001 Seconds
(without alignments)
19.494 Million cell updates/sec

Title: US-10-006-191-19

Perfect score: 27

Sequence: 1 agsgtgcacaaagtacatgttg 27

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 31 seqs, 361 residues

Total number of hits satisfying chosen parameters: 62

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 31 summaries

Database : rnpb19.seq*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20	74.1	20	1	US-10-006-191-47
C 2	20	74.1	20	1	US-10-006-191-48
C 3	20	74.1	20	1	US-10-006-191-63
C 4	20	74.1	20	1	US-10-006-191-64
C 5	16	59.3	20	1	US-10-006-191-46
C 6	10	37.0	10	1	US-10-293-222-313
C 7	9	33.3	10	1	US-10-033-145-571
C 8	9	33.3	11	1	US-09-918-715-62
C 9	8.4	31.1	10	1	US-09-986-944-2
C 10	8.4	31.1	10	1	US-10-329-465-30
C 11	8.4	31.1	10	1	US-10-423-765-213
C 12	8.4	31.1	10	1	US-10-330-627-88
C 13	8.4	31.1	10	1	US-10-330-627-150
C 14	8.4	31.1	10	1	US-10-330-627-202
C 15	8.4	31.1	10	1	US-10-330-627-204
C 16	8.4	31.1	10	1	US-10-423-621-11
C 17	8	29.6	10	1	US-09-989-789-1315
C 18	8	29.6	10	1	US-09-989-789-1323
C 19	8	29.6	10	1	US-09-989-789-1324
C 20	8	29.6	10	1	US-09-989-186-1315
C 21	8	29.6	10	1	US-09-990-186-1323
C 22	8	29.6	10	1	US-09-990-186-1324
C 23	8	29.6	10	1	US-09-989-994-1315
C 24	8	29.6	10	1	US-09-989-994-1323
C 25	8	29.6	10	1	US-09-989-994-1324
C 26	8	29.6	10	1	US-10-033-145-639
C 27	8	29.6	10	1	US-10-033-145-697
C 28	8	29.6	10	1	US-10-033-145-1053
C 29	8	29.6	10	1	US-10-330-627-1311
C 30	8	29.6	10	1	US-10-091-281-239
C 31	8	29.6	10	1	US-10-160-401-28

ALIGNMENTS

RESULT 1

US-10-006-191-47/c
; Sequence 47, Application US/10006191
; Publication No. US20030144223A1
; GENERAL INFORMATION:

; APPLICANT: William Gaarde

; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274

; CURRENT APPLICATION NUMBER: US/10/006,191

; CURRENT FILING DATE: 2001-12-10

; NUMBER OF SEQ ID NOS: 153

; SEQ ID NO 47

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-006-191-47

Query Match 74.1%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.32;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGACCAAAAGTTTACA 2232

DB 20 GAGTGTGACCAAAAGTTTACA 1

RESULT 2

US-10-006-191-48/c

; Sequence 48, Application US/10006191

; Publication No. US20030144223A1

; GENERAL INFORMATION:

; APPLICANT: William Gaarde

; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274

; CURRENT APPLICATION NUMBER: US/10/006,191

; CURRENT FILING DATE: 2001-12-10

; NUMBER OF SEQ ID NOS: 153

; SEQ ID NO 48

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-006-191-48

Query Match 74.1%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.32;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 TGACCAAAAGTTTACATGTTT 2237

DB 20 TGACCAAAAGTTTACATGTTT 1

RESULT 3

US-10-006-191-63/c

; Sequence 63, Application US/10006191

; Publication No. US20030144223A1

; GENERAL INFORMATION:

; APPLICANT: William Gaarde

; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274

; CURRENT APPLICATION NUMBER: US/10/006,191

; CURRENT FILING DATE: 2001-12-10

; NUMBER OF SEQ ID NOS: 153

```
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-63

Query Match          74.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAGTTAC 2231
      |||||
Db 20 AGAGTGTGACCAAAAGTTAC 1

RESULT 4
US-10-006-191-64/c
; Sequence 64, Application US/10006191
; Publication No. US20030144223A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
; FILE REFERENCE: RTS-0274
; CURRENT APPLICATION NUMBER: US/10/006,191
; CURRENT FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-64

Query Match          74.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTTACATGTTTG 2238
      |||||
Db 20 GACCAAAAGTTACATGTTTG 1

RESULT 5
US-10-006-191-46/c
; Sequence 46, Application US/10006191
; Publication No. US20030144223A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
; FILE REFERENCE: RTS-0274
; CURRENT APPLICATION NUMBER: US/10/006,191
; CURRENT FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-46

Query Match          59.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAG 2227
      |||||
Db 16 AGAGTGTGACCAAAAG 1
```

```
RESULT 6
US-10-293-222-313/c
; Sequence 313, Application US/10293222
; Publication No. US20040033932A1
; GENERAL INFORMATION:
; APPLICANT: Versteeg, Rogier
; APPLICANT: Caron, Hubertus N.
; TITLE OF INVENTION: MYC targets
; FILE REFERENCE: 2183-5580US
; CURRENT APPLICATION NUMBER: US/10/293,222
; CURRENT FILING DATE: 2002-11-12
; PRIOR APPLICATION NUMBER: PCT/NL01/00361
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: EP 00201698.8
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: EP 00202284.6
; PRIOR FILING DATE: 2000-06-29
; NUMBER OF SEQ ID NOS: 455
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 313
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
; OTHER INFORMATION:
US-10-293-222-313

Query Match          37.0%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAAGTTA 2230
      |||||
Db 10 CCAAAAAGTTA 1

RESULT 7
US-10-033-145-571/c
; Sequence 571, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GA0201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 571
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
; OTHER INFORMATION:
US-10-033-145-571

Query Match          33.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222
      |||||
Db 9 AGTGTGACC 1

RESULT 8
US-09-918-715-62
; Sequence 62, Application US/09918715
; Publication No. US20030017157A1
; GENERAL INFORMATION:
; APPLICANT: Brad St. Croix
```

```
; APPLICANT: Bert Vogelstein
; APPLICANT: Kenneth Kinzler
; TITLE OF INVENTION: ENDOTHELIAL CELL EXPRESSION PATTERNS
; FILE REFERENCE: 1107.00134
; CURRENT APPLICATION NUMBER: US/09/918,715
; CURRENT FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: 60/222,599
; PRIOR FILING DATE: 2000-08-02
; PRIOR APPLICATION NUMBER: 60/224,360
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/282,850
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 62
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-918-715-62

Query Match      33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2212 AGAGTGTGA 2220
Db      3 AGAGTGTGA 11

RESULT 9
US-09-986-944-2/c
; Sequence 2, Application US/09985944
; Patent No. US20020072589A1
; GENERAL INFORMATION:
; APPLICANT: Desmond MASCARENHAS
; APPLICANT: David PASSMORE
; APPLICANT: Stephen DANKO
; TITLE OF INVENTION: INSULIN-LIKE GROWTH FACTOR BINDING
; TITLE OF INVENTION: PROTEIN VARIANTS
; FILE REFERENCE: 22095209100
; CURRENT APPLICATION NUMBER: US/09/986,944
; CURRENT FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 09/322,484
; PRIOR FILING DATE: 1999-05-27
; PRIOR APPLICATION NUMBER: 60/087,559
; PRIOR FILING DATE: 1998-06-01
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
; US-09-986-944-2

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2226 AGTTACATGT 2235
Db      10 AATTACATGT 1

RESULT 10
US-10-329-465-30/c
; Sequence 30, Application US/10329465
; Publication No. US20030165949A1
; GENERAL INFORMATION:
; APPLICANT: Wang et al.
; TITLE OF INVENTION: GENES ABNORMALLY EXPRESSED IN MYELOID LEUKEMIA CELLS WITH AN MLL-
; TITLE OF INVENTION: FUSION
; FILE REFERENCE: 27373/37928A
; CURRENT APPLICATION NUMBER: US/10/329,465
```

```
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/343,826
; PRIOR FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 315
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; US-10-329-465-30

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2214 AGTGTGACCA 2223
Db      10 AGTATGACCA 1

RESULT 11
US-10-223-765-213
; Sequence 213, Application US/10223765
; Publication No. US20030165997A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jin-Soo
; APPLICANT: Bae, Kwang-Hee
; APPLICANT: Park, Kyung-Soon
; APPLICANT: Kwon, Young Do
; APPLICANT: Ryu, Eun-Hyun
; APPLICANT: Hwang, Moon-Sun
; TITLE OF INVENTION: ZINC FINGER DOMAIN LIBRARIES
; FILE REFERENCE: 12279-005001
; CURRENT APPLICATION NUMBER: US/10/223,765
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: 60/374,355
; PRIOR FILING DATE: 2002-04-22
; PRIOR APPLICATION NUMBER: 60/313,402
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 305
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetically generated oligonucleotide
; US-10-223-765-213

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2213 GAGTGTGACC 2222
Db      1 GAGTGAGACC 10

RESULT 12
US-10-330-627-88
; Sequence 88, Application US/10330627
; Publication No. US20030175771A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
```

```
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-88

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2221 CCAAAAGTTA 2230
Db 1 CAAAAGTTA 10

RESULT 13
US-10-330-627-150
; Sequence 150, Application US/10330627
; Publication No. US20030175771A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330.627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 150
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-150

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2218 TGACCAAAAG 2227
Db 1 TGACCAATAG 10

RESULT 14
US-10-330-627-202/c
; Sequence 202, Application US/10330627
; Publication No. US20030175771A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330.627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 202
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-202

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2216 TGTGACCAAA 2225
Db 10 TGTAAACCAAA 1

RESULT 15
US-10-330-627-204/c
; Sequence 204, Application US/10330627
; Publication No. US20030175771A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330.627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 204
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-204

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2216 TGTGACCAAA 2225
Db 10 TGTAAACCAAA 1

RESULT 16
US-10-423-621-11
; Sequence 11, Application US/10423621
; Publication No. US20040033518A1
; GENERAL INFORMATION:
; APPLICANT: The University of Utah
; TITLE OF INVENTION: Characterization of Single Stranded Nucleic Acids By Melting
; TITLE OF INVENTION: Analysis of Secondary Structure Using Double Strand-Specific
; FILE REFERENCE: A-70575-1
; CURRENT APPLICATION NUMBER: US/10/423.621
; CURRENT FILING DATE: 2003-04-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-423-621-11

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2220 ACCAAAAGTT 2229
Db 1 ACCAAAAGT 10

RESULT 17
US-09-989-789-1315
; Sequence 1315, Application US/09989789
; Patent No. US20020063379A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
```


;
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1315
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-989-789-1315

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 18
US-09-989-789-1323
; Sequence 1323, Application US/09989789
; Publication No. US20020063379A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1323
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-989-789-1323

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 19
US-09-989-789-1324
; Sequence 1324, Application US/09989789
; Patent No. US20020063379A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1324
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence

;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-989-789-1324

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 20
US-09-990-186-1315
; Sequence 1315, Application US/09990186
; Publication No. US20030068675A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.21 / S11-US3
; CURRENT APPLICATION NUMBER: US/09/990,186
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1315
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-990-186-1315

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 21
US-09-990-186-1323
; Sequence 1323, Application US/09990186
; Publication No. US20030068675A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.21 / S11-US3
; CURRENT APPLICATION NUMBER: US/09/990,186
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1323
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-990-186-1323

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||


```
; ORGANISM: Homo sapiens
US-10-033-145-639

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2224 AAAGTTAC 2231
Db      3 AAAGTTAC 10

RESULT 27
US-10-033-145-697/c
; Sequence 697, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GA0201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 697
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-145-697

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2221 CCAAAAGT 2228
Db      9 CCAAAAGT 2

RESULT 28
US-10-033-145-1053/c
; Sequence 1053, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GA0201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1053
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-145-1053

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2226 AGTTACAT 2233
Db      10 AGTTACAT 3
```

```
RESULT 29
US-10-330-627-1311/c
; Sequence 1311, Application US/10330627
; Publication No. US2003017571A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq For Windows Version 4.0
; SEQ ID NO 1311
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-1311

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2221 CCAAAAGT 2228
Db      9 CCAAAAGT 2

RESULT 30
US-10-091-281-239
; Sequence 239, Application US/10091281
; Publication No. US2003019061A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 239
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative VBPF/VBP.01 motif
US-10-091-281-239

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2228 TTACATGT 2235
Db      2 TTACATGT 9

RESULT 31
US-10-160-401-28
; Sequence 28, Application US/10160401
; Publication No. US20030207281A1
; GENERAL INFORMATION:
; APPLICANT: Genesance Pharmaceuticals, Inc.
; APPLICANT: Bentivegna, Steven C.
; APPLICANT: Biesiecki, Karyn M.
; APPLICANT: Koshy, Beena
; APPLICANT: Monroe, Glen
```

```

; APPLICANT: Rounds, Eileen
; TITLE OF INVENTION: HAPLOTYPES OF THE CXCR4 GENE
; FILE REFERENCE: MWH-0121US
; CURRENT APPLICATION NUMBER: US/10/160,401
; PRIOR FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: PCT/US01/12268
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: US 60/197,025
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-160-401-28

```

```

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred.No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 2223 AAAAGTTA 2230
   |||||
Db 3 AAAAGTTA 10

```

Search completed: November 18, 2004, 08:18:59
Job time : 0.001 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:20:33 ; Search time 0.001 Seconds
(without alignments)
9.828 Million cell updates/sec

Title: US-10-006-191-19

Perfect score: 27
Sequence: 1 agagtgtgacaaaagtacatgtttg 27

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 17 seqs, 182 residues

Total number of hits satisfying chosen parameters: 34

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 18 summaries

Database : rst19.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %	Match	Length	DB ID	Description
C 1	12.8	47.4	17	1	AJ592065	ACCESSION:AJ592065
C 2	9.4	34.8	12	1	AJ587276	ACCESSION:AJ587276
C 3	9.4	34.8	13	1	CAB51722	ACCESSION:CAB51722
C 4	8.8	32.6	12	1	AJ587214	ACCESSION:AJ587214
C 5	8.4	31.1	10	1	AJ587288	ACCESSION:AJ587288
C 6	8.4	31.1	10	1	CL437117	ACCESSION:CL437117
C 7	8.4	31.1	10	1	CL437320	ACCESSION:CL437320
C 8	8	29.6	10	1	CL438191	ACCESSION:CL438191
C 9	7.4	27.4	10	1	AJ587436	ACCESSION:AJ587436
C 10	7.4	27.4	10	1	AJ587438	ACCESSION:AJ587438
C 11	7.4	27.4	10	1	CL435950	ACCESSION:CL435950
C 12	7.4	27.4	10	1	CL439224	ACCESSION:CL439224
C 13	7	25.9	10	1	CL436271	ACCESSION:CL436271
C 14	7	25.9	10	1	CL437495	ACCESSION:CL437495
C 15	7	25.9	10	1	CL437824	ACCESSION:CL437824
C 16	7	25.9	12	1	AJ587214	ACCESSION:AJ587214
C 17	6.4	23.7	9	1	CF300175	ACCESSION:CF300175
C 18	6.4	23.7	9	1	CF301840	ACCESSION:CF301840

ALIGNMENTS

RESULT 1
AJ592065/c
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, right border, clone
602E03, genomic survey sequence.
ACCESSION AJ592065
VERSION AJ592065.1 GI:37941689
KEYWORDS GSS; right border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana

REFERENCE AUTHORS

1 Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.

TITLE

T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites

JOURNAL

EMBO Rep. 3 (12), 1152-1157 (2002)

MEDLINE

22363535

PUBMED

12446565

REFERENCE

2 (bases 1 to 17)

AUTHORS

Balzergue, S.

TITLE

Direct Submission

JOURNAL

Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue

COMMENT

Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.inbio.gen.fr/>).

FEATURES

source

1..17

/organism="Arabidopsis thaliana"

/mol_type="genomic DNA"

/cultivar="Wassillewskija"

/db_xref="taxon:3702"

/clone="602E03"

/clone_lib="Arabidopsis thaliana T-DNA insertion lines"

misc_feature

1..17

/note="T-DNA flanking sequence

right border"

Query Match 47.4%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 0.18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTACATCTTTG 2238

|||||

17 AAAAGTACATCTTTG 2

RESULT 2

AJ587276/c

LOCUS

DEFINITION

Arabidopsis thaliana T-DNA flanking sequence, left border, clone

257E01, genomic survey sequence.

ACCESSION

AJ587276

VERSION

AJ587276.1 GI:37936865

KEYWORDS

GSS; left border; T-DNA flanking sequence.

SOURCE

Arabidopsis thaliana (thale cress)

ORGANISM

Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

1

AUTHORS

Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.

T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

22363535

PUBMED

12446565

REFERENCE

2 (bases 1 to 12)

AUTHORS

Balzergue, S.

TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
source 1..12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="257501"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1..12
/note="T-DNA flanking sequence
left border"

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.3;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
|||||
Db 11 AAAATTACAT 1

RESULT 3
LOCUS CA851722
DEFINITION D16G12_N24.14.abi cDNA Peking library 2, 4 day SCN3 Glycine max
ACCESSION CA851722
VERSION CA851722.1 GI:33388515
KEYWORDS EST.
SOURCE Glycine max (soybean)
ORGANISM Glycine max
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae; Glycine.

REFERENCE 1 (bases 1 to 13)
Alkharouf, N.W., Khan, R. and Matthews, B.F.
Analysis of expressed sequence tags from roots of resistant soybean infected by the soybean cyst nematode
Unpublished (2002)
Contact: Alkharouf, N.W.
Soybean Genomics and Improvement Laboratory (SGIL)
US Department of Agriculture (USDA), ARS, PSI
Bldg. 006, Rm 118, 10300 Baltimore Ave., Beltsville, MD 20705-2350, USA
Tel: 301 504 5750
Fax: 301 504 5728
Email: alkharouf@ba.ars.usda.gov.

FEATURES
source 1..13
/organism="Glycine max"
/mol_type="mRNA"
/cultivar="Peking"
/db_xref="taxon:3847"
/clone="D16G12"
/tissue_type="Roots"
/dev_stage="Seedlings"
/clone_lib="cDNA Peking library 2, 4 day SCN3"
/note="Vector: pBluescript SK-; cDNA clones from mRNA

extracted from Peking roots 2 and 4 days past invasion."

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.1;
Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATG 2235
|||||
Db 1 AAAAATACATNT 13

RESULT 4
AJ587214
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone 243A02, genomic survey sequence.
DEFINITION AJ587214
ACCESSION AJ587214.1 GI:37936803
VERSION AJ587214.1
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (chale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE 1
Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Craud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
2363535
12446565
2 (bases 1 to 12)
Balzergue, S.
Direct Submission
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
source 1..12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="243A02"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1..12
/note="T-DNA flanking sequence
left border"

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 3.3;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
|||||
Db 1 AATAACATGTTT 12

RESULT 5
AJ587288/c
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone 243A02, genomic survey sequence.
DEFINITION AJ587288/c
ACCESSION AJ587288/c
VERSION AJ587288/c
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (chale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

```

DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
259D10 genomic survey sequence.
ACCESSION AJ581288
VERSION AJ581288.1 GI:37936877
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE 1
AUTHORS Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., Dekosse,R., Pelletier,G.,
Leplincic,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 10)
AUTHORS Balzergue,S.
TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES
    source
        Location/Qualifiers
            1..10
                /organism="Arabidopsis thaliana"
                /mol_type="genomic DNA"
                /cultivar="Wassilewskij"
                /db_xref="taxon:3702"
                /clone="259D10"
                /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
            misc_feature
                1..10
                /note="T-DNA flanking sequence
                left border"

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2224 AAGTTACAT 2233
Db 10 AAGTTGCAT 1

RESULT 6
CL437117/c
LOCUS CL437117
DEFINITION PST4537-NL.Seq MICB1 Mus musculus genomic clone PST4537-NL.Seq,
genomic survey sequence.
ACCESSION CL437117
VERSION CL437117.1 GI:45572568
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 10)
AUTHORS Hicks G.G.
TITLE www.EScells.ca
JOURNAL Unpublished (2002)
COMMENT Contact: Hicks GG

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST4537-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST4537-NL.Seq"
        /sex="Male"
        /cell_type="Embryonic stem cell"
        /cell_lines="D3H (J1 subclone)"
        /clone_lib="MICB1"
        /note="Vector: U3NeosV1"

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2225 AAGTTACATG 2234
Db 10 AAGTCACATG 1

RESULT 7
CL437320/c
LOCUS CL437320
DEFINITION PST5052-NL.Seq MICB1 Mus musculus genomic clone PST5052-NL.Seq,
genomic survey sequence.
ACCESSION CL437320
VERSION CL437320.1 GI:45572935
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 10)
AUTHORS Hicks,G.G.
TITLE www.EScells.ca
JOURNAL Unpublished (2002)
COMMENT Contact: Hicks GG

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST5052-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST5052-NL.Seq"
        /sex="Male"

```

```

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST4537-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST4537-NL.Seq"
        /sex="Male"

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2225 AAGTTACATG 2234
Db 10 AAGTCACATG 1

RESULT 7
CL437320/c
LOCUS CL437320
DEFINITION PST5052-NL.Seq MICB1 Mus musculus genomic clone PST5052-NL.Seq,
genomic survey sequence.
ACCESSION CL437320
VERSION CL437320.1 GI:45572935
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 10)
AUTHORS Hicks,G.G.
TITLE www.EScells.ca
JOURNAL Unpublished (2002)
COMMENT Contact: Hicks GG

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST5052-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST5052-NL.Seq"
        /sex="Male"

```

```

/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/notes="Vector: U3NeoSV1"

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2225 AAGTTACATG 2234
Db 10 AGGTTACATG 1

RESULT 8
CL438191
LOCUS
DEFINITION PST6982-NL.Seq MICB1 Mus musculus genomic clone PST6982-NL.Seq
similar to Gf2a1, genomic survey sequence.
ACCESSION CL438191
VERSION CL438191.1 GI:45574499
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Hicks,G.G.
1 (bases 1 to 10)
www.Escellis.ca
Unpublished (2002)
Contact: Hicks GG
Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicksgg@cc.umanitoba.ca
U3NeoSV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST6982-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
1..10
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST6982-NL.Seq"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/notes="Vector: U3NeoSV1"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2231 CATGTTTG 2238
Db 1 CATGTTTG 8

RESULT 9
AJ587436
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
277E10, genomic survey sequence.
ACCESSION AJ587436
VERSION AJ587436.1 GI:37937060

/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/notes="Vector: U3NeoSV1"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2231 CATGTTTG 2238
Db 1 CATGTTTG 8

RESULT 9
AJ587436
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
277E10, genomic survey sequence.
ACCESSION AJ587436
VERSION AJ587436.1 GI:37937060

```

```

GSS; left border; T-DNA flanking sequence.
Arabidopsis thaliana (thale cress)
Arabidopsis thaliana
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., Derose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
MEDLINE 22363535
PUBMED 12446585
REFERENCE
2 (bases 1 to 10)
Balzerque,S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr/).
Location/Qualifiers
1..10
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassilewskija"
/db_xref="taxon:3702"
/clone="277E10"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
1..10
misc_feature
/notes="T-DNA flanking sequence
left border"

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 9;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
Db 1 TACATGTTT 9

RESULT 10
AJ587438
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
277H05, genomic survey sequence.
ACCESSION AJ587438
VERSION AJ587438.1 GI:37937062
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., Derose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
MEDLINE 22363535

```


similar to Zfp162, genomic survey sequence.

ACCESSION CL436271
 VERSION CL436271.1 GI:45570909
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 10)
 Hicks,G.G.
 www.Escells.ca
 Unpublished (2002)
 Contact: Hicks GG
 Mammalian Functional Genomics Centre
 Manitoba Institute of Cell Biology, University of Manitoba
 ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
 Tel: 204 787 2133
 Fax: 204 787 2190
 Email: hicksgg@cc.umanitoba.ca
 U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES cell line harboring insertion mutation of target gene is available. Sequence analysis available from
 http://140.193.242.7/esdb/public_search_frame.php?PST=PST633-NR.Se

q
 Class: Gene Trap.

FEATURES
 source
 1..10
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="129 sv"
 /db_xref="taxon:10090"
 /clone="PST633-NR.Seq"
 /sex="Male"
 /cell_type="Embryonic stem cell"
 /cell_line="D3H (J1 subclone)"
 /clone_lib="MICB1"
 /note="Vector: U3NeosV1"

Query Match 25.9%; Score 7; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred.No.11;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 TGACCAA 2224
 |||||
 Db 7 TGACCAA 1

RESULT 14
 CL437495
 LOCUS CL437495
 DEFINITION PST5634-NL.Seq MICB1 Mus musculus genomic clone PST5634-NL.Seq, genomic survey sequence.
 ACCESSION CL437495
 VERSION CL437495.1 GI:45573235
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 10)
 Hicks,G.G.
 www.Escells.ca
 Unpublished (2002)
 Contact: Hicks GG
 Mammalian Functional Genomics Centre
 Manitoba Institute of Cell Biology, University of Manitoba
 ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
 Tel: 204 787 2133
 Fax: 204 787 2190
 Email: hicksgg@cc.umanitoba.ca
 U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES

cell line harboring insertion mutation of target gene is available. Sequence analysis available from
 http://140.193.242.7/esdb/public_search_frame.php?PST=PST5634-NL.Se

q

Class: Gene Trap.
 Location/Qualifiers
 1..10
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="129 sv"
 /db_xref="taxon:10090"
 /clone="PST5634-NL.Seq"
 /sex="Male"
 /cell_type="Embryonic stem cell"
 /cell_line="D3H (J1 subclone)"
 /clone_lib="MICB1"
 /note="Vector: U3NeosV1"

Query Match 25.9%; Score 7; DB 1; Length 10;
 Best Local Similarity 87.5%; Pred.No.11;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2231 CATGTTTG 2238
 |||||
 Db 1 CATGNTG 8

RESULT 15
 CL437824/c
 LOCUS CL437824
 DEFINITION PST632-NR.Seq MICB1 Mus musculus genomic clone PST632-NR.Seq, genomic survey sequence.
 ACCESSION CL437824
 VERSION CL437824.1 GI:45573802
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 10)
 Hicks,G.G.
 www.Escells.ca
 Unpublished (2002)
 Contact: Hicks GG
 Mammalian Functional Genomics Centre
 Manitoba Institute of Cell Biology, University of Manitoba
 ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
 Tel: 204 787 2133
 Fax: 204 787 2190
 Email: hicksgg@cc.umanitoba.ca
 U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES cell line harboring insertion mutation of target gene is available. Sequence analysis available from
 http://140.193.242.7/esdb/public_search_frame.php?PST=PST632-NR.Se

q

Class: Gene Trap.
 Location/Qualifiers
 1..10
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="129 sv"
 /db_xref="taxon:10090"
 /clone="PST632-NR.Seq"
 /sex="Male"
 /cell_type="Embryonic stem cell"
 /cell_line="D3H (J1 subclone)"
 /clone_lib="MICB1"
 /note="Vector: U3NeosV1"

Query Match 25.9%; Score 7; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred.No.11;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAG 2227
 Db 9 CCAAAG 3

RESULT 16
 AJ587214/c 12 bp DNA linear GSS 15-JAN-2004
 LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone
 DEFINITION 243A02, genomic survey sequence.

ACCESSION AJ587214
 VERSION AJ587214.1 GI:37936803
 KEYWORDS GSS; left border; T-DNA flanking sequence.
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1
 AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
 Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
 Lepiniec, L., Caboche, M. and Lecharny, A.
 TITLE T-DNA integration into the Arabidopsis genome depends on sequences
 of pre-insertion sites
 JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
 MEDLINE 22363535
 PUBMED 12446565

REFERENCE 2 (bases 1 to 12)
 AUTHORS Balzerque, S.
 TITLE Direct Submission
 JOURNAL Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
 Gaston Cremieux, 91057 Evry cedex, FRANCE

COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
 plants from INRA (Versailles). The DNA fragment(s) resulting from
 the PCR were directly sequenced from the left or the right border
 to determine the genomic sequence flanking the insertion. T-DNA
 derived sequences were removed. Information to order the
 corresponding mutant line and a link to a database providing a
 graphical display of the insertion site are available at
 http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
 been generated in the framework of the French plant genomics
 program 'Genoplante' (http://www.genoplante.com and
 http://genoplante-info.infobiogen.fr).

FEATURES
 source
 1..12
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Wassilewskija"
 /db_xref="taxon:3702"
 /clone="243A02"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 misc_feature
 1..12
 /note="T-DNA flanking sequence
 left border"

Query Match 25.98; Score 7; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 9.3;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2230 ACATGTT 2236
 Db 10 ACATGTT 4

RESULT 17
 CF300175 9 bp mRNA linear EST 15-AUG-2003
 LOCUS 7LEAF--04-H16.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
 DEFINITION sativa (japonica cultivar-group) cDNA clone 7LEAF--04-H16, mRNA
 sequence.

ACCESSION CF300175
 VERSION CF300175.1 GI:33671936

KEYWORDS EST.
 SOURCE Oryza sativa (japonica cultivar-group)
 ORGANISM Oryza sativa (japonica cultivar-group)
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE 1 (bases 1 to 9)
 AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
 Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
 TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)
 COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnam@ggbio.com, bhnam@bio.myongji.ac.kr.
 Location/Qualifiers
 1..9
 /organism="Oryza sativa (japonica cultivar-group)"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:39947"
 /clone="7LEAF--04-H16"
 /tissue_type="leaf"
 /dev_stage="7 days after germination"
 /lab_host="E.coli DH10B"
 /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
 /note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
 with oligoribonucleotides and then used as templates for
 RT-PCR."

Query Match 23.7%; Score 6.4; DB 1; Length 9;
 Best Local Similarity 87.5%; Pred. No. 36;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTA 2230
 Db 2 AAAAGTTA 9

RESULT 18
 CF301840 9 bp mRNA linear EST 15-AUG-2003
 LOCUS 7LEAF--06-N14.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
 DEFINITION sativa (japonica cultivar-group) cDNA clone 7LEAF--06-N14, mRNA
 sequence.

ACCESSION CF301840
 VERSION CF301840.1 GI:33673601
 KEYWORDS EST.
 SOURCE Oryza sativa (japonica cultivar-group)
 ORGANISM Oryza sativa (japonica cultivar-group)
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE 1 (bases 1 to 9)
 AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
 Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
 TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)
 COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnam@ggbio.com, bhnam@bio.myongji.ac.kr.
 Location/Qualifiers
 1..9
 /organism="Oryza sativa (japonica cultivar-group)"
 /mol_type="mRNA"
 /cultivar="Nackdong"

```

/db_xref="taxon:39947"
/clone="7LEAF-06-N14"
/tissue_type="leaf"
/dev_stages="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

```

```

Query Match      23.7%; Score 6.4; DB 1; Length 9;
Best Local Similarity 87.5%; Pred.No.36;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 2223 AAAAGTTA 2230
    |||||
Db 1 AAAATTGA 8

```

```

Search completed: November 18, 2004, 08:20:33
Job time : 0.001 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:14:46 ; Search time 1 Seconds
(without alignments)
0.106 Million cell updates/sec

Title: US-10-006-191-19
Perfect score: 27
Sequence: 1 agagtgaccacaaagtacattgttg 27

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 178 seqs, 1971 residues

Total number of hits satisfying chosen parameters: 356

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 179 summaries

Database : rge19.seq*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	14.4	53.3	20	1	AX201565
C 2	12.2	45.2	17	1	AX306622
C 3	12.2	45.2	17	1	AX735739
C 4	11.4	42.2	15	1	AR179963
C 5	10.8	40.0	15	1	A00722
C 6	10.8	37.0	10	1	AX301599
C 7	9.4	34.8	11	1	AX190692
C 8	9.4	34.8	11	1	AX190703
C 9	9.4	34.8	11	1	AX623188
C 10	9.4	34.8	11	1	AX624319
C 11	9.4	34.8	11	1	AX628728
C 12	9.4	34.8	11	1	AX630609
C 13	9.4	34.8	11	1	AX6311740
C 14	9.4	34.8	12	1	AR343744
C 15	9.4	34.8	13	1	AR279729
C 16	9.4	34.8	13	1	ATH530046
C 17	9.4	34.8	13	1	ATH530079
C 18	9.4	34.8	13	1	BD239153
C 19	9.4	34.8	13	1	BD239153
C 20	9.4	34.8	13	1	BD239153
C 21	9.4	34.8	13	1	BD239153
C 22	9.4	34.8	13	1	BD239153
C 23	9.4	34.8	13	1	BD239153
C 24	9.4	34.8	13	1	BD239153
C 25	9.4	34.8	13	1	BD239153
C 26	9.4	34.8	13	1	BD239153
C 27	9.4	34.8	13	1	BD239153
C 28	9.4	34.8	13	1	BD239153
C 29	9.4	34.8	13	1	BD239153
C 30	9.4	34.8	13	1	BD239153
C 31	9.4	34.8	13	1	BD239153
C 32	9.4	34.8	13	1	BD239153
C 33	9.4	34.8	13	1	BD239153

C 34	8.4	31.1	11	1	BD174614
C 35	8.4	31.1	11	1	CQ828431
C 36	8.4	31.1	11	1	CQ828449
C 37	8.4	31.1	11	1	CQ833045
C 38	8.4	31.1	11	1	CQ833265
C 39	8.4	31.1	11	1	CQ833328
C 40	8.4	31.1	11	1	CQ833707
C 41	8.4	31.1	11	1	CQ833903
C 42	8.4	31.1	11	1	CQ835443
C 43	8.4	31.1	11	1	CQ835784
C 44	8.4	31.1	11	1	CQ835979
C 45	8.4	31.1	11	1	CQ836035
C 46	8.4	31.1	11	1	CQ836131
C 47	8.4	31.1	11	1	CQ837874
C 48	8.4	31.1	11	1	AX175020
C 49	8.4	31.1	11	1	AX175021
C 50	8.4	31.1	11	1	AX393176
C 51	8.4	31.1	11	1	AX470684
C 52	8.4	31.1	11	1	AX471221
C 53	8.4	31.1	11	1	AX471460
C 54	8.4	31.1	11	1	AX471712
C 55	8.4	31.1	11	1	AX623270
C 56	8.4	31.1	11	1	AX624779
C 57	8.4	31.1	11	1	AX625318
C 58	8.4	31.1	11	1	AX625811
C 59	8.4	31.1	11	1	AX626606
C 60	8.4	31.1	11	1	AX626934
C 61	8.4	31.1	11	1	AX627178
C 62	8.4	31.1	11	1	AX627466
C 63	8.4	31.1	11	1	AX627566
C 64	8.4	31.1	11	1	AX627903
C 65	8.4	31.1	11	1	AX628167
C 66	8.4	31.1	11	1	AX629648
C 67	8.4	31.1	11	1	AX629854
C 68	8.4	31.1	11	1	AX630691
C 69	8.4	31.1	11	1	AX632200
C 70	8.4	31.1	11	1	AX632739
C 71	8.4	31.1	12	1	CQ766537
C 72	8.4	31.1	12	1	CQ766563
C 73	8.4	31.1	12	1	I38923
C 74	8.4	31.1	12	1	I87954
C 75	8.4	31.1	12	1	AX572515
C 76	8.4	31.1	12	1	E02036
C 77	8.4	31.1	12	1	AR176517
C 78	8.4	31.1	12	1	BD239221
C 79	8.4	31.1	12	1	BD239279
C 80	8.4	31.1	12	1	BD239635
C 81	8.4	31.1	12	1	Q828615
C 82	8.4	31.1	12	1	AR303494
C 83	8.4	31.1	12	1	AR351773
C 84	8.4	31.1	12	1	AR351781
C 85	8.4	31.1	12	1	AR351782
C 86	8.4	31.1	12	1	AX153396
C 87	8.4	31.1	12	1	AX667866
C 88	8.4	31.1	12	1	AX667874
C 89	8.4	31.1	12	1	AX667875
C 90	8.4	31.1	12	1	AX955930
C 91	8.4	31.1	12	1	BD07825
C 92	8.4	31.1	12	1	BD166573
C 93	8.4	31.1	12	1	Q833105
C 94	8.4	31.1	12	1	Q833109
C 95	8.4	31.1	12	1	Q836060
C 96	8.4	31.1	12	1	Q836293
C 97	8.4	31.1	12	1	AR301541
C 98	8.4	31.1	12	1	AX470578
C 99	8.4	31.1	12	1	AX472174
C 100	8.4	31.1	12	1	AX625287
C 101	8.4	31.1	12	1	AX625400
C 102	8.4	31.1	12	1	AX625627
C 103	8.4	31.1	12	1	AX626945
C 104	8.4	31.1	12	1	AX627307
C 105	8.4	31.1	12	1	AX627680
C 106	8.4	31.1	12	1	AX628092

C 34	8.4	31.1	11	1	BD174614
C 35	8.4	31.1	11	1	CQ828431
C 36	8.4	31.1	11	1	CQ828449
C 37	8.4	31.1	11	1	CQ833045
C 38	8.4	31.1	11	1	CQ833265
C 39	8.4	31.1	11	1	CQ833328
C 40	8.4	31.1	11	1	CQ833707
C 41	8.4	31.1	11	1	CQ833903
C 42	8.4	31.1	11	1	CQ835443
C 43	8.4	31.1	11	1	CQ835784
C 44	8.4	31.1	11	1	CQ835979
C 45	8.4	31.1	11	1	CQ836035
C 46	8.4	31.1	11	1	CQ836131
C 47	8.4	31.1	11	1	CQ837874
C 48	8.4	31.1	11	1	AX175020
C 49	8.4	31.1	11	1	AX175021
C 50	8.4	31.1	11	1	AX393176
C 51	8.4	31.1	11	1	AX470684
C 52	8.4	31.1	11	1	AX471221
C 53	8.4	31.1	11	1	AX471460
C 54	8.4	31.1	11	1	AX471712
C 55	8.4	31.1	11	1	AX623270
C 56	8.4	31.1	11	1	AX624779
C 57	8.4	31.1	11	1	AX625318
C 58	8.4	31.1	11	1	AX625811
C 59	8.4	31.1	11	1	AX626606
C 60	8.4	31.1	11	1	AX626934
C 61	8.4	31.1	11	1	AX627178
C 62	8.4	31.1	11	1	AX627466
C 63	8.4	31.1	11	1	AX627566
C 64	8.4	31.1	11	1	AX627903
C 65	8.4	31.1	11	1	AX628167
C 66	8.4	31.1	11	1	AX629648
C 67	8.4	31.1	11	1	AX629854
C 68	8.4	31.1	11	1	AX630691
C 69	8.4	31.1	11	1	AX632200
C 70	8.4	31.1	11	1	AX632739
C 71	8.4	31.1	12	1	CQ766537
C 72	8.4	31.1	12	1	CQ766563
C 73	8.4	31.1	12	1	I38923
C 74	8.4	31.1	12	1	I87954
C 75	8.4	31.1	12	1	AX572515
C 76	8.4	31.1	12	1	E02036
C 77	8.4	31.1	12	1	AR176517
C 78	8.4	31.1	12	1	BD239221
C 79	8.4	31.1	12	1	BD239279
C 80	8.4	31.1	12	1	BD239635
C 81	8.4	31.1	12	1	Q828615
C 82	8.4	31.1	12	1	AR303494
C 83	8.4	31.1	12	1	AR351773
C 84	8.4	31.1	12	1	AR351781
C 85	8.4	31.1	12	1	AR351782
C 86	8.4	31.1	12	1	AX153396
C 87	8.4	31.1	12	1	AX667866
C 88	8.4	31.1	12	1	AX667874
C 89	8.4	31.1	12	1	AX667875
C 90	8.4	31.1	12	1	AX955930
C 91	8.4	31.1	12	1	BD07825
C 92	8.4	31.1	12	1	BD166573
C 93	8.4	31.1	12	1	Q833105
C 94	8.4	31.1	12	1	Q833109
C 95	8.4	31.1	12	1	Q836060
C 96	8.4	31.1	12	1	Q836293
C 97	8.4	31.1	12	1	AR301541
C 98	8.4	31.1	12	1	AX470578
C 99	8.4	31.1	12	1	AX472174
C 100	8.4	31.1	12	1	AX625287
C 101	8.4	31.1	12	1	AX625400
C 102	8.4	31.1	12	1	AX625627
C 103	8.4	31.1	12	1	AX626945
C 104	8.4	31.1	12	1	AX627307
C 105	8.4	31.1	12	1	AX627680
C 106	8.4	31.1	12	1	AX628092

11 1 AX632708
 11 1 BD124291
 11 1 BD241065
 11 1 Q828430
 11 1 Q832851
 11 1 Q833007
 11 1 Q833297
 11 1 Q833314
 11 1 Q833337
 11 1 Q833857
 11 1 Q835548
 11 1 Q835599
 11 1 Q835746
 11 1 Q836423
 11 1 Q836724
 11 1 Q836996
 11 1 Q837135
 11 1 Q837140
 11 1 Q837309
 11 1 Q837817
 11 1 Q837851
 11 1 AX367561
 11 1 AX482566
 11 1 AX190714
 11 1 AX190725
 11 1 AX190727
 11 1 AX190728
 11 1 AX252926
 11 1 AX470847
 11 1 AX470905
 11 1 AX471379
 11 1 AX471509
 11 1 AX472091
 11 1 AX623259
 11 1 AX623274
 11 1 AX623312
 11 1 AX623525
 11 1 AX624334
 11 1 AX624403
 11 1 AX624408
 11 1 AX624854
 11 1 AX625019
 11 1 AX625472
 11 1 AX625510
 11 1 AX625578
 11 1 AX626006
 11 1 AX626175
 11 1 AX626353
 11 1 AX626353
 11 1 AX626437
 11 1 AX626538
 11 1 AX626611
 11 1 AX626972
 11 1 AX627073
 11 1 AX627090
 11 1 AX627203
 11 1 AX627736
 11 1 AX628352
 11 1 AX628372
 11 1 AX629084
 11 1 AX629205
 11 1 AX629421
 11 1 AX629615
 11 1 AX629663
 11 1 AX630680
 11 1 AX630695
 11 1 AX630733
 11 1 AX630946
 11 1 AX631755
 11 1 AX631824
 11 1 AX631829
 11 1 AX632275
 11 1 AX632440
 11 1 AX772275

ALIGNMENTS

RESULT 1
 AX201565/c
 LOCUS AX201565 20 bp DNA linear PAT 30-AUG-2001
 DEFINITION Sequence 244 from Patent WO0153486.
 ACCESSION AX201565
 VERSION AX201565.1 GI:15391412
 KEYWORDS synthetic construct
 ORGANISM synthetic construct
 SOURCE artificial sequences.
 REFERENCE 1
 AUTHORS Ashkenazi, A.J., Goddard, A., Godowski, P.J., Gurney, A.L.,
 Hillan, K.J., Marsters, S.A., Pan, J., Pitti, R.M., Roy, M.A., Smith, V.,
 Stone, D.M., Watanabe, C.K., and Wood, W.I.
 TITLE Compositions and methods for the treatment of tumour
 JOURNAL Patent: WO 0153486-A 244 26-JUL-2001;
 Genentech, Inc. (US)
 FEATURES
 source 1..20
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Synthetic Oligonucleotide Probe."
 Query Match 53.3%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 5;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2212 AGACTGTGACCAAG 2227
 |||||
 Db 20 AGAGTGACCAAG 5
 RESULT 2
 AX530622 17 bp DNA linear PAT 22-NOV-2002
 LOCUS AX530622
 DEFINITION Sequence 131 from Patent EP1239051.
 ACCESSION AX530622
 VERSION AX530622.1 GI:25253051
 KEYWORDS Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Shannon, M.
 TITLE Human pish-like protein 1
 JOURNAL Patent: EP 1239051-A 131 11-SEP-2002;
 Asomica, Inc. (US)
 FEATURES
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 45.2%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 13;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAGTTACATG 2234
 |||||
 Db 1 TCAGCAGAACTTACATG 17
 RESULT 3
 AX735739 17 bp DNA linear PAT 08-MAY-2003
 LOCUS AX735739
 DEFINITION Sequence 1329 from Patent WO03025177.

AX735739	/organism="synthetic construct"
AX735739.1 GI:30515016	/mol_type="unassigned DNA"
KEYWORDS	/db_xref="taxon:32630"
SOURCE	
ORGANISM	
Homo sapiens (human)	
Homosapiens	
REFERENCE	
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M.
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL	Patent: WO 03025177-A 1329 27-MAR-2003;
FEATURES	Molecular Engines Laboratories (PR) Location/Qualifiers source 1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match	45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred.No.13;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	2219 GACCAAAAGTTACATGT 2235
Db	1 GATCAAAAATTACCTGT 17
RESULT 4	
AX79963/c	
LOCUS	AX79963
DEFINITION	Sequence 31 from patent US 6333152.
ACCESSION	AX79963
VERSION	AX79963.1 GI:20221996
KEYWORDS	Unknown.
SOURCE	Unknown.
ORGANISM	Unclassified. 1 (bases 1 to 15) Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W. Gene expression profiles in normal and cancer cells Patent: US 6333152-A 31 25-DEC-2001; Location/Qualifiers source 1..15 /organism="unknown" /mol_type="unassigned DNA"
Query Match	42.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity	92.3%; Pred.No.18;
Matches	12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2222 CAAAGTTACATG 2234
Db	13 CAAAAAATACATG 1
RESULT 5	
AX0722/c	
LOCUS	AX0722
DEFINITION	Artificial sequence for oligonucleotide N10.
ACCESSION	AX0722
VERSION	AX0722.1 GI:344228
KEYWORDS	synthetic construct artificial sequences. 1 (bases 1 to 15) EUCARYOTIC EXPRESSION VECTORS Patent: WO 860926-A 41 13-FEB-1986; Location/Qualifiers source 1..15
Query Match	34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity	90.9%; Pred.No.37;
Matches	10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2223 AAAAGTTACAT 2233
Db	1 AAAAGTTACAT 1
RESULT 6	
AX301599/c	
LOCUS	AX301599
DEFINITION	Sequence 313 from Patent WO0185941.
ACCESSION	AX301599
VERSION	AX301599.1 GI:17382682
KEYWORDS	Homo sapiens (human)
SOURCE	Homosapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 Versteeg,R. and Caron,H.N. Myc targets TITLE JOURNAL Academisch Ziekenhuis bij de Universiteit van Amsterdam (NL) Location/Qualifiers source 1..10 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match	37.0%; Score 10; DB 1; Length 10;
Best Local Similarity	100.0%; Pred.No.24;
Matches	10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	2221 CCAAAAGTTA 2230
Db	10 CCAAAGTTA 1
RESULT 7	
AX190692/c	
LOCUS	AX190692
DEFINITION	Sequence 43 from Patent WO0142493.
ACCESSION	AX190692
VERSION	AX190692.1 GI:15143975
KEYWORDS	synthetic construct synthetic construct artificial sequences. 1 Olek,A. and Piepenbrock,C. Method for the parallel detection of the degree of methylation of genomic dna Patent: WO 0142493-A 43 14-JUN-2001; Epigenomics AG (DE) Location/Qualifiers source 1..11 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630" /note="chemisch vorbehandelte Genom-DNA"
Query Match	34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity	90.9%; Pred.No.37;
Matches	10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2223 AAAAGTTACAT 2233
Db	1 AAAAGTTACAT 1

```

Db      11 AAAAATTACAT 1

RESULT 8
LOCUS   AX190703
DEFINITION Sequence 54 from Patent WO0142493.
ACCESSION AX190703
VERSION   AX190703.1 GI:15143987
KEYWORDS
SOURCE   synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
AUTHORS Olek,A. and Piepenbrock,C.
TITLE    Method for the parallel detection of the degree of methylation of
JOURNAL  genomic dna
          Patent: WO 0142493-A 54 14-JUN-2001;
          Epigenomics AG (DE)
FEATURES
          Location/Qualifiers
            source
              1..11
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2220 ACCAAAGTTA 2230
Db      11 ACCAAAGTTAA 1

RESULT 11
LOCUS   AX628728/c
DEFINITION Sequence 5769 from Patent WO02053774.
ACCESSION AX628728
VERSION   AX628728.1 GI:28456766
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE    Method for determining homeostasis of the skin
JOURNAL  Patent: WO 02053774-A 1360 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
          Location/Qualifiers
            source
              1..11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2222 CAAAAGTTACA 2232
Db      11 CAAAAGTTACA 1

RESULT 12
LOCUS   AX630609/c
DEFINITION Sequence 7650 from Patent WO02053774.
ACCESSION AX630609
VERSION   AX630609.1 GI:28458647
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE    Method for determining homeostasis of the skin
JOURNAL  Patent: WO 02053774-A 7650 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
          Location/Qualifiers
            source
              1..11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACAT 2233
Db      11 AAAAGTTACAT 1

RESULT 9
LOCUS   AX623188/c
DEFINITION Sequence 229 from Patent WO02053774.
ACCESSION AX623188
VERSION   AX623188.1 GI:28451129
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE    Method for determining homeostasis of the skin
JOURNAL  Patent: WO 02053774-A 229 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
          Location/Qualifiers
            source
              1..11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACAT 2233
Db      11 AAAAGTTACAT 1

RESULT 10
LOCUS   AX624319/c
DEFINITION Sequence 1360 from Patent WO02053774.
ACCESSION AX624319
VERSION   AX624319.1 GI:28452260
KEYWORDS

```



```

misc_feature 1..13
/notes="T-DNA flanking sequence
left border"

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
||| |||||
Db 12 AAACGTTACAT 2

RESULT 17
ATHS30079/c
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone
201H01.
ACCESSION AJ530079.1 GI:26798339
VERSION left border; T-DNA flanking sequence.
KEYWORDS Arabidopsis thaliana (thale cress)
SOURCE Arabidopsis thaliana
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE 1
AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Sanson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., Denose, R., Pelletier, G.,
Lepiniec, L., Caboche, M., and Lecharny, A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 13)
AUTHORS Balzerque, S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap-versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.inbio.gen.fr).
FEATURES
source
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskij"
/db_xref="taxon:3702"
/clone="201H01"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1..13
/notes="T-DNA flanking sequence
left border"

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
||| |||||
Db 12 AAACGTTACAT 2

RESULT 18

```

```

BD239153/c
LOCUS Preparation and use of superior vaccines.
DEFINITION BD239153
ACCESSION BD239153
VERSION BD239153.1 GI:33048923
KEYWORDS JP 2002534056-A/571.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 10)
AUTHORS Roberts, B.L. and Shankara, S.
TITLE Preparation and use of superior vaccines
JOURNAL Patent: JP 2002534056-A 571 15-OCT-2002;
GENZYME CORP
COMMENT OS Homo sapiens (human)
PN JP 2002534056-A/571
PD 15-OCT-2002
PF 18-JUN-1998 JP 2000554749
PR 19-JUN-1998 US 60/090039, 19-JUN-1998 US 60/090040 PR
19-JUN-1998 US 60/090041, 19-JUN-1998 US 60/089853 PR
19-JUN-1998 US 60/089957, 19-JUN-1998 US 60/090079 PR
19-JUN-1998 US 60/090035, 19-JUN-1998 US 60/089993 PR
19-JUN-1998 US 60/089952, 19-JUN-1998 US 60/090072 PR
19-JUN-1998 US 60/089878, 19-JUN-1998 US 60/089991 PR
19-JUN-1998 US 60/090000, 19-JUN-1998 US 60/090048 PR
19-JUN-1998 US 60/089999, 19-JUN-1998 US 60/090043 PR
19-JUN-1998 US 60/090042, 19-JUN-1998 US 60/090036 PR
19-JUN-1998 US 60/090044, 19-JUN-1998 US 60/089844 PR
19-JUN-1998 US 60/090080, 19-JUN-1998 US 60/089833 PR
19-JUN-1998 US 60/089994, 19-JUN-1998 US 60/090077 PR
19-JUN-1998 US 60/090078, 19-JUN-1998 US 60/090047 PR
19-JUN-1998 US 60/090076, 19-JUN-1998 US 60/090045 PR
08-DEC-1998 US 60/111715
PI BRUCE L. ROBERTS, SRINIVAS SHANKARA
PC C12N15/09, C12N15/09, A61K39/00, A61P35/00, A61P37/04, C12N1/15, PC
C12N1/19, C12N5/10, G01N33/15, G01N33/50, G01N33/53, G01N33/566, PC
G01N37/00,
PC C12N15/00, C12N5/00, C12N15/00
CC Preparation and use of superior vaccines
FH Key Location/Qualifiers
FT source 1..10
/organism="Homo sapiens (human)"
/organism="Homo sapiens"
/mb_type="genomic DNA"
/db_xref="taxon:9606"
/Location/Qualifiers
1..10
/Location/Qualifiers
source
1..10
/organism="Homo sapiens"
/mb_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 33.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222
|||||
Db 9 AGTGTGACC 1

RESULT 19
CQ835434
LOCUS Sequence 492 from Patent WO2004059001.
DEFINITION CQ835434
ACCESSION CQ835434
VERSION CQ835434.1 GI:50834968
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn, D., Schlottmann, K., Gassenmeier, T., Holtkoetter, O.,
Conradt, M. and Hofmann, K.

```

TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 432 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
source

1. .11

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2218 TGACCAAAA 2226

Db 1 TGACCAAAA 9

RESULT 20

CQ837632/c CQ837632 11 bp DNA linear PAT 29-JUL-2004
LOCUS Sequence 2690 from Patent WO2004059001.

DEFINITION CQ837632

ACCESSION CQ837632

VERSION CQ837632.1 GI:50837166

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,

Conradt,M. and Hofmann,K.

TITLE Method for determining markers of human facial skin

JOURNAL Patent: WO 2004059001-A 2690 15-JUL-2004;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES Location/Qualifiers

1. .11

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTT 2229

Db 9 CCAAAAGTT 1

RESULT 21

AX393132 AX393132 11 bp DNA linear PAT 23-MAR-2002
LOCUS Sequence 62 from Patent WO0210217.

DEFINITION AX393132

ACCESSION AX393132

VERSION AX393132.1 GI:19701182

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS St Croix,B., Kinzler,K.W. and Vogelstein,B.

TITLE Endothelial cell expression patterns

JOURNAL Patent: WO 0210217-A 62 07-FEB-2002;

The Johns Hopkins University (US)

FEATURES Location/Qualifiers

1. .11

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2212 AGAGTGGA 2220

Db 3 AGAGTGGA 11

RESULT 22

AX623097

LOCUS AX623097

DEFINITION Sequence 138 from Patent WO02053774.

ACCESSION AX623097

VERSION AX623097.1 GI:28451038

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.

TITLE Method for determining homeostasis of the skin

JOURNAL Patent: WO 02053774-A 138 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES Location/Qualifiers

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2212 AGAGTGGA 2220

Db 3 AGAGTGGA 11

RESULT 23

AX626998/c

LOCUS AX626998

DEFINITION Sequence 4039 from Patent WO02053774.

ACCESSION AX626998

VERSION AX626998.1 GI:28455036

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.

TITLE Method for determining homeostasis of the skin

JOURNAL Patent: WO 02053774-A 4039 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES Location/Qualifiers

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTT 2229

Db 11 CCAAAAGTT 3

RESULT 24

AX630518

LOCUS AX630518

mcgarry191-19.rge

Thu Nov 18 12:41:57 2004

JOURNAL Patent: US 5686242-A 5 11-NOV-1997;
 FEATURES Location/Qualifiers
 source 1..10
 /organism="unknown"
 /mol_type="unassigned DNA"
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 55;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2215 GTGTGAGCAA 2224
 Db 10 GTGTGAGCAA 1
 RESULT 27
 AR217931/c 10 bp DNA linear PAT 25-SEP-2002
 LOCUS AR217931
 DEFINITION Sequence 2 from patent US 6417330.
 ACCESSION AR217931
 VERSION AR217931.1 GI:23318234
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 10)
 AUTHORS Mascarenhas, D., Passmore, D. and Danko, S.
 TITLE Insulin-like growth factor binding protein variants
 JOURNAL Patent: US 6417330-A 2 09-JUL-2002;
 FEATURES Location/Qualifiers
 source 1..10
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 55;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGT 2235
 Db 10 AATTACATGT 1
 RESULT 28
 AX152173 10 bp DNA linear PAT 22-JUN-2001
 LOCUS AX152173
 DEFINITION Sequence 88 from Patent WO0138577.
 ACCESSION AX152173
 VERSION AX152173.1 GI:14533824
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Velculescu, V.E., Vogelstein, B. and Kinzler, K.W.
 TITLE Human transcriptomes
 JOURNAL Patent: WO 0138577-A 88 31-MAY-2001;
 The Johns Hopkins University (US)
 FEATURES Location/Qualifiers
 source 1..10
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 55;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 Db 1 CAAAGTTA 10
 JOURNAL Sequence 7559 from Patent WO02053774.
 ACCESSION AX630518
 VERSION AX630518.1 GI:28458556
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.
 TITLE Method for determining homeostasis of the skin
 JOURNAL Patent: WO 02053774-A 7559 11-JUL-2002;
 Henkel Kommanditgesellschaft auf Aktien (DE)
 FEATURES Location/Qualifiers
 source 1..11
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 33.3%; Score 9; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2212 AGAGTGGA 2220
 Db 3 AGAGTGGA 11
 RESULT 25
 AX573600/c 12 bp DNA linear PAT 07-JAN-2003
 LOCUS AX573600
 DEFINITION Sequence 10 from Patent WO02079467.
 ACCESSION AX573600
 VERSION AX573600.1 GI:27551270
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Nielsen, P.E. and Good, L.
 TITLE Antibiotic-free bacterial strain selection with antisense molecules
 JOURNAL Patent: WO 02079467-A 10 10-OCT-2002;
 Koebenhavns Universitet (DK)
 FEATURES Location/Qualifiers
 source 1..12
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="synthetic antisense oligonucleotide"
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 54;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2212 AGAGTGGA 2223
 Db 12 AGAGTAGGCA 1
 RESULT 26
 I73191/c 10 bp DNA linear PAT 03-APR-1998
 LOCUS I73191
 DEFINITION Sequence 5 from patent US 5686242.
 ACCESSION I73191
 VERSION I73191.1 GI:3009330
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 10)
 AUTHORS Bruce, T.W. and Lima, W.F.
 TITLE Determination of oligonucleotides for therapeutics, diagnostics and research reagents

```
RESULT 29
LOCUS AX152235 10 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 150 from Patent WO0138577.
ACCESSION AX152235
VERSION AX152235.1 GI:14533886
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
TITLE Human transcripts
JOURNAL Patent: WO 0138577-A 150 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES
source 1..10
Location/Qualifiers
/db_xref="taxon:9606"
/organism="Homo sapiens"
/mol_type="unassigned DNA"
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2218 TGACCAAAAG 2227
Db 1 TGACCAATAG 10
RESULT 30
LOCUS AX152287/C 10 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 202 from Patent WO0138577.
ACCESSION AX152287
VERSION AX152287.1 GI:14533938
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
TITLE Human transcripts
JOURNAL Patent: WO 0138577-A 202 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES
source 1..10
Location/Qualifiers
/db_xref="taxon:9606"
/organism="Homo sapiens"
/mol_type="unassigned DNA"
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2216 TGTGACCAAA 2225
Db 10 TGTACCAAAA 1
RESULT 31
LOCUS AX152289/C 10 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 204 from Patent WO0138577.
ACCESSION AX152289
VERSION AX152289.1 GI:14533940
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
TITLE Human transcripts
JOURNAL Patent: WO 0138577-A 204 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES
source 1..10
Location/Qualifiers
/db_xref="taxon:9606"
/organism="Homo sapiens"
/mol_type="unassigned DNA"
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2218 TGACCAAAAG 2227
Db 1 TGACCAAGAG 10
RESULT 32
LOCUS BD166495 10 bp DNA linear PAT 17-JAN-2003
DEFINITION Human liver disease-expressing genes.
ACCESSION BD166495
VERSION BD166495.1 GI:27872307
KEYWORDS JP 2002209591-A/40.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
AUTHORS Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
TITLE Human liver disease-expressing genes
JOURNAL Patent: JP 2002209591-A 40 30-JUL-2002;
JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT OS Homo sapiens (human)
PN JP 2002209591-A/40
PD 30-JUL-2002
PF 19-JAN-2001 JP 2001012328
PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
YAMASHITA
PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC C12P21/08,
PC C12N15/08,
CC Human liver disease-expressing genes
FH Key Location/Qualifiers
FT source 1..10
FT /organism='Homo sapiens (human)'.
FEATURES
source 1..10
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2218 TGACCAAAAG 2227
Db 1 TGACCAAGAG 10
RESULT 33
LOCUS BD167034 10 bp DNA linear PAT 17-JAN-2003
DEFINITION Human liver disease-expressing genes.
ACCESSION BD167034
VERSION BD167034.1 GI:27872846
KEYWORDS JP 2002209591-A/579.
SOURCE unidentified
ORGANISM unidentified
```

```
REFERENCE
AUTHORS Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
TITLE Human transcripts
JOURNAL Patent: WO 0138577-A 204 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES
source 1..10
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2216 TGTGACCAAA 2225
Db 10 TGTACCAAAA 1
RESULT 32
LOCUS BD166495 10 bp DNA linear PAT 17-JAN-2003
DEFINITION Human liver disease-expressing genes.
ACCESSION BD166495
VERSION BD166495.1 GI:27872307
KEYWORDS JP 2002209591-A/40.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
AUTHORS Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
TITLE Human liver disease-expressing genes
JOURNAL Patent: JP 2002209591-A 40 30-JUL-2002;
JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT OS Homo sapiens (human)
PN JP 2002209591-A/40
PD 30-JUL-2002
PF 19-JAN-2001 JP 2001012328
PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
YAMASHITA
PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC C12P21/08,
PC C12N15/08,
CC Human liver disease-expressing genes
FH Key Location/Qualifiers
FT source 1..10
FT /organism='Homo sapiens (human)'.
FEATURES
source 1..10
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2218 TGACCAAAAG 2227
Db 1 TGACCAAGAG 10
RESULT 33
LOCUS BD167034 10 bp DNA linear PAT 17-JAN-2003
DEFINITION Human liver disease-expressing genes.
ACCESSION BD167034
VERSION BD167034.1 GI:27872846
KEYWORDS JP 2002209591-A/579.
SOURCE unidentified
ORGANISM unidentified
```

GAGTGTGACC 2222

[illegible]

```

Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
   ||| |||||
Db 1 GACCAAAAGT 10

RESULT 42
CQ835443/c
LOCUS CQ835443 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 501 from Patent WO2004059001.
ACCESSION CQ835443
VERSION CQ835443.1 GI:50834977
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 501 15-JUL-2004; (DE)
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
   ||| |||||
Db 11 GGCCAAAGT 2

RESULT 43
CQ835784
LOCUS CQ835784 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 842 from Patent WO2004059001.
ACCESSION CQ835784
VERSION CQ835784.1 GI:50835318
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 842 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
   ||| |||||
Db 11 GGCCAAAGT 2

RESULT 44
CQ835784
LOCUS CQ835784 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 842 from Patent WO2004059001.
ACCESSION CQ835784
VERSION CQ835784.1 GI:50835318
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 842 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCAA 2225
   ||| |||||
Db 2 TGTGACCAA 11

RESULT 45
CQ836035
LOCUS CQ836035 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 1093 from Patent WO2004059001.
ACCESSION CQ836035
VERSION CQ836035.1 GI:50835569
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 1093 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
   ||| |||||
Db 11 TTACATGTTT 2

RESULT 46
CQ836131/c
LOCUS CQ836131 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 1189 from Patent WO2004059001.
ACCESSION CQ836131
VERSION CQ836131.1 GI:50835665
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 1189 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAAGTTA 2230
   ||| |||||
Db 1 CCAAAAAGTTA 10

RESULT 47
CQ836131/c
LOCUS CQ836131 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 1189 from Patent WO2004059001.
ACCESSION CQ836131
VERSION CQ836131.1 GI:50835665
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 1189 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAAGTTA 2230
   ||| |||||
Db 1 CCAAAAAGTTA 10

```



```

REFERENCE
AUTHORS
  1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE
  Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
  Conrad,M. and Hofmann,K.
JOURNAL
  Method for determining markers of human facial skin
  Patent: WO 2004059001-A 1189 15-JUL-2004;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"
Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTAC 2232
Db 11 AAAAGTTTAC 2

RESULT 47
CQ837874/c
LOCUS      CQ837874      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 2932 from Patent WO2004059001.
ACCESSION CQ837874
VERSION   CQ837874.1 GI:50837408
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conrad,M. and Hofmann,K.
TITLE      Method for determining markers of human facial skin
            Patent: WO 2004059001-A 2932 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
              1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACAGTTT 2237
Db 11 TTACAGTTT 2

RESULT 48
AX175020/c
LOCUS      AX175020      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 9 from Patent WO0142493.
ACCESSION AX175020
VERSION   AX175020.2 GI:15142039
KEYWORDS
SOURCE     synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM   Olek,A. and Piepenbrock,C.
            Method for the parallel detection of the degree of methylation of
            genomic dna
            Patent: WO 0142493-A 9 14-JUN-2001;
            Epigenomics AG (DE)
REFERENCE  1
AUTHORS    Olek,A. and Piepenbrock,C.
TITLE      Method for the parallel detection of the degree of methylation of
            genomic dna
JOURNAL
  COMMENT   On Aug 9, 2001 this sequence version replaced gi:14598480.
FEATURES   Location/Qualifiers
            source
              1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2229 AAAAGTTTAC 2232
Db 11 AAAAGTTTAC 10

RESULT 50
AX393176
LOCUS      AX393176      11 bp      DNA      linear      PAT 23-MAR-2002
DEFINITION Sequence 106 from Patent WO0210217.
ACCESSION AX393176
VERSION   AX393176.1 GI:19701226
KEYWORDS
SOURCE     Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    St Croix,B., Kinzler,K.W. and Vogelstein,B.
TITLE      Endothelial cell expression patterns
            Patent: WO 0210217-A 106 07-FEB-2002;
            The Johns Hopkins University (US)
FEATURES   Location/Qualifiers
            source
              1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="chemisch vorbehandelte Genom-DNA"
Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTAC 2232
Db 11 AAAAGTTTAC 2

RESULT 49
AX175021
LOCUS      AX175021      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 10 from Patent WO0142493.
ACCESSION AX175021
VERSION   AX175021.2 GI:15142040
KEYWORDS
SOURCE     synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM   Olek,A. and Piepenbrock,C.
            Method for the parallel detection of the degree of methylation of
            genomic dna
            Patent: WO 0142493-A 10 14-JUN-2001;
            Epigenomics AG (DE)
COMMENT     On Aug 9, 2001 this sequence version replaced gi:14598481.
FEATURES   Location/Qualifiers
            source
              1. .11
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"
Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTAC 2232
Db 11 AAAAGTTTAC 10

RESULT 50
AX393176
LOCUS      AX393176      11 bp      DNA      linear      PAT 23-MAR-2002
DEFINITION Sequence 106 from Patent WO0210217.
ACCESSION AX393176
VERSION   AX393176.1 GI:19701226
KEYWORDS
SOURCE     Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    St Croix,B., Kinzler,K.W. and Vogelstein,B.
TITLE      Endothelial cell expression patterns
            Patent: WO 0210217-A 106 07-FEB-2002;
            The Johns Hopkins University (US)
FEATURES   Location/Qualifiers
            source
              1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 2213 GAGTGTGACC 2222
Db 1 GAGTGTGACC 10

RESULT 51
AX470684/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 261 from Patent WO02053773.
ACCESSION AX470684
VERSION AX470684.1 GI:22205809
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 261 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source
1..11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AACAGTTTACA 2232
Db 11 AACAGTTTACA 2

RESULT 52
AX471221/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 798 from Patent WO02053773.
ACCESSION AX471221
VERSION AX471221.1 GI:22206346
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 798 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source
1..11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AACAGTTTACA 2232
Db 11 AACAGTTTACA 2

RESULT 53
AX471460/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 1037 from Patent WO02053773.
ACCESSION AX471460
VERSION AX471460.1 GI:22206585

QY 2228 TTACATGTTT 2237
Db 11 TTACATGTTT 2

RESULT 54
AX471712/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 1289 from Patent WO02053773.
ACCESSION AX471712
VERSION AX471712.1 GI:22206837
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 1289 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source
1..11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
Db 11 GCCCAAAAGT 2

RESULT 55
AX623270/c
LOCUS 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 311 from Patent WO02053774.
ACCESSION AX623270
VERSION AX623270.1 GI:28451211
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 311 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
Location/Qualifiers

```

source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTA 2230
Db 1 CCAAAAGTTA 10
|||||

RESULT 56
AX624779
LOCUS
DEFINITION Sequence 1820 from Patent WO02053774.
ACCESSION AX624779
VERSION AX624779.1 GI:28452720
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 1820 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
Db 2 AAAACTTACA 11
|||||

RESULT 57
AX625318/c
LOCUS
DEFINITION Sequence 2359 from Patent WO02053774.
ACCESSION AX625318
VERSION AX625318.1 GI:28453259
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2359 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
Db 1 AAAAGTTACA 10
|||||

```

```

Db 10 AAAAGGTACA 1

RESULT 58
AX625811/c
LOCUS
DEFINITION Sequence 2852 from Patent WO02053774.
ACCESSION AX625811
VERSION AX625811.1 GI:28453752
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2852 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAA 2226
Db 10 GTGATCAAAA 1
|||||

RESULT 59
AX626606/c
LOCUS
DEFINITION Sequence 3647 from Patent WO02053774.
ACCESSION AX626606
VERSION AX626606.1 GI:28454644
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3647 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAA 2226
Db 11 GTGGCCAAAA 2
|||||

RESULT 60
AX626934/c
LOCUS
DEFINITION Sequence 3975 from Patent WO02053774.
ACCESSION AX626934
VERSION AX626934.1 GI:28454972
KEYWORDS
SOURCE Homo sapiens (human)

```

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 3975 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 10 AAAAGTTTCA 1

RESULT 61
AX627178 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4219 from Patent WO02053774.
DEFINITION
ACCESSION AX627178
VERSION AX627178.1 GI:28455216
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4219 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
Db 1 GTACCAAAA 10

RESULT 62
AX627466/c 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4507 from Patent WO02053774.
DEFINITION
ACCESSION AX627466
VERSION AX627466.1 GI:28455504
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4507 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1..11
/organism="Homo sapiens"

```

```

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 11 TTACAGGTTT 2

RESULT 63
AX627566 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4607 from Patent WO02053774.
DEFINITION
ACCESSION AX627566
VERSION AX627566.1 GI:28455604
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4607 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
Db 1 GACAAAGT 10

RESULT 64
AX627903 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4944 from Patent WO02053774.
DEFINITION
ACCESSION AX627903
VERSION AX627903.1 GI:28455941
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4944 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2213 GAGTGTGACC 2222
Db 1 GAGTGAGACC 10

```

```

RESULT 65
AX628167/c
LOCUS      AX628167      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 5208 from Patent WO02053774.
ACCESSION  AX628167
VERSION     AX628167.1  GI:28456205
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 5208 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACA 2232
DB      11 AAAAGATACA 2

RESULT 66
AX629648/c
LOCUS      AX629648      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 6689 from Patent WO02053774.
ACCESSION  AX629648
VERSION     AX629648.1  GI:28457686
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 6689 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2229 TACATGTTTG 2238
DB      11 TACACGTTTG 2

RESULT 67
AX629854/c
LOCUS      AX629854      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 6895 from Patent WO02053774.
ACCESSION  AX629854
VERSION     AX629854.1  GI:28457892
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 6895 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2219 GACCAAAAGT 2228
DB      11 GCCCAAAAGT 2

RESULT 68
AX630691
LOCUS      AX630691      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 7732 from Patent WO02053774.
ACCESSION  AX630691
VERSION     AX630691.1  GI:28458729
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 7732 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2221 CCAAAAGTTA 2230
DB      1 CCAAAAGTTA 10

RESULT 69
AX632200
LOCUS      AX632200      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 9242 from Patent WO02053774.
ACCESSION  AX632200
VERSION     AX632200.1  GI:28467815
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 9242 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

```

```

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
Db 2 AAAAGTTACA 11

RESULT 70
LOCUS AX632739/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 9781 from Patent WO20053774.
ACCESSION AX632739
VERSION AX632739.1 GI:28468354
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 9781 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DB)
FEATURES Location/Qualifiers
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
Db 10 AAAAGGTACA 1

RESULT 71
LOCUS CQ766537 12 bp DNA linear PAT 03-MAR-2004
DEFINITION Sequence 498 from Patent WO2004005547.
ACCESSION CQ766537
VERSION CQ766537.1 GI:44908797
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE Weinzierl,R.
AUTHORS Method
TITLE synthetic construct
JOURNAL artificial sequences.
FEATURES Location/Qualifiers
source
1..12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="HS motif"

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 1 TTTCATGTTT 10

RESULT 72
LOCUS CQ766563 12 bp DNA linear PAT 03-MAR-2004
DEFINITION Sequence 524 from Patent WO2004005547.
ACCESSION CQ766563
VERSION CQ766563.1 GI:44908823
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE Weinzierl,R.
AUTHORS Method
TITLE synthetic construct
JOURNAL artificial sequences.
FEATURES Location/Qualifiers
source
1..12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="HS motif"

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 1 TTTCATGTTT 10

RESULT 73
LOCUS I38923 12 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 33 from patent US 5616483.
ACCESSION I38923
VERSION I38923.1 GI:2083401
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
Bjursell,K.G., Carlsson,P.N.I., Enerback,C.S.M., Hansson,S.L.,
Lidberg,U.F.P., Nilsson,J.A. and Tornell,J.B.F.
TITLE Genomic DNA sequences encoding human BSSL/CEL
JOURNAL Patent: US 5616483-A 33 01-APR-1997;
FEATURES Location/Qualifiers
source
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
Db 1 GGTACATGTT 10

RESULT 74
LOCUS I87954 12 bp DNA linear PAT 10-AUG-1998
DEFINITION Sequence 33 from patent US 5716817.
ACCESSION I87954
VERSION I87954.1 GI:3407894
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
Tornell,J Birger,Fredrik.
TITLE Transgenic non-human mammals that express human BSSL/CEL
JOURNAL Patent: US 5716817-A 33 10-FEB-1998;

```

	FH	CDS	6...>8 /codon_start=1.
	FT		
	FEATURES	Location/Qualifiers	
	source	1..8	/organism="synthetic construct"
			/mol_type="genomic DNA"
			/db_xref="taxon:32630"
	Query Match	29.6%; Score 8;	DB 1; Length 8;
	Best Local Similarity	100.0%; Pred. No. 4.9e+02;	
	Matches	8; Conservative 0; Mismatches 0;	Indels 0; Gaps 0;
	QY	2231 CATGTTTG 2238	
	Dbl		
		8 CATGTTTG 1	
	RESULT 77		
	LOCUS	ARI76517	10 bp DNA linear PAT 17-DEC-2001
	DEFINITION	Sequence 34 from patent US 6312890.	
	ACCESSION	ARI76517	
	VERSION	ARI76517.1 GI:17918872	
	KEYWORDS		
	SOURCE	Unknown.	
	ORGANISM	Unclassified.	
	REFERENCE	1 (bases 1 to 10)	
	AUTHORS	Lerman,M.I., Latif,F. and Zbar,B.	
	TITLE	Partial intron sequence of von hippel-lindau (VHL) disease gene and its use in diagnosis of disease	
	JOURNAL	Patent: US 6312890-A 34 06-NOV-2001;	
	FEATURES	Location/Qualifiers	
	source	1..10	/organism="unknown"
			/mol_type="unassigned DNA"
	Query Match	29.6%; Score 8;	DB 1; Length 10;
	Best Local Similarity	100.0%; Pred. No. 68;	
	Matches	8; Conservative 0; Mismatches 0;	Indels 0; Gaps 0;
	QY	2217 GTGACCAA 2224	
	Dbl		
		10 GTGACCAA 3	
	RESULT 78		
	LOCUS	BD239221	10 bp DNA linear PAT 17-JUL-2003
	DEFINITION	Preparation and use of superior vaccines.	
	ACCESSION	BD239221	
	VERSION	BD239221.1 GI:33048991	
	KEYWORDS	JP 2002534056-A/639	
	SOURCE	Homo sapiens (human)	
	ORGANISM	Homo sapiens	
	REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
	AUTHORS	1 (bases 1 to 10)	
	TITLE	Roberts,B.L. and Shankara,S.	
	JOURNAL	Preparation and use of superior vaccines Patent: JP 2002534056-A 539 15-OCT-2002;	
	COMMENT	GENZYME CORP	
		CS Homo sapiens (human)	
		PN JP 2002534056-A/639	
		PD 15-OCT-2002	
		PF 18-JUN-1999 JP 2000554749	
		PR 19-JUN-1998 US 60/090039,19-JUN-1998 US 60/090040 PR	
		19-JUN-1998 US 60/090041,19-JUN-1998 US 60/089853 PR	
		19-JUN-1998 US 60/089977,19-JUN-1998 US 60/089993 PR	
		19-JUN-1998 US 60/090035,19-JUN-1998 US 60/090072 PR	
		19-JUN-1998 US 60/089992,19-JUN-1998 US 60/089979 PR	
		19-JUN-1998 US 60/089878,19-JUN-1998 US 60/089991 PR	

[illegible]

Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2226 AGTTACAT 2233
Db 10 AGTTACAT 3

RESULT 81
LOCUS C0828615 10 bp DNA linear PAT 05-JUL-2004
DEFINITION Sequence 333 from Patent WO2004053120.
ACCESSION C0828615
VERSION C0828615.1 GI:49732098
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM
REFERENCE 1
AUTHORS Weihe, E., Bieller, A. and Schaefer, M.K.
TITLE Regulatory elements in the 5' region of the vrl gene
JOURNAL Patent: WO 2004053120-A 333 24-JUN-2004;
Gruenthal GmbH (DE)
FEATURES
source
Location/Qualifiers
1..10
/organism="Rattus norvegicus"
/mol_type="unassigned DNA"
/db_xref="taxon:10116"
/note="VSVEP 01"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2227 GTTACATG 2234
Db 1 GTTACATG 8

RESULT 82
LOCUS AR303494/c 10 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 219 from patent US 6544736.
ACCESSION AR303494
VERSION AR303494.1 GI:31692270
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 10)
AUTHORS Shimamoto, A., Furuichi, Y., Shibata, Y., Funaki, H., Ohara, E. and Watahiki, M.
TITLE Method for synthesizing cDNA from mRNA sample
JOURNAL Patent: US 6544736-A 219 08-APR-2003;
FEATURES
source
Location/Qualifiers
1..10
/organism="unknown"
/mol_type="genomic DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
Db 8 CCAAAAGT 1

RESULT 83
LOCUS AR351773 10 bp DNA linear PAT 17-AUG-2003

DEFINITION Sequence 1315 from patent US 6588746.
ACCESSION AR351773
VERSION AR351773.1 GI:33753569
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 10)
AUTHORS Dobrindt, D. and Fischer, U.
TITLE Device for generating an offset of transported flexible sheet material
JOURNAL Patent: US 6588746-A 1315 08-JUL-2003;
FEATURES
source
Location/Qualifiers
1..10
/organism="unknown"
/mol_type="genomic DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8

RESULT 84
LOCUS AR351781 10 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 1323 from patent US 6588746.
ACCESSION AR351781
VERSION AR351781.1 GI:33753577
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 10)
AUTHORS Dobrindt, D. and Fischer, U.
TITLE Device for generating an offset of transported flexible sheet material
JOURNAL Patent: US 6588746-A 1323 08-JUL-2003;
FEATURES
source
Location/Qualifiers
1..10
/organism="unknown"
/mol_type="genomic DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8

RESULT 85
LOCUS AR351782 10 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 1324 from patent US 6588746.
ACCESSION AR351782
VERSION AR351782.1 GI:33753578
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 10)
AUTHORS Dobrindt, D. and Fischer, U.
TITLE Device for generating an offset of transported flexible sheet material
JOURNAL Patent: US 6588746-A 1324 08-JUL-2003;
FEATURES
source
Location/Qualifiers
1..10
/organism="unknown"

/mol_type="genomic DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 8; Conservative 0; Mismatches 0; Gaps 0;

QY 2213 GAGTGTGA 2220
 |||||
 Db 1 GAGTGTGA 8

RESULT 86

AX153396/c
 LOCUS AX153396 10 bp DNA linear PAT 22-JUN-2001
 DEFINITION Sequence 1311 from Patent WO0138577.
 ACCESSION AX153396
 VERSION AX153396.1 GI:14535047

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 Velculescu, V.E., Vogelstein, B. and Kinzler, K.W.
 AUTHORS Human transcriptomes
 TITLE Patent: WO 0138577-A 1311 31-MAY-2001;
 JOURNAL The Johns Hopkins University (US)

FEATURES Location/Qualifiers

source

1..10
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 8; Conservative 0; Mismatches 0; Gaps 0;

QY 2221 CCAAAAGT 2228
 |||||
 Db 9 CCAAAAGT 2

RESULT 87

AX667866
 LOCUS AX667866 10 bp DNA linear PAT 26-MAR-2003
 DEFINITION Sequence 1315 from Patent WO0242459.
 ACCESSION AX667866
 VERSION AX667866.1 GI:29291403

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1 Liu, Q.

AUTHORS Position dependent recognition of gnn nucleotide triplets by zinc

TITLE fingers

JOURNAL Patent: WO 0242459-A 1315 30-MAY-2002;

Sangamo Biosciences Inc. (US)

FEATURES Location/Qualifiers

source

1..10
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="example target DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 8; Conservative 0; Mismatches 0; Gaps 0;

QY 2213 GAGTGTGA 2220
 |||||
 Db 1 GAGTGTGA 8

RESULT 88

AX667874
 LOCUS AX667874 10 bp DNA linear PAT 26-MAR-2003
 DEFINITION Sequence 1323 from Patent WO0242459.
 ACCESSION AX667874
 VERSION AX667874.1 GI:29291411

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1 Liu, Q.

AUTHORS Position dependent recognition of gnn nucleotide triplets by zinc

TITLE fingers

JOURNAL Patent: WO 0242459-A 1323 30-MAY-2002;

Sangamo Biosciences Inc. (US)

FEATURES Location/Qualifiers

source

1..10
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="example target DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 8; Conservative 0; Mismatches 0; Gaps 0;

QY 2213 GAGTGTGA 2220
 |||||
 Db 1 GAGTGTGA 8

RESULT 89

AX667875
 LOCUS AX667875 10 bp DNA linear PAT 26-MAR-2003
 DEFINITION Sequence 1324 from Patent WO0242459.
 ACCESSION AX667875
 VERSION AX667875.1 GI:29291412

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1 Liu, Q.

AUTHORS Position dependent recognition of gnn nucleotide triplets by zinc

TITLE fingers

JOURNAL Patent: WO 0242459-A 1324 30-MAY-2002;

Sangamo Biosciences Inc. (US)

FEATURES Location/Qualifiers

source

1..10
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="example target DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 8; Conservative 0; Mismatches 0; Gaps 0;

QY 2213 GAGTGTGA 2220
 |||||
 Db 1 GAGTGTGA 8

RESULT 90

AX955930/c
 LOCUS AX955930 10 bp DNA linear PAT 08-JAN-2004
 DEFINITION Sequence 12 from Patent WO03095653.
 ACCESSION AX955930
 VERSION AX955930.1 GI:40784552

KEYWORDS Pichia angusta

SOURCE

```

ORGANISM Pichia angusta
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; Saccharomycetaceae; Pichia.
REFERENCE 1
AUTHORS Suckow,M.
TITLE Promoters having a modified transcription efficiency and derived
        from methylotropic yeast
JOURNAL Patent: WO 03095653-A 12 20-NOV-2003;
        RHEIN BIOTECH GESELLSCHAFT FUER NEUE BIOTECHNOLOGISCHE PRO; ZESSE
        UND PRODUKTE MBH (DE)
FEATURES
    source
        1..10
        /organism="Pichia angusta"
        /mol_type="unassigned DNA"
        /db_xref="taxon:4905"
        /note="Beschreibung der Sequenz: MOX-Promotorabschnitt"
Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2218 TGACCAA 2225
Db 9 TGACCAA 2

RESULT 91
BD007825
LOCUS BD007825 10 bp DNA linear PAT 31-JAN-2002
DEFINITION LPS activated human monocyte expressing genes.
ACCESSION BD007825
VERSION BD007825.1 GI:18636198
KEYWORDS JP 2001069993-A/101.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 10)
Matsushima,K., Hashimoto,S. and Suzuki,T.
LPS activated human monocyte expressing genes
Patent: JP 2001069993-A 101 21-MAR-2001;
JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT OS Homo sapiens (human)
        PN JP 2001069993-A/101
        PD 21-MAR-2001
        PR 28-APR-2000 JP 200031079
        PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,TAKUJI SUZUKI PC
        C12N15/09,C07K14/47,C07K16/18,G01N33/50,G01N33/53//A61K45/00, PC
        A61P29/00,
        CC A61P31/00,C12P21/08,C12N15/00
        FH Key Location/Qualifiers
        FT source
        1..10
        /organism="Homo sapiens (human)"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2215 GTGTGACC 2222
Db 2 GTGTGACC 9

RESULT 92
BD166573/c
LOCUS BD166573 10 bp DNA linear PAT 17-JAN-2003

```

```

DEFINITION Human liver disease-expressing genes.
ACCESSION BD166573
VERSION BD166573.1 GI:27872385
KEYWORDS JP 200220591-A/118.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 10)
AUTHORS Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
TITLE Human liver disease-expressing genes
JOURNAL Patent: JP 200220591-A 118 30-JUL-2002;
        JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT OS Homo sapiens (human)
        PN JP 200220591-A/118
        PD 30-JUL-2002
        PR 19-JAN-2001 JP 2001012328
        PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
        YAMASHITA
        PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
        PC C12P21/08,
        PC C12N15/00,
        CC Human liver disease-expressing genes
        FH Key Location/Qualifiers
        FT source
        1..10
        /organism="Homo sapiens (human)"
        /mol_type="genomic DNA"
        /db_xref="taxon:32644"
Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2225 AAGTTACA 2232
Db 8 AAGTTACA 1

RESULT 93
CQ833105/c
LOCUS CQ833105 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 476 from Patent WO2004059002.
ACCESSION CQ833105
VERSION CQ833105.1 GI:50832712
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conrad,M. and Hofmann,K.
Method for determining the homeostasis of hairy skin
Patent: WO 2004059002-A 476 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
    source
        1..11
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2226 AGTTACAT 2233
Db 8 AGTTACAT 1

RESULT 94

```



```

Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
Db 11 CCAAAAGT 4

RESULT 99
AX472174/c
LOCUS AX472174 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 165 from Patent WO02053775.
ACCESSION AX472174
VERSION AX472174.1 GI:22207211
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Hustert,E., Haberl,M. and Wojnowski,L.
TITLE Identification of the genetic determinants of the polymorphic
JOURNAL cyp3a5 expression
Patent: WO 02053775-A-165 11-JUL-2002;
EPIDAUROS BIOTECHNOLOGIE AG (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2214 AGTGTGAC 2221
Db 10 AGTGTGAC 3

RESULT 100
AX625287/c
LOCUS AX625287 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2328 from Patent WO02053774.
ACCESSION AX625287
VERSION AX625287.1 GI:28453228
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A-2328 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2220 ACCAAAG 2227
Db 10 ACCAAAG 3

RESULT 101
AX625400/c
LOCUS AX625400 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2441 from Patent WO02053774.
ACCESSION AX625400
VERSION AX625400.1 GI:28453341
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A-2441 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
Db 10 GAGTGTGA 3

RESULT 102
AX625627/c
LOCUS AX625627 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2668 from Patent WO02053774.
ACCESSION AX625627
VERSION AX625627.1 GI:28453568
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A-2668 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
Db 11 CCAAAAGT 4

RESULT 103
AX626945/c
LOCUS AX626945 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 3986 from Patent WO02053774.
ACCESSION AX626945
VERSION AX626945.1 GI:28454983
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.

```

```

TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 3986 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2223 AAAAGTTA 2230
DB      8 AAAAGTTA 1

RESULT 104
AX627307/c
LOCUS      AX627307
DEFINITION Sequence 4348 from Patent WO02053774.
ACCESSION  AX627307
VERSION     AX627307.1 GI:28455345
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE    Method for determining homeostasis of the skin
  JOURNAL  Patent: WO 02053774-A 4348 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2223 AAAAGTTA 2230
DB      9 AAAAGTTA 2

RESULT 105
AX627680/c
LOCUS      AX627680
DEFINITION Sequence 4721 from Patent WO02053774.
ACCESSION  AX627680
VERSION     AX627680.1 GI:28455718
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE    Method for determining homeostasis of the skin
  JOURNAL  Patent: WO 02053774-A 4721 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;

QY      2222 CAAAAGTT 2229
DB      10 CAAAAGTT 3

RESULT 106
AX628092
LOCUS      AX628092
DEFINITION Sequence 5133 from Patent WO02053774.
ACCESSION  AX628092
VERSION     AX628092.1 GI:28456130
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE    Method for determining homeostasis of the skin
  JOURNAL  Patent: WO 02053774-A 5133 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGTGACCA 2223
DB      4 TGTGACCA 11

RESULT 107
AX632708/c
LOCUS      AX632708
DEFINITION Sequence 9750 from Patent WO02053774.
ACCESSION  AX632708
VERSION     AX632708.1 GI:28468323
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE    Method for determining homeostasis of the skin
  JOURNAL  Patent: WO 02053774-A 9750 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2220 ACCAAAAG 2227
DB      10 ACCAAAAG 3

RESULT 108
BD124291
LOCUS      BD124291
DEFINITION Compositions and method for healing wound.

```

```

ACCESSION      BD124291
VERSION        BD124291.1  GI:23219236
KEYWORDS       JP 2002503460-A/122.
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
               Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      Katz,B.H.
AUTHORS        (bases 1 to 11)
TITLE          Compositions and method for healing wound
JOURNAL        THE WISTAR INSTITUTE
COMMENT        OS Mus musculus (mouse)
               PD 05-FEB-2002
               PF 12-FEB-1999 JP 2000531545
               PR 13-FEB-1998 US 60/074737,26-AUG-1998 US 60/097937 PR
               28-SEP-1998 US 60/102051
               PI ELLEN HEBER KATZ
               PC C12N15/09,A01K67/027,C12N5/10,C12Q1/68,G01N33/50,C12N15/00, PC
               C12N5/00
               CC Compositions and method for healing wound
               FH Key
               FT source
               FT Location/Qualifiers
               1..11
               /organism="Mus musculus"
               /mol_type="genomic DNA"
               /db_xref="taxon:10090"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGTGACCA 2223
Db 3 TGTGACCA 10

RESULT 109
BD241065
LOCUS          BD241065          11 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION     Methods and products related to genotyping and DNA analysis.
ACCESSION      BD241065
VERSION        BD241065.1  GI:33050835
KEYWORDS       JP 2002525127-A/12.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
AUTHORS        Methods and products related to genotyping and DNA analysis
TITLE          Patent: JP 2002525127-A 12 13-AUG-2002;
JOURNAL        MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT        OS Homo sapiens (human)
               PN JP 2002525127-A/12
               PD 13-AUG-2002
               PF 24-SEP-1999 JP 2000572407
               PR 25-SEP-1998 US 60/101757
               PI JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
               C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
               G01N37/00,
               CC C12N15/00
               PC Methods and products related to genotyping and DNA analysis FH
               FH Key
               FT source
               FT Location/Qualifiers
               1..11
               /organism="Homo sapiens"
               /mol_type="genomic DNA"

ACCESSION      BD124291
VERSION        BD124291.1  GI:23219236
KEYWORDS       JP 2002503460-A/122.
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
               Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      Katz,B.H.
AUTHORS        (bases 1 to 11)
TITLE          Compositions and method for healing wound
JOURNAL        THE WISTAR INSTITUTE
COMMENT        OS Mus musculus (mouse)
               PD 05-FEB-2002
               PF 12-FEB-1999 JP 2000531545
               PR 13-FEB-1998 US 60/074737,26-AUG-1998 US 60/097937 PR
               28-SEP-1998 US 60/102051
               PI ELLEN HEBER KATZ
               PC C12N15/09,A01K67/027,C12N5/10,C12Q1/68,G01N33/50,C12N15/00, PC
               C12N5/00
               CC Compositions and method for healing wound
               FH Key
               FT source
               FT Location/Qualifiers
               1..11
               /organism="Mus musculus"
               /mol_type="genomic DNA"
               /db_xref="taxon:10090"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGTGACCA 2223
Db 3 TGTGACCA 10

RESULT 109
BD241065
LOCUS          BD241065          11 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION     Methods and products related to genotyping and DNA analysis.
ACCESSION      BD241065
VERSION        BD241065.1  GI:33050835
KEYWORDS       JP 2002525127-A/12.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
AUTHORS        Methods and products related to genotyping and DNA analysis
TITLE          Patent: JP 2002525127-A 12 13-AUG-2002;
JOURNAL        MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT        OS Homo sapiens (human)
               PN JP 2002525127-A/12
               PD 13-AUG-2002
               PF 24-SEP-1999 JP 2000572407
               PR 25-SEP-1998 US 60/101757
               PI JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
               C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
               G01N37/00,
               CC C12N15/00
               PC Methods and products related to genotyping and DNA analysis FH
               FH Key
               FT source
               FT Location/Qualifiers
               1..11
               /organism="Homo sapiens"
               /mol_type="genomic DNA"

ACCESSION      BD124291
VERSION        BD124291.1  GI:23219236
KEYWORDS       JP 2002503460-A/122.
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
               Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      Katz,B.H.
AUTHORS        (bases 1 to 11)
TITLE          Compositions and method for healing wound
JOURNAL        THE WISTAR INSTITUTE
COMMENT        OS Mus musculus (mouse)
               PD 05-FEB-2002
               PF 12-FEB-1999 JP 2000531545
               PR 13-FEB-1998 US 60/074737,26-AUG-1998 US 60/097937 PR
               28-SEP-1998 US 60/102051
               PI ELLEN HEBER KATZ
               PC C12N15/09,A01K67/027,C12N5/10,C12Q1/68,G01N33/50,C12N15/00, PC
               C12N5/00
               CC Compositions and method for healing wound
               FH Key
               FT source
               FT Location/Qualifiers
               1..11
               /organism="Mus musculus"
               /mol_type="genomic DNA"
               /db_xref="taxon:10090"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
Db 1 AAATTAATGT 11

RESULT 110
CQ828430
LOCUS          CQ828430          11 bp      DNA      linear      PAT 05-JUL-2004
DEFINITION     Sequence 148 from Patent WO2004053120.
ACCESSION      CQ828430
VERSION        CQ828430.1  GI:49731913
KEYWORDS       Mus musculus (house mouse)
SOURCE         Mus musculus
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      Weihe,B., Bieller,A. and Schaefer,M.K.
AUTHORS        Regulatory elements in the 5' region of the vrl gene
TITLE          Patent: WO 2004053120-A 148 24-JUN-2004;
JOURNAL        Gruenenthal GmbH (DE)
FEATURES       Location/Qualifiers
               1..11
               /organism="Mus musculus"
               /mol_type="unassigned DNA"
               /db_xref="taxon:10090"
               /note="V$APIFJ Q2"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 1 TGTGACCAATA 11

RESULT 111
CQ832651/c
LOCUS          CQ832651          11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION     Sequence 22 from Patent WO2004059002.
ACCESSION      CQ832651
VERSION        CQ832651.1  GI:50832258
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
AUTHORS        Conrad,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 22 15-JUL-2004;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGAGTAAAA 1

RESULT 111
CQ832651/c
LOCUS          CQ832651          11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION     Sequence 22 from Patent WO2004059002.
ACCESSION      CQ832651
VERSION        CQ832651.1  GI:50832258
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
AUTHORS        Conrad,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 22 15-JUL-2004;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGAGTAAAA 1

```

```

RESULT 112
CQ833007
LOCUS      CQ833007          11 bp      DNA          linear          PAT 29-JUL-2004
DEFINITION Sequence 378 from Patent WO2004059002.
ACCESSION CQ833007
VERSION   CQ833007.1  GI:50832614
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
           Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 378 15-JUL-2004; (DE)
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
      |||||
Db 1 TATGAACAAA 11

RESULT 113
CQ833297/c
LOCUS      CQ833297          11 bp      DNA          linear          PAT 29-JUL-2004
DEFINITION Sequence 668 from Patent WO2004059002.
ACCESSION CQ833297
VERSION   CQ833297.1  GI:50832904
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
           Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 668 15-JUL-2004;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234
      |||||
Db 11 AAACCTAAATG 11

RESULT 114
CQ833314/c
LOCUS      CQ833314          11 bp      DNA          linear          PAT 29-JUL-2004
DEFINITION Sequence 685 from Patent WO2004059002.
ACCESSION CQ833314
VERSION   CQ833314.1  GI:50832921
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
           Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 1228 15-JUL-2004;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
      |||||
Db 1 TGTGACCAAGA 11

RESULT 115
CQ833337
LOCUS      CQ833337          11 bp      DNA          linear          PAT 29-JUL-2004
DEFINITION Sequence 708 from Patent WO2004059002.
ACCESSION CQ833337
VERSION   CQ833337.1  GI:50832944
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
           Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 708 15-JUL-2004;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
      |||||
Db 11 TGTGACTAATA 11

RESULT 116
CQ833857/c
LOCUS      CQ833857          11 bp      DNA          linear          PAT 29-JUL-2004
DEFINITION Sequence 1228 from Patent WO2004059002.
ACCESSION CQ833857
VERSION   CQ833857.1  GI:50833464
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
           Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 1228 15-JUL-2004;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
      |||||
Db 1 TGTGACCAAGA 11

```


Best Local Similarity 81.8%; Pred. No. 81;

```

LOCUS      CQ836724                11 bp    DNA          linear    PAT 29-JUL-2004
DEFINITION Sequence 1782 from Patent WO2004059001.
ACCESSION  CQ836724
VERSION    CQ836724.1  GI:50836258
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
TITLE     Method for determining markers of human facial skin
JOURNAL   Patent: WO 2004059001-A 1782 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. NO. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2227 GTTACATGTTT 2237
Db      11 GTTCTTGTTT 1

RESULT 122
LOCUS      CQ836996/c              11 bp    DNA          linear    PAT 29-JUL-2004
DEFINITION Sequence 2054 from Patent WO2004059001.
ACCESSION  CQ836996
VERSION    CQ836996.1  GI:50836530
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
TITLE     Method for determining markers of human facial skin
JOURNAL   Patent: WO 2004059001-A 2054 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. NO. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2216 TGTGACCAAAA 2226
Db      11 TGTGAGTAAAA 1

RESULT 123
LOCUS      CQ837135                11 bp    DNA          linear    PAT 29-JUL-2004
DEFINITION Sequence 2193 from Patent WO2004059001.
ACCESSION  CQ837135
VERSION    CQ837135.1  GI:50836669
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

```

REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
TITLE     Method for determining markers of human facial skin
JOURNAL   Patent: WO 2004059001-A 2193 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. NO. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2212 AGAGTGTGACC 2222
Db      1 ACAGGTGACC 11

RESULT 124
LOCUS      CQ837140/c              11 bp    DNA          linear    PAT 29-JUL-2004
DEFINITION Sequence 2198 from Patent WO2004059001.
ACCESSION  CQ837140
VERSION    CQ837140.1  GI:50836674
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
TITLE     Method for determining markers of human facial skin
JOURNAL   Patent: WO 2004059001-A 2198 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. NO. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2221 CCAAAAGTTAC 2231
Db      11 CTAAGATTCC 1

RESULT 125
LOCUS      CQ837309/c              11 bp    DNA          linear    PAT 29-JUL-2004
DEFINITION Sequence 2367 from Patent WO2004059001.
ACCESSION  CQ837309
VERSION    CQ837309.1  GI:50836843
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
TITLE     Method for determining markers of human facial skin
JOURNAL   Patent: WO 2004059001-A 2367 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"

```

```

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 11 GATACATCTTT 1

RESULT 126
LOCUS COB37817
DEFINITION Sequence 2875 from Patent WO2004059001.
ACCESSION COB37817
VERSION COB37817.1 GI:50937351
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
JOURNAL Conrad,M. and Hofmann,K.
FEATURES Method for determining markers of human facial skin
source Patent: WO 2004059001-A 2875 15-JUL-2004;
LOCATION/Qualifiers Henkel Kommanditgesellschaft auf Aktien (DE)
1. .11
/mol_type="genomic DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 1 TGTGATCACAA 11

RESULT 127
LOCUS AR367561/c
DEFINITION Sequence 42 from patent US 6375954.
ACCESSION AR367561
VERSION AR367561.1 GI:34600872
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 11)
AUTHORS Dutta,S., Biswas,B. and Vemulapalli,R.
TITLE Size-variable strain-specific protective antigen for potomac horse
JOURNAL fever
FEATURES Patent: US 6375954-A 42 23-APR-2002;
source Location/Qualifiers
1. .11
/mol_type="genomic DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
Db 11 AAGTTACCGT 1

RESULT 128
LOCUS AR482566
DEFINITION Sequence 12 from patent US 6703228.
ACCESSION AR482566
VERSION AR482566.1 GI:47245089
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 11)
AUTHORS Landers,J., Jordan,B., Housman,D.E. and Charest,A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 12 09-MAR-2004;
FEATURES Location/Qualifiers
1. .11
/mol_type="genomic DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
Db 1 AAATTAAATGT 11

RESULT 129
LOCUS AX190714/c
DEFINITION Sequence 65 from Patent WO0142493.
ACCESSION AX190714
VERSION AX190714.1 GI:15143998
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 artificial sequences.
AUTHORS Olek,A. and Piepenbrock,C.
TITLE Method for the parallel detection of the degree of methylation of
JOURNAL genomic dna
FEATURES Patent: WO 0142493-A 65 14-JUN-2001;
source Ep-genomics AG (DE)
Location/Qualifiers
1. .11
/mol_type="synthetic construct"
/db_xref="taxon:32630"
/note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Db 11 AAATATTACAT 1

RESULT 130
LOCUS AX190725
DEFINITION Sequence 76 from Patent WO0142493.
ACCESSION AX190725
VERSION AX190725.1 GI:15144009
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 artificial sequences.
AUTHORS Olek,A. and Piepenbrock,C.
TITLE Method for the parallel detection of the degree of methylation of

```

```

genomic dna
Patent: WO 0142493-A 76 14-JUN-2001;
Epigenomics AG (DE)
FEATURES
    source
        1..11
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2223 AAAAGTTACAT 2233
Db      1 AAATATTACAT 11

RESULT 131
AX190727/c
LOCUS      AX190727      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 78 from Patent WO0142493.
ACCESSION  AX190727
VERSION     AX190727.1 GI:15144011
KEYWORDS    .
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM    .
REFERENCE   1
AUTHORS     Olek, A. and Piepenbrock, C.
TITLE       Method for the parallel detection of the degree of methylation of
            genomic dna
JOURNAL     Patent: WO 0142493-A 78 14-JUN-2001;
            Epigenomics AG (DE)
FEATURES    Location/Qualifiers
            source
                1..11
                    /organism="synthetic construct"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:32630"
                    /note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2226 AGTTACATGTT 2236
Db      11 ATTACATATT 11

RESULT 132
AX190728
LOCUS      AX190728      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 79 from Patent WO0142493.
ACCESSION  AX190728
VERSION     AX190728.1 GI:15144012
KEYWORDS    .
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM    .
REFERENCE   1
AUTHORS     Olek, A. and Piepenbrock, C.
TITLE       Method for the parallel detection of the degree of methylation of
            genomic dna
JOURNAL     Patent: WO 0142493-A 79 14-JUN-2001;
            Epigenomics AG (DE)
FEATURES    Location/Qualifiers
            source
                1..11
                    /organism="synthetic construct"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:32630"
                    /note="chemisch vorbehandelte Genom-DNA"

genomic dna
Patent: WO 0142493-A 76 14-JUN-2001;
Epigenomics AG (DE)
FEATURES
    source
        1..11
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2223 AAAAGTTACAT 2233
Db      1 AAATATTACAT 11

RESULT 133
AX252926/c
LOCUS      AX252926      11 bp      DNA      linear      PAT 05-OCT-2001
DEFINITION Sequence 396 from Patent WO0168910.
ACCESSION  AX252926
VERSION     AX252926.1 GI:15986197
KEYWORDS    .
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM    .
REFERENCE   1
AUTHORS     Berlin, K.
TITLE       Oligonucleotides or pna oligomers and a method for detecting the
            methylation state of genomic dna in a parallel manner
JOURNAL     Patent: WO 0168910-A 396 20-SEP-2001;
            Epigenomics AG (DE)
FEATURES    Location/Qualifiers
            source
                1..11
                    /organism="synthetic construct"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:32630"
                    /note="Beschreibung der kunstlichen
                        Sequenz:Oligonukleotid"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2228 TTACATGTTTG 2238
Db      11 TTGAATGTTTG 11

RESULT 134
AX470847
LOCUS      AX470847      11 bp      DNA      linear      PAT 09-AUG-2002
DEFINITION Sequence 424 from Patent WO02053773.
ACCESSION  AX470847
VERSION     AX470847.1 GI:22205972
KEYWORDS    .
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Hofmann, K., Conradt, M. and Petersohn, D.
TITLE       Method for determining skin stress or skin ageing in vitro
JOURNAL     Patent: WO 02053773-A 424 11-JUL-2002;
            HENKEL KGAA (DE)
FEATURES    Location/Qualifiers
            source
                1..11
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2227 GTTACATGTTT 2237
Db      1 GTTACCAGTTT 11

```

```

RESULT 135
AX470905
LOCUS AX470905 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 482 from Patent WO02053773.
ACCESSION AX470905
VERSION AX470905.1 GI:22206030
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 482 11-JUL-2002;
HENKEL KGAA (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2214 AGTGTGACCAA 2224
| | | | |
| | | | |
Db 1 AGTATGACCTA 11

RESULT 136
AX471379/c
LOCUS AX471379 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 956 from Patent WO02053773.
ACCESSION AX471379
VERSION AX471379.1 GI:22206504
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 956 11-JUL-2002;
HENKEL KGAA (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2214 AGTGTGACCAA 2224
| | | | |
| | | | |
Db 1 AGTATGACCTA 11

RESULT 137
AX471509/c
LOCUS AX471509 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 1086 from Patent WO02053773.
ACCESSION AX471509
VERSION AX471509.1 GI:22206634
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 1086 11-JUL-2002;
HENKEL KGAA (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2214 AGTGTGACCAA 2224
| | | | |
| | | | |
Db 1 AGTGTGCCAA 1

RESULT 138
AX472091/c
LOCUS AX472091 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 82 from Patent WO02053775.
ACCESSION AX472091
VERSION AX472091.1 GI:22207132
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Huster,E., Habert,M. and Wojnowski,L.
TITLE Identification of the genetic determinants of the polymorphic
cytochrome expression
JOURNAL Patent: WO 02053775-A 82 11-JUL-2002;
EPIDAUROS BIOTECHNOLOGIE AG (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATG 2234
| | | | |
| | | | |
Db 11 AAAGTCCCATG 1

RESULT 139
AX623259
LOCUS AX623259 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 300 from Patent WO02053774.
ACCESSION AX623259
VERSION AX623259.1 GI:28451200
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 300 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"

```

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 81;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTA 2230

Db 1 ATCAAGGTTA 11

RESULT 140

AX623274

LOCUS AX623274 11 bp DNA linear PAT 21-FEB-2003

DEFINITION Sequence 315 from Patent WO02053774.

ACCESSION AX623274

VERSION AX623274.1 GI:28451215

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.

TITLE Method for determining homeostasis of the skin

JOURNAL Patent: WO 02053774-A 315 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234

Db 1 AAAGTGAAATG 11

RESULT 141

AX623312/c

LOCUS AX623312 11 bp DNA linear PAT 21-FEB-2003

DEFINITION Sequence 353 from Patent WO02053774.

ACCESSION AX623312

VERSION AX623312.1 GI:28451253

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.

TITLE Method for determining homeostasis of the skin

JOURNAL Patent: WO 02053774-A 353 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAG 2227

Db 11 GTGGCAAAAG 1

RESULT 142

AX623252/c

LOCUS AX623252 11 bp DNA linear PAT 21-FEB-2003

DEFINITION Sequence 566 from Patent WO02053774.

ACCESSION AX623252

VERSION AX623252.1 GI:28451466

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.

TITLE Method for determining homeostasis of the skin

JOURNAL Patent: WO 02053774-A 566 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 11 CAAAAGTTTACA 1

RESULT 143

AX624334

LOCUS AX624334 11 bp DNA linear PAT 21-FEB-2003

DEFINITION Sequence 1375 from Patent WO02053774.

ACCESSION AX624334

VERSION AX624334.1 GI:28452275

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.

TITLE Method for determining homeostasis of the skin

JOURNAL Patent: WO 02053774-A 1375 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAA 2224

Db 1 AGTATGACCTA 11

RESULT 144

AX624403/c

LOCUS AX624403 11 bp DNA linear PAT 21-FEB-2003

DEFINITION Sequence 1444 from Patent WO02053774.

ACCESSION AX624403

VERSION AX624403.1 GI:28452344

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE
METHOD for determining homeostasis of the skin
JOURNAL
Patent: WO 02053774-A 1444 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
LOCATION/Qualifiers
SOURCE
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 11 GATACATCTTT 1

RESULT 145
AX624408/c
LOCUS
AX624408 11 bp DNA linear PAT 21-FEB-2003
DEFINITION
Sequence 1449 from Patent WO02053774.
ACCESSION
AX624408
VERSION
AX624408.1 GI:28452349
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE
METHOD for determining homeostasis of the skin
JOURNAL
Patent: WO 02053774-A 1449 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
LOCATION/Qualifiers
SOURCE
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
Db 1 AAGTTGCATCT 11

RESULT 146
AX624854/c
LOCUS
AX624854 11 bp DNA linear PAT 21-FEB-2003
DEFINITION
Sequence 1895 from Patent WO02053774.
ACCESSION
AX624854
VERSION
AX624854.1 GI:28452795
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE
METHOD for determining homeostasis of the skin
JOURNAL
Patent: WO 02053774-A 1895 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
LOCATION/Qualifiers
SOURCE
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACAAAA 2226
Db 11 TCTGACAAAA 1

RESULT 147
AX625019
LOCUS
AX625019 11 bp DNA linear PAT 21-FEB-2003
DEFINITION
Sequence 2060 from Patent WO02053774.
ACCESSION
AX625019
VERSION
AX625019.1 GI:28452960
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE
METHOD for determining homeostasis of the skin
JOURNAL
Patent: WO 02053774-A 2060 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
LOCATION/Qualifiers
SOURCE
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
Db 1 AAGTTGCATCT 11

RESULT 148
AX625472/c
LOCUS
AX625472 11 bp DNA linear PAT 21-FEB-2003
DEFINITION
Sequence 2513 from Patent WO02053774.
ACCESSION
AX625472
VERSION
AX625472.1 GI:28453413
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE
METHOD for determining homeostasis of the skin
JOURNAL
Patent: WO 02053774-A 2513 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
LOCATION/Qualifiers
SOURCE
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
Db 11 TTAAGGTTTG 1

RESULT 149
AX625510

```

mcgarry191-19.rge

Thu Nov 18 12:41:57 2004

```

LOCUS       AX625510                      11 bp      DNA             PAT 21-FEB-2003
DEFINITION   Sequence 2551 from Patent WO02053774.
ACCESSION    AX625510
VERSION      AX625510.1 GI:28453451
KEYWORDS     .
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 2551 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              source          1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches          9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY       2227 GTTACATGTTT 2237
Db       1 GTTACCATGTTT 11

RESULT 150
LOCUS       AX625578                      11 bp      DNA             PAT 21-FEB-2003
DEFINITION   Sequence 2619 from Patent WO02053774.
ACCESSION    AX625578
VERSION      AX625578.1 GI:28453519
KEYWORDS     .
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 2619 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              source          1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches          9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY       2228 TTACATGTTTG 2238
Db       1 TTGAATGTTTG 1

RESULT 151
LOCUS       AX626006                      11 bp      DNA             PAT 21-FEB-2003
DEFINITION   Sequence 3047 from Patent WO02053774.
ACCESSION    AX626006
VERSION      AX626006.1 GI:28454044
KEYWORDS     .
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.

```

```

TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 3047 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              source          1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches          9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY       2219 GACCAAAAGTT 2229
Db       1 GATCAAAATTT 11

RESULT 152
LOCUS       AX626175                      11 bp      DNA             PAT 21-FEB-2003
DEFINITION   Sequence 3216 from Patent WO02053774.
ACCESSION    AX626175
VERSION      AX626175.1 GI:28454213
KEYWORDS     .
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 3216 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              source          1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches          9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY       2219 GACCAAAAGTT 2229
Db       1 GACCAAAATGTT 11

RESULT 153
LOCUS       AX626353                      11 bp      DNA             PAT 21-FEB-2003
DEFINITION   Sequence 3394 from Patent WO02053774.
ACCESSION    AX626353
VERSION      AX626353.1 GI:28454391
KEYWORDS     .
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 3394 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              source          1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches          9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY       2219 GACCAAAAGTT 2229
Db       1 GACCAAAATGTT 11

RESULT 154
LOCUS       AX626606                      11 bp      DNA             PAT 21-FEB-2003
DEFINITION   Sequence 3047 from Patent WO02053774.
ACCESSION    AX626606
VERSION      AX626606.1 GI:28454044
KEYWORDS     .
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.

```



```

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
Db 1 AAATGTAACAT 11

RESULT 154
AX626353/c
LOCUS
DEFINITION Sequence 3394 from Patent WO02053774.
ACCESSION AX626353
VERSION AX626353.1 GI:28454391
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 3394 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGT 2235
Db 11 ATGTTACATTT 1

RESULT 155
AX626437/c
LOCUS
DEFINITION Sequence 3478 from Patent WO02053774.
ACCESSION AX626437
VERSION AX626437.1 GI:28454475
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 3478 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237
Db 11 GTTACATTTT 1

RESULT 156
AX626538
LOCUS
DEFINITION Sequence 3579 from Patent WO02053774.

```

```

ACCESSION AX626538
VERSION AX626538.1 GI:28454576
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 3579 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAAG 2227
Db 1 GCGACAAAAG 11

RESULT 157
AX626611/c
LOCUS
DEFINITION Sequence 3652 from Patent WO02053774.
ACCESSION AX626611
VERSION AX626611.1 GI:28454649
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 3652 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAAG 2227
Db 11 GCGACCAACAG 1

RESULT 158
AX626972/c
LOCUS
DEFINITION Sequence 4013 from Patent WO02053774.
ACCESSION AX626972
VERSION AX626972.1 GI:28455010
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4013 11-JUL-2002;

```

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2225

Db 11 GTGTGACCAA 1

RESULT 159

AX627073 AX627073 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4114 from Patent WO02053774.
DEFINITION
ACCESSION AX627073
VERSION AX627073.1 GI:28455111

KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4114 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2225

Db 1 GTGTGACCAA 11

RESULT 160

AX627090/c AX627090 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4131 from Patent WO02053774.
DEFINITION
ACCESSION AX627090
VERSION AX627090.1 GI:28455128

KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4131 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234

Db 11 AAAATTACAGG 1

RESULT 161

AX627203/c AX627203 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4244 from Patent WO02053774.
DEFINITION
ACCESSION AX627203
VERSION AX627203.1 GI:28455241

KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4244 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAA 2224

Db 11 AGTGTGACCAA 1

RESULT 162

AX627736/c AX627736 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 4777 from Patent WO02053774.
DEFINITION
ACCESSION AX627736
VERSION AX627736.1 GI:28455774

KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4777 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTAC 2231

Db 11 CAAAAAGTTGC 1

RESULT 163

AX628352/c AX628352 11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 5393 from Patent WO02053774.
DEFINITION
ACCESSION AX628352
VERSION AX628352.1 GI:28456390

```
KEYWORDS      Homo sapiens (human)
SOURCE
ORGANISM      Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS       Petersohn,D., Conradt,M. and Hofmann,K.
TITLE         Method for determining homeostasis of the skin
JOURNAL       Patent: WO 02053774-A 5393 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match   28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAG 2227
Db 11 GGGACCATAG 1

RESULT 164
AX628372/c
LOCUS         AX628372
DEFINITION   Sequence 5413 from Patent WO02053774.
ACCESSION    AX628372
VERSION      AX628372.1 GI:28456410
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS       Petersohn,D., Conradt,M. and Hofmann,K.
TITLE         Method for determining homeostasis of the skin
JOURNAL       Patent: WO 02053774-A 5413 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match   28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2213 GACTGTGACCA 2223
Db 11 GAGAGGGACCA 1

RESULT 165
AX629084/c
LOCUS         AX629084
DEFINITION   Sequence 6125 from Patent WO02053774.
ACCESSION    AX629084
VERSION      AX629084.1 GI:28457122
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS       Petersohn,D., Conradt,M. and Hofmann,K.
TITLE         Method for determining homeostasis of the skin
JOURNAL       Patent: WO 02053774-A 6125 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match   28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2213 GACTGTGACCA 2223
Db 11 GAGAGGGACCA 1

RESULT 166
AX629205
LOCUS         AX629205
DEFINITION   Sequence 6246 from Patent WO02053774.
ACCESSION    AX629205
VERSION      AX629205.1 GI:28457243
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS       Petersohn,D., Conradt,M. and Hofmann,K.
TITLE         Method for determining homeostasis of the skin
JOURNAL       Patent: WO 02053774-A 6246 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match   28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGAGTAAAA 1

RESULT 167
AX629421
LOCUS         AX629421
DEFINITION   Sequence 6462 from Patent WO02053774.
ACCESSION    AX629421
VERSION      AX629421.1 GI:28457459
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS       Petersohn,D., Conradt,M. and Hofmann,K.
TITLE         Method for determining homeostasis of the skin
JOURNAL       Patent: WO 02053774-A 6462 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match   28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2212 ACAGGTGACCC 2222
Db 1 ACAGGTGACCC 11

RESULT 168
AX629421
LOCUS         AX629421
DEFINITION   Sequence 6462 from Patent WO02053774.
ACCESSION    AX629421
VERSION      AX629421.1 GI:28457459
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS       Petersohn,D., Conradt,M. and Hofmann,K.
TITLE         Method for determining homeostasis of the skin
JOURNAL       Patent: WO 02053774-A 6462 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match   28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGAGTAAAA 1
```



```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAG 2227
DB 11 GTGGCAAAAAG 1

RESULT 173
AX630946/c
LOCUS      AX630946      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 7987 from Patent WO02053774.
ACCESSION  AX630946
VERSION     AX630946.1 GI:28458988
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 7987 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
            Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAGTTTACA 2232
DB 11 CAAAGTTTACA 1

RESULT 174
AX631755
LOCUS      AX631755      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 8797 from Patent WO02053774.
ACCESSION  AX631755
VERSION     AX631755.1 GI:28459862
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 8797 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
            Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTACCA 2224
DB 1 AGTATGACCTA 11

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
DB 11 TCTGAGCAAAA 1

RESULT 177
AX632275/c
LOCUS      AX632275      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 9317 from Patent WO02053774.
ACCESSION  AX632275
VERSION     AX632275.1 GI:28467890
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 8866 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
            Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
DB 11 GATACATCTTT 1

RESULT 175
AX631824/c
LOCUS      AX631824      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 8866 from Patent WO02053774.
ACCESSION  AX631824
VERSION     AX631824.1 GI:28459931
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 8866 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
            Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
DB 11 GATACATCTTT 1

RESULT 176
AX631829/c
LOCUS      AX631829      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 8871 from Patent WO02053774.
ACCESSION  AX631829
VERSION     AX631829.1 GI:28459936
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 8871 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
            Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
DB 11 TCTGAGCAAAA 1

RESULT 177
AX632275/c
LOCUS      AX632275      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 9317 from Patent WO02053774.
ACCESSION  AX632275
VERSION     AX632275.1 GI:28467890
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
Hensel Kommanditgesellschaft auf Aktien (DE)

FEATURES
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2214 AGTGTGACCAA 2224

Db 11 AGTGTGACCAA 1

RESULT 178

AX632440

LOCUS

AX632440

DEFINITION

Sequence 9482 from Patent WO02053774.

ACCESSION

AX632440

VERSION

AX632440.1 GI:28468055

KEYWORDS

Homo sapiens (human)

SOURCE

Homo sapiens

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE

AUTHORS

Petersohn, D., Conradt, M. and Hofmann, K.

TITLE

Method for determining homeostasis of the skin

JOURNAL

Patent: WO 02053774-A 9482 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source

1..11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGT 2235

Db 1 AAGTTGCACT 11

RESULT 179

AX772275

LOCUS

AX772275

DEFINITION

Sequence 65 from Patent WO03042407.

ACCESSION

AX772275

VERSION

AX772275.1 GI:32438848

KEYWORDS

Drosophila melanogaster (fruit fly)

SOURCE

Drosophila melanogaster

ORGANISM

Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;

Ephydroidea; Drosophilidae; Drosophila.

REFERENCE

AUTHORS

Dickson, B., Berger, J., Suzuki, T. and Knoblich, J.

TITLE

Method for identifying therapeutic targets by use of genetic

JOURNAL

Patent: WO 03042407-A 65 22-MAY-2003;

BOEHRINGER INGELHEIM INTERNATIONAL GMBH; CD Patents (DE)

FEATURES

source

1..11

/organism="Drosophila melanogaster"

/mol_type="unassigned DNA"
/db_xref="taxon:7227"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237

Db 1 GGTATATGTTT 11

Search completed: November 18, 2004, 08:14:47

Job time : 1 secs